CN100569772C

CN100569772C - Azaindole as JAK and other kinases inhibitor

Info

Publication number: CN100569772C
Application number: CNB2005800103488A
Authority: CN
Inventors: F·萨里图罗; L·法默; R·贝蒂尔; E·哈林顿; J·格林; J·考特; J·科姆; D·劳弗; A·阿罗诺夫; H·宾奇; D·博亚尔; J-D·查里尔; S·埃弗里特; D·弗雷斯; M·莫蒂默尔; F·皮耶拉尔; D·鲁滨逊; 王坚; J·平德; 王天生
Original assignee: Vertex Pharmaceuticals Inc
Current assignee: Vertex Pharmaceuticals Inc
Priority date: 2004-03-30
Filing date: 2005-03-30
Publication date: 2009-12-16
Anticipated expiration: 2025-03-30
Also published as: SI2332940T1; CN1938303A; ZA200607981B; UA87494C2

Abstract

The present invention relates to the compound of formula (I), it is a kinases inhibitor.The present invention also provides the pharmaceutical composition that comprises The compounds of this invention and uses said composition to treat the method for various illnesss.

Description

Azaindole as JAK and other kinases inhibitor

Technical field

The present invention relates to kinases inhibitor.The present invention also provides the pharmaceutical composition that comprises The compounds of this invention and uses said composition to treat the method for various illnesss.

Background of invention

In recent years, by understanding the enzyme relevant and the structure of other biomolecules better, helped the research of novel treatment greatly with disease.The important enzyme of a wherein class that has become the broad research target is a protein kinase.

Protein kinase is made up of involved enzyme on the extended familys structure, and they are responsible for the control of various signal transduction processes in the cell.(see, Hardie, G. and Hanks, S.The ProteinKinase Facts Book, I and II, Academic Press, San Diego, CA:1995).Because the conservative property of protein kinase structure and catalysis, they are considered to from common my late grandfather gene evolution.Nearly all kinases all comprises a similar 250-300 amino acid catalytic structural domain.Make the substrate difference of its phosphorylation they can be divided into several families (for example, albumen-tyrosine, albumen-serine/threonine, lipid etc.) by kinases.Identified usually and each the corresponding sequence motifs in these kinases families (see, for example, Hanks, S.K., Hunter, T., FASEB J.1995,9,576-596; People such as Knighton, Science1991,253,407-414; People such as Hiles, Cell 1992,70,419-429; People such as Kunz, Cell 1993,73,585-596; People such as Garcia-Bustos, EMBO J.1994,13,2352-2361).

Usually, protein kinase mediates intracellular signal from ribonucleoside triphosphote to the phosphoryl transfer of the protein receptor that participates in signal transduction path by influence.These phosphorylation events can play modulation or regulate the molecular switch of target protein biological function.These phosphorylation events finally are initiated outside replying various born of the same parents and during other stimulator.The example of this stimulator comprises that environment and chemistry stress signal (for example, osmotic shock, heat shock, ultraviolet radiation, bacterial endotoxin and H ₂O ₂), cytokine (for example, il-1 (IL-1) and tumor necrosis factor alpha (TNF-α)) and somatomedin (for example, granulocyte huge have a liking for cell-G CFS (GM-CSF) and fibroblast growth factor (FGF)).Born of the same parents' external stimulue can influence and cell growth, migration, differentiation, hormone secretion, transcription factor activation, Muscle contraction, glucose metabolism, the synthetic control of albumen, and one or more relevant cell responses of Cycle Regulation.

A lot of diseases are all relevant with the abnormal cells that incident the caused reaction by above-mentioned protein kinase-mediation.These diseases include, but not limited to autoimmune disease, inflammatory disease, osteopathy, metabolic disease, nerve and neurodegenerative disease, cancer, cardiovascular diseases, transformation reactions and asthma, Alzheimer and the disease relevant with hormone.Therefore, the great efforts of medicinal chemical aspect found can be effectively as the kinases inhibitor of therapeutical agent.

Janus kinases (JAK) belongs to family tyrosine kinase, is made up of JAK1, JAK2, JAK3 and TYK2.JAK plays an important role in the cytokine signaling conduction.The downstream substrate of kinases JAK family comprises the signal transduction agent and the activator (STAT) of transcription factor.The conduction of JAK/STAT signal relates to a lot of abnormal immune reactions, as transformation reactions, asthma, autoimmune disease such as transplant rejection, rheumatoid arthritis, amyotrophic lateral sclerosis and multiple sclerosis and entity and hematologic malignancies such as leukemia and lymphadenomatous mediation.The drug intervention of JAK/STAT approach was commented on [Frank Mol.Med.5, people such as 432-456 (1999) and Seidel, Oncogene, 19,2645-2656 (2000)].

JAK1, JAK2 and TYK2 are that omnipresence is expressed, and JAK3 then mainly expresses in hematopoietic cell.JAK3 only with common cytokine receptor γ chain (γ _c) in conjunction with and activated by IL-2, IL-4, IL-7, IL-9 and IL-15.In fact, demonstrated by the propagation of IL-4 and IL-9 inductive mouse mastocyte and survival and depended on JAK3-and γ _c-signal conduction people such as [, Blood, 96,2172-2180 (2000)] Suzuki.

The crosslinked pro-inflammatory mediator that causes of high-affinity immunoglobulin (Ig) (Ig) the E acceptor of sensitization mastocyte, comprise the release of many vasoactive cytokines, thereby cause acute transformation reactions, or mediation (I type) anaphylaxis [people such as Gordon, Nature, 346,274-276 (1990) and Galli, N.Engl.J.Med., 328,257-265 (1993)].The vital role of JAK3 in the reaction of the mastocyte of IgE acceptor-mediation set up people such as [, Biochem.Biophys.Res.Commun., 257,807-813 (1999)] Malaviya in vitro and in vivo.In addition, also reported by suppressing JAK3 and prevented the type i allergic reaction that mediates by mastocyte-activations, comprised allergy people such as [, J.Biol.Chem.274,27028-27038 (1999)] Malaviya.Can regulate the external threshing of mastocyte at mastocyte and prevent the anaphylaxis of IgE acceptor/antigen-mediation in the body with the JAK3 inhibitor.

The successful target-seeking of the JAK3 that is used for immunosuppression and allotransplantation acceptance has been described in recent research.Studies confirm that give the JAK3 inhibitor after, dosage-dependency the survival of buffalo heart allotransplantation in Wistar Furth acceptor shows and regulate harmful immunoreactive possibility [Kirken, Transpl.Proc. in graft versus host disease, 33,3268-3270 (2001)].

The STAT-phosphorylation of IL-4-mediation is related to the early stage and late stage of rheumatoid arthritis (RA) by hint.The rise of the pro-inflammatory cytokine in RA synovial membrane and the synovial membrane liquid is the feature of disease.The activation of the IL-4/STAT approach of verified IL-4 mediation is by Janus kinases (JAK 1﹠amp; 3) mediation, and IL-4 relevant jak kinase is expressed people such as [, J.Immunol., 164,3894-3901 (2000)] Muller-Ladner in the RA synovial membrane.

Familial amyotrophic lateral sclerosis (FALS) is a kind of mortality neurodegenerative disease that influences about 10%ALS patient.The survival rate of FALS mouse is being handled the back increase with the JAK3 specific inhibitor.This shows JAK3 work [people such as Trieu, Biochem.Biophys.Res.Commun., 267,22-25 (2000)] in FALS.

The signal transduction agent of transcription factor and activator (STAT) are especially by JAK family kinase activated.Recent result of study has hinted by intervening the JAK/STAT signal transduction path with specific inhibitor at the JAK family kinase treats leukemic possibility [people such as Sudbeck, Clin.Cancer Res., 5,1569-1582 (1999)].The JAK3 specific compounds has demonstrated and can suppress clone's generation property growth that the JAK3-express cell is DAUDI, RAMOS, LC1-19, NALM-6, MOLT-3 and HL-60.

In animal model, the TEL/JAK2 fusion rotein has been induced the marrow hyperplasia, and in hematopoietic cell system, the introducing of TEL/JAK2 has caused the activation of STAT1, STAT3, STAT5, and cytokine-dependency growth [people such as Schwaller, EMBO J.17,5321-5333 (1998)].

The tyrosine phosphorylation of STAT3 has been eliminated in the inhibition of JAK3 and TYK2, and has suppressed cutaneous T cell lymphoma, a kind of cell growth of skin T-cell lymphoma form.These results have hinted that the JAK family kinase in the JAK/STAT approach of constitutive activation is present in [people such as Nielsen, Proc.Nat.Acad.Sci.U.S.A., 94,6764-6769 (1997)] in the cutaneous T cell lymphoma.Equally, STAT3, STAT5, JAK1 and JAK2 have been proved in being characterized as the mouse T-cell lymphoma of LCK overexpression at first by constitutive activation, thereby further hinted the JAK/STAT approach in the abnormal cell growth [people such as Yu, J.Immunol.159,5206-5210 (1997)].In addition, the STAT3 of IL-6 mediation activates and can be blocked by the JAK inhibitor, causes the myeloma cell to apoptosis sensitivity people such as [, Immunity 10,105-115 (1999)] Catlett-Falcone.

Making the interested kinases family of people is the relevant volution-spiralization albumen serine/threonine kinase (ROCK) of Rho-, and it is considered to the effector of the little GTP enzyme Rho relevant with Ras.ROCK family comprise p160ROCK (ROCK-1) (people such as Ishizaki, EMBO J.1996,15,1885-1893) and ROK α/Rho-kinases/ROCK-II (people such as Leung, J.Biol.Chem.1995,270,29051-29054; People such as Matsui, EMBO J.1996,15,2208-2216; People such as Nakagawa, FEBS Lett.1996,392,189-193), protein kinase PKN (people such as Amano, Science 1996,271,648-650; People such as Watanabe, Science 1996,271,645-648) and lemon and lemon kinases (people such as Madaule, Nature, 1998,394,491-494; People such as Madaule, FEBS Lett.1995,377,243-248).The ROCK family kinase has been proved to be and has related to many functions, comprises formation (people such as Leung, Mol.Cell Biol.1996,16, the 5313-5327 of exciting albumen stress fiber of Rho-inductive and adhesion plaque; People such as Amano, Science, 1997,275,1308-1311; People such as Ishizaki, FEBS Lett.1997,404,118-124) and the downward modulation of myosin Phosphoric acid esterase (people such as Kimura, Science, 1996,273,245-248), platelet activation (people such as Klages, J.Cell.Biol., 1999,144,745-754), the aortal smooth muscle that is caused by various stimulator shrinks (people such as Fu, FEBS Lett., 1998,440,183-187), zymoplasm-inductive aortic smooth muscle cell reply (people such as Seasholtz, Cir.Rez., 1999,84,1186-1193), myocardial cell's hypertrophy (people such as Kuwahara, FEBS Lett., 1999,452,314-318), bronchial smooth muscle shrinks (people such as Yoshii, Am.J.Respir.Cell Mol.Biol., 1999,20,1190-1200), non-myocyte's smooth muscle contraction and cytoskeleton reconstruct (people such as Fukata, Trends in Pharm.Sci2001,22,32-39), the activation of the anion channel of capacity regulating (people such as Nilius, J.Physiol., 1999,516,67-74), aixs cylinder indentation (people such as Hirose, J.Cell.Biol., 1998,141,1625-1636), neutrophil chemotaxis (Niggli, FEBS Lett., 1999,445,69-72), wound healing (Nobes and Hall, J.Cell.Biol., 1999,144,1235-1244), tumor invasion (people such as Itoh, Nat.Med., 1999,5,221-225) and cell transformation (people such as Sahai, Curr.Biol., 1999,9,136-145).

More specifically, ROCK and relate to various diseases and illness comprises hypertension (people such as Satoh, J.Clin.Invest.1994,94,1397-1403; People such as Mukai, FASEBJ.2001,15,1062-1064; People such as Uehata, Nature 1997,389,990-994; People such as Masumoto, Hypertension, 2001,38,1307-1310), cerebral vasospasm (people such as Sato, Circ.Res.2000,87,195-200; People such as Miyagi, J.Neurosurg.2000,93,471-476; People such as Tachibana, Acta Neurochir (Wien) 1999,141,13-19), coronary vasospasm (people such as Shimokawa, Jpn.Cir.J.2000,64,1-12; People such as Kandabashi, Circulation 2000,101,1319-1323; People such as Katsumata, Cirulation 1997,96,4357-4363; People such as Shimokawa, Cardiovasc.Res.2001,51,169-177; People such as Utsunomiya, J.Pharmacol.2001,134,1724-1730; People such as Masumoto, Circulation 2002,105,1545-1547), bronchial asthma (people such as Chiba, Comp.Biochem.Physiol.C Pharmacol.Toxicol.Endocrinol.1995,11,351-357; People such as Chiba, Br.J.Pharmacol.1999,127,597-600; People such as Chiba, Br.J.Pharmacol.2001,133,886-890; People such as Iizuka, Eur.J.Pharmacol.2000,406,273-279), childbirth (people such as Niro, Biochem.Biophys.Res.Commun.1997,230,356-359 in advance; People such as Tahara, Endocrinology 2002,143,920-929; People such as Kupittayanant, PflugersArch.2001,443,112-114), erectile dysfunction (people such as Chitaley, Nat.Med.2001,7,119-122; People such as Mills, J.Appl.Physiol.2001,91,1269-1273), glaucoma (people such as Honjo, Arch.Ophthalmol.2001,1171-1178; People such as Rao, Invest.Ophthalmol.Vis.Sci.2001,42,1029-1037), vascular smooth muscle cell proliferation (people such as Shimokawa, Cardiovasc.Res.2001,51,169-177; People such as Morishige, Arterioscler.Thromb.Vasc.Viol.2001,21,548-554; People such as Eto, Am.J.Physiol.Heart Circ.Physiol.2000,278, H1744-H1750; People such as Sawada, Circulation2000,101,2030-2023; People such as Shibata, Circulation2001,103,284-289), myocardial hypertrophy (people such as Hoshijima, J.Biol.Chem.1998,273,7725-77230; People such as Sah, J.Biol.Chem.1996,271,31185-31190; People such as Kuwahara, FEBS Lett.1999,452,314-318; People such as Yanazume, J.Biol.Chem.2002,277,8618-8625), malignoma (people such as Itoh, Nat.Med.1999,5,221-225; People such as Genda, Hepatology 1999,30,1027-1036; People such as Somlyo, Biochem.Biophys.Res.Commun.2000,269,652-659), local asphyxia/pour into inductive damage (people such as Ikeda, J.of Surgical Res.2003,109,155-160 again; People such as Miznuma, Transplantation2003,75,579-586), endothelial dysfunction (people such as Hernandez-Perera, Circ.Res.2000,87,616-622; People such as Laufs, J.Biol.Chem.1998,273,24266-24271; People such as Eto, Circ.Res.2001,89,583-590), Crohn disease and colitis (people such as Segain, Gastroenterology 2003,124 (5), 1180-1187), axon process (people such as Fournier, J.Neurosci.2003,23,1416-1423), Raynaud disease (people such as Shimokawa, J.Cardiovasc.Pharmacol.2002,39,319-327), angina (people such as Utsunomiya, Br.J.Pharmacol.2001,134,1724-1730; People such as Masumoto, Circulation 2002,105,1545-1547; People such as Shimokawa, J.Cardiovasc.Pharmacol., 2002,40,751-761; People such as Satoh, Jpn.J.Pharmacol., 2001,87,34-40), Alzheimer's (people such as Zhou, Science 2003,302,1215-1218), benign prostatic hyperplasia (people such as Rees, J.Urology, 2003,170,2517-2522) and atherosclerosis (people such as Retzer, FEBS Lett.2000,466,70-74; People such as Ishibashi, Biochim.Biophys.Acta2002,1590,123-130).Therefore, the exploitation of ROCK kinase inhibitor can be used as the treatment of conditions agent that treatment relates to the ROCK kinase pathways.

Aurora albumen be a family three kinds of very relevant serine/threonine kinases (be called Aurora-A ,-B and-C), the m period of their cell cycle is very important.Particularly, Aurora-A the maturation of centrosome with separate, play a significant role in the formation of mitotic spindle body and chromosomal certain separation.Aurora-B is a kind of karyomit(e) courier albumen, and it plays a significant role aspect correctly the finishing of arrangement, spindle body fit-up inspection point and the cell movement of karyomit(e) on metaphase plate regulating.

At many human cancers, comprise observe in colorectum, ovary, stomach and the invasive duct adenocarcinoma Aurora-A ,-B or-overexpression of C.Except the amplification of AURKA, the locus of coding Aurora-A is relevant with the patient with breast cancer's of tubercle-feminine gender poor prognosis.In addition, but the overexpression of Aurora-A has demonstrated the transformed mammalian inoblast, produces the aneuploid cell that contains multipolar spindle.

Now, many researchs verified in the human cancer cell line due to the siRNA Aurora-A or-disappearance or the inhibition of B, dominance feminine gender or neutralizing antibody destroy along with the mitotic development of cell cumulative with 4NDNA, and in some cases, endoreduplication and necrocytosis appear then.

Protein kinase is attractive and the target of attested novel treatment, is used for the treatment of human diseases, comprises Gleevec and Tarceva.The Aurora kinases is attractive especially be since they relevant with many human cancers and they aspect these cancer cell multiplications of promotion role (people such as Harrington, Nature Med., 2004,10:262-267).

Therefore, be starved of to develop to be used for the treatment of and activate the relevant various diseases or JAK, ROCK and the Aurora of illness with JAK, ROCK and Aurora, the inhibitor of preferred JAK-3, ROCK and AuroraA protein kinase, particularly for most these diseases, adopted not too suitable treatment at present.

Summary of the invention

Having been found that compound of the present invention now, and the pharmacy acceptable composition, is effective as the inhibitor of JAK, ROCK and Aurora protein kinase.In specific embodiments, these compounds are effective as the inhibitor of JAK-3, ROCK and Aurora protein kinase.These compounds or its pharmacologically acceptable salts have general formula I:

R wherein ¹, R ², R ³, R ⁴, X ¹, X ², X ³, R ⁵With x be as following and trifle is defined herein.

These compounds and pharmaceutical composition thereof are used for the treatment of or prevent various illnesss, comprise, but be not limited to, heart trouble, diabetes, Alzheimer's, immunodeficiency illness, inflammatory diseases, hypertension, allergic disease, autoimmune disease, destructive bone disorders such as osteoporosis, proliferative disorders, catch, the disease and the virus disease of immunity-mediation.Said composition also be used for preventing necrocytosis and outgrowth method and therefore can be used for treating or preventing apoplectic in perfusion/local asphyxia again, heart attack and organ hypoxia.Said composition also is used to prevent the method for zymoplasm-inductive platelet aggregation.Said composition is used in particular for following illness, (comprise as chronic lymphocytic leukemia (CML), acute myelogenous leukemia (AML), acute promyelocytic leukemia (APL), rheumatoid arthritis, asthma, osteoarthritis, local asphyxia, cancer, but be not limited to, ovarian cancer, mammary cancer and carcinoma of endometrium), hepatopathy comprises liver local asphyxia, heart trouble, as myocardial infarction and congestive heart failure, relate to the pathologic immune disorders and the neurodegenerative disorders of T cell activation.

Detailed Description Of The Invention

1. the generality of The compounds of this invention is described:

The present invention relates to the compound of formula I:

Or its pharmacologically acceptable salts, wherein:

R ¹Be T-R ' or-Si (R ') ₃

R ², R ³, and R ⁴Independently be halogen, CN, NO separately ₂, or V-R ';

X ¹, X ²And X ³Independently be N or CH separately, wherein the hydrogen atom of CH is optional by R ⁵Replace;

X is 1,2,3 or 4;

R ⁵Each appearance independently be halogen, CN, NO ₂, or U-R ';

T, V and U independently are valence link or the optional C that replaces separately ₁-C ₆Alkylidene chain, wherein this chain at the most optional the and independent quilt-NR ' of two methylene units-,-S-,-O-,-CS-,-CO ₂-,-OCO-,-CO-,-COCO-,-CONR '-,-NR ' CO-,-NR ' CO ₂-,-SO ₂NR '-,-NR ' SO ₂-,-CONR ' NR '-,-NR ' CONR '-,-OCONR '-,-NR ' NR '-,-NR ' SO ₂NR '-,-SO-,-SO ₂-,-PO-,-PO ₂-or-POR '-replacement; And

The each appearance of R ' independently is hydrogen or the optional group that replaces, and is selected from: C ₁-C ₆Aliphatic group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.In specific embodiments, occurring for twice of the R ' of formation ring is (for example, R on single substituting group ¹, R ², R ³, R ⁴Or at single R ⁵On the substituting group) and form monocycle or dicyclo.In other embodiments, occurring for twice of R ' is (for example, at two R on two substituting groups ⁵On the substituting group) and can with and R ⁵The ring that substituting group links to each other forms bicyclic condensed ring.

In specific embodiments, for the compound of top direct description:

If a) R ¹Be the substituted ring amyl group, x is 1, X ¹And X ³Be CH, X so ²Not C-R ⁵, R wherein ⁵Be fluorine or OMe;

B) if R ²And R ³Be H and R simultaneously ¹And R ⁴Independently be selected from H or Me, x is 1, X ¹And X ³Be CH, X so ²Not C-R ⁵, R wherein ⁵Be OMe, NO ₂, or fluorine;

C) if R ¹, R ², R ³And R ⁴Be H simultaneously, x is 1, R ⁵Be-SMe NH ₂Or the optional NH-piperidines that replaces, and X ¹And X ²Be N, X so ³Not CH;

D) if R ², R ³And R ⁴Be H simultaneously, X ¹, X ²And X ³Be CH, and two R ⁵Form the optional dicyclo that replaces of condensed, R so with the ring that links to each other with them ¹Not CH ₂CH ₂N (Me) ₂

E) if R ²And R ³Be H simultaneously, R ⁴Be NH ₂, and X ¹, X ²And X ³Be CH, R so ¹It or not substituted-phenyl;

F) if R ², R ³And R ⁴Be H, R so simultaneously ¹Not Si (R ') ₃

G) if R ¹, R ²And R ⁴Be H and (i) X simultaneously ²And X ³Be CH or CR ⁵Or (ii) X ¹, X ²Or X ³In any one is N, R so ³It or not phenyl or by O-phenyl or N (Me) ₂The phenyl that replaces.

2. compound and definition:

General those that describe above compound of the present invention comprises, and their disclosed from here classes, subclass and kind further illustrate.Except as otherwise noted, otherwise use following definition used herein.With regard to purpose of the present invention, chemical element is according to the periodic table of elements, CAS version, Handbook of Chemistry and Physics, the 75th edition evaluation.In addition, vitochemical rule is at " Organic Chemistry ", Thomas Sorrell, University Science Books, Sausalito:1999, " March ' s AdvancedOrganic Chemistry ", the 5th edition, Smith, M.B. and March, J. compile JohnWiley﹠amp; Sons describes among the New York:2001, and their full content is all introduced herein as a reference.

Just as described herein, compound of the present invention can be chosen wantonly by one or more substituting groups and replace, and these substituting groups are that top generality is illustrational, or by the concrete class of the present invention, subclass with plant illustrational.Should understand phrase " optional replacement " and can exchange use with phrase " replacement or unsubstituted ".Usually, term " replacement ", no matter whether the front has added " choosing wantonly ", all is meant with the hydrogen base in the specified substituting group replacement known structure.Except as otherwise noted, but the optional group that replaces can have substituting group at each the position of substitution of group, and when available more than one when being selected from the substituting group of specifying group and replacing a more than position in any known structure, each locational substituting group can be identical or different.The substituting group combination of the present invention's expection preferably can form those of stable or chemical available compound.Term used herein " stable " is meant when experience be used for their generation, detection, and be preferred for they recovery, purifying condition and when being used for one or more purposes disclosed herein, the compound that can not change basically.In certain embodiments, stable compound or chemical available compound are under the condition that does not have moisture or other chemical reactivity condition to exist, when under 40 ℃ or lower temperature, keeping at least one week, and the compound that can not change basically.

Term used herein " aliphatic series " or " aliphatic group " are meant that straight chain (promptly, unbranched) or side chain, replacement or unsubstituted hydrocarbon chain, it is saturated fully or comprises one or more unsaturated units, or refer to monocyclic hydrocarbon or dicyclic hydrocarbon, it is saturated fully or comprises one or more unsaturated units, but its be not fragrant (being also referred to as " carbocyclic ring " " cyclic aliphatic " or " cycloalkyl " herein), it has the single point that links to each other with the molecule remainder.Except as otherwise noted, aliphatic group comprises 1-20 aliphatic carbon atom.In certain embodiments, aliphatic group comprises 1-10 aliphatic carbon atom.In other embodiments, aliphatic group comprises 1-8 aliphatic carbon atom.In other embodiments, aliphatic group comprises 1-6 aliphatic carbon atom, and in other embodiments, aliphatic group comprises 1-4 aliphatic carbon atom.In certain embodiments, " cyclic aliphatic " (or " carbocyclic ring " or " cycloalkyl ") is meant monocyclic C ₃-C ₈The C of hydrocarbon or dicyclo ₈-C ₁₂Hydrocarbon, it is saturated fully or comprises one or more unsaturated units, but it is not fragrant, has the single point that links to each other with the molecule remainder, the arbitrary independently ring in the wherein said bicyclic system has 3-7 unit.Suitable aliphatic group include, but not limited to line style or side chain, replacement or unsubstituted alkyl, alkenyl, alkynyl and hybrid thereof, as (cycloalkyl) alkyl, (cycloalkenyl group) alkyl or (cycloalkyl) thiazolinyl.

Term used herein " heterolipid family " is meant that one of them or two carbon atoms are independently by the aliphatic groups of one or more oxygen, sulphur, nitrogen, phosphorus or silicon replacement.Heterolipid family group can be to replace or unsubstituted, side chain or unbranched, ring-type or acyclic, and comprises " heterocycle ", " heterocyclic radical ", " heterocycle aliphatic series " or " heterocyclic " group.

Term used herein " heterocycle ", " heterocyclic radical ", " heterocycle aliphatic series " or " heterocyclic " are meant monocycle, dicyclo or the three-loop system of non-fragrance, and wherein one or more links are independent heteroatomss of selecting.In certain embodiments, " heterocycle ", " heterocyclic radical ", " heterocycle aliphatic series " or " heterocyclic " group have 3-14 link, wherein one or more links are the heteroatomss that independently are selected from oxygen, sulphur, nitrogen or phosphorus, and each ring in the system comprises 3-7 link.

Term " heteroatoms " is meant that one or more oxygen, sulphur, nitrogen, phosphorus or silicon (comprise arbitrary oxidised form of nitrogen, sulphur, phosphorus or silicon; The quaternized form of arbitrary basic nitrogen or; Heterocyclic can replace nitrogen, for example N (3,4-dihydro-2 h-pyrrole base), NH (pyrrolidyl) or NR ⁺(as the pyrrolidyl of N-replacement)).

Term used herein " undersaturated " is meant that this part has one or more unsaturated units.

Term used herein " alkoxyl group " or " sulfane base " are meant the alkyl with the previous definition that links to each other with main carbochain by oxygen (" alkoxyl group ") or sulphur (" sulfane base ") atom.

Term " alkylhalide group ", " haloalkenyl " and " halogen alkoxyl group " are meant alkyl, thiazolinyl or the alkoxyl group that replaces with one or more halogen atoms as the case may be.Term " halogen " is meant F, Cl, Br or I.

Use or be used as major part herein separately, term " aryl " as a part in " aralkyl ", " aralkoxy " or " aryloxy alkyl " is meant to have monocycle, dicyclo and the three-loop system of 5-14 link altogether, wherein at least one ring in the system be fragrance and system in each encircle and all comprise 3-7 link.Term " aryl " can exchange with term " aromatic ring " and use.Term " aryl " also refers to the heteroaromatic ring system that defines below herein.

Use or be used as major part separately, term " heteroaryl " as a part in " heteroaralkyl " or " heteroaryl alkoxyl group " is meant to have monocycle, dicyclo and the three-loop system of 5-14 link altogether, wherein at least one ring in the system is fragrant, at least one ring in the system comprises one or more heteroatomss, and wherein the ring of each in the system all comprises 3-7 link.Term " heteroaryl " can exchange with term " hetero-aromatic ring " or term " assorted fragrance " and use.

Aryl (comprising aralkyl, aralkoxy, aryloxy alkyl etc.) or heteroaryl (comprising heteroaralkyl and heteroaryl alkoxyl group etc.) can comprise one or more substituting groups, and therefore can be " the optional replacements ".Unless top and have in addition herein definition, the suitable substituting group on the unsaturated carbon atom of aryl or heteroaryl be selected from halogen ,-R ^o,-OR ^o,-SR ^o, use R ^oThe optional phenyl (Ph) that replaces, use R ^oOptional replace-O (Ph), use R ^oOptional replacement-(CH ₂) _1-2(Ph), use R ^oOptional replace-CH=CH (Ph), use R ^oOptional 5-6 unit's heteroaryl or the heterocycle that replaces;-NO ₂-CN;-N (R ^o) ₂-NR ^oC (O) R ^o-NR ^oC (S) R ^o-NR ^oC (O) N (R ^o) ₂-NR ^oC (S) N (R ^o) ₂-NR ^oCO ₂R ^o-NR ^oNR ^oC (O) R ^o-NR ^oNR ^oC (O) N (R ^o) ₂-NR ^oNR ^oCO ₂R ^o-C (O) C (O) R ^o-C (O) CH ₂C (O) R ^o-CO ₂R ^o-C (O) R ^o-C (S) R ^o-C (O) N (R ^o) ₂-C (S) N (R ^o) ₂-OC (O) N (R ^o) ₂-OC (O) R ^o-C (O) N (OR ^o) R ^o-C (NOR ^o) R ^o-S (O ₂) R ^o-S (O ₃) R ^o-SO ₂N (R ^o) ₂-S (O) R ^o-NR ^oSO ₂N (R ^o) ₂-NR ^oSO ₂R ^o-N (OR ^o) R ^o-C (=NH)-N (R ^o) ₂-P (O) ₂R ^o-PO (R ^o) ₂-OPO (R ^o) ₂Or-(CH ₂) _0-2NHC (O) R ^o, each self-existent R wherein ^oBe selected from hydrogen, the optional C that replaces _1-6Aliphatic series, unsubstituted 5-6 unit's heteroaryl or heterocycle, phenyl ,-(O) Ph or-CH ₂(Ph) or, though in the above the definition, two self-existent R on same substituting group or the different substituents ^oWith with each R ^oGroup bonded atom is common to form that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated unit or dicyclo.

R ^oAliphatic group on optional substituting group be selected from NH ₂, NH (C _1-4Aliphatic group), N (C _1-4Aliphatic group) ₂, halogen, C _1-4Aliphatic group, OH, O (C _1-4Aliphatic group), NO ₂, CN, CO ₂H, CO ₂(C _1-4Aliphatic group), O (halo C _1-4Aliphatic group) or halo C _1-4Aliphatic group, wherein R ^oEach aforesaid C _1-4Aliphatic group all is unsubstituted.

Aliphatic series or heterolipid family group, or therefore the heterocycle of non-fragrance can comprise one or more substituting groups and can be " the optional replacement ".Unless top and have definition, the suitable substituting group on the saturated carbon of aliphatic series or heterolipid family group or nonaromatic heterocycles to be selected from listed those of the unsaturated carbon of top aryl or heteroaryl herein in addition, and comprise following in addition :=O ,=S ,=NNHR ^*,=NN (R ^*) ₂,=NNHC (O) R ^*,=NNHCO ₂(alkyl) ,=NNHSO ₂(alkyl) or=NR ^*, each R wherein ^*Independently be selected from hydrogen or the optional C that replaces _1-6Aliphatic group.

Unless top and definition is arranged in addition, the optional substituting group on the nitrogen of nonaromatic heterocycles is selected from-R herein ⁺,-N (R ⁺) ₂,-C (O) R ⁺,-CO ₂R ⁺,-C (O) C (O) R ⁺,-C (O) CH ₂C (O) R ⁺,-SO ₂R ⁺,-SO ₂N (R ⁺) ₂,-C (=S) N (R ^{+ 1}) ₂,-C (=NH)-N (R ⁺) ₂, or-NR ⁺SO ₂R ⁺R wherein ⁺Be hydrogen, the optional C that replaces _1-6Aliphatic group, the optional phenyl that replaces, optional replace-O (Ph), optional replace-CH ₂(Ph), optional replace-(CH ₂) _1-2(Ph), optional replace-CH=CH (Ph) or have 1-4 first heteroaryl of heteroatomic unsubstituted 5-6 or heterocycle that independently is selected from oxygen, nitrogen or sulphur, or, although as top defined, two self-existent R on same substituting group or the different substituents ⁺With with each R ⁺Group bonded atom is common to form that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated unit or dicyclo.

R ⁺Aliphatic group on optional substituting group be selected from-NH ₂,-NH (C _1-4Aliphatic group) ,-N (C _1-4Aliphatic group) ₂, halogen, C _1-4Aliphatic group ,-OH ,-O (C _1-4Aliphatic group) ,-NO ₂,-CN ,-CO ₂H ,-CO ₂(C _1-4Aliphatic group) ,-O (halogen C _1-4Aliphatic group) or halogen C _1-4Aliphatic group, wherein R ⁺Each aforesaid C _1-4Aliphatic group all is unsubstituted.

Term " alkylidene chain " is meant can be fully saturated or have one or more unsaturated units and have the straight or branched carbochain of two points that link to each other with the molecule remainder.

Term used herein " blocking group " is meant the reagent that is used for the one or more required reaction site of temporary interruption polyfunctional compound.In specific embodiments, blocking group have following one or more, or preferred all character:, produce the stable protection substrate of reaction that takes place at one or more other reaction site places a) with selectivity of productive rate reaction preferably; And b) utilize the reagent that can not attack regeneration functional group, productive rate is removed by selectivity preferably.The blocking group of illustrative is at Greene, T.W., Wuts, P.G " blocking group in the organic synthesis ", the third edition, John Wiley﹠amp; Sons describes in detail among the New York:1999, and its full content is introduced herein as a reference.Term used herein " nitrogen-protecting group group " is meant the reagent that is used for the one or more required nitrogen reaction site of temporary interruption polyfunctional compound.Preferred nitrogen-protecting group is rolled into a ball also has top illustrational character, and the nitrogen-protecting group of specific illustrative is rolled into a ball also at Chapter 7 in Greene T.W., Wuts, P.G " blocking group in the organic synthesis ", the third edition, John Wiley﹠amp; Sons describes in detail among the New York:1999, and its full content is introduced herein as a reference.

As mentioned above, in certain embodiments, two self-existent R ^o(or R ⁺, R, R ' or similar definition herein any other variable) can with form with their bonded atoms are common that 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated unit or dicyclo.

Two self-existent R ^o(or R ⁺, R, R ' or similar definition herein any other variable) with and the example of the common ring that forms of each variable bonded atom include, but are not limited to following: a) two self-existent R ^o(or R ⁺, R, R ' or similar definition herein any other variable) combine with same atom, and form ring jointly with this atom, for example, N (R ^o) ₂, wherein existing two R ^oForm piperidines-1-base, piperazine-1-base or morpholine-4-base jointly with nitrogen-atoms; And b) two self-existent R ^o(or R ⁺, R, R ' or similar definition herein any other variable) with different atom combinations, and form ring jointly with those atoms, for example, wherein phenyl is by existing two OR ^o

Replace existing these two R ^oWith form a condensed 6-unit ether ring with their bonded Sauerstoffatoms are common:

。Will be appreciated that, as two self-existent R ^o(or R ⁺, R, R ' or similar definition herein any other variable) when being connected jointly, can form various other rings, and the example of describing in detail is not above thought restriction with each variable bonded atom.

Except as otherwise noted, structure described herein also can comprise all isomerss (for example, enantiomer, diastereomer and geometrical isomer (or conformer)) form of this structure; For example, the R of each asymmetric center and S configuration, double bond isomer (Z) and (E), and (Z) and conformer (E).Therefore, the single stereoisomers of The compounds of this invention and enantiomer, diastereomer and geometrical isomer (or conformer) mixture also falls within the scope of the present invention.Except as otherwise noted, all tautomeric forms of The compounds of this invention all fall within the scope of the present invention.In addition, except as otherwise noted, structure described herein comprises that also difference only is to exist the compound of one or more isotopic enrichment atoms.For example, have just with deuterium or tritium and replace the structure of the present invention of hydrogen, or have just and use ¹³C-or ¹⁴The compound that the carbon of C-enrichment replaces the structure of the present invention of carbon also falls within the scope of the present invention.This compound can be used as analysis tool or the probe in the biological assay.

3. the description of illustrative compound:

As top general describe, R ¹Be T-R ', or-Si (R ') ₃In specific embodiments, when R1 is T-R ', T is the optional C that replaces ₁-C ₆Alkylidene chain, wherein at the most optional the and independent quilt-O-of two methylene units ,-S-,-NR '-,-OCO-,-COO-,-SO ₂-or-CO-replaces, and R ' is hydrogen, C ₁-C ₄Alkyl or the optional 5-that replaces or 6-unit's aryl or heteroaryl.At R ¹Other embodiment in, R ' can also be C ₁-C ₄Aliphatic group.In other embodiments, work as R ¹Be-Si (R ') ₃, R ' is hydrogen, C ₁-C ₄Alkyl or have the 5-of 0-3 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur or 6-unit is saturated, part is unsaturated or complete undersaturated monocycle.In other embodiments, R ¹Be hydrogen, C ₁-C ₄Alkyl ,-COR ' ,-SO ₂R ' or-Si (R ') ₃In other embodiments, R ¹Be hydrogen, methyl, ethyl, just-propyl group, sec.-propyl, just-butyl, ptoluene-sulfonyl (Ts), tert-butyl dimetylsilyl (TBS), triisopropyl silyl (TIPS) or triethylsilyl (TES).R for example ¹Group is yet described in herein the table 1 and 2.

As top general describe, R ², R ³, and R ⁴Independently be halogen, CN, NO separately ₂Or V-R '.In specific embodiments, R ², R ³, and R ⁴Independently be hydrogen, R ', halogen, CN, NO separately ₂,-N (R ') ₂,-CH ₂N (R ') ₂,-OR ' ,-CH ₂OR ' ,-SR ' ,-CH ₂SR ' ,-COOR ' ,-NR ' COR ' ,-CON (R ') ₂,-SO ₂N (R ') ₂,-CONR ' (CH ₂) ₂N (R ') ₂,-CONR ' (CH ₂) ₃N (R ') ₂,-CONR ' (CH ₂) ₄N (R ') ₂,-O (CH ₂) ₂OR ', O (CH ₂) ₃OR ', O (CH ₂) ₄OR ' ,-O (CH ₂) ₂N (R ') ₂,-O (CH ₂) ₃N (R ') ₂, or-O (CH ₂) ₄N (R ') ₂In other embodiments, R ², R ³, and R ⁴Independently be separately Cl, Br, F ,-CN ,-COOH ,-COOMe ,-NH ₂,-N (CH ₃) ₂,-N (Et) ₂,-N (iPr) ₂,-O (CH ₂) ₂OCH ₃,-CONH ₂,-COOCH ₃,-OH ,-CH ₂OH ,-NHCOCH ₃,-SO ₂NH ₂,-SO ₂N (Me) ₂-or the optional group that replaces, be selected from C ₁-C ₄Alkyl, C ₁-C ₄Alkoxyl group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5.In other embodiments, R ², R ³, and R ⁴Each is hydrogen naturally.In other embodiments, R ², R ³, or R ⁴In one be hydrogen.In other embodiments, R ², R ³, or R ⁴In two be hydrogen.In other embodiments, R ²And R ⁴All be hydrogen, and R ³Be halogen, CN, NO ₂, or V-R '.In other embodiments, R ²And R ⁴All be hydrogen, and R ³It is the optional group that replaces, be selected from and have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5.In other embodiments, R ²And R ⁴All be hydrogen, and R ³Be to have the 5-of 0-3 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur or 6-unit is saturated, part is unsaturated or complete unsaturated ring.In other embodiments, R ²And R ⁴All be hydrogen, and R ³Be the optional ring that replaces, be selected from phenyl, pyridyl, pyrimidyl, thiazolyl, oxazolyl, thienyl, furyl, pyrryl, pyrazolyl, triazolyl, pyrazinyl, thiadiazolyl group, Huo oxadiazole base.In other embodiments, work as R ¹, R ²And R ⁴When being H, R so ³It or not the optional phenyl that replaces.In other embodiments, work as R ¹, R ²And R ⁴When being H, R so ³Not aryl, heteroaryl, carbocylic radical or heterocyclic radical.The R of illustrative ², R ³, and R ⁴Group also comprises those that following table 1 and 2 provides.

As mentioned above, R ², R ³, and R ⁴Be optionally substituted separately, and in specific embodiments, R ², R ³, and R ⁴Optional and independent by R ⁶Occur to replace for z time, wherein z is 0-5 and R ⁶Be=O ,=NR " ,=S, halogen ,-CN ,-NO ₂, or Z-R ", wherein Z is valence link or the optional C that replaces ₁-C ₆Alkylidene chain, wherein this chain optional and independent quilt-NR of two methylene units at the most " ,-S-,-O-,-CS-,-CO ₂-,-OCO-,-CO-,-COCO-,-CONR " ,-NR " CO-,-NR " CO ₂-,-SO ₂NR " ,-NR " SO ₂-,-CONR " NR "-,-NR " CONR "-,-OCONR " ,-NR " NR " ,-NR " SO ₂NR " ,-SO-,-SO ₂-,-PO-,-PO ₂-or-each appearance of POR " replace, and R " independently is the C of hydrogen or optional replacement ₁-C ₆Aliphatic group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or R " twice appearance with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.In other embodiments, z is 0,1,2 or 3, and R ⁶Each appearance independently be hydrogen, R " ,-CH ₂R ", halogen, CN, NO ₂,-N (R ") ₂,-CH ₂N (R ") ₂,-OR " ,-CH ₂OR " ,-SR " ,-CH ₂SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ") ₂,-SO ₂N (R ") ₂,-CONR " (CH ₂) ₂N (R ") ₂,-CONR (CH ₂) ₃N (R ") ₂,-CONR " (CH ₂) ₄N (R ") ₂,-O (CH ₂) ₂OR ", O (CH ₂) ₃OR ", O (CH ₂) ₄OR " ,-O (CH ₂) ₂N (R ") ₂,-O (CH ₂) ₃N (R ") ₂,-O (CH ₂) ₄N (R ") ₂,-NR " CH (CH ₂OH) R " ,-NR " CH (CH ₂CH ₂OH) R " ,-NR " (CH ₂) R " ,-NR " (CH ₂) ₂R " ,-NR " (CH ₂) ₃R " ,-NR " (CH ₂) ₄R " ,-NR " (CH ₂) N (R ") ₂,-NR " (CH ₂) ₂N (R ") ₂,-NR " (CH ₂) ₃N (R ") ₂,-NR " (CH ₂) ₄N (R ") ₂,-NR " (CH ₂) OR ", NR " (CH ₂) ₂OR " ,-NR " (CH ₂) ₃OR " or-NR " (CH ₂) ₄OR ".In another embodiment, R ⁶Can also be-NR " CH (CH ₃) R ".In other embodiments, z is 1,2 or 3 and R ⁶Each appearance independently be F, Cl, Br, CN, OH, NH ₂,-CH ₂OH, C ₁-C ₆Alkyl ,-O (C ₁-C ₆Alkyl) ,-CH ₂O (C _l-C ₆Alkyl) ,-CO (Cl-C ₆Alkyl) ,-COO (C ₁-C ₆Alkyl) ,-NHSO ₂(C ₁-C ₆Alkyl) ,-SO ₂NH ₂,-CONH ₂,-CON (C ₁-C ₆Alkyl) ,-SO ₂(C ₁-C ₆Alkyl) ,-SO ₂Phenyl, phenyl, benzyl ,-N (C ₁-C ₆Alkyl) ₂, or-S (C ₁-C ₆Alkyl), wherein aforementioned phenyl, benzyl and C ₁-C ₆Independent separately and optional being substituted of alkyl, and wherein aforementioned C ₁-C ₆Alkyl each straight chain, side chain or cyclic naturally.The R of other illustrative ⁶Group is described in table 1.

As top generality X is described to formula I compound ¹, X ²And X ³Independently be N or CH separately, wherein the hydrogen atom of CH is optional by R ⁵Replace.In specific embodiments, X ¹, X ², or X ³In two be N, and X ¹, X ², or X ³In remaining one be CH, wherein the hydrogen atom of CH is optional by R ⁵Replace.In other particular, X ¹, X ², or X ³In one be N, and X ¹, X ², or X ³In remaining two be CH, wherein the hydrogen atom of CH is optional by R ⁵Replace.In other embodiments, X ¹, X ²And X ³Each is CH naturally, and wherein the hydrogen atom of CH is optional by R ⁵Replace.In other specific illustrative embodiment, compound has among formula I-A, I-B, I-C or the I-D:

In other embodiments, compound has formula I-E:

Describe as top generality to formula I compound, x is 1,2,3 or 4; And R ⁵Each appearance independently be halogen, CN, NO ₂, or U-R ', wherein each appearance of U independently is the C of valence link or optional replacement ₁-C ₆Alkylidene chain, wherein this chain at the most optional the and independent quilt-NR ' of two methylene units-,-S-,-O-,-CS-,-CO ₂-,-OCO-,-CO-,-COCO-,-CONR '-,-NR ' CO-,-NR ' CO ₂-,-SO ₂NR '-,-NR ' SO ₂-,-CONR ' NR '-,-NR ' CONR '-,-OCONR '-,-NR ' NR '-,-NR ' SO ₂NR '-,-SO-,-SO ₂-,-PO-,-PO ₂-or-POR '-replacement; And

The each appearance of R ' independently is hydrogen or the optional C that replaces ₁-C ₆Aliphatic group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.In specific embodiments, R ⁵Each appearance independently be hydrogen, R ' ,-CH ₂R ', halogen, CN, NO ₂,-N (R ') ₂,-CH ₂N (R ') ₂,-OR ' ,-CH ₂OR ' ,-SR ' ,-CH ₂SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' ,-NR ' CO (CH ₂) ₂R ' ,-NR ' COOR ' ,-CON (R ') ₂,-SO ₂N (R ') ₂,-CONR ' (CH ₂) ₂N (R ') ₂,-CONR (CH ₂) ₃N (R ') ₂,-CONR ' (CH ₂) ₄N (R ') ₂,-O (CH ₂) ₂OR ', O (CH ₂) ₃OR ', O (CH ₂) ₄OR ' ,-O (CH ₂) ₂N (R ') ₂,-O (CH ₂) ₃N (R ') ₂,-O (CH ₂) ₄N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' (CH ₂) ₂R ' ,-NR ' (CH ₂) ₃R ' ,-NR ' (CH ₂) ₄R ' ,-NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-NR ' (CH ₂) ₃N (R ') ₂,-NR ' (CH ₂) ₄N (R ') ₂,-NR ' (CH ₂) OR ' ,-NR ' (CH ₂) ₂OR ' ,-NR ' (CH ₂) ₃OR ' or-NR ' (CH ₂) ₄OR '.In specific embodiments, R ⁵Can also be-NR ' CH (CH ₃) R ', NR ' CH (CF ₃) R ' ,-NR ' CH (CH ₃) C (O) OR ' ,-NR ' CH (CF ₃) C (O) OR ' ,-NR ' CH (CH ₂CH ₃) R ' ,-NR ' CH ₂C (O) N (R ') ₂,-NR ' CH (CH ₃) C (O) N (R ') ₂, NR ' CH (CF ₃) C (O) N (R ') ₂,-NR ' CH (CH ₂CH ₃) C (O) N (R ') ₂,-NR ' CH (CH (CH ₃) ₂) C (O) N (R ') ₂, NR ' CH (C (CH ₃) ₃) C (O) N (R ') ₂,-NR ' CH (CH ₂CH (CH ₃) ₂) C (O) N (R ') ₂,-NR ' CH (CH ₂OR ⁹) C (O) N (R ') ₂Or-NR ' CH (CH ₂CH ₂N (Me) ₂) C (O) N (R ') ₂In specific illustrative embodiment, x is 1,2 or 3, and R ⁵at least once occur be-N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' (CH ₂) ₂R ', NR ' (CH ₂) N (R ') ₂, or-NR ' (CH ₂) ₂N (R ') ₂In other embodiments, x is 1,2 or 3, and R ⁵at least once occur be-OR '.In other embodiments, x is 1,2 or 3, and R ⁵At least once to occur be halogen.In other embodiments, x is 1,2 or 3, and R ⁵at least once occur be-NR ' COR ' ,-NR ' COCH ₂R ' ,-NR ' CO (CH ₂) ₂R ' ,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂OMe) R ' ,-NR ' CH (CH ₂OEt) R ' ,-NR ' CH (CH ₂OCF ₃) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OMe) R ' ,-NR ' CH (CH ₂CH ₂OEt) R ' ,-NR ' CH (CH ₂CH ₂OCF ₃) R ' ,-NR ' CH (CH ₃) C (O) OR ' ,-NR ' CH (CF ₃) C (O) OR ' ,-NR ' CH (CH ₃) C (O) N (R ') ₂,-NR ' CH (CF ₃) C (O) N (R ') ₂,-NR ' CH (CH ₂CH ₃) C (O) N (R ') ₂,-NR ' CH (CH ₂OH) C (O) N (R ') ₂,-NR ' CH (CH ₂OMe) C (O) N (R ') ₂,-NR ' CH (CH ₂OEt) C (O) N (R ') ₂Or-NR ' CH (CH ₂OCF ₃) C (O) N (R ') ₂, wherein R ' is the optional C that replaces ₁-C ₄Aliphatic group; NHCH ₂C (O) NHR ' ,-NHCH (CH ₃) C (O) NHR ' ,-NHCH (CH ₂CH ₃) C (O) NHR ' ,-NHCH (CH (CH ₃) ₂) C (O) NHR ' ,-NHCH (C (CH ₃) ₃) C (O) NHR ' ,-NHCH (CH ₂CH (CH ₃) ₂) C (O) NHR ' ,-NHCH (CH ₂OH) C (O) NHR ' ,-NHCH (CH ₂OMe) C (O) NHR ' or-NHCH (CH ₂CH ₂N (Me) ₂) C (O) NHR ', wherein R ' is the optional C that replaces ₁-C ₄Aliphatic group;-NHR ' ,-NH (CH ₂) R ' ,-NH (CH ₂) ₂R ' ,-NHCH (CH ₃) R ' ,-NHCH ₂C (O) NHR ' ,-NHCH (CH ₃) C (O) NHR ' ,-NHCH (CH ₂CH ₃) C (O) NHR ' ,-NHCH (CH (CH ₃) ₂) C (O) NHR ' ,-NHCH (C (CH ₃) ₃) C (O) NHR ' ,-NHCH (CH ₂CH (CH ₃) ₂) C (O) NHR ' ,-NHCH (CH ₂OH) C (O) NHR ' ,-NHCH (CH ₂OMe) C (O) NHR ' or-NHCH (CH ₂CH ₂N (Me) ₂) C (O) NHR ', wherein R ' is the optional C that replaces ₁-C ₄Aliphatic group;-NHCH (CH ₃) R ', wherein R ' is the optional phenyl that replaces; H, halogen, CH ₃, CF ₃, COOH, COOMe or OR ', wherein R ' is C ₁-C ₄Aliphatic group.

In other embodiments, x is 1,2 or 3, and R ⁵At least once to occur be the optional C that replaces ₁-C ₆Aliphatic group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5.

In other embodiments, x is 1 or 2, and R ⁵Each appearance independently be halogen, R ', CN ,-CH ₂CN ,-(CH ₂) ₂CN, NO ₂,-CH ₂NO ₂,-(CH ₂) ₂NO ₂, CON (R ') ₂,-CH ₂CON (R ') ₂,-(CH ₂) ₂CON (R ') ₂, C0OR ' ,-CH ₂COOR ' ,-(CH ₂) ₂COOR ' ,-SO ₂N (R ') ₂,-CH ₂SO ₂N (R ') ₂,-(CH ₂) ₂SO ₂N (R ') ₂,-NR ' SO ₂R ' ,-CH ₂NR ' SO ₂R ' ,-(CH ₂) ₂NR ' SO ₂R ', NR ' CON (R ') ₂,-CH ₂NR ' CON (R ') ₂,-(CH ₂) ₂NR ' CON (R ') ₂,-NR ' SO ₂N (R ') ₂,-CH ₂NR ' SO ₂N (R ') ₂,-(CH ₂) ₂NR ' SO ₂N (R ') ₂,-COCOR ' ,-CH ₂COCOR ' ,-(CH ₂) ₂COCOR ' ,-N (R ') ₂,-CH ₂N (R ') ₂,-(CH ₂) ₂N (R ') ₂,-OR ' ,-CH ₂OR ' ,-(CH ₂) ₂OR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' ,-NR ' CO (CH ₂) ₂R ' ,-CH ₂NR ' COR ' or-(CH ₂) ₂NR ' COR '.In other embodiments, R ⁵Be CN ,-CH ₂CN ,-(CH ₂) ₂CN ,-NO ₂,-CH ₂NO ₂,-(CH ₂) ₂NO ₂, OR ' ,-CH ₂OR ' ,-CON (R ') ₂,-SO ₂N (R ') ₂,-N (R ') ₂, or R '.In other embodiments, R ⁵Each appearance independently be hydrogen, halogen, CN ,-CH ₂CN ,-(CH ₂) ₂CN, NO ₂,-CH ₂NO ₂,-(CH ₂) ₂NO ₂,-CONH ₂,-CON (C ₁-C ₄Alkyl) ,-SO ₂NH ₂,-SO ₂N (C ₁-C ₄Alkyl), NH ₂,-N (C ₁-C ₄Alkyl) ,-OH ,-O (C ₁-C ₄Alkyl) ,-CH ₂OH ,-CH ₂O (C ₁-C ₄Alkyl), or the unsaturated ring of optional 5-that replaces or 6-unit, wherein 0-3 ring carbon atom is optional by oxygen, sulphur or nitrogen replacement.

As top generality R is described with respect to formula I compound ⁵Optional by R ⁷Occur to replace for y time, wherein y is 0-5 and R ⁷Be=O ,=NR " ,=S, halogen ,-CN ,-NO ₂, or W-R ", wherein W is valence link or the optional C that replaces ₁-C ₆Alkylidene chain, wherein this chain optional and independent quilt-NR of two methylene units at the most " ,-S-,-O-,-CS-,-CO ₂-,-OCO-,-CO-,-COCO-,-CONR " ,-NR " CO-,-NR " CO ₂-,-SO ₂NR " ,-NR " SO ₂-,-CONR " NR "-,-NR " CONR "-,-OCONR " ,-NR " NR " ,-NR " SO ₂NR " ,-SO-,-SO ₂-,-PO-,-PO ₂-or-each appearance of POR " replace, and R " independently is the C of hydrogen or optional replacement ₁-C ₆Aliphatic group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or R " twice appearance with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.In other embodiments, y is 0,1,2 or 3, and R ⁷Each appearance independently be hydrogen, R " ,-CH ₂R ", halogen, CN, NO ₂,-N (R ") ₂,-CH ₂N (R ") ₂,-OR " ,-CH ₂OR " ,-SR " ,-CH ₂SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ") ₂,-SO ₂N (R ") ₂,-CONR " (CH ₂) ₂N (R ") ₂,-CONR (CH ₂) ₃N (R ") ₂,-CONR " (CH ₂) ₄N (R ") ₂,-O (CH ₂) ₂OR ", O (CH ₂) ₃OR ", O (CH ₂) ₄OR " ,-O (CH ₂) ₂N (R ") ₂,-O (CH ₂) ₃N (R ") ₂,-O (CH ₂) ₄N (R ") ₂,-NR " CH (CH ₂OH) R " ,-NR " CH (CH ₂CH ₂OH) R " ,-NR " (CH ₂) R " ,-NR " (CH ₂) ₂R " ,-NR " (CH ₂) ₃R " ,-NR " (CH ₂) ₄R " ,-NR " (CH ₂) N (R ") ₂,-NR " (CH ₂) ₂N (R ") ₂,-NR " (CH ₂) ₃N (R ") ₂,-NR " (CH ₂) ₄N (R ") ₂,-NR " (CH ₂) OR " ,-NR " (CH ₂) ₂OR " ,-NR " (CH ₂) ₃OR " or-NR " (CH ₂) ₄OR ".In specific embodiments, R ⁷Can also be-NR ' CH (CH ₃) R '.In other embodiments, y is 1,2 or 3 and R ⁷Each appearance independently be F, Cl, Br, CN, OH, NH ₂,-CH ₂OH, C ₁-C ₆Alkyl ,-O (C ₁-C ₆Alkyl) ,-CH ₂O (C ₁-C ₆Alkyl) ,-CO (C ₁-C ₆Alkyl) ,-COO (C ₁-C ₆Alkyl) ,-NHSO ₂(C ₁-C ₆Alkyl) ,-SO ₂NH ₂,-CONH ₂-,-CON (C ₁-C ₆Alkyl) ,-SO ₂(C ₁-C ₆Alkyl) ,-SO ₂Phenyl, phenyl, benzyl ,-N (C ₁-C ₆Alkyl) ₂,-S (C ₁-C ₆Alkyl), wherein aforementioned phenyl, benzyl and C ₁-C ₆Independent separately and optional being substituted of alkyl, and aforementioned C ₁-C ₆Alkyl each straight chain, side chain or cyclic naturally.The R of other illustrative ⁷Group is described in table 1.

In other embodiments, x is 1,2 or 3; R ⁵at least once occur be-N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' (CH ₂) ₂R ' ,-NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-OR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' or-NR ' CO (CH ₂) ₂R ', and R ' is C ₁-C ₆Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R ⁷Occur to replace for y time.In specific embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₆Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R ⁷Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₄Alkyl, or ring are selected from:

Wherein y and R ⁷Describe in general in the above description and the subgroup.

In another embodiment, R ' can be

In other embodiments, R ⁵Be-N (R ') ₂And twice appearance of R ' and and common 3-10 unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from:

The specific subgroup of other of compound of Formula I comprises:

1. the compound of formula I-A:

R wherein ¹, R ², R ³, R ⁴, R ⁵With x superincumbent separately general describe and subgroup top and described herein in describe.

In certain embodiments, with regard to the compound of formula I-A:

A.R ¹Be:

I.T-R ', wherein T is valence link or the optional C that replaces ₁-C ₆Alkylidene chain, wherein at the most optional the and independent quilt-O-of two methylene units ,-S-,-NR '-,-OCO-,-COO-,-SO ₂-or-CO-replaces, and R ' is hydrogen, C ₁-C ₄Alkyl or the optional 5-that replaces or 6-unit's aryl or heteroaryl, or

Ii.-Si (R ') ₃, wherein R ' is hydrogen, C ₁-C ₄Alkyl or have the 5-of 0-3 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur or 6-unit is saturated, part is unsaturated or complete undersaturated monocycle;

B.R ², R ³, and R ⁴Independently be hydrogen, R ', halogen, CN, NO separately ₂,-N (R ') ₂,-CH ₂N (R ') ₂,-OR ' ,-CH ₂OR ' ,-SR ' ,-CH ₂SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' ,-NR ' CO (CH ₂) ₂R ' ,-CON (R ') ₂,-SO ₂N (R ') ₂,-CONR ' (CH ₂) ₂N (R ') ₂,-CONR ' (CH ₂) ₃N (R ') ₂,-CONR ' (CH ₂) ₄N (R ') ₂,-O (CH ₂) ₂OR ', O (CH ₂) ₃OR ', O (CH ₂) ₄OR ' ,-O (CH ₂) ₂N (R ') ₂,-O (CH ₂) ₃N (R ') ₂, or-O (CH ₂) ₄N (R ') ₂R wherein ², R ³, and R ⁴Optional separately by R ⁶Occur to replace for z time, wherein z is 0-5 and R ⁶Be=O ,=NR " ,=S, halogen ,-CN ,-NO ₂, or Z-R ", wherein Z is valence link or the optional C that replaces ₁-C ₆Alkylidene chain, wherein this chain optional and independent quilt-NR of two methylene units at the most " ,-S-,-O-,-CS-,-CO ₂-,-OCO-,-CO-,-COCO-,-CONR " ,-NR " CO-,-NR " CO ₂-,-SO ₂NR " ,-NR " SO ₂-,-CONR " NR "-,-NR " CONR "-,-OCONR " ,-NR " NR " ,-NR " SO ₂NR " ,-SO-,-SO ₂-,-PO-,-PO ₂-or-each appearance of POR " replace, and R " independently is the C of hydrogen or optional replacement ₁-C ₆Aliphatic group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or R " twice appearance with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.

C.R ⁵Each appearance independently be hydrogen, R ' ,-CH ₂R ', halogen, CN, NO ₂,-N (R ') ₂,-CH ₂N (R ') ₂,-OR ' ,-CH ₂OR ' ,-SR ' ,-CH ₂SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' ,-NR ' CO (CH ₂) ₂R ' ,-NR ' COOR ' ,-CON (R ') ₂,-SO ₂N (R ') ₂,-CONR ' (CH ₂) ₂N (R ') ₂,-CONR (CH ₂) ₃N (R ') ₂,-CONR ' (CH ₂) ₄N (R ') ₂,-O (CH ₂) ₂OR ', O (CH ₂) ₃OR ', O (CH ₂) ₄OR ' ,-O (CH ₂) ₂N (R ') ₂,-O (CH ₂) ₃N (R ') ₂,-O (CH ₂) ₄N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' (CH ₂) ₂R ' ,-NR ' (CH ₂) ₃R ' ,-NR ' (CH ₂) ₄R ' ,-NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-NR ' (CH ₂) ₃N (R ') ₂,-NR ' (CH ₂) ₄N (R ') ₂,-NR ' (CH ₂) OR ' ,-NR ' (CH ₂) ₂OR ' ,-NR ' (CH ₂) ₃OR ' or-NR ' (CH ₂) ₄OR ', wherein R ⁵Optional by R ⁷Occur to replace for y time, wherein y is 0-5 and R ⁷Be=O ,=NR " ,=S, halogen ,-CN ,-NO ₂, or W-R ", wherein W is valence link or the optional C that replaces ₁-C ₆Alkylidene chain, wherein this chain optional and independent quilt-NR of two methylene units at the most " ,-S-,-O-,-CS-,-CO ₂-,-OCO-,-CO-,-COCO-,-CONR " ,-NR " CO-,-NR " CO ₂-,-SO ₂NR " ,-NR " SO ₂-,-CONR " NR "-,-NR " CONR "-,-OCONR " ,-NR " NR " ,-NR " SO ₂NR " ,-SO-,-SO ₂-,-PO-,-PO ₂-or-each appearance of POR " replace, and R " independently is the C of hydrogen or optional replacement ₁-C ₆Aliphatic group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or R " twice appearance with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.

In other embodiments, with regard to the compound of formula I-A:

A.R ¹Be hydrogen, C ₁-C ₄Alkyl ,-COR ' ,-SO ₂R ' or-Si (R ') ₃

B.R ², R ³, and R ⁴Independently be separately Cl, Br, F ,-CN ,-COOH ,-COOMe ,-NH ₂,-N (CH ₃) ₂,-N (Et) ₂,-N (iPr) ₂,-O (CH ₂) ₂OCH ₃,-CONH ₂,-COOCH ₃,-OH ,-CH ₂OH ,-NHCOCH ₃,-SO ₂NH ₂,-SO ₂N (Me) ₂-or the optional group that replaces, be selected from C ₁-C ₄Alkyl, C ₁-C ₄Alkoxyl group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; R wherein ², R ³, and R ⁴Independent separately and optional by R ⁶Occur to replace for z time, wherein z is 0,1,2 or 3, and R ⁶Each appearance independently be hydrogen, R " ,-CH ₂R ", halogen, CN, NO ₂,-N (R ") ₂,-CON (R ") ₂,-OR " ,-CH ₂OR " ,-SR " ,-CH ₂SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CH ₂N (R ") ₂,-SO ₂N (R ") ₂,-CONR " (CH ₂) ₂N (R ") ₂,-CONR (CH ₂) ₃N (R ") ₂,-CONR " (CH ₂) ₄N (R ") ₂,-O (CH ₂) ₂OR ", O (CH ₂) ₃OR ", O (CH ₂) ₄OR " ,-O (CH ₂) ₂N (R ") ₂,-O (CH ₂) ₃N (R ") ₂,-O (CH ₂) ₄N (R ") ₂,-NR " CH (CH ₂OH) R " ,-NR " CH (CH ₂CH ₂OH) R " ,-NR " (CH ₂) R " ,-NR " (CH ₂) ₂R " ,-NR " (CH ₂) ₃R " ,-NR " (CH ₂) ₄R " ,-NR " (CH ₂) N (R ") ₂,-NR " (CH ₂) ₂N (R ") ₂,-NR " (CH ₂) ₃N (R ") ₂,-NR " (CH ₂) ₄N (R ") ₂,-NR " (CH ₂) OR ", NR " (CH ₂) ₂OR " ,-NR " (CH ₂) ₃OR " or-NR " (CH ₂) ₄OR ";

C.R ⁵Each appearance independently be hydrogen, R ' ,-CH ₂R ', halogen, CN, NO ₂,-N (R ') ₂,-CH ₂N (R ') ₂,-OR ' ,-CH ₂OR ' ,-SR ' ,-CH ₂SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' ,-NR ' CO (CH ₂) ₂R ' ,-NR ' COOR ' ,-CON (R ') ₂,-SO ₂N (R ') ₂,-CONR ' (CH ₂) ₂N (R ') ₂,-CONR (CH ₂) ₃N (R ') ₂,-CONR ' (CH ₂) ₄N (R ') ₂,-O (CH ₂) ₂OR ', O (CH ₂) ₃OR ', O (CH ₂) ₄OR ' ,-O (CH ₂) ₂N (R ') ₂,-O (CH ₂) ₃N (R ') ₂,-O (CH ₂) ₄N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' (CH ₂) ₂R ' ,-NR ' (CH ₂) ₃R ' ,-NR ' (CH ₂) ₄R ' ,-NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-NR ' (CH ₂) ₃N (R ') ₂,-NR ' (CH ₂) ₄N (R ') ₂,-NR ' (CH ₂) OR ' ,-NR ' (CH ₂) ₂OR ' ,-NR ' (CH ₂) ₃OR ' or-NR ' (CH ₂) ₄OR ', wherein R ⁵Optional by R ⁷Occur to replace for y time, wherein y is 0,1,2 or 3, and R ⁷Each appearance independently be hydrogen, R " ,-CH ₂R ", halogen, CN, NO ₂,-N (R ") ₂,-CH ₂N (R ") ₂,-OR " ,-CH ₂OR " ,-SR " ,-CH ₂SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ") ₂,-SO ₂N (R ") ₂,-CONR " (CH ₂) ₂N (R ") ₂,-CONR (CH ₂) ₃N (R ") ₂,-CONR " (CH ₂) ₄N (R ") ₂,-O (CH ₂) ₂OR ", O (CH ₂) ₃OR ", O (CH ₂) ₄OR " ,-O (CH ₂) ₂N (R ") ₂,-O (CH ₂) ₃N (R ") ₂,-O (CH ₂) ₄N (R ") ₂,-NR " CH (CH ₂OH) R " ,-NR " CH (CH ₂CH ₂OH) R " ,-NR " (CH ₂) R " ,-NR " (CH ₂) ₂R " ,-NR " (CH ₂) ₃R " ,-NR " (CH ₂) ₄R " ,-NR " (CH ₂) N (R ") ₂,-NR " (CH ₂) ₂N (R ") ₂,-NR " (CH ₂) ₃N (R ") ₂,-NR " (CH ₂) ₄N (R ") ₂,-NR " (CH ₂) OR " ,-NR " (CH ₂) ₂OR " ,-NR " (CH ₂) ₃OR " or-NR " (CH ₂) ₄OR ".

In other embodiments, with regard to the compound of the subgroup of formula I-A and top direct description, R ¹Be hydrogen, methyl, ethyl, just-propyl group, sec.-propyl, just-butyl, ptoluene-sulfonyl (Ts), tert-butyl dimetylsilyl (TBS), triisopropyl silyl (TIPS) or triethylsilyl (TES).

In other embodiments, with regard to the compound of the subgroup of formula I-A and top direct description, R ², R ³, and R ⁴Each is hydrogen naturally.In other embodiments, R ², R ³, or R ⁴In one be hydrogen.In other embodiments, R ², R ³, or R ⁴In two be hydrogen.In other embodiments, R ²And R ⁴All be hydrogen, and R ³Be halogen, CN, NO ₂, or V-R '.In other embodiments, R ²And R ⁴All be hydrogen, and R ³It is the optional group that replaces, be selected from and have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5.In other embodiments, R ²And R ⁴All be hydrogen, and R ³Be to have the 5-of 0-3 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur or 6-unit is saturated, part is unsaturated or complete unsaturated ring.In other embodiments, R ²And R ⁴All be hydrogen, and R ³Be the optional ring that replaces, be selected from phenyl, pyridyl, pyrimidyl, thiazolyl, oxazolyl, thienyl, furyl, pyrryl, pyrazolyl, triazolyl, pyrazinyl, thiadiazolyl group, Huo oxadiazole base.In other embodiments, R ³Be selected from H, Cl, Br, F ,-CN ,-COOH ,-COOMe ,-NH ₂,-N (R ') ₂,-NO ₂,-OR ' ,-CON (R ') ₂,-COOR ' ,-OH ,-SR ' ,-C (R ') ₂OR ' ,-N (R ') COR ' ,-N (R ') C (O) OR ' ,-SO ₂NH ₂,-SO ₂N (R ') ₂Or the optional group that replaces, be selected from C ₁-C ₄Aliphatic group, C ₁-C ₄Alkoxyl group or-C=C-C ₁-C ₄Aliphatic group.In further embodiment, R ²And R ⁴All be hydrogen and R ³Directly be selected from the tabulation of front.

In other embodiments, with regard to the compound of the subgroup of formula I-A and top direct description, R ², R ³, and R ⁴Independent separately and optional by R ⁶Occur to replace for z time, wherein z is 1,2 or 3 and R ⁶Each appearance independently be F, Cl, Br, CN, OH, NH ₂,-CH ₂OH, C ₁-C ₆Alkyl ,-O (C ₁-C ₆Alkyl) ,-CH ₂O (Cl-C ₆Alkyl) ,-CO (Cl-C ₆Alkyl) ,-COO (C ₁-C ₆Alkyl) ,-NHSO ₂(C ₁-C ₆Alkyl) ,-SO ₂NH ₂,-CONH ₂,-CON (C ₁-C ₆Alkyl) ,-SO ₂(C ₁-C ₆Alkyl) ,-SO ₂Phenyl, phenyl, benzyl ,-N (C ₁-C ₆Alkyl) ₂, or-S (C ₁-C ₆Alkyl), wherein aforementioned phenyl, benzyl and C ₁-C ₆Independent separately and optional being substituted of alkyl, and wherein aforementioned C ₁-C ₆Alkyl each straight chain, side chain or cyclic naturally.

In specific illustrative embodiment, with regard to the compound of the subgroup of formula I-A and top direct description, x is 1,2 or 3, and R ⁵at least once occur be-N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' (CH ₂) ₂R ', NR ' (CH ₂) N (R ') ₂, or-NR ' (CH ₂) ₂N (R ') ₂In other embodiments, x is 1,2 or 3, and R ⁵at least once occur be-OR '.In other embodiments, x is 1,2 or 3, and R ⁵at least once occur be-NR ' COR ' ,-NR ' COCH ₂R ' or-NR ' CO (CH ₂) ₂R '.In other embodiments, x is 1,2 or 3, and R ⁵At least once to occur be the optional C that replaces ₁-C ₆Aliphatic group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5.

In other embodiments, with regard to the compound of the subgroup of formula I-A and top direct description, R ⁵Optional by R ⁷Occur to replace for y time, wherein y is 1,2 or 3 and R ⁷Each appearance independently be F, Cl, Br, CN, OH, NH ₂,-CH ₂OH, C ₁-C ₆Alkyl ,-O (C ₁-C ₆Alkyl) ,-CH ₂O (C ₁-C ₆Alkyl) ,-CO (C ₁-C ₆Alkyl) ,-COO (C ₁-C ₆Alkyl) ,-NHSO ₂(C ₁-C ₆Alkyl) ,-SO ₂NH ₂,-CONH ₂-,-CON (C ₁-C ₆Alkyl) ,-SO ₂(C ₁-C ₆Alkyl) ,-SO ₂Phenyl, phenyl, benzyl ,-N (C ₁-C ₆Alkyl) ₂,-S (C ₁-C ₆Alkyl), wherein aforementioned phenyl, benzyl and C ₁-C ₆Independent separately and optional being substituted of alkyl, and aforementioned C ₁-C ₆Alkyl each straight chain, side chain or cyclic naturally.In other embodiments, with regard to the compound of the subgroup of formula I-A and top direct description, x is 1,2 or 3; R ⁵at least once occur be-N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' (CH ₂) ₂R ' ,-NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-OR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' or-NR ' CO (CH ₂) ₂R ', and R ' is C ₁-C ₆Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R ⁷Occur to replace for y time.In specific embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₆Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R ⁷Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₄Alkyl, or be selected from top described (i)-(X ¹Vi) or (X ¹Ring vii).In other embodiments, R ⁵Be-N (R ') ₂And twice appearance of R ' and and common 3-10-unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from (a)-(o) recited above.

In other embodiments, x be 1 and compound have general formula I-A-i:

R wherein ¹, R ², R ³, and R ⁴Reach herein in general in the above description and the top subgroup and describe, and R ⁵Be-N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' (CH ₂) ₂R ', NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-OR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' or-NR ' CO (CH ₂) ₂R '; And R ' is C ₁-C ₆Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R ⁷Occur to replace for y time.In certain embodiments, R ⁵Be N (R ') ₂In specific embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₆Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R ⁷Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₄Alkyl, or be selected from top described (i)-(X ¹Vi) or (X ¹Ring vii).In other embodiments, R ⁵Be-N (R ') ₂And twice appearance of R ' and and common 3-10-unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from (a)-(o) recited above.

In other embodiments, x is 1 and has the compound of general formula I-A-ii:

R wherein ¹, R ², R ³, and R ⁴Generality describe and above in the subgroup and description herein, and R ⁵Be-N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' (CH ₂) ₂R ', NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-OR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' or-NR ' CO (CH ₂) ₂R '; And R ' is C ₁-C ₆Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R ⁷Occur to replace for y time.In certain embodiments, R ⁵Be N (R ') ₂In specific embodiments, with regard to top described each subgroup, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₆Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R ⁷Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₄Alkyl, or be selected from top described (i)-(X ¹Vi) or (X ¹Ring vii).In other embodiments, R ⁵Be-N (R ') ₂And twice appearance of R ' and and common 3-10-unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from (a)-(o) recited above.

In other embodiments, R ¹, R ², R ³And R ⁴Each is hydrogen naturally, and formula I-A-iii is provided compound:

Wherein x is 1,2 or 3; And R ⁵at least once occur be-N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' (CH ₂) ₂R ', NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-OR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' or-NR ' CO (CH ₂) ₂R '; And R ' is optional by R ⁷The C that occur to replace for y time ₁-C ₆Aliphatic group, or be selected from top described (i)-(X ¹Vi) or (X ¹Ring vii).In other embodiments, R ⁵Be-N (R ') ₂And twice appearance of R ' and and common 3-10-unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from (a)-(o) recited above.

In other embodiments, R ¹, R ², R ³, and R ⁴Each hydrogen naturally, and x is 1, and the compound of formula I-A-iv is provided:

R wherein ⁵Be-N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' (CH ₂) ₂R ', NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-OR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' or-NR ' CO (CH ₂) ₂R '; And R ' is optional by R ⁷The C that occur to replace for y time ₁-C ₆Aliphatic group, or be selected from top described (i)-(X ¹Vi) or (X ¹Ring vii).In other embodiments, R ⁵Be-N (R ') ₂And twice appearance of R ' and and common 3-10-unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from (a)-(o) recited above.

In other embodiments, R ¹, R ², R ³, and R ⁴Each is hydrogen naturally, and x is 1, and the compound of formula I-A-v is provided:

In other embodiments, R ¹, R ², and R ⁴Each is hydrogen naturally, and the compound of formula I-A-vi is provided:

Wherein:

R ³Be to have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; X is 1,2 or 3; And R ⁵at least once occur be-N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' (CH ₂) ₂R ', NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-OR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' or-NR ' CO (CH ₂) ₂R '; And R ' is optional by R ⁷The C that occur to replace for y time ₁-C ₆Aliphatic group, or be selected from top described (i)-(X ¹Vi) or (X ¹Ring vii).In other embodiments, R ⁵Be-N (R ') ₂And twice appearance of R ' and and common 3-10-unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from (a)-(o) recited above.

In other embodiments, with regard to the compound of top direct description, R ³Be to have the 5-of 0-3 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur or 6-unit is saturated, part is unsaturated or complete undersaturated ring.In other embodiments, R ³Be the optional ring that replaces, be selected from phenyl, pyridyl, pyrimidyl, thiazolyl, oxazolyl, thienyl, furyl, pyrryl, pyrazolyl, triazolyl, pyrazinyl, thiadiazolyl group, Huo oxadiazole base.As top general description, R ³Optional by R ⁶Occur to replace for z time.In specific embodiments, wherein z is 0,1,2 or 3, and R ⁶Each appearance independently be hydrogen, R " ,-CH ₂R ", halogen, CN, NO ₂,-N (R ") ₂,-CH ₂N (R ") ₂,-OR " ,-CH ₂OR " ,-SR " ,-CH ₂SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ") ₂,-SO ₂N (R ") ₂,-CONR " (CH ₂) ₂N (R ") ₂,-CONR (CH ₂) ₃N (R ") ₂,-CONR " (CH ₂) ₄N (R ") ₂,-O (CH ₂) ₂OR ", O (CH ₂) ₃OR ", O (CH ₂) ₄OR " ,-O (CH ₂) ₂N (R ") ₂,-O (CH ₂) ₃N (R ") ₂,-O (CH ₂) ₄N (R ") ₂,-NR " CH (CH ₂OH) R " ,-NR " CH (CH ₂CH ₂OH) R " ,-NR " (CH ₂) R " ,-NR " (CH ₂) ₂R " ,-NR " (CH ₂) ₃R " ,-NR " (CH ₂) ₄R " ,-NR " (CH ₂) N (R ") ₂,-NR " (CH ₂) ₂N (R ") ₂,-NR " (CH ₂) ₃N (R ") ₂,-NR " (CH ₂) ₄N (R ") ₂,-NR " (CH ₂) OR ", NR " (CH ₂) ₂OR " ,-NR " (CH ₂) ₃OR " or-NR " (CH ₂) ₄OR ".

In other embodiments, R ¹, R ², R ³And R ⁴Each is hydrogen naturally, and x is 1, and the compound of formula I-A-vii is provided:

Wherein:

R ³It is the optional group that replaces, be selected from and have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; R ⁵Be-N (R ') ₂,-NR " CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' (CH ₂) ₂R ', NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-OR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' or-NR ' CO (CH ₂) ₂R '; And R ' is optional by R ⁷The C that occur to replace for y time ₁-C ₆Aliphatic group, or be selected from top described (i)-(X ¹Vi) or (X ¹Ring vii).In other embodiments, R ⁵Be-N (R ') ₂And twice appearance of R ' and and common 3-10-unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from (a)-(o) recited above.

In other embodiments, with regard to the compound of top direct description, R ³Be to have the 5-of 0-3 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur or 6-unit is saturated, part is unsaturated or complete undersaturated ring.In other embodiments, R ³Be the optional ring that replaces, be selected from phenyl, pyridyl, pyrimidyl, thiazolyl, oxazolyl, thienyl, furyl, pyrryl, pyrazolyl, triazolyl, pyrazinyl, thiadiazolyl group, Huo oxadiazole base.As top general description, R ³Optional by R ⁶Occur to replace for z time.In specific embodiments, wherein z is 0,1,2 or 3, and R ⁶Each appearance independently be hydrogen, R " ,-CH ₂R ", halogen, CN, NO ₂,-N (R ") ₂,-CH ₂N (R ") ₂,-OR " ,-CH ₂OR " ,-SR " ,-CH ₂SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ") ₂,-SO ₂N (R ") ₂,-CONR " (CH ₂) ₂N (R ") ₂,-CONR (CH ₂) ₃N (R ") ₂,-CONR " (CH ₂) ₄N (R ") ₂,-O (CH ₂) ₂OR ", O (CH ₂) ₃OR ", O (CH ₂) ₄OR " ,-O (CH ₂) ₂N (R ") ₂,-O (CH ₂) ₃N (R ") ₂,-O (CH ₂) ₄N (R ") ₂,-NR " CH (CH ₂OH) R " ,-NR " CH (CH ₂CH ₂OH) R " ,-NR " (CH ₂) R " ,-NR " (CH ₂) ₂R " ,-NR " (CH ₂) ₃R " ,-NR " (CH ₂) ₄R " ,-NR " (CH ₂) N (R ") ₂,-NR " (CH ₂) ₂N (R ") ₂,-NR " (CH ₂) ₃N (R ") ₂,-NR " (CH ₂) ₄N (R ") ₂,-NR " (CH ₂) OR " ,-NR " (CH ₂) ₂OR " ,-NR " (CH ₂) ₃OR " or-NR " (CH ₂) ₄OR ".

In other embodiments, R ¹, R ², R ³And R ⁴Each is hydrogen naturally, and x is 1, and the compound of formula I-A-viii is provided:

Wherein:

R ³It is the optional group that replaces, be selected from and have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; R ⁵Be-N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' (CH ₂) ₂R ', NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-OR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' or-NR ' CO (CH ₂) ₂R '; And R ' is optional by R ⁷The C that occur to replace for y time ₁-C ₆Aliphatic group, or be selected from top described (i)-(X ¹Vi) or (X ¹Ring vii).In other embodiments, R ⁵Be-N (R ') ₂And twice appearance of R ' and and common 3-10-unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from (a)-(o) recited above.

The specific subgroup of other of compound of Formula I comprises:

II. the compound of formula I-C

R wherein ¹, R ², R ³, R ⁴, R ⁵With x general in the above separately describe and subgroup in and description herein.

In certain embodiments, with regard to the compound of formula I-C:

A.R ¹Be:

B.R ², R ³, and R ⁴Independently be hydrogen, R ', halogen, CN, NO separately ₂,-N (R ') ₂,-CH ₂N (R ') ₂,-OR ' ,-CH ₂OR ' ,-SR ' ,-CH ₂SR ' ,-COOR ' ,-NR ' COR ' ,-CON (R ') ₂,-SO ₂N (R ') ₂,-CONR ' (CH ₂) ₂N (R ') ₂,-CONR ' (CH ₂) ₃N (R ') ₂,-CONR ' (CH ₂) ₄N (R ') ₂,-O (CH ₂) ₂OR ', O (CH ₂) ₃OR ', O (CH ₂) ₄OR ' ,-O (CH ₂) ₂N (R ') ₂,-O (CH ₂) ₃N (R ') ₂, or-O (CH ₂) ₄N (R ') ₂R wherein ², R ³, and R ⁴Optional separately by R ⁶Occur to replace for z time, wherein z is 0-5 and R ⁶Be=O ,=NR " ,=S, halogen ,-CN ,-NO ₂, or Z-R ", wherein Z is valence link or the optional C that replaces ₁-C ₆Alkylidene chain, wherein this chain optional and independent quilt-NR of two methylene units at the most " ,-S-,-O-,-CS-,-CO ₂-,-OCO-,-CO-,-COCO-,-CONR " ,-NR " CO-,-NR " CO ₂-,-SO ₂NR " ,-NR " SO ₂-,-CONR " NR "-,-NR " CONR "-,-OCONR " ,-NR " NR " ,-NR " SO ₂NR " ,-SO-,-SO ₂-,-PO-,-PO ₂-or-each appearance of POR " replace, and R " independently is the C of hydrogen or optional replacement ₁-C ₆Aliphatic group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or R " twice appearance with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.

C.R ⁵Each appearance independently be hydrogen, halogen, R ', CN ,-CH ₂CN ,-(CH ₂) ₂CN, NO ₂,-CH ₂NO ₂,-(CH ₂) ₂NO ₂, CON (R ') ₂,-CH ₂CON (R ') ₂,-(CH ₂) ₂CON (R ') ₂, COOR ' ,-CH ₂COOR ' ,-(CH ₂) ₂COOR ' ,-SO ₂N (R ') ₂,-CH ₂SO ₂N (R ') ₂,-(CH ₂) ₂SO ₂N (R ') ₂,-NR ' SO ₂R ' ,-CH ₂NR ' SO ₂R ' ,-(CH ₂) ₂NR ' SO ₂R ', NR ' CON (R ') ₂,-CH ₂NR ' CON (R ') ₂,-(CH ₂) ₂NR ' CON (R ') ₂,-NR ' SO ₂N (R ') ₂,-CH ₂NR ' SO ₂N (R ') ₂,-(CH ₂) ₂NR ' SO ₂N (R ') ₂,-COCOR ' ,-CH ₂COCOR ' ,-(CH ₂) ₂COCOR ' ,-N (R ') ₂,-CH ₂N (R ') ₂,-(CH ₂) ₂N (R ') ₂,-OR ' ,-CH ₂OR ' ,-(CH ₂) ₂OR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' ,-NR ' CO (CH ₂) ₂R ' ,-CH ₂NR ' COR ' or-(CH ₂) ₂NR ' COR ', wherein R ⁵Optional by R ⁷Occur to replace for y time, wherein y is 0-5 and R ⁷Be=0 ,=NR " ,=S, halogen ,-CN ,-NO ₂, or W-R ', wherein W is valence link or the optional C that replaces ₁-C ₆Alkylidene chain, wherein this chain optional and independent quilt-NR of two methylene units at the most " ,-S-,-O-,-CS-,-CO ₂-,-OCO-,-CO-,-COCO-,-CONR " ,-NR " CO-,-NR " CO ₂-,-SO ₂NR " ,-NR " SO ₂-,-CONR " NR "-,-NR " CONR "-,-OCONR " ,-NR " NR " ,-NR " SO ₂NR " ,-SO-,-SO ₂-,-PO-,-PO ₂-or-each appearance of POR " replace, and R " independently is the C of hydrogen or optional replacement ₁-C ₆Aliphatic group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or R " twice appearance with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.

In other embodiment, with regard to the compound of formula I-C:

A.R ¹Be hydrogen, C ₁-C ₄Alkyl ,-COR ' ,-SO ₂R ' or-Si (R ') ₃

B.R ², R ³, and R ⁴Independently be separately Cl, Br, F ,-CN ,-COOH ,-COOMe ,-NH ₂,-N (CH ₃) ₂,-N (Et) ₂,-N (iPr) ₂,-O (CH ₂) ₂OCH ₃,-CONH ₂,-COOCH ₃,-OH ,-CH ₂OH ,-NHCOCH ₃,-SO ₂NH ₂,-

-SO ₂N (Me) ₂, or the optional following groups that replaces, be selected from: C ₁-C ₄Alkyl, C ₁-C ₄Alkane is fluorine-based, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5;

R wherein ², R ³, and R ⁴Optional separately by R ⁶Occur to replace for z time, wherein z is 0,1,2 or 3, and R ⁶Each appearance independently be hydrogen.CN，NO ₂，-N(R”) ₂，-CH ₂N(R”) ₂，-OR”，-CH ₂OR”，-SR”，-CH ₂SR”，-COOR”，-NR”COR”，-NR”COOR”，-CON(R”) ₂，-SO ₂N(R”) ₂，-CONR”(CH ₂) ₂N(R”) ₂，-CONR(CH ₂) ₃N(R”) ₂，-CONR”(CH ₂) ₄N(R”) ₂，-O(CH ₂) ₂OR”，O(CH ₂) ₃OR”，O(CH ₂) ₄OR”，-O(CH ₂) ₂N(R”) ₂，-O(CH ₂) ₃N(R”) ₂，-O(CH ₂) ₄N(R”) ₂，-NR”CH(CH ₂OH)R”，-NR”CH(CH ₂CH ₂OH)R”，-NR”(CH ₂)R”，-NR”(CH ₂) ₂R”，-NR”(CH ₂) ₃R”，-NR”(CH ₂) ₄R”，-NR”(CH ₂)N(R”) ₂，-NR”(CH ₂) ₂N(R”) ₂，-NR”(CH ₂) ₃N(R”) ₂，-NR”(CH ₂) ₄N(R”) ₂，-NR”(CH ₂)OR”，-NR”(CH ₂) ₂OR”，-NR”(CH ₂) ₃OR”，or-NR’(CH ₂) ₄OR”；

The heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5;

R wherein ⁵Optional by R ⁷Occur to replace for y time, wherein y is 0,1,2 or 3, and R ⁷Each appearance independently be hydrogen, R " ,-CH ₂R ", halogen,

CN，NO ₂，-N(R”) ₂，-CH ₂N(R”) ₂，-OR”，-CH ₂OR”，-SR”，-CH ₂SR”，-COOR”，-NR”COR”，-NR”COOR”，-CON(R”) ₂，-SO ₂N(R”) ₂，-CONR”(CH ₂) ₂N(R”) ₂，-CONR(CH ₂) ₃N(R”) ₂，-CONR”(CH ₂) ₄N(R”) ₂，-O(CH ₂) ₂OR”，O(CH ₂) ₃OR”，O(CH ₂) ₄OR”，-O(CH ₂) ₂N(R”) ₂，-O(CH ₂) ₃N(R”) ₂，-O(CH ₂) ₄N(R”) ₂，-NR”CH(CH ₂OH)R”，-NR”CH(CH ₂CH ₂OH)R”，-NR”(CH ₂)R”，-NR”(CH ₂) ₂R”，-NR”(CH ₂) ₃R”，-NR”(CH ₂) ₄R”，-NR”(CH ₂)N(R”) ₂，-NR”(CH ₂) ₂N(R”) ₂，-NR”(CH ₂) ₃N(R”) ₂，-NR”(CH ₂) ₄N(R”) ₂，-NR”(CH ₂)OR”，-NR”(CH ₂) ₂OR”，-NR”(CH ₂) ₃OR”，or-NR”(CH ₂) ₄OR”.

In other embodiments, with regard to the compound of the subgroup of formula I-C and top direct description, R ¹Be hydrogen, methyl, ethyl, just-propyl group, sec.-propyl, just-butyl, ptoluene-sulfonyl (Ts), tert-butyl dimetylsilyl (TBS), triisopropyl silyl (TIPS) or triethylsilyl (TES).

In other embodiments, with regard to the compound of the subgroup of formula I-C and top direct description, R ², R ³, and R ⁴Each is hydrogen naturally.In other embodiments, R ², R ³, or R ⁴In one be hydrogen.In other embodiments, R ², R ³, or R ⁴In two be hydrogen.In other embodiments, R ²And R ⁴All be hydrogen, and R ³Be halogen, CN, NO ₂, or V-R '.In other embodiments, R ²And R ⁴All be hydrogen, and R ³It is the optional group that replaces, be selected from and have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5.In other embodiments, R ²And R ⁴All be hydrogen, and R ³Be to have the 5-of 0-3 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur or 6-unit is saturated, part is unsaturated or complete unsaturated ring.In other embodiments, R ²And R ⁴All be hydrogen, and R ³Be the optional ring that replaces, be selected from phenyl, pyridyl, pyrimidyl, thiazolyl, oxazolyl, thienyl, furyl, pyrryl, pyrazolyl, triazolyl, pyrazinyl, thiadiazolyl group, Huo oxadiazole base.

In other embodiments, with regard to the compound of the subgroup of formula I-C and top direct description, R ², R ³, and R ⁴Independent separately and optional by R ⁶Occur to replace for z time, wherein z is 1,2 or 3 and R ⁶Each appearance independently be F, Cl, Br, CN, OH, NH ₂,-CH ₂OH, C ₁-C ₆Alkyl ,-O (C ₁-C ₆Alkyl) ,-CH ₂O (Cl-C ₆Alkyl) ,-CO (Cl-C ₆Alkyl) ,-COO (C ₁-C ₆Alkyl) ,-NHSO ₂(C ₁-C ₆Alkyl) ,-SO ₂NH ₂,-CONH ₂,-CON (C ₁-C ₆Alkyl) ,-SO ₂(C ₁-C ₆Alkyl) ,-SO ₂Phenyl, phenyl, benzyl ,-N (C ₁-C ₆Alkyl) ₂, or-S (C ₁-C ₆Alkyl), wherein aforementioned phenyl, benzyl and C ₁-C ₆Independent separately and optional being substituted of alkyl, and wherein aforementioned C ₁-C ₆Alkyl each straight chain, side chain or cyclic naturally.

In some instances, with regard to formula I-C compound and the top subgroup compound of directly describing, X is 1,2 or 3, and the R that at least once occurs ⁵It is halogen

CN ,-CH ₂CN ,-(CH ₂) ₂CN, NO ₂,-CH ₂NO ₂,-(CH ₂) ₂NO ₂,-CONH ₂,-CON (C ₁-C ₄Alkyl) ,-SO ₂NH ₂,-SO ₂N (C ₁-C ₄Alkyl), NH ₂,-N (C ₁-C ₄Alkyl) ,-OH ,-O (C ₁-C ₄Alkyl) ,-CH ₂OH ,-CH ₂O (C ₁-C ₄Alkyl),

Perhaps have 0-3 the unsaturated ring of heteroatoms 5-or 6-unit that is selected from oxygen, sulphur or nitrogen, in other embodiments, X is 1,2 or 3, and the R that at least once occurs ⁵Be-OR ¹

In other embodiments, with regard to the compound of the subgroup of formula I-C and top direct description, R ⁵Optional by R ⁷Occur to replace for y time, wherein y is 1,2 or 3 and R ⁷Each appearance independently be F, Cl, Br, CN, OH, NH ₂,-CH ₂OH, C ₁-C ₆Alkyl ,-O (C ₁-C ₆Alkyl) ,-CH ₂O (C ₁-C ₆Alkyl) ,-CO (C ₁-C ₆Alkyl) ,-COO (C ₁-C ₆Alkyl) ,-NHSO ₂(C ₁-C ₆Alkyl) ,-SO ₂NH ₂,-CONH ₂-,-CON (C ₁-C ₆Alkyl) ,-SO ₂(C ₁-C ₆Alkyl) ,-SO ₂Phenyl, phenyl, benzyl ,-N (C ₁-C ₆Alkyl) ₂, or-S (C ₁-C ₆Alkyl), wherein aforementioned phenyl, benzyl and C ₁-C ₆Independent separately and optional being substituted of alkyl, and aforementioned C ₁-C ₆Alkyl each straight chain, side chain or cyclic naturally.

In other embodiments, x be 1 and compound have general formula I-C-i:

R wherein ¹, R ², R ³, and R ⁴Generality describe and above in the subgroup and description herein, and R ⁵Be halogen, R ', CN ,-CH ₂CN ,-(CH ₂) ₂CN, NO ₂,-CH ₂NO ₂,-(CH ₂) ₂NO ₂, CON (R ') ₂,-CH ₂CON (R ') ₂,-(CH ₂) ₂CON (R ') ₂, COOR ' ,-CH ₂COOR ' ,-(CH ₂) ₂COOR ' ,-SO ₂N (R ') ₂,-CH ₂SO ₂N (R ') ₂,-(CH ₂) ₂SO ₂N (R ') ₂,-NR ' SO ₂R ' ,-CH ₂NR ' SO ₂R ' ,-(CH ₂) ₂NR ' SO ₂R ', NR ' CON (R ') ₂,-CH ₂NR ' CON (R ') ₂,-(CH ₂) ₂NR ' CON (R ') ₂,-NR ' SO ₂N (R ') ₂,-CH ₂NR ' SO ₂N (R ') ₂,-(CH ₂) ₂NR ' SO ₂N (R ') ₂,-COCOR ' ,-CH ₂COCOR ' ,-(CH ₂) ₂COCOR ' ,-N (R ') ₂,-CH ₂N (R ') ₂,-(CH ₂) ₂N (R ') ₂,-OR ' ,-CH ₂OR ' ,-(CH ₂) ₂OR ' ,-NR ' COR ' ,-CH ₂NR ' COR ' or-(CH ₂) ₂NR ' COR ', and R ' is C ₁-C ₆Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R ⁷Occur to replace for y time.In certain embodiments, R ⁵Be CN ,-CH ₂CN ,-(CH ₂) ₂CN ,-NO ₂,-CH ₂NO ₂,-(CH ₂) ₂NO ₂, OR ' ,-CH ₂OR ' ,-CON (R ') ₂,-SO ₂N (R ') ₂,-N (R ') ₂, or R '.In specific embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₆Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R ⁷Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₄Alkyl, or be selected from top described (i)-(X ¹Vi) or (X ¹Ring vii).

In other embodiments, x be 1 and compound have general formula I-C-ii:

In other embodiments, R ⁵Each appearance independently be CN ,-CH ₂CN ,-(CH ₂) ₂CN ,-NO ₂,-CH ₂NO ₂,-(CH ₂) ₂NO ₂, OR ' ,-CH ₂OR ' ,-CON (R ') ₂,-SO ₂N (R ') ₂,-N (R ') ₂, or R '.In other embodiments, R ⁵Each appearance independently be hydrogen, halogen, CN ,-CH ₂CN ,-(CH ₂) ₂CN, NO ₂,-CH ₂NO ₂,-(CH ₂) ₂NO ₂,-CONH ₂,-CON (C ₁-C ₄Alkyl) ,-SO ₂NH ₂,-SO ₂N (C ₁-C ₄Alkyl), NH ₂,-N (C ₁-C ₄Alkyl) ,-OH ,-O (C ₁-C ₄Alkyl) ,-CH ₂OH ,-CH ₂O (C ₁-C ₄Alkyl), or the unsaturated ring of optional 5-that replaces or 6-unit, wherein 0-3 ring carbon atom is optional by oxygen, sulphur or nitrogen replacement, wherein R ⁵Optional by R ⁷Occur to replace for 0-3 time.

In other embodiments, x be 2 and compound have general formula I-C-iii:

R wherein ¹, R ², R ³, and R ⁴Generality describe and above in the subgroup and description herein, and R ⁵Each appearance independently be halogen, R ', CN ,-CH ₂CN ,-(CH ₂) ₂CN, NO ₂,-CH ₂NO ₂,-(CH ₂) ₂NO ₂, CON (R ') ₂,-CH ₂CON (R ') ₂,-(CH ₂) ₂CON (R ') ₂, COOR ' ,-CH ₂COOR ' ,-(CH ₂) ₂COOR ' ,-SO ₂N (R ') ₂,-CH ₂SO ₂N (R ') ₂,-(CH ₂) ₂SO ₂N (R ') ₂,-NR ' SO ₂R ' ,-CH ₂NR ' SO ₂R ' ,-(CH ₂) ₂NR ' SO ₂R ', NR ' CON (R ') ₂,-CH ₂NR ' CON (R ') ₂,-(CH ₂) ₂NR ' CON (R ') ₂,-NR ' SO ₂N (R ') ₂,-CH ₂NR ' SO ₂N (R ') ₂,-(CH ₂) ₂NR ' SO ₂N (R ') ₂,-COCOR ' ,-CH ₂COCOR ' ,-(CH ₂) ₂COCOR ' ,-N (R ') ₂,-CH ₂N (R ') ₂,-(CH ₂) ₂N (R ') ₂,-OR ' ,-CH ₂OR ' ,-(CH ₂) ₂OR ' ,-NR ' COR ' ,-CH ₂NR ' COR ' or-(CH ₂) ₂NR ' COR ', and R ' is C ₁-C ₆Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R ⁷Occur to replace for y time.In certain embodiments, R ⁵Be CN ,-CH ₂CN ,-(CH ₂) ₂CN ,-NO ₂,-CH ₂NO ₂,-(CH ₂) ₂NO ₂, OR ' ,-CH ₂OR ' ,-CON (R ') ₂,-SO ₂N (R ') ₂,-N (R ') ₂, or R '.In specific embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₆Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R ⁷Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₄Alkyl, or be selected from top described (i)-(X ¹Vi) or (X ¹Ring vii).

In other embodiments, R ¹, R ², R ³, and R ⁴Each is hydrogen naturally, and x is 2, and the compound of formula I-C-iv is provided:

R wherein ⁵Be halogen, R ', CN ,-CH ₂CN ,-(CH ₂) ₂CN, NO ₂,-CH ₂NO ₂,-(CH ₂) ₂NO ₂, CON (R ') ₂,-CH ₂CON (R ') ₂,-(CH ₂) ₂CON (R ') ₂, COOR ' ,-CH ₂COOR ' ,-(CH ₂) ₂COOR ' ,-SO ₂N (R ') ₂,-CH ₂SO ₂N (R ') ₂,-(CH ₂) ₂SO ₂N (R ') ₂,-NR ' SO ₂R ' ,-CH2NR ' SO ₂R ' ,-(CH ₂) ₂NR ' SO ₂R ', NR ' CON (R ') ₂,-CH ₂NR ' CON (R ') ₂,-(CH ₂) ₂NR ' CON (R ') ₂,-NR ' SO ₂N (R ') ₂,-CH ₂NR ' SO ₂N (R ') ₂,-(CH ₂) ₂NR ' SO ₂N (R ') ₂,-COCOR ' ,-CH ₂COCOR ' ,-(CH ₂) ₂COCOR ' ,-N (R ') ₂,-CH ₂N (R ') ₂,-(CH ₂) ₂N (R ') ₂,-OR ' ,-CH ₂OR ' ,-(CH ₂) ₂OR ' ,-NR ' COR ' ,-CH ₂NR ' COR ' or-(CH ₂) ₂NR ' COR ', and R ' is C ₁-C ₆Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R ⁷Occur to replace for y time.In certain embodiments, R ⁵Be CN ,-CH ₂CN ,-(CH ₂) ₂CN ,-NO ₂,-CH ₂NO ₂,-(CH ₂) ₂NO ₂, OR ' ,-CH ₂OR ' ,-CON (R ') ₂,-SO ₂N (R ') ₂,-N (R ') ₂, or R '.In specific embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₆Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R ⁷Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₄Alkyl, or be selected from top described (i)-(X ¹Vi) or (X ¹Ring vii).

In other embodiments, R ¹, R ², R ³, and R ⁴Each is hydrogen naturally, and x is 1, and the compound of formula I-C-v is provided:

R wherein ⁵Be halogen, R ', CN ,-CH ₂CN ,-(CH ₂) ₂CN, NO ₂,-CH ₂NO ₂,-(CH ₂) ₂NO ₂, CON (R ') ₂,-CH ₂CON (R ') ₂,-(CH ₂) ₂CON (R ') ₂, COOR ' ,-CH ₂COOR ' ,-(CH ₂) ₂COOR ' ,-SO ₂N (R ') ₂,-CH ₂SO ₂N (R ') ₂,-(CH ₂) ₂SO ₂N (R ') ₂,-NR ' SO ₂R ' ,-CH ₂NR ' SO ₂R ' ,-(CH ₂) ₂NR ' SO ₂R ', NR ' CON (R ') ₂,-CH ₂NR ' CON (R ') ₂,-(CH ₂) ₂NR ' CON (R ') ₂,-NR ' SO ₂N (R ') ₂,-CH ₂NR ' SO ₂N (R ') ₂,-(CH ₂) ₂NR ' SO ₂N (R ') ₂,-COCOR ' ,-CH ₂COCOR ' ,-(CH ₂) ₂COCOR ' ,-N (R ') ₂,-CH ₂N (R ') ₂,-(CH ₂) ₂N (R ') ₂,-OR ' ,-CH ₂OR ' ,-(CH ₂) ₂OR ' ,-NR ' COR ' ,-CH ₂NR ' COR ' or-(CH ₂) ₂NR ' COR ', and R ' is C ₁-C ₆Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R ⁷Occur to replace for y time.In certain embodiments, R ⁵Be CN ,-CH ₂CN ,-(CH ₂) ₂CN ,-NO ₂,-CH ₂NO ₂,-(CH ₂) ₂NO ₂, OR ' ,-CH ₂OR ' ,-CON (R ') ₂,-SO ₂N (R ') ₂,-N (R ') ₂, or R '.In specific embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₆Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R ⁷Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₄Alkyl, or be selected from top described (i)-(X ¹Vi) or (X ¹Ring vii).

In other embodiments, R ¹, R ², R ³, and R ⁴Each is hydrogen naturally, and x is 2, and the compound of formula I-C-vi is provided:

R wherein ⁵Each appearance independently be halogen, R ', CN ,-CH ₂CN ,-(CH ₂) ₂CN, NO ₂,-CH ₂NO ₂,-(CH ₂) ₂NO ₂, CON (R ') ₂,-CH ₂CON (R ') ₂,-(CH ₂) ₂CON (R ') ₂, COOR ' ,-CH ₂COOR ' ,-(CH ₂) ₂COOR ' ,-SO ₂N (R ') ₂,-CH ₂SO ₂N (R ') ₂,-(CH ₂) ₂SO ₂N (R ') ₂,-NR ' SO ₂R ' ,-CH ₂NR ' SO ₂R ' ,-(CH ₂) ₂NR ' SO ₂R ', NR ' CON (R ') ₂,-CH ₂NR ' CON (R ') ₂,-(CH ₂) ₂NR ' CON (R ') ₂,-NR ' SO ₂N (R ') ₂,-CH ₂NR ' SO ₂N (R ') ₂,-(CH ₂) ₂NR ' SO ₂N (R ') ₂,-COCOR ' ,-CH ₂COCOR ' ,-(CH ₂) ₂COCOR ' ,-N (R ') ₂,-CH ₂N (R ') ₂,-(CH ₂) ₂N (R ') ₂,-OR ' ,-CH ₂OR ' ,-(CH ₂) ₂OR ' ,-NR ' COR ' ,-CH ₂NR ' COR ' or-(CH ₂) ₂NR ' COR ', and R ' is C ₁-C ₆Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R ⁷Occur to replace for y time.In certain embodiments, R ⁵Be CN ,-CH ₂CN ,-(CH ₂) ₂CN ,-NO ₂,-CH ₂NO ₂,-(CH ₂) ₂NO ₂, OR ' ,-CH ₂OR ' ,-CON (R ') ₂,-SO ₂N (R ') ₂,-N (R ') ₂, or R '.In specific embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₆Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R ⁷Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₄Alkyl, or be selected from top described (i)-(X ¹Vi) or (X ¹Ring vii).

The representative ion of formula I compound proposes in the following Table 1:

The example of table 1. formula I compound

The compound of Formula I of other specific subgroup comprises:

The compound of formula I-B

In certain embodiments, with regard to the compound of formula I-B:

A.R ¹Be:

B.R ², R ³, and R ⁴Independently be hydrogen, R ', halogen, CN, NO separately ₂,-N (R ') ₂,-CH ₂N (R ') ₂,-OR ' ,-CH ₂OR ' ,-SR ' ,-CH ₂SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' C (O) OR ' ,-NR ' COCH ₂R ' ,-NR ' CO (CH ₂) ₂R ' ,-CON (R ') ₂,-SO ₂N (R ') ₂,-CONR ' (CH ₂) ₂N (R ') ₂,-CONR ' (CH ₂) ₃N (R ') ₂,-CONR ' (CH ₂) ₄N (R ') ₂,-O (CH ₂) ₂OR ', O (CH ₂) ₃OR ', O (CH ₂) ₄OR ' ,-O (CH ₂) ₂N (R ') ₂,-O (CH ₂) ₃N (R ') ₂, or-O (CH ₂) ₄N (R ') ₂R wherein ², R ³, and R ⁴Optional separately by R ⁶Occur to replace for z time, wherein z is 0-5 and R ⁶Be=O ,=NR " ,=S, halogen ,-CN ,-NO ₂, or Z-R ", wherein Z is valence link or the optional C that replaces ₁-C ₆Alkylidene chain, wherein this chain optional and independent quilt-NR of two methylene units at the most " ,-S-,-O-,-CS-,-CO ₂-,-OCO-,-CO-,-COCO-,-CONR " ,-NR " CO-,-NR " CO ₂-,-SO ₂NR " ,-NR " SO ₂-,-CONR " NR "-,-NR " CONR "-,-OCONR " ,-NR " NR " ,-NR " SO ₂NR " ,-SO-,-SO ₂-,-PO-,-PO ₂-or-each appearance of POR " replace, and R " independently is the C of hydrogen or optional replacement ₁-C ₆Aliphatic group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or R " twice appearance with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.

C.R ⁵Each appearance independently be hydrogen, R ' ,-CH ₂R ', halogen, CN, NO ₂,-N (R ') ₂,-CH ₂N (R ') ₂,-OR ' ,-CH ₂OR ' ,-SR ' ,-CH ₂SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' ,-NR ' CO (CH ₂) ₂R ' ,-NR ' COOR ' ,-CON (R ') ₂,-SO ₂N (R ') ₂,-CONR ' (CH ₂) ₂N (R ') ₂,-CONR (CH ₂) ₃N (R ') ₂,-CONR ' (CH ₂) ₄N (R ') ₂,-O (CH ₂) ₂OR ', O (CH ₂) ₃OR ', O (CH ₂) ₄OR ' ,-O (CH ₂) ₂N (R ') ₂,-O (CH ₂) ₃N (R ') ₂,-O (CH ₂) ₄N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' CH ₂(CH ₃) R ' ,-NR ' (CH ₂) ₂R ' ,-NR ' (CH ₂) ₃R ' ,-NR ' (CH ₂) ₄R ' ,-NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-NR ' (CH ₂) ₃N (R ') ₂,-NR ' (CH ₂) ₄N (R ') ₂,-NR ' (CH ₂) OR ' ,-NR ' (CH ₂) ₂OR ' ,-NR ' (CH ₂) ₃OR ' or-NR ' (CH ₂) ₄OR ', wherein R ⁵Optional by R ⁷Occur to replace for y time, wherein y is 0-5 and R ⁷Be=O ,=NR " ,=S, halogen ,-CN ,-NO ₂, or W-R ', wherein W is valence link or the optional C that replaces ₁-C ₆Alkylidene chain, wherein this chain optional and independent quilt-NR of two methylene units at the most " ,-S-,-O-,-CS-,-CO ₂-,-OCO-,-CO-,-COCO-,-CONR " ,-NR " CO-,-NR " CO ₂-,-SO ₂NR " ,-NR " SO ₂-,-CONR " NR "-,-NR " CONR "-,-OCONR " ,-NR " NR " ,-NR " SO ₂NR " ,-SO-,-SO ₂-,-PO-,-PO ₂-or-each appearance of POR " replace, and R " independently is the C of hydrogen or optional replacement ₁-C ₆Aliphatic group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or R " twice appearance with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo.

In other embodiments, with regard to the compound of formula I-B:

A.R ¹Be hydrogen, C ₁-C ₄Alkyl ,-COR ' ,-SO ₂R ' or-Si (R ') ₃

B.R ², and R ⁴Independently be separately Cl, Br, F ,-CN ,-COOH ,-COOMe ,-NH ₂,-N (CH ₃) ₂,-N (Et) ₂,-N (iPr) ₂,-O (CH ₂) ₂OCH ₃,-CONH ₂,-COOCH ₃,-OH ,-CH ₂OH ,-NHCOCH ₃,-SO ₂NH ₂,-SO ₂N (Me) ₂, or the optional group that replaces, be selected from C ₁-C ₄Alkyl, C ₁-C ₄Alkoxyl group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; R wherein ², and R ⁴Independent separately and optional by R ⁶Occur to replace for z time, wherein z is 0,1,2 or 3, and R ⁶Each appearance independently be hydrogen, R " ,-CH ₂R ", halogen, CN, NO ₂,-N (R ") ₂,-CH ₂N (R ") ₂,-OR " ,-CH ₂OR " ,-SR " ,-CH ₂SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ") ₂,-SO ₂N (R ") ₂,-CONR " (CH ₂) ₂N (R ") ₂,-CONR (CH ₂) ₃N (R ") ₂,-CONR " (CH ₂) ₄N (R ") ₂,-O (CH ₂) ₂OR ", O (CH ₂) ₃OR ", O (CH ₂) ₄OR " ,-O (CH ₂) ₂N (R ") ₂,-O (CH ₂) ₃N (R ") ₂,-O (CH ₂) ₄N (R ") ₂,-NR " CH (CH ₂OH) R " ,-NR " CH (CH ₂CH ₂OH) R " ,-NR " (CH ₂) R " ,-NR " (CH ₂) ₂R " ,-NR " (CH ₂) ₃R " ,-NR " (CH ₂) ₄R " ,-NR " (CH ₂) N (R ") ₂,-NR " (CH ₂) ₂N (R ") ₂,-NR " (CH ₂) ₃N (R ") ₂,-NR " (CH ₂) ₄N (R ") ₂,-NR " (CH ₂) OR " ,-NR " (CH ₂) ₂OR " ,-NR " (CH ₂) ₃OR " or-NR " (CH ₂) ₄OR ";

C.R ³Independently be Cl, Br, F ,-CN ,-COOH ,-COOMe ,-NH ₂,-N (CH ₃) ₂,-N (Et) ₂,-N (iPr) ₂,-O (CH ₂) ₂OCH ₃,-CONH ₂,-COOCH ₃,-OH ,-CH ₂OH ,-NHCOCH ₃,-SO ₂NH ₂,-SO ₂N (Me) ₂, or the optional group that replaces, be selected from C ₁-C ₄Alkyl, C ₁-C ₄Alkoxyl group; R wherein ³Independent of and optional R ⁶Occur to replace for z time, wherein z is 0 or 1, and R ⁶Each appearance independently be hydrogen, R " ,-CH ₂R ", halogen, CN, NO ₂,-N (R ") ₂,-CH ₂N (R ") ₂,-OR " ,-CH ₂OR " ,-SR " ,-CH ₂SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ") ₂,-SO ₂N (R ") ₂,-CONR " (CH ₂) ₂N (R ") ₂,-CONR (CH ₂) ₃N (R ") ₂,-CONR " (CH ₂) ₄N (R ") ₂,-O (CH ₂) ₂OR ", O (CH ₂) ₃OR ", O (CH ₂) ₄OR " ,-O (CH ₂) ₂N (R ") ₂,-O (CH ₂) ₃N (R ") ₂,-O (CH ₂) ₄N (R ") ₂,-NR " CH (CH ₂OH) R " ,-NR " CH (CH ₂CH ₂OH) R " ,-NR " (CH ₂) R " ,-NR " (CH ₂) ₂R " ,-NR " (CH ₂) ₃R " ,-NR " (CH ₂) ₄R " ,-NR " (CH ₂) N (R ") ₂,-NR " (CH ₂) ₂N (R ") ₂,-NR " (CH ₂) ₃N (R ") ₂,-NR " (CH ₂) ₄N (R ") ₂,-NR " (CH ₂) OR " ,-NR " (CH ₂) ₂OR " ,-NR " (CH ₂) ₃OR " or-NR " (CH ₂) ₄OR ";

D.R ⁵Each appearance independently be hydrogen, R ' ,-CH ₂R ', halogen, CN, NO ₂,-N (R ') ₂,-CH ₂N (R ') ₂,-OR ' ,-CH ₂OR ' ,-SR ' ,-CH ₂SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' ,-NR ' CO (CH ₂) ₂R ' ,-NR ' COOR ' ,-CON (R ') ₂,-SO ₂N (R ') ₂,-CONR ' (CH ₂) ₂N (R ') ₂,-CONR (CH ₂) ₃N (R ') ₂,-CONR ' (CH ₂) ₄N (R ') ₂,-O (CH ₂) ₂OR ', O (CH ₂) ₃OR ', O (CH ₂) ₄OR ' ,-O (CH ₂) ₂N (R ') ₂,-O (CH ₂) ₃N (R ') ₂,-O (CH ₂) ₄N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' CH ₂(CH ₃) R ' ,-NR ' (CH ₂) ₂R ' ,-NR ' (CH ₂) ₃R ' ,-NR ' (CH ₂) ₄R ' ,-NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-NR ' (CH ₂) ₃N (R ') ₂,-NR ' (CH ₂) ₄N (R ') ₂,-NR ' (CH ₂) OR ' ,-NR ' (CH ₂) ₂OR ' ,-NR ' (CH ₂) ₃OR ' or-NR ' (CH ₂) ₄OR ', wherein R ⁵Optional by R ⁷Occur to replace for y time, wherein y is 0,1,2 or 3, and R ⁷Each appearance independently be hydrogen, R " ,-CH ₂R ", halogen, CN, NO ₂,-N (R ") ₂,-CH ₂N (R ") ₂,-OR " ,-CH ₂OR " ,-SR " ,-CH ₂SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ") ₂,-SO ₂N (R ") ₂,-CONR " (CH ₂) ₂N (R ") ₂,-CONR (CH ₂) ₃N (R ") ₂,-CONR " (CH ₂) ₄N (R ") ₂,-O (CH ₂) ₂OR ", O (CH ₂) ₃OR ", O (CH ₂) ₄OR " ,-O (CH ₂) ₂N (R ") ₂,-O (CH ₂) ₃N (R ") ₂,-O (CH ₂) ₄N (R ") ₂,-NR " CH (CH ₂OH) R " ,-NR " CH (CH ₂CH ₂OH) R " ,-NR " (CH ₂) R " ,-NR " (CH ₂) ₂R " ,-NR " (CH ₂) ₃R " ,-NR " (CH ₂) ₄R " ,-NR " (CH ₂) N (R ") ₂,-NR " (CH ₂) ₂N (R ") ₂,-NR " (CH ₂) ₃N (R ") ₂,-NR " (CH ₂) ₄N (R ") ₂,-NR " (CH ₂) OR " ,-NR " (CH ₂) ₂OR " ,-NR " (CH ₂) ₃OR " or-NR " (CH ₂) ₄OR ".

In other embodiments, with regard to the compound of the subgroup of formula I-B and top direct description, R ¹Be hydrogen, methyl, ethyl, just-propyl group, sec.-propyl, just-butyl, ptoluene-sulfonyl (Ts), tert-butyl dimetylsilyl (TBS), triisopropyl silyl (TIPS) or triethylsilyl (TES).

In other embodiments, with regard to the compound of the subgroup of formula I-B and top direct description, R ², R ³, and R ⁴Each is hydrogen naturally.In other embodiments, R ², R ³, or R ⁴In one be hydrogen.In other embodiments, R ², R ³, or R ⁴In two be hydrogen.In other embodiments, R ²And R ⁴All be hydrogen, and R ³Be halogen, CN, NO ₂, or V-R '.In other embodiments, R ²And R ⁴All be hydrogen, and R ³It is halogen.In other embodiments, R ²And R ⁴All be hydrogen, and R ³Be Cl.

In other embodiments, with regard to the compound of the subgroup of formula I-B and top direct description, R ², R ³, and R ⁴Independent separately and optional by R ⁶Occur to replace for z time, wherein z is 1,2 or 3 and R ⁶Each appearance independently be F, Cl, Br, CN, OH, NH ₂,-CH ₂OH, C ₁-C ₆Alkyl ,-O (C ₁-C ₆Alkyl) ,-CH ₂O (Cl-C ₆Alkyl) ,-CO (Cl-C ₆Alkyl) ,-COO (C ₁-C ₆Alkyl) ,-NHSO ₂(C ₁-C ₆Alkyl) ,-SO ₂NH ₂,-CONH ₂,-CON (C ₁-C ₆Alkyl) ,-SO ₂(C ₁-C ₆Alkyl) ,-SO ₂Phenyl, phenyl, benzyl ,-N (C ₁-C ₆Alkyl) ₂, or-S (C ₁-C ₆Alkyl), wherein aforementioned phenyl, benzyl and C ₁-C ₆Independent separately and optional being substituted of alkyl, and wherein aforementioned C ₁-C ₆Alkyl each straight chain, side chain or cyclic naturally, condition is R ³It or not phenyl.

In specific illustrative embodiment, with regard to the compound of the subgroup of formula I-B and top direct description, x is 1,2 or 3, and R ⁵at least once occur be-N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' CH ₂(CH ₃) R ' ,-NR ' (CH ₂) ₂R ', NR ' (CH ₂) N (R ') ₂, or-NR ' (CH ₂) ₂N (R ') ₂In other embodiments, x is 1,2 or 3, and R ⁵at least once occur be-OR '.In other embodiments, x is 1,2 or 3, and R ⁵at least once occur be-NR ' COR ' ,-NR ' COCH ²R ' or-NR ' CO (CH ₂) ₂R '.In other embodiments, x is 1,2 or 3, and R ⁵At least once to occur be the optional C that replaces ₁-C ₆Aliphatic group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5.

In other embodiments, with regard to the compound of the subgroup of formula I-B and top direct description, R ⁵Optional by R ⁷Occur to replace for y time, wherein y is 1,2 or 3 and R ⁷Each appearance independently be F, Cl, Br, CN, OH, NH ₂,-CH ₂OH, C ₁-C ₆Alkyl ,-O (C ₁-C ₆Alkyl) ,-CH ₂O (C ₁-C ₆Alkyl) ,-CO (C ₁-C ₆Alkyl) ,-COO (C ₁-C ₆Alkyl) ,-NHSO ₂(C ₁-C ₆Alkyl) ,-SO ₂NH ₂,-CONH ₂-,-CON (C ₁-C ₆Alkyl) ,-SO ₂(C ₁-C ₆Alkyl) ,-SO ₂Phenyl, phenyl, benzyl ,-N (C ₁-C ₆Alkyl) ₂,-S (C ₁-C ₆Alkyl), wherein aforementioned phenyl, benzyl and C ₁-C ₆Independent separately and optional being substituted of alkyl, and aforementioned C ₁-C ₆Alkyl each straight chain, side chain or cyclic naturally.

In other embodiments, with regard to the compound of the subgroup of formula I-B and top direct description, x is 1,2 or 3; R ⁵at least once occur be-N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' CH ₂(CH ₃) R ' ,-NR ' (CH ₂) ₂R ', NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-OR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' or-NR ' CO (CH ₂) ₂R '; And R ' is C ₁-C ₆Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R ⁷Occur to replace for y time.In specific embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₆Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R ⁷Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₄Alkyl, or be selected from top described (i)-(X ¹Vi) or (X ¹Ring vii).In other embodiments, R ⁵Be-N (R ') ₂, and twice appearance of R ' and and common 3-10-unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from above-described (a)-(o).

Wherein y and R ⁷Generality describe and above subgroup in describe.

In other embodiments, x be 1 and compound have general formula I-B-i:

R wherein ¹, R ², R ³, and R ⁴Generality describe and above in the subgroup and description herein; R ⁵Be-N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' CH ₂(CH ₃) R ' ,-NR ' (CH ₂) ₂R ', NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-OR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' or-NR ' CO (CH ₂) ₂R '; And R ' is C ₁-C ₆Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R ⁷Occur to replace for y time.In certain embodiments, R ⁵Be N (R ') ₂In specific embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₆Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R ⁷Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₄Alkyl, or be selected from top described (i)-(X ¹Vi) or (X ¹Ring vii).In other embodiments, R ⁵Be-N (R ') ₂, and twice appearance of R ' and and common 3-10 unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from above-described (a)-(o).

In other embodiments, x is that 0-3 and compound have general formula I-B-ii:

R wherein ¹, R ², R ³, and R ⁴Generality describe and above in the subgroup and description herein; R ⁵Independently be selected from halogen, the optional C that replaces separately ₁-C ₆Alkyl ,-SR ' ,-CN ,-COOH ,-CO ₂R ' ,-CON (R ') ₂,-N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' CH ₂(CH ₃) R ' ,-NR ' (CH ₂) ₂R ', NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-OR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' or-NR ' CO (CH ₂) ₂R '; And R ' is C ₁-C ₆Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R ⁷Occur to replace for y time.In certain embodiments, R ⁵Be N (R ') ₂In specific embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₆Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R ⁷Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₄Alkyl, or be selected from top described (i)-(X ¹Vi) or (X ¹Ring vii).In other embodiments, R ⁵Be-N (R ') ₂, and twice appearance of R ' and and common 3-10 unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from above-described (a)-(o).

In other embodiments, x is that 1-4 and compound have general formula I-B-iii:

Wherein:

R ³Be the optional group that replaces, be selected from halogen, the optional C that replaces _1-6Alkyl, CN, N (R ') ₂, CO ₂R ', NR ' COR ', CON (R ') ₂, CH ₂N (R ') ₂, OR ', SR ', CH ₂OR ';

X is 1,2 or 3; And R ⁵Halogen, the optional C that replaces at least once appear being selected from ₁-C ₆Aliphatic group ,-SR ' ,-CN ,-COOH ,-CO ₂R ' ,-CON (R ') ₂,-N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' CH ₂(CH ₃) R ' ,-NR ' (CH ₂) ₂R ', NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-OR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' or-NR ' CO (CH ₂) ₂R '; And R ' is selected from hydrogen, optional by R ⁷The C that occur to replace for y time ₁-C ₆Aliphatic group, or be selected from top described (i)-(X ¹Vi) or (X ¹Ring vii).In other embodiments, R ⁵Be-N (R ') ₂, and twice appearance of R ' and and common 3-10 unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from above-described (a)-(o).

In other embodiments, R ¹, R ²And R ⁴Each hydrogen naturally, and x is 0-3, and the compound of formula I-B-iv is provided:

Wherein:

R ³Be the optional group that replaces, be selected from halogen, the optional C that replaces _1-6Aliphatic group, CN, N (R ') ₂, CO ₂R ', NR ' COR ', CON (R ') ₂, CH ₂N (R ') ₂, OR ', SR ', CH ₂OR ';

R ⁵Be selected from halogen, the optional C that replaces ₁-C ₆Aliphatic group ,-SR ' ,-CN ,-COOH ,-CO ₂R ' ,-CON (R ') ₂,-N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' CH ₂(CH ₃) R ' ,-NR ' (CH ₂) ₂R ', NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-OR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' or-NR ' CO (CH ₂) ₂R '; And R ' is selected from hydrogen, optional by R ⁷The C that occur to replace for y time ₁-C ₆Aliphatic group, or be selected from top described (i)-(X ¹Vi) or (X ¹Ring vii).In other embodiments, R ⁵Be-N (R ') ₂, and twice appearance of R ' and and common 3-10 unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from above-described (a)-(o).

In other embodiments, R ¹, R ²And R ⁴Each hydrogen naturally, and x is 2, and the compound of formula I-B-v is provided:

Wherein:

R ⁵Be selected from halogen, the optional C that replaces ₁-C ₆Aliphatic group ,-SR ' ,-CN ,-COOH ,-CO ₂R ' ,-CON (R ') ₂,-N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' CH (CH ₃) R ' ,-NR ' (CH ₂) ₂R ', NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-OR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' or-NR ' CO (CH ₂) ₂R '; And R ' is selected from hydrogen, optional by R ⁷The C that occur to replace for y time ₁-C ₆Aliphatic group, or be selected from top described (i)-(X ¹Vi) or (X ¹Ring vii).In other embodiments, R ⁵Be-N (R ') ₂, and twice appearance of R ' and and common 3-10 unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from above-described (a)-(o).

In other embodiments, R ¹, R ²And R ⁴Each hydrogen naturally, and x is 2, and the compound of formula I-B-vi is provided:

Wherein:

The compound of the general formula I of other specific subgroup comprises:

The compound of formula I-E:

In certain embodiments, with regard to the compound of formula I-E:

A.R ¹Be:

In other embodiments, with regard to the compound of formula I-E:

A.R ¹Be hydrogen, C ₁-C ₄Alkyl ,-COR ' ,-SO ₂R ' or-Si (R ') ₃

B.R ², and R ⁴Independently be separately Cl, Br, F ,-CN ,-COOH ,-COOMe ,-NH ₂,-N (CH ₃) ₂,-N (Et) ₂,-N (iPr) ₂,-O (CH ₂) ₂OCH ₃,-CONH ₂,-COOCH ₃,-OH ,-CH ₂OH ,-NHCOCH ₃,-SO ₂NH ₂,-SO ₂N (Me) ₂, or the optional group that replaces, be selected from C ₁-C ₄Alkyl, C ₁-C ₄Alkoxyl group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; R wherein ², R ³And R ⁴Independent separately and optional by R ⁶Occur to replace for z time, wherein z is 0,1,2 or 3, and R ⁶Each appearance independently be hydrogen, R " ,-CH ₂R ", halogen, CN, NO ₂,-N (R ") ₂,-CH ₂N (R ") ₂,-OR " ,-CH ₂OR " ,-SR " ,-CH ₂SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ") ₂,-SO ₂N (R ") ₂,-CONR " (CH ₂) ₂N (R ") ₂,-CONR (CH ₂) ₃N (R ") ₂,-CONR " (CH ₂) ₄N (R ") ₂,-O (CH ₂) ₂OR ", O (CH ₂) ₃OR ", O (CH ₂) ₄OR " ,-O (CH ₂) ₂N (R ") ₂,-O (CH ₂) ₃N (R ") ₂,-O (CH ₂) ₄N (R ") ₂,-NR " CH (CH ₂OH) R " ,-NR " CH (CH ₂CH ₂OH) R " ,-NR " (CH ₂) R " ,-NR " (CH ₂) ₂R " ,-NR " (CH ₂) ₃R " ,-NR " (CH ₂) ₄R " ,-NR " (CH ₂) N (R ") ₂,-NR " (CH ₂) ₂N (R ") ₂,-NR " (CH ₂) ₃N (R ") ₂,-NR " (CH ₂) ₄N (R ") ₂,-NR " (CH ₂) OR " ,-NR " (CH ₂) ₂OR " ,-NR " (CH ₂) ₃OR " or-NR " (CH ₂) ₄OR ";

D.R ⁵Each appearance independently be hydrogen, R ' ,-CH ₂R ', halogen, CN, NO ₂,-N (R ') ₂,-CH ₂N (R ') ₂,-OR ' ,-CH ₂OR ' ,-SR ' ,-CH ₂SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' ,-NR ' CO (CH ₂) ₂R ' ,-NR ' COOR ' ,-CON (R ') ₂,-SO ₂N (R ') ₂,-CONR ' (CH ₂) ₂N (R ') ₂,-CONR (CH ₂) ₃N (R ') ₂,-CONR ' (CH ₂) ₄N (R ') ₂,-O (CH ₂) ₂OR ', O (CH ₂) ₃OR ', O (CH ₂) ₄OR ' ,-O (CH ₂) ₂N (R ') ₂,-O (CH ₂) ₃N (R ') ₂,-O (CH ₂) ₄N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' CH ₂(CH ₃) R ' ,-NR ' (CH ₂) ₂R ' ,-NR ' (CH ₂) ₃R ' ,-NR ' (CH ₂) ₄R ' ,-NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-NR ' (CH ₂) ₃N (R ') ₂,-NR ' (CH ₂) ₄N (R ') ₂,-NR ' (CH ₂) OR ' ,-NR ' (CH ₂) ₂OR ' ,-NR ' (CH ₂) ₃OR ' or-NR ' (CH ₂) ₄OR ', wherein R ⁵Optional by R ⁷Occur to replace for y time, wherein y is 0,1,2 or 3, and R ⁷Each appearance independently be hydrogen, R " ,-CH ₂R ", halogen, CN, NO ₂,-N (R ") ₂,-CH ₂N (R ") ₂,-OR " ,-CH ₂OR " ,-SR " ,-CH ₂SR " ,-COOR " ,-NR " COR " ,-NR " COOR " ,-CON (R ") ₂,-SO ₂N (R ") ₂,-CONR " (CH ₂) ₂N (R ") ₂,-CONR (CH ₂) ₃N (R ") ₂,-CONR " (CH ₂) ₄N (R ") ₂,-O (CH ₂) ₂OR " ,-O (CH ₂) ₃OR " ,-O (CH ₂) ₄OR " ,-O (CH ₂) ₂N (R ") ₂,-O (CH ₂) ₃N (R ") ₂,-O (CH ₂) ₄N (R ") ₂,-NR " CH (CH ₂OH) R " ,-NR " CH (CH ₂CH ₂OH) R " ,-NR " (CH ₂) R " ,-NR " (CH ₂) ₂R " ,-NR " (CH ₂) ₃R " ,-NR " (CH ₂) ₄R " ,-NR " (CH ₂) N (R ") ₂,-NR " (CH ₂) ₂N (R ") ₂,-NR " (CH ₂) ₃N (R ") ₂,-NR " (CH ₂) ₄N (R ") ₂,-NR " (CH ₂) OR " ,-NR " (CH ₂) ₂OR " ,-NR " (CH ₂) ₃OR " or-NR " (CH ₂) ₄OR ".

In other embodiments, with regard to the compound of the subgroup of formula I-E and top direct description, R ¹Be hydrogen, methyl, ethyl, just-propyl group, sec.-propyl, just-butyl, ptoluene-sulfonyl (Ts), tert-butyl dimetylsilyl (TBS), triisopropyl silyl (TIPS) or triethylsilyl (TES).

In other embodiments, with regard to the compound of the subgroup of formula I-E and top direct description, R ², R ³, and R ⁴Each is hydrogen naturally.In other embodiments, R ², R ³, or R ⁴In one be hydrogen.In other embodiments, R ², R ³, or R ⁴In two be hydrogen.In other embodiments, R ²And R ⁴All be hydrogen, and R ³Be halogen, CN, NO ₂, or V-R '.In other embodiments, R ²And R ⁴All be hydrogen, and R ³It is halogen.In other embodiments, R ²And R ⁴All be hydrogen, and R ³Be Cl.

In other embodiments, with regard to the compound of the subgroup of formula I-E and top direct description, R ², R ³, and R ⁴Independent separately and optional by R ⁶Occur to replace for z time, wherein z is 1,2 or 3 and R ⁶Each appearance independently be F, Cl, Br, CN, OH, NH ₂,-CH ₂OH, C ₁-C ₆Alkyl ,-O (C ₁-C ₆Alkyl) ,-CH ₂O (Cl-C ₆Alkyl) ,-CO (Cl-C ₆Alkyl) ,-COO (C ₁-C ₆Alkyl) ,-NHSO ₂(C ₁-C ₆Alkyl) ,-SO ₂NH ₂,-CONH ₂,-CON (C ₁-C ₆Alkyl) ,-SO ₂(C ₁-C ₆Alkyl) ,-SO ₂Phenyl, phenyl, benzyl ,-N (C ₁-C ₆Alkyl) ₂, or-S (C ₁-C ₆Alkyl), wherein aforementioned phenyl, benzyl and C ₁-C ₆Independent separately and optional being substituted of alkyl, and wherein aforementioned C ₁-C ₆Alkyl each straight chain, side chain or cyclic naturally.

In specific illustrative embodiment, with regard to the compound of the subgroup of formula I-E and top direct description, x is 1,2 or 3, and R ⁵at least once occur be-N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' CH (CH ₃) R ' ,-NR ' (CH ₂) ₂R ', NR ' (CH ₂) N (R ') ₂, or-NR ' (CH ₂) ₂N (R ') ₂In other embodiments, x is 1,2 or 3, and R ⁵at least once occur be-OR '.In other embodiments, x is 1,2 or 3, and R ⁵at least once occur be-NR ' COR ' ,-NR ' COCH ₂R ' or-NR ' CO (CH ₂) ₂R '.In other embodiments, x is 1,2 or 3, and R ⁵At least once to occur be the optional C that replaces ₁-C ₆Aliphatic group, the heteroatomic 3-8 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5.

In other embodiments, with regard to the compound of the subgroup of formula I-E and top direct description, R ⁵Optional by R ⁷Occur to replace for y time, wherein y is 1,2 or 3 and R ⁷Each appearance independently be F, Cl, Br, CN, OH, NH ₂,-CH ₂OH, C ₁-C ₆Alkyl ,-O (C ₁-C ₆Alkyl) ,-CH ₂O (C ₁-C ₆Alkyl) ,-CO (C ₁-C ₆Alkyl) ,-COO (C ₁-C ₆Alkyl) ,-NHSO ₂(C ₁-C ₆Alkyl) ,-SO ₂NH ₂,-CONH ₂-,-CON (C ₁-C ₆Alkyl) ,-SO ₂(C ₁-C ₆Alkyl) ,-SO ₂Phenyl, phenyl, benzyl ,-N (C ₁-C ₆Alkyl) ₂, or-S (C ₁-C ₆Alkyl), wherein aforementioned phenyl, benzyl and C ₁-C ₆Independent separately and optional being substituted of alkyl, and aforementioned C ₁-C ₆Alkyl each straight chain, side chain or cyclic naturally.

In other embodiments, with regard to the compound of the subgroup of formula I-E and top direct description, x is 1,2 or 3; R ⁵at least once occur be-N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' CH (CH ₃) R ' ,-NR ' (CH ₂) ₂R ', NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-OR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' or-NR ' CO (CH ₂) ₂R '; And R ' is C ₁-C ₆Aliphatic group or have 0-3 the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle, the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo, wherein each appearance of R ' is chosen wantonly by R ⁷Occur to replace for y time.In specific embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₆Alkyl, or have 0-4 independently be selected from nitrogen, oxygen or sulphur heteroatomic saturated, part is unsaturated or complete undersaturated 5-10 unit's monocycle or dicyclo, and is wherein should ring optional by R ⁷Occur to replace for 1-3 time.In other embodiments, R ' is a hydrogen, optional by R ⁷The C that occur to replace for 1-3 time ₁-C ₄Alkyl, or be selected from top described (i)-(X ¹Vi) or (X ¹Ring vii).In other embodiments, R ⁵Be-N (R ') ₂, and twice appearance of R ' and and common 3-10 unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from above-described (a)-(o).

Wherein y and R ⁷Generality describe and above subgroup in describe.

In other embodiments, x be 1 and compound have general formula I-E-i:

In other embodiments, R ¹, R ², and R ⁴Each is hydrogen naturally, and formula I-E-ii is provided compound:

Wherein:

X is 1,2 or 3; And R ⁵at least once go out and be-N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NRCH ₂(CH ₃) R ' ,-NR ' (CH ₂) ₂R ', NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-OR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' or-NR ' CO (CH ₂) ₂R '; And R ' is optional by R ⁷The C that occur to replace for y time ₁-C ₆Aliphatic group, or be selected from top described (i)-(X ¹Vi) or (X ¹Ring vii).In other embodiments, R ⁵Be-N (R ') ₂, and twice appearance of R ' and and common 3-10 unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from above-described (a)-(o).

In other embodiments, R ¹, R ², and R ⁴Each is hydrogen naturally, and x is 0-3, and the compound of formula I-E-iii is provided:

Wherein:

R ⁵Be-N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' CH ₂(CH ₃) R ' ,-NR ' (CH ₂) ₂R ', NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-OR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' or-NR ' CO (CH ₂) ₂R '; And R ' is optional by R ⁷The C that occur to replace for y time ₁-C ₆Aliphatic group, or be selected from top described (i)-(X ¹Vi) or (X ¹Ring vii).In other embodiments, R ⁵Be-N (R ') ₂, and twice appearance of R ' and and common 3-10 unit's monocycle or the bicyclic heterocycle that forms optional replacement of their bonded nitrogen-atoms.In specific embodiments, this ring is selected from above-described (a)-(o).

In other embodiments, R ¹, R ², and R ⁴Each hydrogen naturally, and x is 1, and the compound of formula I-E-iv is provided:

Wherein:

Propose in the representative example table 2 below of formula I compound.The compound of table 2 also can be represented by II-x, and wherein x is the compound number of expression in the table 2.

The example of table 2. formula I compound:

4. purposes, preparation and administration

The pharmacy acceptable composition

As discussed above, the invention provides the kinases inhibitor compound, and therefore compound of the present invention can be used for treating disease, illness and situation, include but not limited to illness, virus disease or the osteopathy of proliferative disorders, heart trouble, neurodegenerative disorders, psychosis, autoimmune disorder, the situation relevant, inflammatory conditions, immunity-mediation with organ transplantation.In specific embodiments, this compound is used for the treatment of immune response, as allergy or type i allergic reaction or asthma; Autoimmune disease such as transplant rejection, graft versus host disease, rheumatoid arthritis, amyotrophic lateral sclerosis and multiple sclerosis; Neurodegenerative disorders such as familial amyotrophic lateral sclerosis (PALS); With entity and hematologic malignancies, as leukemia and lymphoma.

These compounds and pharmaceutical composition thereof also can be used for treatment or prevent various illnesss, comprise, but be not limited to, heart trouble, diabetes, Alzheimer's, immunodeficiency illness, inflammatory diseases, hypertension, allergic disease, autoimmune disease, destructive osteopathy such as osteoporosis, proliferative disorders, catch, the disease and the virus disease of immunity-mediation.Said composition also can be used for preventing in necrocytosis and the outgrowth method and therefore can be used for treating or preventing apoplectic in perfusion/local asphyxia again, heart attack and organ hypoxia.Said composition also can be used for preventing zymoplasm-inductive platelet aggregation.Said composition is used in particular for illness such as chronic lymphocytic leukemia (CML), acute myelogenous leukemia (AML), acute promyelocytic leukemia (APL), rheumatoid arthritis, asthma, osteoarthritis, local asphyxia, cancer (comprises, but be not limited to ovarian cancer, mammary cancer and carcinoma of endometrium), hepatopathy comprises liver local asphyxia, heart trouble such as myocardial infarction and congestive heart failure, relate to the pathologic immune state and the neurodegenerative disorders of T cell activation.

Therefore, in the present invention on the other hand, provide the pharmacy acceptable composition, wherein these compositions comprise arbitrary compound described herein, and optional pharmaceutically acceptable carrier, auxiliary agent or the vehicle of comprising.In certain embodiments, these compounds are chosen wantonly and are also comprised one or more additional treatment agent.

It is also recognized that some compound of the present invention can the free form existence be used for handling, or suitable, exist with its pharmacy acceptable derivates form.According to the present invention, the pharmacy acceptable derivates comprises, but be not limited to, the salt of the acceptable prodrug of pharmacy, salt, ester, this ester or any other adducts or derivative, they are behind the patient who needs, compound described herein can directly or indirectly be provided, or its metabolite or resistates.

Term used herein " pharmacologically acceptable salts " is meant and drops in the rational medical evaluation scope, is applicable to and contacts with human and zootic tissue and do not have toxicity, pungency, an atopic reaction etc., and with rational income/risk than those salt that match." pharmacologically acceptable salts " is meant any nontoxic salt of The compounds of this invention or the salt of ester, give acceptor after, they can directly or indirectly provide compound of the present invention or its to suppress active metabolite or its residue.Term used herein " it suppresses active metabolite or its residue " is meant that its metabolite or its residue also are the inhibitor of JAK-3, ROCK and Aurora.

Pharmacologically acceptable salts is well known in the art.For example, people such as S.M.Berge are at J.Pharmaceutical Sciences, and 1977,66, describe pharmacologically acceptable salts among the 1-19 in detail, it is introduced herein as a reference.The pharmacologically acceptable salts of The compounds of this invention comprise from suitable inorganic and organic bronsted lowry acids and bases bronsted lowry deutero-those.The example of the acid salt that pharmacy is acceptable, nontoxic is and mineral acid, example hydrochloric acid, Hydrogen bromide, phosphoric acid, sulfuric acid and perchloric acid or the amide that forms with organic acid such as acetic acid, oxalic acid, toxilic acid, tartrate, citric acid, succsinic acid or propanedioic acid, or by using other used method of this area, as the amide of ion-exchange formation.Other pharmacologically acceptable salts comprises adipate, alginate, ascorbate salt, aspartate, benzene sulfonate, benzoate, bisul-phate, borate, butyrates, camphorate, camsilate, Citrate trianion, cyclopentane propionate, digluconate, dodecyl sulfate, esilate, formate, fumarate, the glucoheptose hydrochlorate, glycerophosphate, gluconate, Hemisulphate, enanthate, hexanoate, hydriodide, 2-hydroxyl-esilate, Lactobionate, lactic acid salt, lauroleate, dodecyl sulfate, malate, maleate, malonate, mesylate, the 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinic acid salt, persulphate, the 3-phenpropionate, phosphoric acid salt, picrate, Pivalate, propionic salt, stearate, succinate, vitriol, tartrate, thiocyanate-, right-tosylate, the undecane hydrochlorate, valerate etc.The salt that derives from suitable alkali comprises basic metal, alkaline-earth metal, ammonium and N ⁺(C _1-4Alkyl) ₄Salt.The present invention has also expected arbitrary alkaline nitrogen-containing group quaternized of compound disclosed herein.Water-soluble or oil soluble or dispersible product can be by this quaternized acquisitions.Representational basic metal or alkaline earth salt comprise sodium, lithium, potassium, calcium, magnesium etc.Other pharmacologically acceptable salts comprises, suits the nontoxic ammonium, quaternary ammonium and the amine positively charged ion that use counter ion such as halogenide, oxyhydroxide, carboxylate radical, sulfate radical, phosphate radical, nitrate radical, low alkyl group sulfonic group and aryl sulfonic acid groups to form.

As mentioned above, pharmacy acceptable composition of the present invention also can comprise pharmaceutically acceptable carrier, auxiliary agent or vehicle, as used herein, they comprise any and all solvents, thinner or other liquid excipient, dispersion or suspendible auxiliary agent, tensio-active agent, isotonic agent, thickening material or emulsifying agent, sanitas, solid binder, lubricant etc., are suitable for required given dose form.Remington ' s Pharmaceutical Sciences, the 16 edition, E.W.Martin (Mack Publishing Co., Easton, Pa., 1980) various carriers used when preparation pharmacy acceptable composition and the known technology that is used to prepare them are disclosed.Except with the inconsistent any conventional mounting medium of The compounds of this invention, as produce any bad biological action or can accept any other component interaction of composition with deleterious mode and pharmacy, expect that its use falls within the scope of the present invention.Some examples that can be used as the material of pharmaceutical acceptable carrier comprise, but be not limited to, ion-exchanger, aluminum oxide, aluminum stearate, Yelkin TTS, serum protein such as human serum albumin, buffer substance such as phosphoric acid salt, glycine, Sorbic Acid, or potassium sorbate, the partial glyceride mixture of saturated vegetable fatty acid, water, salt or ionogen, as protamine sulfate, Sodium phosphate dibasic, dipotassium hydrogen phosphate, sodium-chlor, zinc salt, colloid silica, Magnesium Trisilicate, polyvinylpyrrolidone, polyacrylic ester, wax, polyethylene-polyoxytrimethylene block polymer, lanolin, sugar is as lactose, dextrose plus saccharose; Starch such as W-Gum and yam starch; Mierocrystalline cellulose and derivative thereof such as Xylo-Mucine, ethyl cellulose and cellulose acetate; Powdered tragacanth; Fructus Hordei Germinatus; Gelatin; Talcum powder; Vehicle such as Oleum Cocois and suppository wax; Oil is as peanut oil, Oleum Gossypii semen; Safflower oil; Sesame oil; Sweet oil; Semen Maydis oil and soya-bean oil; Glycols; As propylene glycol or polyoxyethylene glycol; Ester class such as ethyl oleate and Laurate ethyl; Agar; Buffer reagent such as magnesium hydroxide and aluminium hydroxide; Lalgine; Apirogen water; Deng oozing physiological saline; Ringer's solution; Ethanol and phosphate buffer soln and other nontoxic compatible lubricant such as sodium lauryl sulphate and Magnesium Stearate, and tinting material, releasing agent, Drug coating, sweeting agent, seasonings and flavouring agent, sanitas and antioxidant also can be present in the composition, and this will be according to makers-up's judgement.

The use of compound and pharmacy acceptable composition

On the other hand, a kind of method of severity that is used for the treatment of or alleviates illness, virus disease or the osteopathy of proliferative disorders, heart trouble, neurodegenerative disorders, psychosis, autoimmune disorder, the situation relevant with organ transplantation, inflammatory conditions, immunity-mediation is provided, comprise that the curee to needs gives the compound of its significant quantity, or the pharmacy acceptable composition of inclusion compound.In certain embodiments of the invention, " significant quantity " that compound or pharmacy can be accepted composition is meant effective treatment or alleviates the consumption of severity of illness, virus disease or the osteopathy of proliferative disorders, heart trouble, neurodegenerative disorders, psychosis, autoimmune disorder, the situation relevant with organ transplantation, inflammatory conditions, immunity-mediation.

In others, the present invention includes and be used for the treatment of or alleviate various illnesss, include, but are not limited to heart trouble, diabetes, Alzheimer's, immunodeficiency illness, inflammatory diseases, hypertension, allergic disease, autoimmune disease, destructive osteopathy such as osteoporosis, proliferative disorders, catch, the method for the severity of the disease of immunity-mediation and virus disease.In others, the present invention includes and be used for preventing necrocytosis and outgrowth method and therefore can be used for treating or perfusion/local asphyxia again, heart attack and the organ hypoxia of preventing apoplectic.In other embodiments, the present invention includes the method that is used to prevent zymoplasm-inductive platelet aggregation.The present invention also comprises and being used for the treatment of, alleviates illness such as chronic lymphocytic leukemia (CML), acute myelogenous leukemia (AML), acute promyelocytic leukemia (APL), rheumatoid arthritis, asthma, osteoarthritis, local asphyxia, cancer (comprises, but be not limited to ovarian cancer, mammary cancer and carcinoma of endometrium), hepatopathy comprises liver local asphyxia, heart trouble such as myocardial infarction and congestive heart failure, relate to the severity of the pathologic immune state of T cell activation and neurodegenerative disorders or prevent the method for these illnesss.

According to method of the present invention, described compound can use effective treatment with composition or alleviate any consumption and any route of administration administration of illness, virus disease or the osteopathy of proliferative disorders, heart trouble, neurodegenerative disorders, autoimmune disorder, the situation relevant with organ transplantation, inflammatory conditions, immunity-mediation.Required accurate consumption will be according to being changed by curer's difference, and this depends on by curer's ethnic group, age and general situation, the severity of infection, specific medicament, its administering mode etc.Preferably compound of the present invention is mixed with and is convenient to administration and the uniform dosage unit form of dosage.Phraseology used herein " dosage unit form " is meant the substantial sepn unit of the medicament that is suitable for the patient that treats.Yet, should be appreciated that total service condition every day of The compounds of this invention and composition will be determined by the doctor in charge in rational medical evaluation scope.Any specific patient or biological concrete effective dose level depend on various factors, comprise the illness of being treated and the severity of illness; The activity of used particular compound; Used concrete composition; Patient's age, body weight, general health situation, sex and diet; Administration time; Route of administration; Discharge rate with used particular compound; The time length of treatment; With associating of used particular compound or the medicine that uses simultaneously; And the factor known of medical field.Term used herein " patient " is meant animal, preferred mammal, and optimum is chosen.

Can pharmacy acceptable composition of the present invention is oral, in the rectum, non-enteron aisle, brain pond, intravaginal, intraperitoneal, part (as pulvis, ointment or drops), oral cavity, give the patient by oral cavity or nose spraying etc., this depends on the severity that infects for the treatment of.In certain embodiments, compound of the present invention can every day about 0.01mg/kg by curer's body weight-Yue 50mg/kg by curer's body weight, preferred about 1mg/kg by curer's body weight-Yue 25mg/kg by the dosage level of curer's body weight oral or parenterai administration, once a day or repeatedly, thus obtain required result of treatment.

The liquid dosages form that is used for oral administration includes, but not limited to the acceptable emulsion of pharmacy, micro emulsion, solution, suspension, syrup and elixir.Remove the active ingredient beyond the region of objective existence, described liquid dosages form also can comprise the normally used inert diluent in this area as, for example, water or other solvent, solubilizing agent and emulsifying agent such as ethanol, Virahol, ethyl-carbonate, vinyl acetic monomer, phenylcarbinol, peruscabin, propylene glycol, 1,3 butylene glycol, dimethyl formamide, oil (particularly cottonseed, peanut, corn, embryo, olive, castor-oil plant and sesame oil), glycerine, tetrahydrofurfuryl alcohol, polyoxyethylene glycol and sorbitan fatty acid esters, and composition thereof.Except that inert diluent, described oral compositions also can comprise auxiliary agent, as wetting agent, emulsifying agent and suspension agent, sweeting agent, condiment and perfuming agent.

Injectable preparation, for example, aseptic aqueous injectable or oily suspension can use the preparation of suitable dispersion agent or wetting agent and suspension agent according to known in the art.The preparation of described sterile injectable can also be to be dissolved in nontoxic non-enteron aisle acceptable diluent or solvent, for example, and the sterile injectable solution in the 1,3 butylene glycol, suspension or emulsion.Used acceptable vehicle and solvent are water, Ringer's solution, U.S.P. and isoosmotic sodium chloride solution.In addition, aseptic expressed oil can be used as solvent or suspension matrix usually.With regard to this purpose, the expressed oil of any gentleness all can use, and comprises synthetic direactive glyceride or two glyceryl ester.In addition, lipid acid such as oleic acid can be used for preparing injectable preparation.

Injectable preparation can pass through, for example, be detained the filter of bacterium, or sterilize by the disinfectant that mixes the aseptic solid composite form, the disinfectant of described aseptic fixing composition form can be dissolved in it or be scattered in sterilized water or other the aseptic injectable matrix before use.

In order to prolong the effect of The compounds of this invention, often need slow down compound and absorb from subcutaneous or intramuscularly.This can realize by the liquid suspension that use has relatively poor water miscible crystallization or an amorphism material.The uptake rate of compound just depends on its dissolution rate then, successively, can be depending on crystalline size and crystallized form.Optionally, the delay of the compound form of parenterai administration absorbs by with compound dissolution or be suspended in the oily vehicle and realize.Injectable storage form is by at biological degradation polyalcohol, makes as the micro-capsule matrix that forms compound in polylactide-polyglycolide.According to the ratio of compound and polymkeric substance and the character of used particular polymers, the rate of release of may command compound.The example of other biological degradation polyalcohol comprises poly-(ortho ester) and poly-(acid anhydrides).The injectable formulation that stores also can prepare by compound being imbedded in liposome compatible with when injected organism tissue or the micro emulsion.

The preferred suppository of composition that is used for rectum or vagina administration, they can pass through compound of the present invention and suitable nonirritant excipient or carrier, mix and prepare as Oleum Cocois, polyoxyethylene glycol or suppository wax, they at room temperature are solid, but be liquid under body temperature, therefore can in rectum or vaginal canal, dissolve and release of active compounds.

The solid dosage form that is used for oral administration comprises capsule, tablet, pill, pulvis and granule.In this solid dosage form, with active compound and at least a inertia, acceptable vehicle of pharmacy or carrier such as Trisodium Citrate or Lin Suanergai and/or a) weighting agent or filler such as starch, lactose, sucrose, glucose, mannitol, and silicic acid, b) binding agent as, for example, carboxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and gum arabic, c) wetting agent such as glycerine, d) disintegrating agent such as agar, lime carbonate, potato or tapioca (flour), Lalgine, some silicate, and yellow soda ash, e) dissolving delayed-action activator such as paraffin, f) absorption enhancer such as quaternary ammonium compound, g) wetting agent as, for example, hexadecanol and glyceryl monostearate, h) absorption agent such as kaolin and wilkinite, and i) lubricant such as talcum powder, calcium stearate, Magnesium Stearate, solid polyethylene glycol, sodium lauryl sulphate, and composition thereof mix.For capsule, tablet and pill, described dosage form also can comprise buffer reagent.

The solids composition of similar type also can be used as soft hard-fill the weighting agent in the gelatine capsule, wherein use vehicle such as lactose or lactose and high-molecular weight polyoxyethylene glycol etc.The solid dosage form of tablet, drageeing, capsule, pill and granule can be with dressing and housing, other dressing preparation of knowing as enteric coating and medicine formulation art.They can be chosen wantonly and comprise opacifying agent and only can also be, or preferred, at a certain specific part of enteron aisle, randomly, with the composition of delayed mode release of active ingredients.The example of available embedding component comprises polymeric material and wax.The solids composition of similar type also can be used as soft hard-fill the weighting agent in the gelatine capsule, wherein use vehicle such as lactose or lactose and high-molecular weight polyoxyethylene glycol etc.

Described active compound can also be the micro-capsule form with above-mentioned one or more vehicle.Other dressing preparation that the solid dosage form of tablet, drageeing, capsule, pill and granule can be known with dressing and housing such as enteric coating, controlled release coat and medicine formulation art.In this solid dosage form, described active compound can mix with at least a inert diluent such as sucrose, lactose or starch.This dosage form also can comprise, according to standard practices, and other material except that inert diluent, for example tablet lubricants and other compressing tablet used additives are as Magnesium Stearate and Microcrystalline Cellulose.With regard to capsule, tablet and pill, described dosage form also can comprise buffer reagent.They also can be chosen wantonly and comprise opacifying agent and only can also be, or preferably at the specific part of enteron aisle, randomly, with the composition of delayed mode release of active ingredients.The example of available embedding component comprises polymeric material and wax.

The dosage form that is used for part or transdermal administration The compounds of this invention comprises ointment, paste, creme, lotion, gel, pulvis, solution, sprays, inhalation or patch.Described activeconstituents mixes with pharmaceutically acceptable carrier under aseptic condition, and may need any required sanitas or buffer reagent.Ophthalmic preparation, ear drop and eye drops are also comprised within the scope of the present invention by expection.In addition, the present invention has expected the use of transdermal patch, and it has the attendant advantages of compound sustained release to human body.This dosage form can be by with compound dissolution or be scattered in the suitable medium and prepare.Absorption enhancer also can be used for increasing the flux that compound passes skin.Speed can be by providing the rate-controlling film or controlling by compound is dispersed in polymeric matrix or the gel.

As above general described, compound of the present invention can be used as kinases inhibitor.Therein in embodiment, compound of the present invention and composition are one or more inhibitor in JAK-3, ROCK and the Aurora isotype, and therefore, do not wish to be subject to any particular theory limit, described compound and composition be used in particular for treating or palliate a disease, the severity of illness or situation, wherein one or more activation relates to described disease, illness or situation among JAK-3, ROCK or the Aurora.When the activation of JAK-3 related to specific disease, illness or situation, described disease, illness or situation also can be known as " disease of JAK-3-mediation ", " disease of ROCK-mediation ", " disease of Aurora-mediation " or disease symptoms.Therefore, on the other hand, the invention provides a kind of be used for the treatment of or palliate a disease, the method for illness or situation severity, wherein one or more activation relates to described disease condition among JAK-3, ROCK or the Aurora.

In the present invention as the activity of the compound of JAK-3, ROCK or Aurora inhibitor can be external, in the body or in clone, measure.The external test method comprises the phosphorylation activity of mensuration activated JAK-3, ROCK or Aurora or the assay method that atpase activity suppresses.Optionally the external test method can quantize inhibitor and JAK-3, ROCK or Aurora bonded ability.Inhibitor be in conjunction with can separating inhibitor/JAK-3, inhibitor/ROCK or inhibitor/Aurora complex body by in conjunction with the described inhibitor of preceding radio-labeling, and measures radio-labeling bonded amount and measure.Optionally, inhibitor is in conjunction with measuring by the experiment that is at war with, wherein with new inhibitor and and known radioligand bonded JAK-3, ROCK or Aurora cultivation.

Term used herein " can suppress " to be meant with measuring and comprise described composition and JAK-3, ROCK or the kinase whose sample of Aurora and do not having to comprise under the condition of described composition JAK-3, ROCK or the active measurable change of Aurora between JAK-3, ROCK or the kinase whose sample of equal value of Aurora.

Term used herein " disease of JAK-mediation " is meant any disease or other harmful illness that known JAK family kinase works.This illness comprises, but be not limited to, immune response such as allergy or type i allergic reaction, asthma, autoimmune disease such as transplant rejection, graft versus host disease, rheumatoid arthritis, amyotrophic lateral sclerosis and multiple sclerosis, neurodegenerative disorders are as familial amyotrophic lateral sclerosis (FALS) and entity and hematologic malignancies such as leukemia and lymphoma.

Term used herein " illness of ROCK-mediation " or " disease " are meant any disease or other the harmful illness that known ROCK family kinase works.Term " illness of ROCK-mediation " or " disease " also refer to those diseases or the situation by alleviating with the ROCK inhibitor for treating.This class situation comprises, but be not limited to, hypertension, stenocardia, cerebrovascular atrophy, asthma, peripheral circulation illness, premature labor, cancer, erectile dysfunction, arteriosclerosis, spasm (cerebral vasospasm and coronary artery spasm), retinopathy (for example, glaucoma), inflammatory conditions, autoimmune disorder, AIDS, osteoporosis, myocardial hypertrophy, local asphyxia/again damage of perfusion-inductive or endothelial dysfunction.

Term used herein " illness of Aurora-mediation " or " disease " are meant any disease or other the harmful illness that known Aurora family kinase works.Term " illness of Aurora-mediation " or " disease " also refer to those diseases or the situation by alleviating with the Aurora inhibitor for treating.This class situation comprises, but be not limited to, immune response, as allergy or type i allergic reaction, asthma, autoimmune disease such as transplant rejection, graft versus host disease, rheumatoid arthritis, amyotrophic lateral sclerosis and multiple sclerosis, neurodegenerative disorders such as familial amyotrophic lateral sclerosis (PALS) and entity and hematologic malignancies, as leukemia and lymphoma.

It is also understood that compound of the present invention and pharmacy acceptable composition can be used in the conjoint therapy, that is, described compound and pharmacy acceptable composition can with one or more other required treatment or medical procedure simultaneously, before it or afterwards, give.The particular combinations that is used for the therapy (treatment or process) of scheme for combining will be considered the consistency of the result of treatment of required treatment and/or process and desired acquisition.It is also recognized that used therapy can (for example obtain desirable effect with respect to same illness, compound of the present invention can with other medicament that is used for the treatment of same illness administration simultaneously), or they can obtain different effect (for example, the control of any side effect).Other therapeutical agent used herein, that be administered for treatment or prevention specified disease or illness usually is known as " be suitable for treated disease or illness ".

Can include, but are not limited to the example of the medicament of inhibitor Combined Preparation of the present invention: the treatment of Alzheimer such as Aricept

And Excelon

Parkinsonian treatment such as L-DOPA/ carbidopa, Entacapone, Ropinrole, send rummy Soviet Union, bromocriptine, PERGLIDE, Trihexyphenidyl (trihexephendyl) and amantadine; The medicament such as beta-interferon (for example, the Avonex of treatment multiple sclerosis (MS)

And Rebif

), Copaxone

, and mitoxantrone; Treatment of asthma such as salbutamol and Singulair

Be used for the treatment of schizoid medicament such as olanzapine, Wei Sitong, quetiapine and (halogen) haloperidol; Anti-inflammatory agent such as reflunomide, TNF blocker, IL-1RA, azathioprine, endoxan and sulfasalazine; Immunomodulatory and immunosuppressor such as S-Neoral, tacrolimus, rapamycin, mycophenlate mofetil, Interferon, rabbit, reflunomide, endoxan, azathioprine and sulfasalazine; Neurotrophic factor such as acetylcholinesterase depressant, MAO inhibitor, Interferon, rabbit, anticonvulsive agent, ion channel blocking agent, Riluzole and antiparkinsonian medicament; The medicament such as beta blocker, ACE inhibitor, diuretic(s), nitrate, calcium channel blocker and the Statins that are used for the treatment of cardiovascular diseases; The medicament such as reflunomide, Colestyramine, Interferon, rabbit and the antiviral agent that are used for the treatment of hepatopathy; Be used for the treatment of the medicament of hematologic disease such as reflunomide, anti--leukemic medicament and somatomedin; And the medicament such as the gamma globulin that are used for the treatment of the immunodeficiency disease.

The consumption that is present in other therapeutical agent in the present composition can not surpass the consumption that gives usually in only comprising the composition of this therapeutical agent as promoting agent.Preferably, the consumption of other therapeutical agent in the present disclosed composition only comprises the about 50%-100% of this medicament as consumption in the composition of therapeutic activity agent for being present in usually.

Compound of the present invention or its pharmacy acceptable composition also can be incorporated into and be used to apply implantable medical treatment device, in the composition as prosthese, artificial valve, blood vessel graft, stent and conduit.Therefore, but the present invention comprises the composition that is used to apply injection device on the other hand, The compounds of this invention of describing in general description and class herein and the group above it comprises and the carrier that is suitable for applying described implantable device.On the other hand, but the present invention includes the injection device that applies with composition, the The compounds of this invention of describing in general description and class herein and the group above said composition comprises, and the carrier that is suitable for applying described implantable device.

Vascular transplantation sheet fixed mould for example, has been used to overcome restenosis (restenosis of damage back vessel wall).Yet the patient of use stent or other implantable device has the danger of grumeleuse formation or platelet activation.These deleterious effects can prevent or relax by apply described device in advance with the pharmacy acceptable composition that comprises kinase inhibitor.The generality preparation of the suitable dressing and the implantable device of coating is at United States Patent (USP) 6,099, describes in 562,5,886,026 and 5,304,121.Dressing normally the polymeric material of biocompatible such as aquogel polymer, poly-methyl sily oxide, polycaprolactone, polyoxyethylene glycol, poly(lactic acid), ethylene vinyl acetate, and composition thereof.Described dressing also can be chosen wantonly by the suitable dressing of fluorosilicone, polysaccharide, polyoxyethylene glycol, phosphatide or its combination and further cover, thereby gives the composition controlled release characteristics.

The present invention relates to JAK-3, ROCK or the Aurora activity that suppresses among biological sample or the patient on the other hand, and this method comprises and give the patient, or makes the compound of described biological sample and general formula I or comprise described compound compositions and contact.Term used herein " biological sample " includes, but not limited to cell culture or its extract; Biopsy material from Mammals or the acquisition of its extract; And blood, saliva, urine, ight soil, tear or other body fluid or its extract.

The inhibition of JAK-3, ROCK or Aurora kinase activity can be used for various purpose well known by persons skilled in the art in the biological sample.The example of this purpose includes, but not limited to blood transfusion, organ transplantation, biological sample storage and biological assay.

Embodiment

Though describe the embodiment of specific illustrative below in detail, will be appreciated that other compound of general formula I can be according to the general method of describing herein, by those of ordinary skills' used method usually, use suitable initial substance and prepare.

Flow process 1

3-bromo-1H-pyrrolo-[2,3-b] pyridines (2)

(4g, 0.025mol) solution that is dissolved in the 100mL chloroform is cooled to 0 ℃ with azaindole 1.Dripping bromine is dissolved in the solution of 20mL chloroform, and 0 ℃ was stirred the gained mixture 1 hour.With 0.5N HCl dilution gained suspension, make the water layer alkalization with 0.5N NaOH, and cross filter solid, obtain 4g (82%) crude product 2, it is directly used in next step.

3-bromo-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridines (3)

2 solution that are dissolved in the anhydrous THF of 20mL of 3g (0.015mol) are cooled to-78 ℃, just dripping-BuLi 2.5M is dissolved in hexane (6.7mL, solution 0.167mol).Stir after 15 minutes, drip the solution that toluene sulfonyl chloride is dissolved in 5mL THF.Removed cooling bath and stirring at room reaction mixture 1 hour.With the ether extraction and with salt water washing organic phase, with dried over mgso and vacuum concentration, obtain white solid, make it through silicon-dioxide pad (70%EtOAc then; 30% hexane), obtain 3 of 4.65g (84%). ¹H NMR CDCl ₃ 8.4(s，1H)，8.1(d，2H)，7.8(s，2H)，7.2(m，3H)，2.3(s，3H)。

3-(4,4,5,5-tetramethyl--[1,3,2] two oxa-boron pentamethylene (dioxaborolan)-2-yls)-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridines (4)

With 3 (850mg 0.0024mol) is dissolved among the 20mL DME, add the pinnacol borine (921mg, 0.0036mol), Pd ₂Cl ₂(dppf) ₂(197mg, 0.24mmol) and KOAc (713mg, 0.00726mol), 90 ℃ were stirred and reflux this mixture 18 hours.With ethyl acetate dilution and water and salt water washing organic phase, dry then (Na ₂SO ₄) and vacuum concentration.Make resistates obtain the required product 4 of 900mg (99%) through flash chromatography (20%E t OAc/80% hexane).

3-(2-methyl sulfane base-pyrimidine-4-yl)-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3b] pyridines (5)

Under the nitrogen, make boric acid ester (boronic ester) 4 (900mg, 0.0023mol), 4-chloro-2-thiomethyl pyrimidine (341mg, 0.0029mol), Pd (Ph ₃P) ₄(260mg, 0.23mmol) and 2M yellow soda ash (3.4mL, 0.0068mol) mixture that is dissolved in 20mL DME refluxed 18 hours.With ethyl acetate dilution and water and salt water washing organic phase, dry then (Na ₂SO ₄) and vacuum concentration.Make resistates through flash chromatography (40%Et OAc/60% hexane), obtain the required product 5 of 460mg (51%). ¹H NMR CDCl ₃ 8.8(d，1H)，8.7(m，2H)，8.4(s，1H)，8.1(d，2H)，7.2(m，4H)，2.6(s，3H)，2.3(s，3H)。

3-(2-methylsulfonyl-pyrimidine-4-yl)-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridines (6)

With pyrimidine 5 (460mg 0.0012mol) is dissolved in the 20mL methanol-water (1: 1), add then oxone (2.14g, 0.0035mol), back flow reaction 18 hours.Vacuum is removed methyl alcohol and is used the ethyl acetate extraction water.Water and salt water washing organic phase, dry then (Na ₂SO ₄) and vacuum concentration.Make resistates through flash chromatography (40%EtOAc/60% hexane), obtain the required product 6 of 160mg (32%).LCMS ES ⁺＝428.9。

Under (7) 80 ℃ of the benzyls-[4-(1H-pyrrolo-[2,3-b] pyridin-3-yl)-pyrimidine-2-base]-amine, in the sealing test tube, heat 6 (20mg, 0.047mmol) and benzylamine (0.007mL 0.061mmol) is dissolved in 1mL alcoholic acid solution 18 hours.Evaporating solvent obtains the 20mg product also by preparation type TLC (50%EtOAc/50% hexane) purifying crude product, uses 2ml 3N NaOH methanol solution to make the product deprotection 4 hours then.Add 2mL 3N HCl and be evaporated to dried.(20-70%MeCN-water and 0.1%TFA (20mL/ branch) obtain 7 of 10mg (75%) to reversed-phase HPLC. ¹H NMR DMSOD ₆ 8.7(s，1H)，8.4(s，1H)，8.25(d，1H)，8.1(d，1H)，7.4(m，2H)，7.25(m，3H)，7.2(s，1H)，7.15(dd，1H)，7.1(s，1H)，4.8(s，2H)。LCMS ES ⁺＝302.0。

3-(6-chloro-pyrimidine-4-yl)-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridines (8)

160 ℃ of microwave heating boric acid esters (boronate) 4 (0.11g, 0.276mmol), 4, the 6-dichloro pyrimidine (0.049g, 0.331mmol), catalysis Pd (PPh ₃) ₄Be dissolved in the solution 5 minutes of DMF with excessive salt of wormwood, by TLC (20%EtOAc: hexane) change into product.At EtOAc/H ₂Distribute in reactant, extraction, the vacuum stripping between the O and by silicagel column purifying (eluent: 5%EtOAc: hexane), obtain white solid 8 (0.035g), productive rate 33%.

1-{4-[6-(1H-pyrrolo-[2,3-b] pyridin-3-yl)-pyrimidine-4-yl]-[1,4] Diazesuberane-1-yl }-ethyl ketone (9)

80 ℃ of heating 8 (0.035g, 0.091mmol), (0.025g, 0.181mmol), excessive salt of wormwood is dissolved in the solution of DMF, color changes N-ethanoyl-Gao piperazine piperazine (homopiperizine) after 5 minutes.LC/MS and TLC show the product that is converted into the tosyl group protection after 15 minutes.In reactant, add 1ml 6N NaOH and 1ml methyl alcohol, remove the tosyl group group immediately by LC/MS (M+1=337).At EtOAc/H ₂Distribute reactant and extraction between the O.By preparation HPLC purifying crude product, obtain clarifying buttery 9 (0.022g), productive rate 73%.

NMR：MeOD 2.0bs(2H)，2.1s(3H)，3.6m(2H)，3.8-4.3bm(6H)，7.1d(1H)，7.3m(1H)，8.2d(1H)，8.35m(2H)，8.65d(1H)。LC/MS(M+1)＝337

Benzyl-(2-chloro-pyrimidine-4-yl)-amine (10)

To 2,4-dichloro pyrimidine (0.15g, 1.0mmol), benzylamine (0.109ml, 1.0mmol) be dissolved in the solution of THF and add DIPEA (0.526ml, 3.0mmol) and heating reflux reaction 2 hours, by TLC (5% methyl alcohol: methylene dichloride) form 4: 1 mixtures of regional isomer (required with unwanted).The stripping reactant is also by silicagel column purifying (eluent: 2% methyl alcohol: methylene dichloride), obtain the required product 10 of 0.12g (0.548mmol), productive rate 54% in the vacuum.LC/MS(M+1)＝220

Benzyl-(6-chloro-pyrimidine-4-yl)-amine (12)

With benzylamine (0.697ml 6.76mmol) joins 4, the 6-dichloro pyrimidine (1.0g, 6.76mmol) in, cause vigorous reaction and colour-change.With the slow diluting reaction thing of methylene dichloride, produce white precipitate.Add the 1ml triethylamine, and TLC shows and changes into product (5%MeOH: methylene dichloride).Directly install on the silicon-dioxide reactant and purifying (eluent: 2%MeOH: methylene dichloride), obtain 12 of yellow waxy 1.17g (5.32mmol), productive rate 79%.

Benzyl-[2-(1H-pyrrolo-[2,3-b] pyridin-3-yl)-pyrimidine-4-yl]-amine (11)

160 ℃ of microwave heating 4 (0.36g, 0.09mmol), 10 (0.028g, 0.108mmol), 2.0M Na ₂CO ₃(0.108ml is 0.271mmol) with catalysis PdCl ₂(PPh ₃) ₂Be dissolved in the solution 5 minutes of 1ml DMSO, be converted into the product of tosyl group protection, LC/MS (M+1)=456.(0.026g, 0.271mmol), 160 ℃ of microwave heating 5 minutes is converted into product 11 fully to add NaOtBu in reactant.The filtering reaction thing also passes through the preparation HPLC purifying, obtains the 0.0032g 11 of white solid, productive rate 11%.

NMR：MeOD 4.95bs(2H)，6.6d(1H)，7.2m(1H)，7.3-7.5mm(5H)，8.0d(1H)，8.3d(1H)，8.4s(1H)，8.55d(1H)。LC/MS(M+1)＝302

End product 13 obtains 0.012g (0.039mmol) white solid 13 according to 11 described formation.NMR：MeOD 4.8s(2H)，7.05s(1H)，7.2-7.6m(6H)，8.2s(1H)，8.4m(2H)，8.55s(1H).LC/MS(M+1)＝302

Flow process 2Synthesizing of 5-H-azaindole pyrimidine and pyridine analogs

3-(2-chloro-pyridin-4-yl)-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridines (14)

Under nitrogen, 160 ℃ of microwave heating azaindoles 3 (80mg, 0.23mmol), 2-chloropyridine-4-boric acid (41mg, 0.27mmol), Pd (Ph ₃P) ₄(20mg, 0.11mmol) and 2M yellow soda ash (.34mL 0.68mmol) is dissolved in the mixture 15 minutes of 2mL DME.With ethyl acetate dilution and water and salt water washing organic phase, dry then (Na ₂SO ₄) and vacuum concentration.Make resistates obtain the required product 14 of 60mg (68%) through flash chromatography (40%EtOAc/60% hexane). ¹H NMR CDCl ₃ 8.6(d，2H)，8.1(m，4H)，7.25(m，5H)，2.5(s，3H)。For example, available benzylamine replaces 2-chloropyridine microwave reaction 30 minutes under 250 ℃ of conditions, and then deprotection obtains compound 15.

1-(5-bromo-1H-pyrrolo-[2,3-b] pyridin-3-yl)-ethyl ketone (16)

(2.16g 0.011mmol) is dissolved among the anhydrous DCM of 75mL with 7-azaindole 13.In solution, add aluminum chloride (4.36g, 0.0327mol) and stirring at room reaction mixture 1 hour.Dripping acetyl chloride in mixture (1.16mL, 0.0164mol) and stirring at room 18 hours.Adding 20mL methyl alcohol also reacted 1 hour.Vacuum concentration also is suspended among water-EtOAc.With EtOAc extraction and dry organic phase, behind the vacuum concentration, obtain 2.37g (91%) compound 14. ¹H NMRCDCl ₃ 9.5(bs，1H)，8.8(s，1H)，8.5(s，1H)，7.9(s，1H)，2.4(s，3H)。

1-[5-bromo-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridin-3-yl]-3-dimethylamino-acrylketone (propenone) (17)

0 ℃, (263mg is dissolved in slowly adds 16 in the suspension of anhydrous THF 0.0104mol) that (2.37g 0.01mol) is dissolved in the solution of THF to NaH.0 ℃ was stirred 15 minutes, and (2.27g 0.012mol) is dissolved in the solution of THF, stirring at room reaction mixture 18 hours to add Tosyl chloride then.With water quenching and use ethyl acetate extraction.Dry organic layer and vacuum concentration obtain the 3.37g solid residue, and it is directly used in next step.(5.7mL 0.0428mol) mixes, 100 ℃ of heating 22 hours with above-mentioned intermediate and DMF-DMA.Vacuum concentration, and, obtain the required product 15 of 3.37g (76% comes from 17) through flash chromatography (60%EtOAc/40% hexane). ¹H NMR CDCl ₃ 8.8(s，1H)，8.3(s，1H)，8.1(s，1H)，8.05(d，2H)，7.8(d，1H)，7.2(s，2H)，5.7(d，1H)，3.0(bs，6H)，2.2(s，3H)。

6-(5-bromo-1H-pyrrolo-[2,3-b] pyridin-3-yl)-1H-pyrimidine-2-thioketones (thione) (18)

To the sodium of prepared fresh (175mg, 0.0076mol) be dissolved in add continuously in the solution of ethanol (18mL) compound 17 (1.0g, 0.0022mol) and thiocarbamide (187mg, 0.0025mol).This mixture of reflux 4 hours.Except that desolvating and resistates being dissolved in the 8mL water.With 1N HCl neutralization solution and use ethyl acetate extraction.Dry organic phase and vacuum concentration provide 570mg (75%) technical purified 18. ¹H NMR CDCl ₃ 12.2(s，1H)，8.6(s，1H)，8.3(s，1H)，8.2(s，1H)，7.6(d，1H)，5.8(d，1H)。

5-bromo-3-(2-methyl sulfane base-pyrimidine-4-yl)-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridines (19)

Reflux 18 (565mg, 0.0018mol), sodium acetate (526mg, 0.0039mol), (0.126mL 0.0020mol) is dissolved in the suspension 2 hours of 15mL ethanol-THF (9: 1) to methyl iodide.Be cooled to room temperature and filtration.Chromatogram (70%EtOAc-30% hexane) provides 48mg (9%) thiomethyl intermediate.Tosylation provides 49mg (70%) required compound 19. ¹H NMR CDCl ₃8.8(d，1H)，8.5(m，2H)，8.35(s，1H)，8.1(d，2H)，7.25(m，3H)，2.7(s，3H)，2.3(s，3H)。

Benzyl-[4-(5-bromo-1H-pyrrolo-[2,3-b] pyridin-3-yl)-pyrimidine-2-base]-amine (20)

This compound can be replaced through oxone oxidation and benzylamine since 19, according to flow process 1 preparation.

Flow process 3Synthesizing of azaindole pyrimidine that 5-replaces and pyridine analogs

5-bromo-1-(tert-butyl-dimethyl-silylation)-1H-pyrrolo-[2,3-b] under (19) 0 ℃ of the pyridines, (200mg 0.0078mol) is dissolved in and adds azaindole 13 in the suspension of 15mL dry DMF (1.36g 0.007mol) is dissolved in the solution of 5mL DMF to NaH.0 ℃ was stirred 10 minutes, added the solution that TBDMSCl is dissolved in 3mL DMF, stirred gained mixture O.N..Put into EtOAc and water, salt water washing.Dry organic layer and vacuum concentration become oil, and it is used for next step under situation about not being further purified. ¹H NMR CDCl ₃ 8.3(d，1H)，7.9(d，1H)，7.2(d，1H)，6.4(d，1H)，0.85(s，H)，0.5(s，6H)。

1-(tert-butyl-dimethyl-silylation)-5-pyridin-3-yl-1H-pyrrolo-[2,3-b] pyridines (20)

Under the nitrogen, and to 19 (1.77g, 0.0057mol), (1.0g 0.0068mol) is dissolved in the solution of 80mL DME and adds PdCl 3-parvoline base borine ₂(Ph ₃P) ₂(320mg, 0.455mmol) and the 2M aqueous sodium carbonate (8.5mL, 0.017mol).Made reaction mixture refluxed 3 hours.Be cooled to room temperature and, use the salt water washing with the ethyl acetate dilution.Dry organic layer also is condensed into oil, and it obtains 1g (57%) desired substance 20 through flash chromatography (30%EtOAc-70% hexane). ¹H NMR CDCl ₃8.9(s，1H)，8.5(d，1H)，8.4(d，1H)，8.0(d，1H)，7.9(d，1H)，7.5(d，1H)，7.2(d，1H)，6.5(d，1H)，0.85(s，9H)，0.55(s，6H)。

3-bromo-1-(tert-butyl-dimethyl-silylation)-5-pyridin-3-yl-1H-pyrrolo-[2,3-b] pyridines (21)

Under 0 ℃, (0.166mL 0.0032mol) is dissolved in 1mL CCl with bromine ₄Drips of solution be added to 20 (1.0g, 0.0032mol) and pyridine (0.314mL 0.0039mol) is dissolved in anhydrous CHCl ₃In the stirred solution (30ml).0 ℃ of stirred reaction mixture 1 hour is used mixture (1: the 1) neutralization of 10mL sodium bicarbonate-Sulfothiorine then.Separate organic layer, and further extract, dry organic layer and the vacuum-drying that merges with methylene dichloride (3X10mL).Resistates obtains 0.97g (78%) desired substance 21 through flash chromatography (30%EtOAc-70% hexane). ¹H NMRCDCl ₃ 8.9(s，1H)，8.55(d，1H)，8.4(d，1H)，8.0(d，1H)，7.9(d，1H)，7.4(dd，1H)，7.2(s，1H)，0.9(s，9H)，0.5(s，6H)。

5-pyridin-3-yl-3-(4,4,5,5-tetramethyl--[1,3,2] two oxa-boron pentamethylene-2-yls)-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridines (22)

Compound 21 can use, and for example, the 10%HCl desilylationization is also used, for example, and NaH and p-toluenesulfonyl chloride tosylation.Compound 22 can use the scheme preparation identical with compound 4 in the flow process 1.

3-(2-methylsulfonyl-pyrimidine-4-yl)-5-pyridin-3-yl-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridines (24)

Compound 24 can use the scheme preparation identical with compound 6 in the flow process 1.

3-(6-chloro-pyrimidine-4-yl)-5-pyridin-3-yl-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridines (25)

Compound 25 can use the scheme preparation identical with compound 8 in the flow process 1.

3-(2-chloro-pyridin-4-yl)-5-pyridin-3-yl-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridines (26)

Compound 26 can use the scheme preparation identical with compound 14 in the flow process 2.

Flow process 4

2-methoxyl group-4-[1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridin-3-yl]-benzonitrile (29)

With the azaindole 3 (65.5mg, 194 μ mol) of boric acid 28 (35.4mg, 200 μ mol) and tosyl group protection, yellow soda ash (61.8mg, 583 μ mol) and tetrakis triphenylphosphine palladium (0) (8.3mg, 7.2 μ mol) are put in the test tube.Add entry (323mg) and glycol dimethyl ether (848mg) and make the mixture deoxidation.With the test tube sealing, under the magnetic stirring condition, 160 ℃ were heated 10 minutes, and wherein utilized microwave radiation.With ethyl acetate and water extraction crude product.With salt water washing organic phase, dry on sodium sulfate, filter and concentrate, obtain crude product (83mg).Be dissolved in the solution gradient wash-out of methyl alcohol via the purification by flash chromatography crude product and with 1: 1 ethyl acetate/hexane-100% ethyl acetate-4/4/1 ethyl acetate/hexane/7N ammoniacal liquor, obtain 29 (42mg, 54%) and 30 (7.7mg, 15%).

2-methoxyl group-4-(1H-pyrrolo-[2,3-b] pyridin-3-yl)-benzonitrile (30)

By (200 μ l 2eq.) refluxed 4.5 hours in the De diox (5ml) and remove tosyl group blocking group in 29 containing 1N sodium hydroxide.The concentration response thing, and with the extraction of ethyl acetate and saturated sodium bicarbonate aqueous solution.With salt water washing organic phase, dry on sodium sulfate, filter and concentrate, obtain 30 (30mg, 100%). ¹H NMR CD ₃CN 10.00(s，1H)，8.32(m，2H)，7.83(s，1H)，7.65(d，1H)，7.40(m，2H)，7.20(dd，1H)，4.02(s，3H).LC/MS(M+1)＝250

2-methoxyl group-4-(1H-pyrrolo-[2,3-b] pyridin-3-yl)-benzamide (31)

(10mg, 40 μ mol) are dissolved in the dimethyl sulfoxide (DMSO) (0.5ml) with nitrile 30.To the solution that wherein adds salt of wormwood (20mg) and 30% hydrogen peroxide water-soluble (100 μ l).Reactant is warmed to about 60 ℃ reaches 15 minutes.Reactant is concentrated into the dry doubling water to be ground.Filtration gained precipitation, and vacuum-drying spends the night, and obtains 31 (10mg, 93%).1H NMR DMSO-d6 11.99(s，1H)，8.32(d，1H)，8.24(m，1H)，8.01(m，1H)，7.88(d，1H)，7.59(s，1H)，7.40(s，1H)，7.37(m，2H)，7.15(dd，1H)，4.00(s，3H)。LC/MS(M+1)＝268。

Flow process 5

Boric acid 32B-32F (500 μ mol) is placed in the test tube that contains azepine indoles 3 (87mg, 250 μ mol).In each bottle, put into yellow soda ash (53mg, 500 μ mol) and tetrakis triphenylphosphine palladium (0) (15mg, 13 μ mol).Add entry (1ml) and glycol dimethyl ether (2ml) and with the test tube deoxidation and the sealing.With test tube via microwave heating to 140 ℃ 10 minutes.Reactant is cooled to 0 ℃ also to quench with 2N aqueous hydrochloric acid (1ml).Use the ethyl acetate extraction reactant.With salt water washing organic phase, dry on sodium sulfate, filter and concentrate.Go up purified product at silicon-dioxide (50% ethyl acetate/hexane-100% ethyl acetate gradient), obtain 33B-33F.

Under the room temperature, compound 33B-33F is dissolved in the methyl alcohol (20ml) and spends the night with 2N aqueous sodium hydroxide solution (1ml) processing.With 2N hydrochloric acid (1ml) neutralization reactant and be concentrated into dried.Via silica gel chromatography (50% ethyl acetate/hexane-100% ethyl acetate gradient) or on C18, carry out the directed reverse-phase chromatography of quality and (contain 15% acetonitrile/water of 0.09% trifluoroacetic acid-contain, 35% acetonitrile/water of 0.09% trifluoroacetic acid, 15 minutes) purifying, obtain product 34B-34F.

3-(3-benzyloxy-phenyl)-1H-pyrrolo-[2,3-b] pyridines (34B).

¹H NMR DMSO-d6 11.95(s，1H)，8.29(m，1H)，8.20(d，1H)，7.89(s，1H)，7.49(d，2H)，7.41(t，2H)，7.34(m，2H)，7.29(m，2H)，7.13(dd，1H)，6.90(m，1H)，5.20(s，2H).LC/MS(M+1)＝301.

3-(4

Benzyloxy

Phenyl)-1H-pyrrolo-[2,3-b] pyridines (34C).

¹H NMR DMSO-d6 11.84(s，1H)，8.28(m，2H)，7.76(s，1H)，7.61(d，2H)，7.48(d，2H)，7.39(t，2H)，7.32(t，1H)，7.15(dd，1H)，7.09(d，2H)，5.13(s，2H).LC/MS(M+1)＝301.

3-(3,4-dimethoxy-phenyl 1)-1H-pyrrolo-[2,3-b] pyridines (34D).

¹H NMR DMSO-d6 11.90(s，1H)，8.31(d，1H)，8.28(d，1H)，7.80(s，1H)，7.21(m，2H)，7.19(dd，1H)，7.02(d，1H)，3.86(s，3H)，3.78(s，3H).LC/MS(M+1)＝255.

3-(3,4,5-dimethoxy-phenyl)-1H-pyrrolo-[2,3-b] pyridines (34E).

¹H NMR DMSO-d6 11.85(s，1H)，8.29(d，1H)，8.27(d，1H)，7.83(s，1H)，7.15(d，1H)，6.92(s，2H)，3.86(s，6H)，3.69(s，3H).LC/MS(M+1)＝285.

2-methoxyl group-4-(1H-pyrrolo-[2,3-b] pyridin-3-yl)-phenol (34F).

¹H NMR DMSO-d6/D ₂O 8.25-8.30(m，2H)，7.74(s，1H)，7.20(d，1H)，7.17(dd，1H)，7.10(dd，1H)，6.86(d，1H)，3.88(s，3H).LC/MS(M+1)＝241.

Flow process 6

2-methoxyl group-5-[1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridin-3-yl]-phenyl aldehyde (36)

In test tube, put into boric acid ester 35 (131mg, 500 μ mol) and 3 (175mg, 500 μ mol), yellow soda ash (114mg, 1.08mmol) and tetrakis triphenylphosphine palladium (0) (22mg, 19 μ mol).Add entry (0.9g) and glycol dimethyl ether (2.1g) and make the mixture deoxidation.With test tube sealing and under the magnetic stirring condition, be heated to 110 ℃ and spend the night.With ethyl acetate and water extraction crude product.With salt water washing organic phase, dry on sodium sulfate, filter and concentrate, obtain crude product.Be dissolved in solution gradient wash-out in the methyl alcohol via the purification by flash chromatography crude product and with 1: 1 ethyl acetate/hexane-100% ethyl acetate-4/4/1 ethyl acetate/hexane/7N ammoniacal liquor, obtain 36 (98mg, 48%).

2-methoxyl group-5-[1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridin-3-yl]-benzonitrile (37)

(98mg, 241 μ mol) are dissolved in the tetrahydrofuran (THF) (5ml) with aldehyde 36.To wherein adding 30% ammoniacal liquor (3ml) and iodine (79mg, 313 μ mol).The stirring at room reaction is spent the night.The dilute with water reactant is also used ethyl acetate extraction.With S-WAT (50mg) water (10ml) solution washing organic phase.With salt water washing organic phase, dry on sodium sulfate, filter and concentrate, obtain 37 (95.8mg, 98%).

2-methoxyl group-5-(1H-pyrrolo-[2,3-b] pyridin-3-yl)-benzonitrile (38)

Nitrile 37 (95.8mg, 237 μ mol) is dissolved in the diox (5ml) also with water-soluble solution (250 μ l, the 500 μ mol) processing of 2N sodium hydroxide.With reactant sealing and reflux 2 hours.Reactant is concentrated into dry doubling to extract with ethyl acetate and water.With salt water washing organic phase, dry on sodium sulfate, filter and the concentrated crude product (72.3mg) that obtains.Be dissolved in the solution gradient wash-out of methyl alcohol via the purification by flash chromatography crude product and with 1: 1 ethyl acetate/hexane-100% ethyl acetate-4/4/1 ethyl acetate/hexane/7N ammoniacal liquor, obtain 38 (26.7mg, 45%).

2-methoxyl group-5-(1H-pyrrolo-[2,3-b] pyridin-3-yl)-benzamide (39)

The nitrile 38 (26.7mg, 107 μ mol) of piptonychia benzenesulfonyl is dissolved in the dimethyl sulfoxide (DMSO) (2.49g).Spend the night to wherein adding salt of wormwood (32.7mg, 237 μ mol) and the solution and the stirring at room reactant of 30% hydrogen peroxide water-soluble (85.5mg).Dilute with water reactant and water, acetonitrile and ether washing gained precipitation obtain end product 39 (25.3mg, 88%). ¹H NMRDMSO-d6 11.86(s，1H)，8.28(m，1H)，8.19(d，1H)，8.11(m，1H)，7.81(m，2H)，7.70(s，1H)，7.55(s，1H)，7.21(d，1H)，7.16(m，1H)，3.91(s，3H).LC/MS(M+1)＝268

4-bromine 2-HOMOVERATRONITRILE

In the 1L round-bottomed flask, 53.94g (270mmol) 4-bromo-2-fluorine benzonitrile is dissolved among the 500mLTHF.Add sodium methylate (21.99g, 407mmol) and this mixture of reflux up to TLC (SiO ₂: CH ₂Cl ₂) show that initial substance exhausts fully.This mixture is poured among the 1N HCl, and vacuum-evaporation THF.Extract remaining mixture with diethyl ether.Dry (MgSO ₄) extract and filter through silica gel plug.Use CH ₂Cl ₂Wash-out stopper and vacuum-evaporation filtrate obtain 45.56g (80%) white solid product. ¹H NMR(500MHz，CDCl ₃)δ7.42(d，1H)，7.17(dd，1H)，7.14(d，1H)，3.95(s，3H)。

4-cyano group-3-anisole ylboronic acid (28)

Assembling overhead and nitrogen pipeline on the 1L of 3 necks round-bottomed flask.45.56g (215mmol) 4-bromo-2-HOMOVERATRONITRILE, 64mL (277mmol) three-sec.-propyl borate and 500mL THF pack in flask.In dry ice/acetone batch, solution is cooled to-78 ℃.Via addition funnel drip n-Butyl Lithium (2.5M, 110mL, 275mmol).Stir this mixture 30 minutes and added 2N HCl.Stirred the mixture 1 hour and pour in the water.Use Et ₂O extracts mixture.With 1N NaOH reextraction organic solution.Use Et ₂O washing water layer is also with dense HCl acidifying.Use Et ₂O extracts mixture.Dry organic extract (MgSO ₄) and vacuum-evaporation obtain 20.77g (55%) white solid product. ¹H NMR(500MHz，d6-DMSO)87.68(d，1H)，7.59(s，1H)，7.47(d，1H)，3.95(s，3H).

Flow process 7:

5-chloro-3-iodo-pyridine-2-base amine (40)

With iodine (16.28g, 64mmol) join 1-amino-5-chloropyridine (8.25g, 64mmol) and Sulfuric acid disilver salt (20g 64mmol) is dissolved in the 400mL alcoholic acid mixture, this mixture of stirring at room 20 hours.On the C ore deposit, filter this mixture and solvent removed in vacuo.Resistates is dissolved among the DCM (600mL) also with the 5%NaOH aqueous solution (500mL), water and salt water washing.Dry organic layer and vacuum concentration obtain solid residue, and it produces 9.8g (60%) 40 through flash chromatography (20%EtOAc-80% hexane). ¹H NMR(500MHz，CDCl3)7.9(s，1H)，7.7(s，1H)，5.0(bs，2H)。

5-chloro-2-(triethyl-silylation)-1H-pyrrolo-[2,3-b] pyridines (41)

Add 40 (9.5g, 37.3mmol) be dissolved in 320mL DMF and triethylsilyl acetylene (20mL, 112mmol), Pd ₂Cl ₂(dppf) ₂(1.52g, 1.9mmol), lithium chloride (1.58g, 37.3mmol) and 2M Na ₂CO ₃(7.9mL, mixture 74.7mL) stir this mixture and 90 ℃ and refluxed 15 hours under condition of nitrogen gas.With ethyl acetate-ether mixture (1: 1) dilution and water and salt water washing organic phase, dry then (Na ₂SO ₄) and vacuum concentration.Make resistates obtain the required product 41 of 4.37g (44%) through flash chromatography (20% EtOAc/80% hexane). ¹HNMR(500MHz，CDCl ₃)9.4(bs，1H)，8.2(s，1H)，7.9(s，1H)，6.6(s，1H)，0.9(t，9H)，0.75(q，6H)。

5-chloro-1H-pyrrolo-[2,3-b] pyridines (42)

(4.37g 0.0164mol) is dissolved among the THF with compound 41.Adding molecular sieve (10g3A), then is TBAF (32.75mL, 0.0328).Stirring at room reaction mixture 5 hours.Dilute also water, salt water washing several times with ethyl acetate, dry organic layer and vacuum concentration become oil, and it obtains 0.23g (90%) desired substance 42 through flash chromatography (30%EtOAc-70% hexane). ¹H NMR DMSO d ₆ 11.8(bs，1H)，8.2(s，1H)，8.1(s，1H)，7.5(s，1H)，6.5(s，1H)。

1-(tert-butyl-dimethyl-silylation)-5-chloro-1H-pyrrolo-[2,3-b] pyridines (43)

In the spaced sealing test tube of assembling, under nitrogen, (600mg 0.00396mol) is cooled to 0 ℃ with the anhydrous THF of 20mL and with solution to add 42.Add gradually NaH (110mg, 0.00435mol), 0 ℃ was stirred after 15 minutes, add TBSCl (656mg, 0.00435mol).Replace at interval with the Teflon nut, and the test tube of 80 ℃ of heated sealants 3 hours.Hexane extraction is used in cooling and with ammonium chloride solution neutralization.Dry organic phase and vacuum concentration become oil, and it filters (10%EtOAc-90% hexane) through too short stopper, obtains 871mg (82%) compound 43. ¹H NMR(500MHz，CDCl ₃)8.2(s，1H)，7.8(s，1H)，7.25(s，1H)，6.4(s，1H)，0.9(s，9H)，0.6(s，6H)。

Can be according to describing with respect to compound 21 in the previous flow process 3, with compound 43 in C-3 place bromination.

Compound 19 can be used, and for example, uncle-BuLi lithiumation is also used the DMF cancellation, and 5-formyl radical azaindole 44 is provided.Also can be at palladium catalyst, Pd (Ph for example ₃P) ₄Under the condition that exists, handle compound 19 with carbon monoxide (carbon moxoxide) and methyl alcohol, thereby 5-methoxycarbonyl base azaindole 44 is provided.By standard conversion, functional group is converted to acid, primary, the second month in a season and teritary amide mutually, as 45.Compound 44 can via, for example, Witting reaction homology turns to compound as 49.

Compound 19 can be used, for example, KCN, under the condition that has catalyzer such as copper or palladium to exist, cyaniding in hot DMF, thus 5-cyano group azaindole 46 is provided.

Under the condition that has palladium catalyst to exist, make compound 19 aminations with amine, can provide 5-ammonification azaindole as 48.

Compound 19 can use Suzuki or Stille coupling arylation or heteroarylization, thereby provides compound as 47.

In others, provide other synthesis flow and compound synthetic:

Flow process 9

5-chloro-3-iodo-pyridine-2-base amine (1): the 5-chloropyridine of in being equipped with the round-bottomed flask of air condenser, packing into-2-base amine (26g, 0.2ml), acetate (78ml) and water (18ml).Then drip the vitriol oil (2.6ml), add gradually periodic acid (9.5g, 0.04mol) and iodine (20g, 0.08mol).80 ℃ of stirred reaction mixtures 6 hours firmly are cooled to room temperature then.

With reaction mixture be poured on ice (～700g) in.With the 5M NaOH aqueous solution with the pH regulator of this suspension to 8-9.Filter brown solid and it is dissolved among the EtOAc (1.21).Use saturated Na ₂S ₂O ₃The aqueous solution, 1M NaOH solution and salt water washing organic phase.At MgSO ₄Go up dry organic phase and concentrated.Make resistates recrystallization from hexanaphthene, obtain orange solids (42g, 80%). ¹H NMR(CDCl ₃)：4.8-5.1(2H，brs)，7.9(1H，s)，8.0(1H，s)。

5-chloro-3-(trimethylammonium-silylation ethynyl)-pyridine-2-base amine (2): under nitrogen, 5-chloro-3-iodo-pyridine-2-base amine (1) (42g packs in the 250ml round-bottomed flask, 165mmol), THF (100ml), cupric iodide (315mg, 1.65mmol) and PdCl ₂(PPh ₃) ₂(1.15g, 1.65mmol), triethylamine (70ml, 0.5mol) and trimethyl silyl acetylene (30ml, 0.21mol).Stirring at room reaction mixture 2 hours.Then reaction mixture is cooled to 0 ℃ and add diethyl ether.By filtering this suspension and thoroughly wash in the C ore deposit with diethyl ether.Concentrated filtrate and make that it is pre--absorb on the silica gel, and use pentane/DCM 10%-100% as eluent, by the column chromatography purifying, provide rice white solid (36g, 100%). ¹HNMR(CDCl ₃)：0.3(9H，s)，5.0-5.1(2H，brs)，7.6(1H，s)，7.9(1H，s)。MS(ES+)：225，227。

5-chloro-1H-pyrrolo-[2,3-b] pyridines (3): under the condition of nitrogen gas, (36g, 320mmol) solution that is dissolved in N-Methyl pyrrolidone (70ml) is heated to 80 ℃ with potassium tert.-butoxide.Via dropping funnel Dropwise 5-chloro-3-(trimethylammonium-silylation ethynyl)-pyridine-2-base amine (2) (36g, 160mmol) solution in NMP (200ml).80 ℃ of stirred reaction mixtures are 50 minutes once more.Make reaction mixture be cooled to room temperature.In reaction mixture, add bromine (500ml), and extract with diethyl ether (5x200ml).With salt water washing blended organic layer, dry and vacuum concentration on sal epsom.Use pentane/EtOAc 0%-40% as eluent, by column chromatography purifying resistates, and from hexanaphthene recrystallization, title compound (10g, 41%) is provided. ¹H NMR(CDCl ₃)6.5(1H，s)，7.4(1H，s)，8.0(1H，s)，8.2(1H，s)，10.4-10.6(1H，brs)。MS(ES+)153。

3-bromo-5-chloro-1H-pyrrolo-[2,3-b] pyridines (4): the drips of solution that bromine (3.5ml) is dissolved in chloroform (40ml) is added to 5-chloro-1H-pyrrolo-[2,3-b] pyridines (3), and (10g 65mM) is dissolved in the ice-cold solution of chloroform (260ml).0 ℃ of stirred reaction mixture 60 minutes.Water makes the reaction mixture hydrolysis then, and with the pH regulator to 10 of solution.Remove by filter the gained solid, and use the dichloromethane extraction water.Wash organic layer with water, dry on sal epsom, and vacuum concentration, title compound (10.5g, 69%) is provided. ¹H NMR(DMSO-d6)7.8(1H，s)，7.9(1H，s)，8.3(1H，s)。

3-bromo-5-chloro-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2; 3-b] pyridine (5): under the condition of nitrogen gas; with sodium hydride (2.2g; 54mmol) join 3-bromo-5-chloro-1H-pyrrolo-[2 gradually; 3-b] (10.5g 45mmol) is dissolved in the ice-cold solution of dimethyl formamide (70ml) pyridine (4).After 30 minutes, (8.7g 46mmol) joins in the reaction mixture, and stirring at room reaction mixture 18 hours with toluene sulfonyl chloride.(～150ml) hydrolysis reaction mixture, and filtration obtains brown solid to water, and vacuum-drying provides title compound (14,8g, 85%). ¹HNMR(CDCl ₃)2.4(3H，s)，7.3-7.4(2H，d)，7.8-7.9(2H.2s)，8.1-8.2(2H，d)，8.4(1H，s)；MS(ES+)387

5-chloro-3-(4; 4; 5,5-tetramethyl--[1,3; 2] two oxa-boron pentamethylene-2-yls)-1-(toluene-4-alkylsulfonyl)-1H-[2; 3-b] pyridine (6): under condition of nitrogen gas, 3-bromo-5-chloro-1-(toluene-4-alkylsulfonyl)-1H-pyrrolo-[2,3-b] pyridines (5) (6.9g packs in the 500ml round-bottomed flask; 18mmol), bispinacolatodiboron (6.9g, 27mmol), PdCl ₂(dppf) ₂(1.5g, 1.8mmol), potassium acetate (5.3g, 54mmol) and glycol dimethyl ether (100ml).90 ℃ of stirred reaction mixtures 18 hours.Dilute this reaction mixture and use the salt water washing with ethyl acetate (200ml).Dry organic phase and vacuum concentration on sal epsom.Use pentane/EtOAc 0%-20% as eluent,, grind with pentane then, title compound (4g, 50%) is provided by column chromatography purifying resistates. ¹HNMR(CDCl ₃)1.4(9H，s)，2.4(3H，s)，7.2(2H，d)，8.00-8.05(2H，d)，8.10(2H，s)，8.3(1H，s)。MS(ES+)433

(6-bromo-pyridine-2-yl)-(4-chloro-benzyl)-amine (7): 4-chlorobenzylamine (700mg packs in the microwave bottle; 5mmol; 5 equivalents) and 2, and the 6-dibromo pyridine (238mg, 1mmol).Under 150 ℃, microwave stirred reaction mixture 3 times 10 minutes (maximum 200W).With diethyl ether (50ml) diluted reaction mixture, with 10% aqueous citric acid solution, saturated sodium bicarbonate aqueous solution and salt water washing.Dry organic phase on sal epsom, after the filtration, vacuum concentration provides buttery title compound (300mg, 100% productive rate).LC/MS：299[M+H]

(4-chloro-benzyl)-[6-(5-chloro-1H-pyrrolo-[2; 3-b] pyridine-3 base)-pyridine-2 base]-amine (8): in the microwave bottle, pack into (6-bromo-pyridine-2-yl)-(4-chloro-benzyl)-amine (300mg; 1mmol), 5-chloro-3-(4; 4; 5; 5-tetramethyl--[1; 3; 2] dioxaborolan-2-yl)-1-(toluene-4-alkylsulfonyl-1H-[2; 3-b] pyridine (7) (215mg; 0.5mmol), tetrakis (triphenylphosphine) palladium (60mg, 0.05mmol), 2M sodium hydroxide (0.75ml) and glycol dimethyl ether (5ml).Make this suspension degassing with nitrogen.130 ℃ of microwave stirred reaction mixtures 10 minutes (maximum 200W).Then with ethyl acetate dilute it (60ml), use the salt solution washed twice, on sal epsom drying also, after the filtration, vacuum concentration.By flash chromatography (eluent: petrol ether/ethyl acetate 60/40) this compound of purifying, the title compound that provides the 50mg tosyl group to protect.This resistates is dissolved in the mixture of methyl alcohol and tetrahydrofuran (THF) (1/3ml).(1ml) joins in the reaction mixture with the 1M sodium hydroxide solution, and stirring at room is 3 hours then.The vacuum concentration reaction mixture is also used the methyl alcohol grinding residues.Filter this suspension, title compound (35mg, 10%) is provided. ¹H NMR(DMSO-d6)：4.60-4.70(2H，m)，6.35-6.40((1H，d)，7.05-7.10(1H，d)，7.20-7.25(1H，t)，7.35-7.45(4H，m)，8.15-8.20(2H，m)，8.55-8.60(1H，s)，12.5(1H，s)。LC/MS：369[M+H]，367[M-H]

Below table 3 data of specific illustrative compound are described.Compound number is corresponding with those compounds of description in the table 1."-" expression is not measured.

Table 3

Cmpd#	LC_MASS_ PLUS	NMR_RESULT
Cmpd#	LC_MASS_ PLUS	NMR_RESULT	1	-	8.91H，d；8.351H，s；8.251H，d；8.11H，d；7.21H，dd，7.1 1H，d；6.51Hs
2	309.10	CDCl39.21(m，1H)9.18(s，1H)8.51(s，1H)，8.16(dd，J＝ 5.4，1.0，1H)7.34(dd，J＝8.0，5.4，1H)，7.25(m 1H)7.19(m， 1H)7.03(m，1H)6.85(s，1H)	1	-	8.91H，d；8.351H，s；8.251H，d；8.11H，d；7.21H，dd，7.1 1H，d；6.51Hs
2	309.10		3	324.00	MeOD(500MHz)8.76(s，1H)8.45(s，1H)8.43(s，1H)，8.34 (s，1H)7.66(m，1H)7.40(m，1H)7.38(m，1H)，7.27(m，2H)
4	288.00	MeOD，7.2s(1H)，7.25t(1H)，7.35m(1H)，7.5t(2H)，7.65 d(2H)，8.25s(1H)，8.4m(2H)，8.7s(1H)	3	324.00

Cmpd#	LC_MASS_ PLUS	NMR_RESULT
Cmpd#	LC_MASS_ PLUS	NMR_RESULT	5	310.00	MeOD，0.6m(2H)，1.0m(2H)，1.6s(3H)，1.8m(1H)，2.1 m(1H)，2.3d(1H)，2.6d(1H)，4.3s(1H)，6.0m(2H)，6.95 s(1H)，7.05m(1H)，7.5m(2H)
6	212.00	MeOD，7.05s(1H)，7.35m(1H)，8.2s(1H)，8.4m(2H)，8.55 s(1H)	5	310.00
6	212.00	MeOD，7.05s(1H)，7.35m(1H)，8.2s(1H)，8.4m(2H)，8.55 s(1H)	7	302.00	MeOD，4.8s(2H)，7.05s(1H)，7.2-7.6m(6H)，8.2s(1H)，8.4 m(2H)，8.55s(1H)
8	240.10	1H 8.94，1H 8.19，1H 8.14，2H 7.25，1H 7.02，2H 3.52，，3H 1.31	7	302.00
8	240.10	1H 8.94，1H 8.19，1H 8.14，2H 7.25，1H 7.02，2H 3.52，，3H 1.31	9	337.00	MeOD，2.0bs(2H)，2.1s(3H)，3.6m(2H)，3.8-4.3bm(6H)，7.1 d(1H)，7.3m(1H)，8.2d(1H)，8.35m(2H)，8.65d(1H)
10	332.00	MeOD，3.8s(3H)，4.7bs(2H)，7.0m(3H)，7.35m(4H)，8.2 s(1H)，8.4m(2H)，8.6bs(1H)	9	337.00
10	332.00		11	308.00	MeOD，1.05m(2H)，1.3m(3H)，1.7m(2H)，1.75-1.9m(4H)， 3.5d(2H)，7.0s(1H)，7.3(1H)，8.1s(1H)，8.35d(1H)，8.4 d(1H)，8.6s(1H)
12	310.00	MeOD1.4m(2H)，1.7m(2H)，2.0m(1H)，2.65s(1H)，3.45 m(2H)，3.6m(1H)，4.0d(2H)，7.0s(1H)，7.35m(1H)，8.2 s(1H)，8.35d(1H)，8.45m(1H)，8.6s(1H)	11	308.00
12	310.00		13	240.00	MeOD；1.3t(3H)，3.65m(2H)，7.0s(1H)，7.3m(1H)，8.2 s(1H)，8.4d(2H)，8.6m(1H)
14	256.00	MeOD；3.7-3.9dm(4H)，7.0s(1H)，7.3m(1H)，8.1s(1H)，8.4 d(2H)，8.6bs(1H)	13	240.00
14	256.00		15	360.10	¹HNMR 500MHz(DMSO-d6)12.35ppm，1H，s；，11.02ppm， 1H，s；8.88ppm，1H，s；8.63ppm，1H，d；，8.42ppm，1H，s； 8.33ppm，2H，m；7.25ppm，2H，m；，6.97ppm，2H，m；6.87 ppm，1H，d；3.78ppm，2H，s；，3.77ppm，3H，s.
16	302.00	DMSO d ₆ 8.7(bs，1H)；8.4(bs，1H)；8.25(d，1H)；8.1(d，1H)； 7.4(m，2H)；7.25(m，3H)；7.2(bs，1H)；7.15(bs，1H)；4.7(bs， 2H)	15	360.10
16	302.00		17	313.00	DMSO，7.2q(2H)，8.3mm(3H)，8.6d(2H)，8.85dd(2H)，9.1 s(1H)，12.35bs(2H)
18	336.00	MeOD，4.8s(2H)，7.0s(1H)，7.3bs(5H)，8.1s(1H)，8.3 m(2H)，8.6s(1H)	17	313.00
18	336.00		19	295.00	-
20	337.00	-	19	295.00	-
20	337.00	-	21	347.90	-
22	347.90	-	21	347.90	-
22	347.90	-	23	365.90	-
24	422.90	-	23	365.90	-
24	422.90	-	25	343.95	-
26	328.00	MeOD，3.1bm(2H)，4.0-4.4bd(2H)，5.0-5.3bs(2H)，7.25 s(1H)，7.3-7.35m(4H)，7.4m(1H)，8.3s(1H)，8.4d(1H)，8.5 d(1H)，8.7s(1H)	25	343.95	-

Cmpd#	LC_MASS_ PLUS	NMR_RESULT
Cmpd#	LC_MASS_ PLUS	NMR_RESULT	27	366.10	¹H NMR 500MHz(DMSO-d6)12.33ppm，1H，s；11.03ppm， 1H，s；8.86ppm，1H，s；8.62ppm，1H，m；8.43ppm，1H，s； 8.29ppm，2H，m；7.45ppm，2H，m；7.25ppm，1H，m；7.20 ppm，2H，m；3.87ppm，2H，s；.
28	348.00	¹H NMR500MHz(DMSO-d6)12.42ppm，1H，s；11.05ppm， 1H，s；9.72ppm，1H，s；8.89ppm，1H，s；8.63ppm，1H，m； 8.43ppm，1H，s；8.31ppm，2H，m；7.25ppm，6H，m；1H，m； 3.87ppm，2H，s；3.00ppm，3H，s.	27	366.10
28	348.00		29	423.10	¹H NMR 500MHz(DMSO-d6)12.33ppm，1H，s；11.00ppm， 1H，s；8.84ppm，1H，s；8.59ppm，1H，m；8.45ppm，1H，s； 8.30ppm，2H，m；7.30ppm，6H，m；3.83ppm，2H，s.
30	330.00	¹H NMR 500MHz(DMSO-d6)12.35ppm，1H，s；11.10ppm， 1H，s；8.88ppm，1H，s；8.62ppm，1H，m；8.42ppm，1H，s； 8.31ppm，2H，m；7.30ppm，5H，m；3.90ppm，2H，s；	29	423.10
30	330.00		31	348.00	¹H NMR 500MHz(DMSO-d6)12.35ppm，1H，s；11.10ppm， 1H，s；8.88ppm，1H，s；8.62ppm，1H，m；8.42ppm，1H，s； 8.31ppm，2H，m；7.30ppm，5H，m；3.90ppm，2H，s；
32	309.00	12.25(s，1H)，8.67(d，1H)，8.40(s，1H)，，8.30(d，1H)，8.27(d， 1H)，7.23dd，1H)，，7.09(d，1H)，4.63(d，2H)，3.30(s，2H)， 2.80(m，2H)，2.45(m，1H)，1.07(d，6H)，DMSO-d6，	31	348.00
32	309.00		33	351.00	12.28(s，1H)，8.72(d，1H)，8.42(s，1H)，，8.31(d，1H)，8.28(d， 1H)，7.25(dd，1H)，，7.14(d，1H)，4.71(d，2H)，4.10-4.70(m， 2H)，3.30(s，1H)，3.12(s，2H)，2.09(s，3H)，，1.21(m， 6H)，DMSO-d6，
34	308.00	8.90(s，1H)，8.60(s，1H)，8.39(m，1H)，，8.01(m，1H)，7.33 (m，2H)，4.80(s，10H，solvent)，，3.55(m，1H)，3.30(m，14H， solvent)，1.92(m，2H)，1.81(m，3H)，1.72(m，1H)，，1.25-1.40 (m，3H)，1.08-1.25(m，2H)，MeOH-d4，	33	351.00
34	308.00		35	385.00	MeOD，1.8-2.8bm(2H)，2.35bm(2H)，3.2bm(1H)，3.6(2H)， 4.5-4.5bs(3H)，7.0bs(1H)，7.3m(1H)，7.s(5H)，8.2s(1H)， 8.3m(2H)，8.6s(1H)
36	367.00	MeOD，1.25t(3H)，1.55q(2H)，2.1d(2H)，3.1m(2H)，4.15 m(4H)，4，6m(1H)，7.0s(1H)，7.3m(1H)，8.2s(1H)，8.3 d(1H)，8.4d(1H)，8.6s(1H)	35	385.00
36	367.00		37	337.00	12.32(s，1H)，9.3-10.5(s，4H)，9.01(d，1H)，，851(s，1H)， 8.48(d，1H)，8.19(d，1H)，，7.53(m，1H)，7.25(d，1H)，4.82 (m，1/2H)，，4.25-4.53(m，21/2H)，3.81-3.93(m，1/2H)，3.58- 3.71(m，11/2H)，3.14-3.58(m，11/2H)，，2.12(s，3H)，1.18- 1.40(m，3H)，CD3CN，
38	337.00	12.4(s，1H)，8.96(d，1H)，，8.48(s，1H)，8.40(d，1H)，8.12(d， 1H)，，7.49(m，1H)，7.20(d，1H)，4.8(m，1/2H)，，4.2-4.5(m，2 1/2H)，3.79-3.91(m，1/2H)，3.58-3.69(m，11/2H)，3.12-3.58 (m，11/2H)，，2.1(s，3H)，1.12-1.35(m，3H)，CD3CN，，	37	337.00
38	337.00		39	351.00	MeOD，1.4s(1H)，1.7t(2H)，2.3d(2H)，7.0s(1H)，7.3m(1H)， 8.1s(1H)，8.3d(1H)，8.35d(1H)，8.6s(1H)

Cmpd#	LC_MASS_ PLUS	NMR_RESULT
Cmpd#	LC_MASS_ PLUS	NMR_RESULT	40	378.90	12.9(s，1H)；9.1(s，1H)；8.9(s，1H)；8.8(s，1H)；8.7(bs，2H)； 8.5(d，1H)；8.3(d，1H)；7.6(bs，1H)；7.4(m，6H)；4.7(s，2H)
41	335.90	CDCl ₃8.7(bs，2H)；8.4(bs，2H)；8.3(s，1H)；7.4(m，5H)； 4.8(s，2H)	40	378.90
41	335.90	CDCl ₃8.7(bs，2H)；8.4(bs，2H)；8.3(s，1H)；7.4(m，5H)； 4.8(s，2H)	42	362.00	10.94(m，1H)，8.96(d，1H)，8.71(s，1H)，8.55(s，1H)，，8.19 (dd，1H)，7.24(d，1H)，4.5-6.0(6H)，3.7-4.3(m，6H)，，3.60(m， 2H)，2.1(s，3H)
43	302.00	MeOD，4.95bs(2H)，6.6d(1H)，7.2m(1H)，7.3-7.5mm(5H)， 8.0d(1H)，8.3d(1H)，8.4s(1H)，8.55d(1H)	42	362.00
43	302.00		44	230.10	1H 8.45，3H 8.35，2H 7.82，1H 7.25
45	250.00	10.00(s，1H)，8.32(m，2H)，7.83(s，1H)，7.65(d，1H)，，7.40 (m，2H)，7.20(dd，1H)，4.02(s，3H)，，CD3CN	44	230.10	1H 8.45，3H 8.35，2H 7.82，1H 7.25
45	250.00		46	268.00	11.99(s，1H)，8.32(d，1H)，8.24(m，1H)，，8.01(m，1H)，7.88 (d，1H)，7.59(s，1H)，，7.40(s，1H)，7.37(m，2H)，7.15(dd， 1H)，，4.00(s，3H)，，DMSO-d6
47	268.00	-	46	268.00
47	268.00	-	48	238.00	11.98(s，1H)，8.32(d，1H)，8.26(m，1H)，8.15(s，1H)，，8.00 (s，1H)，7.91(d，1H)，7.82(d，1H)，7.71(d，1H)，，7.47(t，1H)， 7.34(s，1H)，7.16(dd，1H)，DMSO-d6
49	238.00	11.97(s，1H)，8.29(d，1H)，8.21(d，1H)，7.92(d，1H)，，7.85 (d，2H)，7.71(d，2H)，7.17(s，1H)，7.10(dd，1H)，DMSO-d6	48	238.00
49	238.00		50	292.00	11.97(s，1H)，8.48(s，1H)，8.29(m，2H)，8.00(d，1H)，，7.88 (d，1H)，7.71(dd，1H)，7.61(s，1H)，7.27(d，1H)，，7.21(dd， 1H)，4.01(s，3H)，DMSO-d6
51	301.00	-	50	292.00
51	301.00	-	52	301.00	-
53	255.00	-	52	301.00	-
53	255.00	-	54	285.00	-
55	241.00	-	54	285.00	-

Following table 4 is described the data of specific illustrative compound, and compound number is corresponding with those compounds of description in the table 2.Blank expression is measured.

Table4

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	1	380.00	12.68(m，1H)，9.20(s，1H)，8.82(s，1H)，8.62(m，1H)， 8.28(m，1H)，8.05(s，1H)，7.35(s，1H)，7.25(m，1H)， 3.6-4.2(m，6H)，3.45(m，2H)，1.7-2.1(m，5H) DMSO-d6	1.45
2	379.00		1.70	1	380.00		1.45
2	379.00		1.70	3	414.00		2.30
4	335.90		2.60	3	414.00		2.30
4	335.90		2.60	5	371.00		2.10
6		MeOD 5.0s(2H)，7.1s(1H)，7.3m(1H)，7.6m(1H)，8.1d(1H)，8.2 s(1H)，8.3-8.4m(2H)，8.55d(1H)，8.6s(1H)，8.7s(1H)		5	371.00		2.10
6				7		MeOD 5.1s(2H)，7.25m(1H)，7.35m(1H)，7.9d(2H)，8.25s(1H)， 8.4d(2H)，8.65s(1H)，8.7d(2H)
8	385.00，385.00	11.35(s，1H)，9.25(s，1H)，9.10(s，1H)，9.00(s，1H)，8.69 (d，1H)，7.82(d，1H)，5.00(m，2H)，4.10(m，2H)，2.73(s， 3H)，1.91(m，6H)DMSO-d6，12.5(s，1H)，8.70(s，1H)，8.50 (s，1H)，8.31(s，1H)， 8.29(d，1H)，7.10(d，1H)，4.66(d，2H)，4.2-4.6(m，2H)， 3.15(m，2H)，2.09(s，3H)，1.20(m 6H) DMSO-d6	2.02， 4.63	7
8	385.00，385.00		2.02， 4.63	9	328.00	12.73(s，1H)，8.71(s，1H)，8.67(s，1H)，8.32(s，1H)，8.25 (d，1H)，7.21(m，1H)，3.65-3.95(m，4H)，1.82(m，4H)， 1.53(m，4H)DMSO-d6	2.35
10	346.00		2.23	9	328.00		2.35
10	346.00		2.23	11	328.00	12.75(s，1H)，8.71(s，1H)，8.68(s，1H)，8.35(s，1H)，8.25 (d，1H)，7.22(d，1H)，4.62(m，2H)，3.10(m，2H)，1.75(m， 3H)，1.20(m，2H)，0.91(m，3H)DMSO-d6	2.40
12	332.00	DMDO d612.6(s，1H)；9，5(bs，1H)；8.8(s，1H)；8.4(s， 1H)；8.1(s，1H)；7.8(bs，1H)：7.4(m，5H)；7.1(bs，1H)；4.8 (d，2H)，3.8(s，3H)	2.10	11	328.00		2.40
12	332.00		2.10	13	346.00	DMSO d612.8(s，1H)；9，4(bs，1H)；8.8(s，1H)；8.3(s， 1H)；8.2(s，1H)；7.9(bs，1H)：7.4(m，5H)；7.2(bs，1H)；5.2 (bs，1H)，3.8(s，3H)；1.5(d，3H)	2.20
14	346.00	DMSO d612.8(s，1H)；9，4(bs，1H)；8.8(s，1H)；8.3(s， 1H)；8.2(s，1H)；7.9(bs，1H)：7.4(m，5H)；7.2(bs，1H)；5.2 (bs，1H)，3.8(s，3H)；1.5(d，3H)	2.20	13	346.00		2.20
14	346.00		2.20	15	413.00	MeOD 1.2s(3H)，1.9m(1H)，2.2m(1H)，2.55m(1H)，2.6s(3H)， 3.2-3.4m(2H)，3.55m(1H)，3.8m(1H)，4.5s(2H)，5.5 bs(0.7H)，7.1s(1H)，7.35m(1H)，7.5-7.6mm(5H)，8.3 s(1H)，8.4-8.5mm(2H)，8.7s(1H)	1.31

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	16	320.00	MeOD 4.9s(2H)，7.0-7.6mm(7H)，8.2s(1H)，8.3d(1H)，8.7s(1H)	1.98
17		MeOD 1.2d(3H)，1.9m(1H)，2.2m(1H)，2.4s(1H)，2.6m(3H)，3.0 s(1H)3.5m(1H)，3.8m(1H)，7.1s(1H)，7.2d(1H)，7.35 m(1H)，7.7d(1H)，8.3s(1H)，8.4d(1H)，8.5d(1H)，8.7 s(1H)		16	320.00	MeOD 4.9s(2H)，7.0-7.6mm(7H)，8.2s(1H)，8.3d(1H)，8.7s(1H)	1.98
17				18	380.00，380.00	11.95(s，1H)，10.47(s，3H)，8.51(s，1H)， 8.17(s，1H)，8.09(s，1H)，7.77(t，1H)， 7.18(d，1H)，6.87(d，1H)，4.4-4.6(s，2H) 3.99(s，3H)，3.32(m，2H)，2.13(s，3H)，1.35(m，6H) DMSO-d6，9.82(s，1H)，8.32(d，1H)，8.08(d，1H)，7.93(s， 1H)，7.58(t，1H)，7.20(d，1H)，6.66(d，1H)，4.2-4.7(m， 4H)，3.91(s，3H)，3.12(m，2H)，2.10(s，3H)，1.35(m，6H) CD3CN	1.98， 2.02
19	384.00，384.00， 384.00，384.00， 384.00，384.00， 384.00，384.00， 384.00，384.00， 384.00	10.75(s，1H)，8.46(s，1H)，8.39(s，1H)， 8.10(s，1H)，7.91(t，1H)，7.19(d，1H)， 7.02(d，1H)，6.25-6.75(s，9H)，4.4-4.6(s，2H) 4.10(d，2H)，3.49(m，2H)，2.18(s，3H)，1.38(d，6H) DMSO-d6，good，good，good，11-12.2(s，2H)，10.6-11.0(s， 1H)，8.54(s，1H)， 8.35(s，1H)，8.05(s，1H)，7.69(t，1H)，7.11(d，1H)， 6.89(d，1H)，4.2-4.7(s，2H)，4.18(d，2H)，3.35(m，2H)， 2.17(s，3H)，1.38(m，6H) CD3CN，12.20(s，1H)，8.71(s，1H)，8.25(d，2H)，7.55(t， 1H)， 7.17(d，1H)，6.69(d，1H)，4.0-4.5(s，2H)，4.29(d，2H)， 3.05(m，2H)，2.09(s，3H)，1.28(m，6H)，12.24(s，1H)，8.73 (s，1H)，8.27(d，2H)，7.58(t，1H)， 7.18(d，1H)，6.71(d，1H)，4.2-4.5(m，14H)，3.08(m，2H)， 2.32(s，3H)，2.09(s，3H)，1.28(s，6H) DMSO-d6，12.20(s，1H)，8.72(s，1H)，8.25(d，2H)，7.57(t， 1H)， 7.19(d，1H)，6.71(d，1H)，4.3-4.7(s，1H)，4.3(d，2H)， 3.27(s，9H)，3.07(m，2H)，2.70(q，1H)，2.10(s，3H)， 1.29(s，6H) DMSO-d6 DMSO-d6，12.31(s，1H)，8.70(s，1H)，8.29(m，2H)，7.65 (m，1H)，7.20(d，1H0，6.80(d，1H)，6.5-6.8(s，4H)，4.28(d， 2H)，4.0-4.6(s，1H)，3.15(m，2H)，2.41(s，6H)，good	2.39， 2.70， 3.26， 2.42， 3.22， 2.39， 3.35， 3.38， 3.32， 3.32， 3.32	18	380.00，380.00		1.98， 2.02

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	20	335.00	10.55(s，1H)，8.38(m，1H)，8.30(m，2H)， 7.89(t，1H)，7.41(m，4H)，7.34(m，1H)， 7.12(d，1H)，6.73(d，1H)，4.7-5.7(s，4H) 4.60(s，2H) CD3CN	2.39
21	336.00	MeOD 2.65s(0.3H，DMSO)，4.9s(2H)，7.1s(1H)，7.3-7.5m(6H)， 8.2s(1H)，8.4-8.5m(2H)，8.7s(1H)	2.20	20	335.00		2.39
21	336.00		2.20	22	370.00	MeOD 4.9s(2H)，7.1s(1H)，7.3bs(1H)，7.6-7.8m(5H)，8.2s(1H)， 8.4m(2H)，8.675s(1H)	2.60
23	378.00	MeOD 2.65s(0.9H，DMSO)4.9s(2H)，7.1s(1H)，7.3-7.5m(6H)， 7.6-7.7m(5H)，8.2s(1H)，8.4m(2H)，8.65s(1H)	2.60	22	370.00		2.60
23	378.00		2.60	24	367.00	DMSO d612.5(bs，1H)；8.5(bs，1H)；8.2(m，2H)；8.0(d， 1H)；7.3(d，1H)；4.0(bs，2H)；3.9(s，3H)；3.8(bs，2H)；3.5 (t，2H)；2.5(s，3H)；1.9(bs，2H)	1.70
25	381.10，381.40	DMSO d612.5(bs，1H)；8.4(s，1H)；8.3(d，1H)；8.25(s， 1H)；8.1(s，1H)；7.3(d，1H)；4.7(app d，2H)；3.9(s，3H)； 3.2(bd，2H)；2.1(s，3H)；1.2(bs，6H)，DMSO d612.3(bs， 1H)；8.5(s，1H)；8.25(m，2H)；8.1(d，1H)；7.2(d，1H)；4.65 (d，4H)；3.9(s，3H)；3.2(bd，2H)；2.1(s，3H)；1.2(bs，6H)	2.00， 2.00	24	367.00		1.70
25	381.10，381.40		2.00， 2.00	26	316.00	H1MeOD：1.3m(1H)，3.4s(3H)，5.1s(2H)，7.0s(1H)，7.1- 7.4m(7H)，8.1s(1H)，8.3d(1H)，8.6s(1H)	2.10
27	320.00	H1DMSO：4.7s(2H)，7.2t(4H)，7.3m(1H)，7.55m(2H)， 8.3m(3H)，8.7s(1H)，9.1-9.3bs(0.75H)	2.00	26	316.00		2.10
27	320.00		2.00	28	317.00	H1MeOD：1.8bs(2H)，4.7s(2H)，6.7-6.85mm(4H)7.0-7.2 m(1H)，7.3m(1H)，8.15s(1H)，8.3m(2H)，8.6s(1H)	1.60
29	338.00	MeOD 4.9s(2H)，6.9m(1H)，7.0m(2H)，7.2s(1H)，7.3m(1H)，8.2 s(1H)，8.4m(2H)，8.65s(1H)	2.00	28	317.00		1.60
29	338.00		2.00	30	403.20	CD3CN，10.7(bs，1H)；8.15(s，1H)；8-8.1(m，3H)；7(d， 1H)；3.8-4.05(bs，4H)；3.8(s，3H)；3.6(bs，2H)；3.3(t，2H)； 2.8(s，3H)；2.4(s，2H)	1.90
31	417.20	CD3CN，10.7(s，1H)；8.15(s，1H)；8(m，3H)；7(d，1H)； 3.8-4(bs，4H)；3.85(s，3H)；3.6(bs，2H)；3.3(m，4H)；2.9 (m，2H)；1.1(m，3H)	2.00	30	403.20		1.90
31	417.20		2.00	32	427.00	12.33(s，1H)，8.78(d，1H)，8.37(d，1H)，8.28(d，1H)， 7.87(s，1H)，7.69(d，1H)，7.49(s，1H)，7.44(d，1H)， 4.37(s，2H)，3.5-4.2(m，14H)，3.10(m，2H)， 2.08(s，3H)，1.32(m，6H) DMSO-d6	2.24

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	33	397.30	DMSO-d612.25(1H，bs)；8.5(1H，s)；8.3(1H，d)；8.2(1H， d)；8.05(1H，d)；7.15(1H，bs)；4.0(4H，m)；3.9(3H，s)；3.8- 4.0(4H，bm)；3.6-3.8(2H，bs)；3.4(2H，bs)；1.1(3H，bm)	2.10
34	411.30	DMSO-d612.25(1H，bs)；8.5(1H，s)；8.3(1H，d)；8.2(1H， d)；8.05(1H，d)；7.15(1H，bs)；3.85(3H，s)；3.7-4.0(8H， bm)；3.6-3.8(2H，bs)；3.4(2H，bs)；1.5(2H，bs)；0.8(3H， bm)	2.30	33	397.30		2.10
34	411.30		2.30	35	408.30，408.29	DMSOd612.4(s，1H)；9.5(s，1H)；8.8(s，1H)；8.3(s，1H)； 7.5(dd，1H)；7.2(d，1H)；6.7(d，1H)；4.6(bs，2H)；4.3(d， 2H)；3.9(s，3H)；3.1(bd，2H)；2.1(s，3H)；1.2(bs，6H)	2.90， 2.94
36	428.00	12.41(s，1H)，8.78(s，1H)，8.41(s，1H)，8.29(s，1H)， 7.95(d，1H)，7.45(d，1H)，6.3-7.5(s，1H)，4.39(s，2H)， 3.69(m，2H)，3.23(m，2H)，2.05(s，3H)，1.29(m，6H) DMSO-d6	2.38	35	408.30，408.29		2.90， 2.94
36	428.00		2.38	37	465.40，465.30	DMSOd611.9(s，1H)；9.4(s，1H)；9.2(s，1H)；8.2(s，1H)； 7.5(dd，1H)；7.2(d，1H)；6.6(d，1H)；4.4(bs，4H)；3.1(bs， 2H)；2.1(s，3H)；1.5(s，9H)；1.2(bs，6H)	3.10， 3.10
38	365.20	8.9(s，1H)；8.4(s，1H)；8.2(s，1H)；7.7(dd，1H)；7.2(d， 1H)；6.9(d，1H)；4.4(bs，4H)；3.3(bs，2H)；2.2(s，3H)；1.4 (bs，6H)	2.53	37	465.40，465.30		3.10， 3.10
38	365.20		2.53	39	315.10	DMSO-d6：12.3(1H，bs)；8.3(2H，m)；8.2(1H，bs)；7.8 (1H，bs)；7.5(6H，m)；6.8(1H，bs)；4.7(2H，s)；4-4.5(1H， bs)；2.3(3H，s)	2.30
40	350.09	DMSO-d6：11.9(bs，1H)；8.5(d，1H)；8.2(s，1H)；8.1(s， 1H)；7.5(t，1H)；7.1(t，1H)；6.5(d，1H)；3.9-4.5(bs，1H)； 4.0(t，1H)；3.7(m，4H)；3.4(dt，2H)；2.4(s，3H)；2.1(s， 3H)；1.9(m，2H)	1.90	39	315.10		2.30
40	350.09		1.90	41	364.20	DMSO-d6：11.9(s，1H)；8.5(s，1H)；8.2(s，1H)；8.1(s， 1H)；7.6(dd，1H)；7.2(d，1H)；6.7(d，1H)；4.5-5.4(bs， 1H)；4.3(d，4H)；3.1(bd，2H)；2.4(s，3H)；2.1(s，3H)；1.3 (bs，6H)	2.40
42	379.00	12.6-13.0(s，1H)，12.38(s，1H)，8.65(s，1H)， 8.61(m，1H)，8.40(m，1H)，8.21(m，1H)，8.06(d，1H)， 7.49(d，2H)，7.31(t，2H)，7.21(t，1H)，7.18(d，1H)， 6.1-6.9(s，1H)，4.88(m，2H)，3.4-4.7(s，2H) DMSO-d6	3.18	41	364.20		2.40
42	379.00		3.18	43	393.00	12.39(s，1H)，8.60(s，1H)，8.50(t，1H)，8.41(s，1H)， 8.22(s，1H)，8.09(d，1H)，7.39(m，2H)，7.29(m，2H)， 7.20(m，1H)，6.3-6.8(m，3H)，4.90(d，2H)，3.85(s，3H) DMSO-d6	3.92
44	379.00	12.12(s，1H)，8.20(s，1H)，8.10(s，1H)，7.82(m，2H)， 7.32(m，3H)，7.21(m，2H)，6.50(d，1H)，4.60(s，2H)， 3.8-4.5(s，8H) DMSO-d6	2.20	43	393.00		3.92

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	45	393.00	9.94(s，1H)，8.20(d，2H)，7.88(d，1H)，7.73(s，1H)， 7.31-7.42(m，4H)，7.26(t，1H)，6.44(d，1H)， 6.27(m，11)，4.68(d，2H)，3.70(s，3H) CD3CN	2.52
46	378.00	mixture	2.94	45	393.00		2.52
46	378.00	mixture	2.94	47	394.27	DMSOD612.3(s，1H)；9.4(s，1H)；8.8(s，1H)；8.2(s，1H)； 7.5(dd，1H)；7.2(d，1H)；6.7(d，1H)；4.4(d，4H)；3.1(bd， 2H)；2.1(s，3H)；1.2(bs，6H)	2.47
48	319.20	DMSOd612.3(bs，1H)；8.4(bd，1H)；8.3(d，2H)；7.6(bs， 1H)；7.5(m，4H)；7.2(dd，1H)；7.1(bd，1H)；6.5(bs，1H)； 4.5(s，2H)	2.30	47	394.27		2.47
48	319.20		2.30	49	354.30	DMSOd612.2(bs，1H)；8.4(app.t，1H)；8.2(m，2H)；7.5 (dd，1H)；7.1(dd，1H)；6.5(bs，1H)；3.9(t，1H)；3.8-3.6 (m，4H)；3.4(dt，2H)；2.1and 1.8(s，3H)；2.0(t，1H)	2.20
50	368.40	DMSO D612.1(s，1H)；8.5(dd，1H)；8.2(s，2H)；7.6(dd， 1H)；7.2(d，1H)；6.8(d，1H)；4.3(bd，4H)；3.1(db，2H)；2.1 (s，3H)；1.2(bs，6H)	2.90	49	354.30		2.20
50	368.40		2.90	51	462.00	11.60(s，1H)，8.70(s，1H)，8.48(s，1H)，8.11(s，1H)， 7.82(t，1H)，7.15(d，1H)，7.1-8.1(s，4H)，6.95(d，1H)， 4.55(s，2H)，4.14(m，2H)，3.68(m，6H)，3.39(m，2H)， 2.15(s，3H)，1.38(m，6H) CD3CN	1.84
52	490.00	11.29(s，1H)，8.90(s，1H)，8.50(s，1H)，8.61(m，2H)，8.11 (s，1H)， 7.68(t，1H)，7.12(d，1H)，6.78(d，1H)，4.0-4.5(m，12H)， 3.40(m，2H)， 3.27(m，4H)，2.15(s，3H)，1.25-1.45(m，12H)	1.89	51	462.00		1.84
52	490.00		1.89	53	436.40	DMSO d612.4(s，1H)；9.4(s，1H)；8.8(s，1H)；8.3(s，1H)； 7.5(t，1H)；7.2(d，1H)；6.7(d，1H)；5.2(sept，1H)；4.3(bs， 4H)；3.1(bs，2H)；2.1(s，3H)；1.3(d，6H0；1.2(bs，6H)	3.40
54	461.00			53	436.40		3.40
54	461.00			55	475.00
56	462.00			55	475.00
56	462.00			57	476.00
58	475.00			57	476.00
58	475.00			59	407.00
60	421.00			59	407.00
60	421.00			61	499.30	DMSO-d6：11.9ppm(s，1H)，10.2(s，1H)，9.2(s，1H)，8.2 (s，1H)，8.15(s，1H)，7.5(t，1H)，7.15-7.25(dd，4H)，7.15(s， 1H)，6.7(d，1H)，4.2-4.8(bs，4H)，3.0(bd，2H)，2.5(s，6H)， 2.3(s，3H)，2.0(s，3H)	3.40

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	62	451.30	DMSO-d6：11.9ppm(s，1H)，9.6(s，1H)，9.1(s，1H)，8.15 (s，1H)，8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.7(d，1H)， 4.35(m，4H)，4.1(t，2H)，3.05(bd，2H)，2.1(s，3H)，1.7(m， 2H)，1.3(bs，6H)，0.95(t，3H)	2.90
63	465.40	DMSO-d6：11.9ppm(s，1H)，9.6(s，1H)，9.1(s，1H)，8.15 (s，1H)，8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.7(d，1H)， 4.35(m，4H)，3.9(d，2H)，3.05(bd，2H)，2.1(s，3H)，1.9(m， 1H)，1.3(bs，6H)，0.95(d，6H)	3.20	62	451.30		2.90
63	465.40		3.20	64	479.40	DMSO-d6：11.9ppm(s，1H)，9.6(s，1H)，9.1(s，1H)，8.15 (s，1H)，8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.7(d，1H)， 4.35(m，4H)，3.85(s，2H)，3.05(bd，2H)，2.1(s，3H)，1.3 (bs，6H)，0.95(s，9H)	3.40
65	451.40	DMSO-d6：11.9ppm(s，1H)，9.6(s，1H)，9.1(s，1H)，8.15 (s，1H)，8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.7(d，1H)，4.9 (q，1H)，4.35(m，4H)，3.05(bd，2H)，2.1(s，3H)，1.3(m， 12H)	2.90	64	479.40		3.40
65	451.40		2.90	66	423.30	DMSO-d6：11.9ppm(s，1H)，9.6(s，1H)，9.1(s，1H)，8.15 (s，1H)，8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.7(d，1H)， 4.35(m，4H)，3.7，(s，3H)，3.05(bd，2H)，2.1(s，3H)，1.3 (bs，6H)	2.40
67	428.00	12.31(s，1H)，8.71(d，1H)，8.41(d，1H)，8.29(d，1H)，7.56 (s，1H)，7.07(s，1H)，4.0-4.8(m，4H)，3.3-3.9(m，20H)， 3.13(m，2H)，2.10(s，3H)，1.16(m，6H)	3.20	66	423.30		2.40
67	428.00		3.20	68	427.00	12.54(s，1H)，8.50(d，1H)，8.35(d，1H)，8.31(d，1H)，8.09 (s，1H)，8.07(s，1H)，4.0-5.4(m，9H)，3.3(m，2H)，2.09(s， 3H)，1.26(m，6H)	3.70
69	485.30	DMSO d611.9(s，1H)，10.3(s，1H)，9.2(s，1H)，8.25(s， 1H)，8.15(s，1H)，7.5(t，1H)，7.45(t，2H)，7.25(d，3H)， 7.15(d，1H)，6.7(d，1H)，4.0-4.8(bs，4H)，3.0(bd，2H)，2.0 (s，3H)，1.2(bs，6H)	3.20	68	427.00		3.70
69	485.30		3.20	70	437.30	DMSO d611.8(s，1H)，9.6(s，1H)，9.1(s，1H)，8.2(s，1H)， 8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.7(d，1H)，4.4(m，4H)， 4.15(q，2H)，3.0(bd，2H)，2.0(s，3H)，1.25(m，9H)	3.20
71	515.30	DMSO d611.9(s，1H)，10.2(s，1H)，9.2(s，1H)，8.2(s， 1H)，8.15(s，1H)，7.5(t，1H)，7.1(m，3H)，7.0(d，2H)，6.7 (d，1H)，4.0-4.8(bs，4H)，3.8(s，3H)，3.0(bd，2H)，2.0(s， 3H)，1.2(m，6H)	3.20	70	437.30		3.20
71	515.30		3.20	72	445.00	12.17(s，1H)，8.41(d，1H)，8.27(d，1H)，7.88(d，1H)，7.77 (s，1H)，7.61(s，1H)，7.59(s，1H)，7.50(s，1H)，6.48(s，1H)， 4.05(m，2H)，3.10(m，2H)，2.08(s，3H)，1.31(m，6H) DMSO-d6	2.84
73	422.40	DMSOd612.3(bs，1H)；9.3(s，1H)；8.8(s，1H)；8.2(s，1H)； 7.5(dd，1H)；7.2(d，1H)；6.8(d，1H)；4.4(q，2H)；4.3(bs， 4H)；3.1(bs，2H)；2.1(s，3H)；1.3(t，3H)；1.2(bs，6H)	3.20	72	445.00		2.84

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	74	450.40	DMSOd612.3(bs，1H)；9.4(s，1H)；8.9(s，1H)；8.2(s，1H)； 7.7(dd，1H)；7.2(d，1H)；6.8(d，1H)；4.4(bd，4H)；4.1(d， 2H)；3.1(bs，2H)；2.1(s，3H)；2.05(m，1H)；1.3(bs，6H)； 1.0(d，6H)	3.70
75	429.00	good	3.70	74	450.40		3.70
75	429.00	good	3.70	76	399.00	good	3.17
77	366.30	MeOD48.4(s，1H)；8.1(s，1H)；7.9(s，1H)；7.6(dd，1H)； 7.2(d，1H)；6.8(d，1H)；4.3(bs，4H)；3.2(bs，2H)；2.2(s， 3H)；1.3(bs，6H)	2.10	76	399.00	good	3.17
77	366.30		2.10	78	429.00
79	423.00			78	429.00
79	423.00			80	423.00
81	399.00	12.43(s，1H)，8.48(s，1H)，8.33(d，1H)，8.06(d，1H)， 7.59(d，1H)，6.87(d，1H)，4.7-6.3(m，4H)， 4.2-4.6(m，1H)，4.20(m，2H)，3.05(m，2H)， 2.06(s，3H)，1.25(m，6H) DMSO-d6	2.21	80	423.00
81	399.00		2.21	82	368.50	DMSO d612.3(s，1H)；8.9(s，1H)；8.2(s，1H)；7.6(s，1H)； 7.2(s，1H)；6.7(s，1H)；4.4(d，1H)；3.7-4.1(m，5H)；2.9(s， 3H)；1.9-2.4(m，5H)；1.6(s，1H)	2.10
83	386.40	DMSO d612.2ppm(s，1H)，8.7(s，1H)，8.26(s，1H)，8.23 (s，1H)，7.5(t，1H)，7.1(d，1H)，6.5(d，1H)，3.8(m，2H)， 3.75(t，2H)，3.6(m，2H)，3.55(s，1H)，3.45(s，1H)，3.35 (m，2H)，1.9(m，3H)	3.10	82	368.50		2.10
83	386.40		3.10	84	400.40	DMSO d612.2ppm(s，1H)，8.7(s，1H)，8.26(s，1H)，8.23 (s，1H)，7.5(t，1H)，7.1(d，1H)，6.5(d，1H)，4.0(m，1H)，3.9 (m，1H)，3.8(m，2H)，3.75(m，2H)，3.65(m，2H)，3.35(m， 2H)，1.9(m，2H)，1.0(dt，3H)	3.30
85	369.90	DMSO-D6：12.2(1H，s)；8.7(1H，s)；8.25(2H，m)；7.6(1H， dd)；7.25(1H，d)；6.7(1H，d)；3.8-3.5(8H，m)；2.4(2H，q)； 1.05(3H，t).	2.62	84	400.40		3.30
85	369.90		2.62	86	384.00	DMSO-D6：12.2(1H，s)；8.7(1H，s)；8.25(2H，m)；7.6(1H， dd)；7.25(1H，d)；6.7(1H，d)；3.8-3.5(8H，m)；2.4(2H，q)； 1.55(2H，sextet)；0.95(3H，t).	2.86
87	302.90	DMSO d6：12.2(s，1H)，10.3(s，1H)，9.3(d，1H)，8.3(d， 1H)，8.2(d，1H)，7.7(t，1H)，7.6(m，2H)，3.7(s，3H)	3.20	86	384.00		2.86
87	302.90		3.20	88	330.90	DMSO d6：12.2(s，1H)，10.3(s，1H)，9.3(s，1H)，8.35(s， 1H)，8.25(s，1H)，7.7(t，1H)，7.6(d，1H)，7.55(d，1H)，4.1 (t，2H)，1.7(m，2H)，2 0(t，3H)	3.90
89	398.00	DMSO-D6：12.2(1H，s)；8.7(1H，s)；8.25(2H，m)；7.6(1H， dd)；7.2(1H，d)；6.7(1H，d)；3.6-3.3(8H，m)；2.3(2H，d)； 2.0(1H，m)；0.9(6H，d).	3.08	88	330.90		3.90

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	90	344.80	DMSO d6：12.2ppm(s，1H)，10.3(s，1H)，9.3(s，1H)，8.3 (s，1H)，8.25(s，1H)，7.7(t，1H)，7.6(d，1H)，7.55(d，1H)， 3.95(d，2H)，2.0(m，1H)，1.0(d，6H)	4.20
91	378.80	DMSO d6：12.2ppm(s，1H)，10.4(s，1H)，9.3(s，1H)，8.3 (s，1H)，8.2(s，1H)，7.7(t，1H)，7.62(d，1H)，7.57(d，1H)， 7.5(m，2H)，7.4(m，2H)，5.2(s，2H)	4.20	90	344.80		4.20
91	378.80		4.20	92	409.00	12.56(s，1H)，8.73(d，1H)，8.52(d，1H)，8.32(d，1H)，8.05 (d，1H)，7.52(d，1H)，4.0-4.7(m，4H)，3.24(m，2H)，2.09(s， 3H)，1.36(m，6H) DMSO-d6	2.95
93	409.00	12.54(s，1H)，8.57(d，1H)，8.36(d，1H)，8.33(d，1H)，7.93 (d，1H)，6.92(d，1H)，4.0-4.6(m，4H)，3.2(m，2H)，2.05(s， 3H)，1.24(m，6H) DMSO-d6	2.82	92	409.00		2.95
93	409.00		2.82	94	437.00	DMSOd68.2(s，1H)；8.1(s，1H)；8.0(s，1H)；7.6(dd，1H)； 7.1(d，1H)；6.8(d，1H)；4.5(t，2H)；4.4(bs，2H)；4.3(d， 2H)；3.7(bs，2H)；3.1(bs，2H)；3.0(s，6H)；2.0(s，3H)；1.2 (bs，6H)	1.59
95	479.00	DMSO d68.2(s，1H)；8.1(s，1H)；7.9(s，1H)；7.5(dd，1H)； 7.0(d，1H)；6.6(d，1H)；4.7(t，2H)；4.4(d，2H)；4.0-3.8(bs， 6H)；3.8(t，2H)；3.7-3.5(bs，4H)；3.1(bs，2H)；3.0(s，6H)； 2.0(s，3H)；1.2(bs，6H)	1.63	94	437.00		1.59
95	479.00		1.63	96	436.00	DMSO d68.2(s，1H)；8.1(s，1H)；7.9(s，1H)；7.5(dd，1H)； 7.0(d，1H)；6.6(d，1H)；4.7(t，2H)；4.4(d，2H)；4.0-3.8(bs， 6H)；3.8(t，2H)；3.7-3.5(bs，4H)；3.1(bs，2H)；3.0(s，6H)； 2.0(s，3H)；1.2(bs，6H)	2.25
97	427.00	12.29(s，1H)，8.73(d，1H)，8.30(m，2H)，8.09(s，1H)，7.59 (s，1H)，7.52(s，1H)，7.06(s，1H)，4.1-4.8(m，4H)，3.1(m， 2H)，2.09(s，3H)，1.25(m，6H) DMSO-d6	2.35	96	436.00		2.25
97	427.00		2.35	98	409.00	12.39(s，1H)，8.70(d，1H)，8.43(d，1H)，8.31(s，1H)，7.52 (s，1H)，7.17(s，1H)，4.39(m，4H)，3.15(m，2H)，2.09(s， 3H)，1.25(m，6H) DMSO-d6	3.04
99	300.90	CDCl3：10.3(s，1H)；9.7(s，1H)；8.3(s，1H)；8.1(s，1H)； 7.9(s，1H)；7.7(dd，1H)；6.8(d，1H)；6.5(d，1H)；3.05(d， 2H)；2.0(m，1H)；1.0(d 6H).	2.01	98	409.00		3.04
99	300.90		2.01	100	364.90	DMSO-D6：12.3(br s，1H)；8.6(s，1H)；8.3(s，1H)；8.2(s， 1H)；7.5(m，3H)；7.3(m，2H)；7.2(m 1H)；7.1(m，1H)；6.5 (br s，1H)；5.05(br s 1H)；3.75(m，1H)；3.7(m，1H).	1.99
101	364.90	CDCl3：10.6(br s，1H)；10.25(br s，1H)；8.3(s，1H)；8.1(s， 1H)；7.9(s，1H)；7.6(dd，1H)；7.3(m，6H)；6.8(d，1H)；6.25 (d，1H)；4.6(m，1H)；3.95(m，1H)；3.9(m，1H).	1.98	100	364.90		1.99

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	102	302.90	DMSO-D6(～2：1rotational mixture)：12.6(br s，1H)；12.2 (br s，1H)；8.7(s，.33H)；8.6(s，.67H)；8.3(s，.67H)；8.25(s， 1H)；8.2(s，.33H)；7.8(s，.67H)；7.5(s，.33H)；7.15(d， .67H)；7.05(d，.33H)；6.8(s，.67H)；6.45(s，.33H)；4.5(m， 1H)；4.1(m，1H)；3.6(m，2H)；1.3(d，.6H)；1.2(d，2.4H).	1.62
103	302.90	DMSO-D6(～2：1rotational mixture)：12.65(br s，1H)； 12.25(br s，1H)；8.7(s，.4H)；8.6(s，.6H)；8.35(s，.67H)； 8.3(s，1H)；8.25(s，.33H)；7.8(s，.67H)；7.5(s，.33H)；7.2 (d，.67H)；7.1(d，.33H)；6.8(s，.67H)；6.5(s，.33H0；4.5(m， 1H)；4.05(m，1H)；3.5(m，2H)；1.3(d，.6H)；1.2(d，2.4H).	1.63	102	302.90		1.62
103	302.90		1.63	104	272.80	DMSO d612.3(s，1H)；8.4(s，1H)；8.3(s，1H)；8.1(s，1H)； 8.0(d，1H)；7.8(d，1H).	2.61
105	271.90	DMSO d612.2(s，1H)；8.4(s，1H)；8.3(s，1H)；8.1(s，1H)； 7.9(d，1H)；7.8(d，1H).	2.26	104	272.80		2.61
105	271.90		2.26	106	273.80	DMSO d612.4(s，1H)；9.2(s，1H)；8.9(s，1H)；8.5(s，1H)； 8.3(s，1H)；8.2(d，1H)；8.0(d，1H).	2.34
107	272.90	DMSO d612.3(s，1H)；9.1(s，1H)；8.9(s，1H)；8.5(s，1H)； 8.3(s，1H)；8.1(d，1H)；8.0(bs，1H)；7.9(d，1H)；7.5(bs， 1H).	2.01	106	273.80		2.34
107	272.90		2.01	108	506.00	DMSO-d6：12.2(s，1H)；9.6(br s，1H)；9.25(s，1H)；8.8(s， 1H)；8.25(s，1H)；7.6(dd，1H)；7.2(d，1H)；6.7(d，1H)；4.4 (br s，4H)；4.0(m，2H)；3.8-3.6(m，6H)；3.35(m，2H)；3.2 (br s，2H)；3.1(br s，2H)；2.1(s，3H)；1.3(s，6H).	1.59
109	533.00	DMSO-d6：12.2(s，1H)；9.2(s，1H)；8.75(s，1H)；8.6(br s， 1H)；8.2(s，1H)；7.6(dd，1H)；7.2(d，1H)；6.75(d，1H)；4.4 (br s，4H)；3.6-2.7(m，17H)；2.1(s，3H)；1.9(m，2H)；1.3(s， 6H).	1.46	108	506.00		1.59
109	533.00		1.46	110	452.00	12.09(s，1H)，8.28(d，1H)，8.20(d，1H)，7.77(d，1H)，7.11 (d，1H)，6.97(d，1H)，4.0-4.7(m，4H)，3.30(s，8H)，3.18(m， 2H)，2.10(s，3H)，1.28(m，6H) DMSO-d6	2.31
111	452.00	12.32(s，1H)，8.76(d，1H)，8.37(d，1H)，8.31(d，1H)，7.71 (s，1H)，7.27(s，1H)，4.0-4.7(m，4H)，3.30(s，6H)，3.20(m， 2H)，2.09(s，3H)，1.29(m，6H) DMSO-d6	2.59	110	452.00		2.31
111	452.00		2.59	112	366.00	DMSOd612.2(bs，1H)；8.2(s，1H)；8.1(s，1H)；8.0(s，1H)； 7.6(dd，1H)；7.1(dd，1H)；6.5(dd，1H)；4.0(m，1H)；3.9(s， 3H)；3.8(m，2H)；3.75(m，1H)；3.7(m，2H)；3.5(m，2H)； 2.0(s，3H)；1.9(m，2H)	1.90
113	407.00	DMSO d6：11.8ppm(s，1H)，10(s，1H)，9.2(s，1H)，8.2(s， 1H)，8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.7(d，1H)，4.4(m， 4H)，3.05(m，2H)，2.1(s，3H)，2.08(s，3H)，1.3(bs，6H)	2.10	112	366.00		1.90

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	114	421.00	DMSO d6：11.8ppm(s，1H)，9.9(s，1H)，9.3(s，1H)，8.2(s， 1H)，8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.7(d，1H)，4.4(m， 4H)，3.0(m，2H)，2.4(m，2H)，2.1(s，3H)，1.3(bs，6H)，1.1 (t，3H)	2.20
115	491.00	DMSO d6：11.9ppm(s，1H)，10(s，1H)，9.3(s，1H)，8.6 (bs，1H)，8.2(s，1H)，8.15(s，1H)，7.5(t，1H)，7.1(d，1H)， 6.7(d，1H)，4.4(m，4H)，3.4(bs，2H)，3.2(bs，4H)，3.0(m， 2H)，2.9(bs，4H)，2.1(s，3H)，1.3(bs，6H)	1.50	114	421.00		2.20
115	491.00		1.50	116	492.00	DMSO d6：12ppm(s，1H)，10.7(bs，1H)，9.3(s，1H)，8.22 (s，1H)，8.19(s，1H)，7.5(t，1H)，7.2(d，1H)，6.7(d，1H)， 4.4(m，4H)，4.2(bs，2H)，3.8(t，4H)，3.1(m，4H)，3.0(m， 2H)，2.1(s，3H)，1.3(bs，6H)	1.60
117	435.00	DMSO d6：11.8ppm(s，1H)，9.9(s，1H)，9.3(s，1H)，8.2(s， 1H)，8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.7(d，1H)，4.4(m， 4H)，3.0(m，2H)，2.6(m，1H)，2.1(s，3H)，1.3(bs，6H)，1.1 (d，6H)	2.40	116	492.00		1.60
117	435.00		2.40	118	419.00	DMSO d6：11.9ppm(s，1H)，10.2(s，1H)，9.4(s，1H)，8.2 (s，1H)，8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.7(d，1H)，6.5 (m，1H)，6.3(d，1H)，5.8(d，1H)，4.4(m，4H)，3.0(m，2H)， 2.1(s，3H)，1.3(bs，6H)	2.30
119	493.00	DMSO d6：11.8ppm(s，1H)，10.0(s，1H)，9.3(s，1H)，8.2 (s，1H)，8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.7(d，1H)，4.4 (m，4H)，4.0(m，4H)，3.0(m，2H)，2.6(m，2H)，2.1(s，3H)， 1.3(bs，6H)，1.2(t，3H)	2.50	118	419.00		2.30
119	493.00		2.50	120	452.00	8.79(d，1H)，8.46(s，1H)，8.26(d，1H)，8.07(s，1H)，7.69 (d，1H)，7.40(d，1H)，5.71(s，2H)，4.91(s，2H)，4.20(s， 2H)，3.70(s，4H)，3.40(m，2H)，3.25(s，1H)，3.12(s，1H)， 3.03(s，1H)，2.95(m，2H)，1.99(s，3H)，1.09(m，6H) CD3CN with 4drops of DMSO-d6	2.43
121	506.30	DMSO d6：11.9ppm(s，1H)，10.3(S，1H)，9.3(S，1H)，8.2 (s，1H)，8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.7(d，1H)，4.4 (m，4H)，4.0(d，2H)，3.7(t，2H)，3.5(m，4H)，3.1(m，4H)， 3.0(t，2H)，2.1(s，3H)，1.3(bs，6H)	1.70	120	452.00		2.43
121	506.30		1.70	122	272.90	DMSO-d6：12.2(br s，1H)；8.8(s，1H)；8.25(m，2H)；7.55 (dd，1H)；7.1(d，1H)；6.5(d，1H)；3.1(s，6H).	2.05
123	315.00	DMSO-d6：12.2(br s，1H)；8.8(s，1H)；8.25(m，2H)；7.5 (dd，1H)；7.1(d，1H)；6.45(m，1H)；3.5(d，2H)；3.1(s，3H)； 2.15(m，1H)；0.95(d，6H).	3.55	122	272.90		2.05
123	315.00		3.55	124	492.00	DMSO-d6：12.2(br s，1H)；9.7(br s，1H)；9.2(m，1H)；8.8 (s，1H)；8.2(s，1H)；7.5(m，1H)；7.1(m，1H)；6.5(m，1H)； 4.1-3.5(m，14H)；3.4(m，4H)；3.2(br s，2H)；2.0-1.8(m， 5H).	2.24

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	125	519.10	DMSO-d6：12.2(br s，1H)；9.2(d，1H)；8.8(s，1H)；8.65(br s，1H)；8.2(s，1H)；7.5(m，1H)；7.1(m，1H)；6.5(dd，1H)； 4.1-3.1(m，18H)；3.0(br s，4H)；2.8(s，3H)；2.0-1.8(m， 5H).	1.75
126	379.90	DMSO-d6：11.8(br s，1H)；9.2(s，1H)；8.8(s，1H)；8.0(s， 1H)；7.5(dd，1H)；7.1(d，1H)；6.5(dd，1H)；4.0(m，1H)； 3.8-3.65(m，5H)；3.4(m，2H)；2.0-1.8(m，5H).	1.83	125	519.10		1.75
126	379.90		1.83	127	477.90	DMSO d6：11.8ppm(s，1H)，9.0(s，1H)，8.6(s，1H)，8.2(s， 1H)，8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.7(d，1H)，4.3(m， 4H)，3.6(t，4H)，3.5(t，4H)，3.0(m，2H)，2.1(s，3H)，1.2 (bs，6H)	2.10
128	505.00	DMSO d6：11.9ppm(s，1H)，10.3(s，1H)，9.3(s，1H)，8.2 (s，1H)，8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.7(d，1H)，4.4 (m，4H)，3.3(m，12H)，3.0(m，2H)，2.8(m，2H)，2.1(3H)， 1.3(bs，6H)	1.50	127	477.90		2.10
128	505.00		1.50	129	355.10	MeOD-D4：8.4(s，1H)；8.35(s，1H)；8.1(s，1H)；8.0(dd， 1H)；7.2(d，1H)；7.0(d，1H)；3.75(m，1H)；1.9-1.8(m，3H)； 1.7(m，1H)；1.55(m，1H)；1.3-1.1(m，9H).	2.40
130	315.10	MeOD-D4：8.4(s，1H)；8.35(s，1H)；8.15(s，1H)；8.0(dd， 1H)；7.2(d，1H)；7.0(d，1H)；3.8(m，1H)；1.9(m，1H)；1.3 (d，3H)；1.0(m，6H).	2.00	129	355.10		2.40
130	315.10		2.00	131	367.00	MeOD-D4：8.3(m，2H)；8.1(s，1H)；7.9(dd，1H)；7.5(m， 2H)；7.2(d，1H)；7.1(m，2H)；6.75(d，1H)；5.0(m，1H)； 1.65(d，3H).	2.40
132	342.80	DMSO-D6：12.5(br s，1H)；8.7(br s，1H)；8.35-8.15(m， 2H)；7.7(br s，1H)；7.1(m，1H)；6.8(br s，1H)；3.8(br s， 1H)；3.7-3.5(m，2H)；2.0(m，1H)；1.25-0.8(m，8H).	2.00	131	367.00		2.40
132	342.80		2.00	133	360.90	DMSO-D6：12.3(br s，1H)；8.8(br s，1H)；8.25(m，2H)；7.6 (br s，1H)；7.4-7.1(m，5H)；6.5(br s，1H)；5.6(br s，1H)；3.0 (m，1H)；2.9(m，1H)；2.6(m，1H)；1.95(m，1H).	3.00
134	330.80	DMSO-D6：12.5(br s，1H)；8.7(br s，1H)；8.3-8.25(m， 2H)；7.6(br s，1H)；7.2(br s，1H)；6.7(br s，1H)；3.8(br s， 1H)；3.65-3.5(m，3H)；2.0(m，1H)；1.0(m，7H).	2.00	133	360.90		3.00
134	330.80		2.00	135	330.80	DMSO-D6：12.5(br s，1H)；8.6(br s，1H)；8.3-8.2(m，2H)； 7.7(br s，1H)；7.1(br s，1H)；6.8(br s，1H)；3.8(br s，1H)； 3.7-3.5(m，3H)；2.0(m，1H)；1.0(m，7H).	2.00
136	376.90	DMSO-D6：12.5(br s，1H)；8.7(br s，1H)；8.3(m，2H)；7.4- 7.1(m，5H)；5.5(br s，1H)；4.7(m，1H)；3.2(m，1H)；2.9 (m，1H).	2.40	135	330.80		2.00
136	376.90		2.40	137	376.90	DMSO-D6：12.1(br s，1H)；8.8(br s，1H)；8.2(m，2H)； 7.45-7.05(m，5H)；6.5-6.4(m，2H)；5.5(br s，1H)；4.7(m， 1H)；3.15(m，1H)；2.9(m，1H).	2.40

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	138	430.00	DMSO-d611.9ppm(s，1H)，10.2(s，1H)，9.3(s，1H)，8.3 (s，1H)，8.1(s，1H)，7.5(m，1H)，7.1(m，1H)，6.5(m，2H)， 6.3(d，1H)，5.8(d，1H)，3.5-4.0(m，10H)，1.9(m，2H)	2.30
139	405.10	DMSO-d611.9ppm(s，1H)，10.2(s，1H)，9.3(s，1H)，8.3 (s，1H)，8.1(s，1H)，7.5(m，1H)，7.1(m，1H)，6.5(m，2H)， 6.3(s，1H)，5.8(s，1H)，4.0(t，1H)，3.8(dt，2H)，3.7(m， 3H)，3.4(m，2H)，2.0(s，1H)，1.9(t，1H)，1.8(s，3H)	2.00	138	430.00		2.30
139	405.10		2.00	140	393.10	DMSO-d611.9ppm(s，1H)，10.0(s，1H)，9.1(s，1H)，8.2 (s，1H)，8.1(s，1H)，7.5(m，1H)，7.1(m，1H)，6.5(m，2H)， 4.0(t，1H)，3.8(dt，2H)，3.7(m，3H)，3.4(m，2H)，2.1(s， 3H)，2.0(s，1H)，1.9(t，1H)，1.8(s，3H)	1.70
141	407.00	DMSO-d611.8ppm(s，1H)，9.9(s，1H)，9.1(s，1H)，8.2(s， 1H)，8.1(s，1H)，7.5(m，1H)，7.1(m，1H)，6.5(m，2H)，4.0 (t，1H)，3.8(dt，2H)，3.7(m，3H)，3.4(m，2H)，2.4(q，2H)， 2.0(s，1H)，1.9(t，1H)，1.8(s，3H)，1.1(t，3H)	1.90	140	393.10		1.70
141	407.00		1.90	142	334.80	DMSOD612.2(bs，1H)；8.3(s，1H)；8.15(s，1H)；8.0(s， 1H)；7.6(d，2H)；7.5(dd，2H)；7.4(dd，2H)；7.3(d，2H)； 6.95(d，1H)；5.1(s，2H)	4.60
143	287.80	DMSO D612.1(bs，1H)；8.3(s，2H)；7.9(s，1H)；7.55(d， 1H)；7.4(dd，2H)；7.2(d，1H)；2.95(hept，1H)；1.25(d，6H)	4.60	142	334.80		4.60
143	287.80		4.60	144	271.90	DMSOD612.1(bs，1H)；8.3(s，2H)；7.9(s，1H)；7.3(d， 1H)；7.2(bs，2H)；6.8(app d，1H)；2.9(s，6H)	2.60
145	333.80		4.10	144	271.90		2.60
145	333.80		4.10	146	382.90	DMSO d612.1(bs，1H)；8.3(s，1H)；8.25(s，1H)；8.0(s， 1H)；7.3(dd，1H)；7.2(m，2H)；6.9(s，1H)；4.2(bs，2H)；3.6 (d，2H)；2.8(bs，2H)；2.0(s，3H)；1.3(bs，6H)	3.70
147	378.10		3.00	146	382.90		3.70
147	378.10		3.00	148	288.10		2.00
149	395.10	DMSO-D6：12.4(s，1H)；8.7(d，1H)；8.4(s，1H)；8.25(s， 1H)，7.5(s，1H)；6.9(d，1H)；4.0-3.65(m，6H)；3.4(m，2H)； 2.0-1.8(m，5H).	3.30	148	288.10		2.00
149	395.10		3.30	150	326.00	DMSO-D6：12.3(s，1H)；8.9(s，1H)；8.4(s，1H)；8.25(s， 1H)，7.35(s，1H)；7.25(m，1H)；6.6(s，1H)；3.2(m，2H)； 2.0(m，1H)；1.0(d，6H).	3.70
151	353.00	DMSO-D6：12.4(s，1H)；8.75(br s，1H)8.7(s，1H)；8.45(s， 1H)；8.3(s，1H)，7.6(s，1H)；7.0(s，1H)；4.0(m，2H)；3.8 (m，2H)；3.35(m，2H)；3.2(m，2H)；2.1(m，2H).	1.80	150	326.00		3.70
151	353.00		1.80	152	519.20	DMSO d6：11.9ppm(s，1H)，10.1(s，1H)，9.3(s，1H)，9.0 (bs，1H)，8.2(s，1H)，8.1(s，1H)，7.5(t，1H)，7.15(d，1H)， 6.7(d，1H)，4.3(m，4H)，3.0-3.8(m，14H)，3.1(m，2H)，2.1 (s，3H)，2.0(q，2H)，1.3(bs，6H)	1.40

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	153	520.20	DMSO d6：11.9ppm(s，1H)，10.1(s，1H)，9.3(s，1H)，8.2 (s，1H)，8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.7(d，1H)，4.3 (m，4H)，4.0(d，2H)，3.7(t，4H)，3.5(d，2H)，3.2(m，2H)， 3.1(m，4H)，2.1(s，3H)，2.0(q，2H)，1.3(bs，6H)	1.60
154	433.10	DMSO d6：11.9ppm(s，1H)，9.9(s，1H)，9.3(s，1H)，8.3(s， 1H)，8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.7(d，1H)，5.9(s， 1H)，5.5(s，1H)，4.4(m，4H)， 3.0(m，2H)，2.1(s，3H)，2.0(s，3H)，1.3(bs，6H)	2.20	153	520.20		1.60
154	433.10		2.20	155	473.10	DMSO d6：11.8ppm(s，1H)，9.6(s，1H)，9.3(s，1H)，8.3(s， 1H)，8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.75(t，1H)，6.7(d， 1H)，4.4(m，4H)，3.0(m，2H)，2.3(m，2H)，2.2(m，2H)，2.1 (s，3H)，1.7(m，2H)，1.6(m，2H)，1.3(bs，6H)	2.60
156	469.10	DMSO d6：11.9ppm(s，1H)，10.3(s，1H)，9.4(s，1H)，8.4 (s，1H)，8.1(s，1H)，8.0(d，2H)，7.6(m，4H)，7.2(d，1H)， 6.7(d，1H)，4.4(m，4H)，3.1(m，2H)，2.1(s，3H)，1.3(bs， 6H)	2.50	155	473.10		2.60
156	469.10		2.50	157	459.10	DMSO d6：11.9ppm(s，1H)，9.7(s，1H)，9.3(s，1H)，8.3(s， 1H)，8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.75(s，1H)，6.7 (d，1H)，4.4(m，4H)，3.1(m，2H)，2.6(dt，4H)，2.1(s，3H)， 1.9(q，2H)，1.3(bs，6H)	2.40
158	475.20	DMSO d6：11.8ppm(s，1H)，9.8(s，1H)，9.3(s，1H)，8.15 (s，1H)，8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.7(d，1H)，4.4 (m，4H)，3.1(m，2H)，2.4(m，1H)，2.1(s，3H)，1.8(dd，4H)， 1.4(q，2H)，1.3(bs，10H)	2.60	157	459.10		2.40
158	475.20		2.60	159	379.00	12.03(s，1H)，8.7-9.8(s，5H)，8.40(s，1H)，8.08(s，1H)， 7.96(s，1H)，7.77(t，1H)，7.15(d，1H)，6.90(d，1H)，4.15- 4.7(m，4H)，3.31(m，2H)，2.95(s，3H)，2.16(s，3H)，1.37 (m，6H) CD3CN	1.70
160	440.90	DMSO d612.3(bs，1H)；10.0(bs，1H)；8.6(s，1H)；8.2(s， 1H)；8.1(s，1H)；7.3(s，1H)；7.1(s，1H)；4.4(bs，2H)；4.2 (d，2H)；3.1(bd，2H)；2.05(s，3H)；2.01(s，3H)；1.3(bs， 6H)	2.40	159	379.00		1.70
160	440.90		2.40	161	447.00	DMSO d6：11.8ppm(s，1H)，9.7(s，1H)，9.3(s，1H)，8.3(s， 1H)，8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.7(d，1H)，6.5(q， 1H)，4.4(m，4H)，3.1(m，2H)，2.1(s，3H)，1.9(s，3H)，1.8 (d，3H)，1.2(bs，6H)	2.40
162	475.90	DMSO d6：11.9ppm(s，1H)，10.5(s，1H)，9.4(s，1H)，9.3 (s，1H)，8.5(s，1H)，8.45(s，1H)，8.1(s，1H)，7.6(t，1H)，7.1 (d，1H)，6.7(d，1H)，4.3(m，4H)，3.1(m，2H)，2.1(s，3H)， 1.3(bs，6H)	2.30	161	447.00		2.40

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	163	470.00	DMSO d6：11.9ppm(s，1H)，10.6(s，1H)，9.4(s，1H)，9.3 (s，1H)，9.2(s，1H)，8.8(d，1H)，8.4(s，1H)，8.4(d，1H)，8.2 (s，1t)，7.7(q，1H)，7.6(t，1H)，7.2(d，1H)，6.7(d，1H)，4.4 (m，4H)，3.1(m，2H)，2.1(s，3H)，1.3(bs，6H)	2.10
164	471.00	DMSO d6：11.9ppm(s，1H)，10.9(s，1H)，9.5(s，1H)，9.3 (s，1H)，9.0(s，1H)，8.8(s，1H)，8.5(s，1H)，8.2(s，1H)，7.6 (t，1H)，7.1(d，1H)，6.7(d，1H)，4.4(m，4H)，3.0(m，2H)， 2.1(s，3H)，1.3(bs，6H)	2.30	163	470.00		2.10
164	471.00		2.30	165	433.00	DMSO d6：11.8ppm(s，1H)，10.2(s，1H)，9.3(s，1H)，8.2 (s，1H)，8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.7(d，1H)，4.3 (bd，4H)，3.0(bd，2H)，2.1(s，1H)，1.8(m，1H)，1.3(bs， 6H)，0.8(m，4H)	2.30
166	461.10	DMSO d6：11.8ppm(s，1H)，9.9(s，1H)，9.3(s，1H)，8.2(s， 1H)，8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.7(d，1H)，4.4 (bd，4H)，3.0(bd，2H)，2.8(q，1H)，2.1(s，1H)，1.9(m，1H)， 1.8(m，1H)，1.7(m，1H)，1.6(m，1H)，1.3(bs，6H)	2.60	165	433.00		2.30
166	461.10		2.60	167	460.00	DMSO d6：12.0ppm(s，1H)，10.9(s，1H)，9.3(s，1H)，8.8 (s，1H)，8.4(s，1H)，8.2(s，1H)，7.6(t，1H)，7.2(s，1H)，7.15 (d，1H)，6.7(d，1H)，4.4(bd，4H)，3.1(bd，2H)，2.1(s，3H)， 1.3(bs，6H)	2.30
168	483.00	DMSO d6：11.9ppm(s，1H)，10.3(s，1H)，9.4(s，1H)，8.4 (s，1H)，8.2(s，1H)，7.85(s，1H)，7.8(d，1H)，7.6(t，1H)，7.4 (s，2H)，7.4(q，1H)，7.2(d，1H)，6.7(d，1H)，4.4(bd，4H)， 3.1(bd，2H)，2.4(s，3H)，2.1(s，3H)，1.3(bs，6H)	2.70	167	460.00		2.30
168	483.00		2.70	169	487.00	DMSO d6：11.9ppm(s，1H)，10.4(s，1H)，9.4(s，1H)，8.4 (s，1H)，8.2(s，1H)，7.9(d，1H)，7.8(d，1H)，7.6(q，1H)， 7.55(t，1H)，7.45(t，1H)，7.2(d，1H)，6.7(d，1H)，4.4(bd， 4H)，3.1(bd，2H)，2.1(s，3H)，1.3(bs，6H)	2.70
170	437.00	DMSO d6：11.9ppm(s，1H)，9.8(s，1H)，9.3(s，1H)，8.3(s， 1H)，8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.7(d，1H)，4.4 (bd，4H)，4.1(s，2H)，3.4(s，1H)，3.0(bd，2H)，2.1(s，3H)， 1.3(bs，6H)	2.10	169	487.00		2.70
170	437.00		2.10	171	476.00	DMSO d6：12.0ppm(s，1H)，10.5(s，1H)，9.0(s，1H)，8.3 (s，1H)，8.2(s，1H)，7.6(t，1H)，7.1(d，1H)，6.7(d，1H)，4.4 (bd，4H)，3.3(m，2H)，3.0(bd，2H)，2.3(m，2H)，2.1(s，3H)， 1.5-1.9(m，4H)，1.3(bs，6H)	1.70
172	487.00	DMSO d6：11.9ppm(s，1H)，10.4(s，1H)，9.4(s，1H)，8.3 (s，1H)，8.2(s，1H)，7.7(t，1H)，7.6(q，1H)，7.5(t，1H)，7.4 (q，2H)，7.2(d，1H)，6.7(d，1H)，4.4(bd，4H)，3.1(bd，2H)， 2.1(s，3H)，1.3(bs，6H)	2.60	171	476.00		1.70
172	487.00		2.60	173	502.90	DMSO d6：11.9ppm(s，1H)，10.5(s，1H)，9.4(s，1H)，8.3 (s，1H)，8.2(s，1H)，7.4-7.7(m，5H)，7.2(d，1H)，6.7(d， 1H)，4.4(bd，4H)，3.1(bd，2H)，2.0(s，3H)，1.3(bs，6H)	2.60

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	174	502.90	DMSO d6：11.9ppm(s，1H)，10.5(s，1H)，9.4(s，1H)，8.4 (s，1H)，8.2(s，1H)，8.0(d，1H)，7.7(s，1H)，7.6(t，1H)，7.5 (t，1H)，7.2(d，1H)，6.7(d，1H)，4.4(b d，4H)，3.1(bd，2H)， 2.1(s，3H)，1.3(bs，6H)	2.90
175	307.00	DMSO d612.4(bs，1H)；8.4(s，1H)；8.3(s，1H)；8.2(s， 1H)；7.95(d，2H)；7.9(s，1H)	2.80	174	502.90		2.90
175	307.00		2.80	176	253.70	DMSO d612.4(bs，1H)；8.5(s，1H)；8.3(s，1H)；8.2(s， 1H)；8.0(d，2H)；7.9(d，2H)	3.10
177	350.95	DMSO d612.4(bs，1H)；8.35(s，1H)；8.3(s，1H)；8.2(m， 2H)；8.1(s，1H)；7.9(s，1H)	3.16	176	253.70		3.10
177	350.95		3.16	178	287.01	DMSO d612.2(bs，1H)；8.4(s，1H)；8.3(s，1H)；8.0(s， 1H)；7.65(s，1H)；7.6(dd，1H)；7.4(dd，1H)；7.2(dd，1H)； 3.8(S，2H)	2.69
179	494.00	DMSO d6：11.9ppm(s，1H)，10.5(s，1H)，9.4(s，1H)，8.45 (s，1H)，8.4(s，1H)，8.3(d，1H)，8.2(s，1H)，(8.1(d，1H)，7.8 (t，1H)，7.6(t，1H)，7.2(d，1H)，6.7(d，1H)，4.4(bd，4H)， 3.1(bd，2H)，2.1(s，3H)，1.3(bs，6H)	2.60	178	287.01		2.69
179	494.00		2.60	180	449.10	DMSO d6：11.8ppm(s，1H)，9.9(s，1H)，9.3(s，1H)，8.2(s， 1H)，8.1(s，1H)，7.6(t，1H)，7.1(d，1H)，6.7(d，1H)，4.4 (bd，4H)，3.1(bd，2H)，2.4(m，1H)，2.1(s，3H)，1.6(m，1H)， 1.4(m，1H)，1.3(bs，6H)，1.1(d，3H)，0.9(t，3H)	2.50
181	433.00	DMSO d6：11.9ppm(s，1H)，10.0(s，1H)，9.3(s，1H)，8.2 (s，1H)，8.1(s，1H)，7.5(t，1H)，7.1(d，1H)，6.8(m，1H)，6.7 (d，1H)，6.2(d，1H)，4.4(bd，4H)，3.1(bd，2H)，2.1(s，3H)， 1.9(d，3H)，1.3(bs，6H)	2.30	180	449.10		2.50
181	433.00		2.30	182	474.90	DMSO d6：11.9ppm(s，1H)，10.3(s，1H)，9.3(s，1H)，8.4 (s，1H)，8.2(s，1H)，8.0(d，1H)，7.9(d，1H)，7.6(t，1H)， 7.25(t，1H)，7.2(d，1H)，6.7(d，1H)，4.4(bd，4H)，3.1(bd， 2H)，2.1(s，3H)，1.3(bs，6H)	2.50
183	228.80	DMSO d612.2(bs，1H)；8.3(s，1H)；8.25(s，1H)；8.0(s， 1H)；7.7(d，2H)；7.4(dd)；7.2(dd，1H)	3.40	182	474.90		2.50
183	228.80		3.40	184	230.10	DMSO d612.2(bs，1H)；8.3(s，1H)；8.25(s，1H)；8.0(s， 1H)；7.7(d，2H)；7.4(dd)；7.2(dd，1H)	1.60
185	243.10	DMSO d612.2(bs，1H)；8.3(s，1H)；8.25(s，1H)；7.9(s， 1H)；7.5(dd，2H)；7.3(dd，1H)；7.1(d，1H)；2.3(s，3H)	3.40	184	230.10		1.60
185	243.10		3.40	186	334.10	DMSO d612.2(bs，1H)；8.25(s，1H)；8.2(s，1H)；8.0(s， 1H)；7.5(d，1H)；7.4(dd，2H)；7.3(d，1H)；7.05(dd，2H)； 6.7(d，2H)；6.55(dd，1H)；4.3(s，2H)	2.60
187	401.80	DMSO d612.2(bs，1H)；8.3(s，1H)；8.05(s，1H)；8.0(s， 1H)；7.5(m，5H)；7.3(dd，1H)；7.2(s，1H)；7.1(s，1H)；6.8 (s，1H)；4.4(s，2H)	3.90	186	334.10		2.60
187	401.80		3.90	188	291.02		2.30

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	189	487.00	DMSO d6：11.9ppm(s，1H)，10.3(s，1H)，9.3(s，1H)，8.4 (s，1H)，8.15(s，1H)，8.1(m，2H)，7.5(t，1H)，7.4(t，2H)， 7.15(d，1H)，6.7(d，1H)，4.4(bd，4H)，3.1(bd，2H)，2.1(s， 3H)，1.3(bs，6H)	2.60
190	460.00	DMSO d6：11.9ppm(s，1H)，10.6(bs，1H)，9.3(s，1H)，8.5 (s，1H)，8.2(s，1H)，7.5(t，1H)，7.1(d.1H)，6.7(d，1H)，4.4 (bd，4H)，3.1(bd，2H)，2.1(s，3H)，1.2(bs，6H)	2.00	189	487.00		2.60
190	460.00		2.00	191	445.00	DMSO d6：11.9ppm(s，1H)，10.2(bs，1H)，9.4(s，1H)，8.3 (s，1H)，8.1(s，1H)，7.5(t，1H)，7.2(m，1H)，7.1(d.1H)，6.7 (d，1H)，6.6H)，1H)，6.3(d，1H)，5.7(d，1H)，5.5(d，1H)， 4.4(bd，4H)，3.1(bd，2H)，2.1(s，3H)，1.2(bs，6H)	2.40
192	452.90	DMSO d6：11.9ppm(s，1H)，10.3(s，1H)，9.3(s，1H)，8.2 (s，1H)，8.1(s，1H)，7.5(t，1H)，7.4(d，1H)，7.1(d.1H)，6.7 (d，1H)，6.7(s，1H)，4.4(bd，4H)，3.1(bd，2H)，2.1(s，3H)， 1.2(bs，6H)	2.50	191	445.00		2.40
192	452.90		2.50	193	456.10	DMSO-d6：11.9(bs，1H)；8.3(s，1H)；8.1(m，2H)；7.55(dd， 1H)；7.45(d，2H)；7.4(dd，2H)；7.3(m，1H)；7.15(d，1H)； 6.7(d，1H)；5.2(s，2H)；4.2(d，4H)；3.1(m，2H)；2.05(s， 3H)；1.25(s，6H).	3.00
194	451.20	DMSO-d6：11.9(bs，1H)；8.25(s，1H)；8.1(s，1H)；8.05(s， 1H)；7.55(dd，1H)；7.15(d，1H)；6.7(d，1H)；4.3(d，4H)； 4.15(m，2H)；3.25(m，2H)；3.05(m，2H)；2.8(s，6H)；2.15 (m，2H)；2.05(s，3H)；1.25(s，6H).	1.60	193	456.10		3.00
194	451.20		1.60	195	279.80	(d4-methanol，free base)8.87(s，1H)，8.70(s，1H)，8.50(s， 1H)，8.38(s，1H)，8.20(d，1H)，8.18(d，1H)，8.10(m，1H)， 7.96(m，1H)	2.86
196	311.80	(d4-methanol，salt)8.88(s，1H)，8.25(m，2H)，7.86(s，1H)， 7.34(m，1H)，2.72(s，3H)	3.95	195	279.80		2.86
196	311.80		3.95	197	293.80	(d4-methanol，salt)8.71-7.45(m，8H)，2.90(s，3H)	2.33
198	293.90	(d4-methanol，salt)8.53-7.82(m，7H)，7.41(s，1H)，4.34(s， 3H)	2.33	197	293.80	(d4-methanol，salt)8.71-7.45(m，8H)，2.90(s，3H)	2.33
198	293.90	(d4-methanol，salt)8.53-7.82(m，7H)，7.41(s，1H)，4.34(s， 3H)	2.33	199	278.90	(d4-methanol，salt)8.39(dd，1H)，8.25(s，1H)，8.11(s，1H)， 7.94-7.79(m，5H)，7.51-7.44(m，2H)	3.87
200	279.90	(d4-methanol，salt)9.16-7.99(m，9H)	3.87	199	278.90		3.87
200	279.90	(d4-methanol，salt)9.16-7.99(m，9H)	3.87	201	259.90	(d4-methanol，salt)8.86(d，1H)，8.23(s，1H)，8.09(s，1H)， 7.99(m，1H)，7.70(d，1H)，7.39(dd，1H)，6.65(d，1H)，4.17 (s，3H)	3.46
202	279.80	(d4-methanol，salt)9.01(d，1H)，8.98(d，1H)，8.32(s，1H)， 8.31(s，1H)，8.28(d，1H)，8.17(d，1H)，8.01-7.97(m，2H)， 7.94(s，1H)	2.50	201	259.90		3.46
202	279.80		2.50	203	287.90	(CDCl3)10.00(br s，1H)，8.49(s，1H)，8.27(s，1H)，8.00s， 1H)，7.71(m，1H)，7.48(m，1H)，7.20(m，1H)，7.19(d，1H)， 1.97(s，OH，1H)，1.57(s，6H)	2.56

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	204	412.90	DMSO d612.2(bs，1H)；8.7(t，1H)；8.4(s，1H)；82(s， 1H)；8.1(s，1H)；8.0(s，1H)；4，8(q，1H)；3.9(s，3H)；3.85 (m，2H)；1.15(d，3H)	1.90
205	394.20		2.10	204	412.90		1.90
205	394.20		2.10	206	408.10		2.20
207	420.20		2.30	206	408.10		2.20
207	420.20		2.30	208	493.20		1.70
209	452.20		2.20	208	493.20		1.70
209	452.20		2.20	210	343.00	1H NMR(CDCl3)0.30(9H，s)，7.33-7.54(8H，m)，7.59- 7.68(2H，m)，8.05-8.08(1H，m)，8.61-8.65(1H，m)，9.70 (1H，brs).
211	349.10	(400MHz，DMSO-d6)7.30-7.43(8H，br m)，7.48(2H，m)， 7.98(1H，d)，8.34(1H，d)，12.36(1H，br m).		210	343.00
211	349.10			212	364.40	(400MHz，DMSO-d6)7.00(2H，d)，7.23(2H，d)，7.34(3H， m)，7.49(2H，dd)，7.97(1H，s)，8.33(1H，d)and 12.38(1H， s).
213	271.00	1H NMR(CDCl3)7.30-7.57(6H，m)，7.60-7.77(5H，m)， 8.44-8.48(1H，m)，8.65-8.70(1H，m)，11.21(1H，brs).		212	364.40
213	271.00			214	301.00	1H NMR(DMSO)3.84(3H，s)，6.80-6.8891H，m)，7.25- 7.30(1H，m)，7.32-7.41(3H，m)，7.45-7.54(2H，m)，7.72- 7.81(2H，m)，7.90-7.98(1H，m)，8.39-8.4391H，m)，8.54- 8.60(1H，m)，12.04(1H，brs).
215	315.00	1H NMR(DMSO)1.36(3H，t，J＝6.9Hz)，4.10(2H，q，J＝ 6.9Hz)，6.80-6.86(1H，m)，7.22-7.29(1H，m)，7.30-7.41 (3H，m)，7.45-7.55(2H，m)，7.73-7.80(2H，m)，7.91-7.98 (1H，m)，8.38-8.41(1H，m)，8.53-8.59(1H，m)，12.0291H， brs).		214	301.00
215	315.00			216	331.00	1H NMR(DMSO)3.70-3.80(6H，m)，6.81-6.90(1H，m)， 7.02-7.15(2H，m)，7.32-7.40(1H，m)，7.42-7.51(2H，m)， 7.66-7.79(3H，m)，8.11-8.16(1H，m)，8.50-8.56(1H，m)， 11.95(1H，brs).
217	436.70	(400MHz，DMSO-d6)12.31(1H，s)，8.32(1H，d)，7.94(1H， d)，7.52(2H，d)，7.33(3H，m)，7.10(2H，d)，6.98(2H，d)， 3.75(4H，dd)and 3.15(4H，dd).		216	331.00
217	436.70			218	349.00	1H NMR(DMSO)3.30(3H，s)，7.34-7.45(1H，m)，7.49- 7.83(6H，m)，8.16(1H，s)，8.18-8.28(2H，m)，8.45-8.49 91H，m)，8.58-8.62(1H，m)，12.21(1H，brs).
219	342.00	1H NMR(DMSO)3.00(6H，s)，7.35-7.42(1H，m)，7.45- 7.68(4H，m)，7.75-7.90(4H，m)，8.03(1H，s)，8.45-8.50 (1H，m)，8.56-8.60(1H，m)，12.11(1H，brs).		218	349.00

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	220	370.00	1H NMR(DMSO)0.91(3H，t，J＝7.4Hz)，1.30-1.42(2H， m)，1.49-1.59(2H，m)，3.25-3.34(2H，m)，7.35-7.42(1H， m)，7.46-7.58(3H，m)，7.68-7.81(3H，m)，7.92-8.03(2H， m)，8.19-8.22(1H，m)，8.44-8.49(1H，m)，8.50-8.61(2H， m)，12.10(1H，brs).
221	367.00	1H NMR(DMSO)3.36(3H，s)，7.28-7.39(2H，m)，7.50- 7.88(5H，m)，8.10-8.26(3H，m)，8.43-8.46(1H，m)，8.57- 8.59(1H，m)，12.25(1H，brs).		220	370.00
221	367.00			222	349.00	1H NMR(DMSO)3.79(3H，s)，3.86(3H，s)，7.00-7.05 (1H，m)，7.26-7.37(4H，m)，7.78-7.89(2H，m)，8.35-8.40 (1H，m)，8.50-8.56(1H，m)，11.93(1H，brs).
223	307.00	1H NMR(DMSO)7.22-7.37(4H，m)，7.78-7.88(4H，m)， 7.92(1H，brs)，8.36-8.4191H，m)，8.51-8.58(1H，m)，12.02 (1H，brs).		222	349.00
223	307.00			224	319.00	1H NMR(DMSO)3.80(3H，s)，6.99-7.06(2H，m)，7.26- 7.36(2H，m)，7.68-7.84(5H，m)，8.33-8.39(1H，m)，8.50- 8.57(1H，m)，11.91(1H，brs).
225	452.00	1H NMR(DMSO)3.30-3.80(8H，m)，7.25-7.32(1H，m)， 7.50-7.63(2H，m)，7.80(1H，s)，7.88-7.99(2H，m)，8.05 (1H，s)，8.49-8.54(1H，m)，8.60-8.68(1H，m)，12.20(1H， brs).		224	319.00
225	452.00			226	410.00	1H NMR(DMSO)1.16(3H，t)，3.20-3.42(2H，m)，7.50- 7.76(3H，m)，7.88-7.95(2H，m)，7.98-8.06(2H，m)，8.20 (1H，s)，8.51-8.66(3H，m)，12.18(1H，brs).
227	332.00	1H NMR(DMSO)7.28-7.39(3H，m)，7.79-8.03(7H，m)， 8.09(1H，brs)，8.48-8.51(1H，m)，8.53-8.59(1H，m)，12.14 (1H，brs).		226	410.00
227	332.00			228	332.00	1H NMR(DMSO)7.30-7.48(3H，m)，7.42(1H，brs)，7.50- 7.58(1H，m)，7.70-7.86(3H，m)，7.92-8.11(3H，m)，8.20 (1H，brs)，8.41-8.49(1H，m)，8.54-8.59(1H，m)，12.09(1H， brs).
229	299.00	1H NMR(DMSO)7.38-7.4391H，m)，7.48-7.55(2H，m)， 7.78-7.83(2H，m)，7.9792H，d，J＝8.2Hz)，8.09(2H，d，J＝ 8.2Hz)，8.21(1H，s)，8.54-8.6292H，m)，10.0091H，s)， 12.30(1H，brs).		228	332.00
229	299.00			230	342.00	1H NMR(DMSO)1.9093H，s)，4.20-4.3092H，m)，7.27- 7.40(3H，m)，7.45-7.5192H，m)，7.70-7.80(4H，m)，7.85- 7.91(1H，m)，8.30-8.41(2H，m)，8.51-8.60(1H，m)，12.00 (1H，brs).
231	313.00	1H NMR(DMSO)2.60(3H，s)，7.36-7.42(1H，m)，7.47- 7.55(2H，m)，7.76-7.83(2H，m)，7.95-8.08(4H，m)，8.15 (1H，s)，8.50-8.56(1H，m)，8.58-8.6391H，m)，12.24(1H， brs).		230	342.00

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	232	286.00	1H NMR(DMSO)5.08(2H，brs)，6.63-6.70(2H，m)，7.30- 7.5295H，m)，7.60-7.66(1H，m)，7.70-7.80(2H，m)，8.30- 8.35(1H，m)，8.50-8.55(1H，m)，11.75(1H，brs).
233		1H NMR(DMSO)2.40-2.48(3H，m)，7.36-7.55(4H，m)， 7.78-7.85(4H，m)，8.02-8.09(2H，m)，8.15(1H，s)，8.52- 8.56(1H，m)，8.59-8.62(1H，m)，12.25(1H，brs).		232	286.00
233				234	364.00	1H NMR(DMSO)3.00(3H，s)，7.25-7.54(5H，m)，7.70- 7.90(5H，m)，8.40-8.48(1H，m)，8.52-8.60(1H，m)，9.73 (1H，brs)，12.00(1H，brs).	8.93
235	304.00	1H NMR(DMSO)7.15(1H，s)，7.35(1H，brs)，7.78(1H，s)， 7.85-8.08(7H，m)，8.31(1H，s)，8.4991H，brs)，8.61(1H， brs)，12.08(1H，brs).	7.68	234	364.00		8.93
235	304.00		7.68	236	320.00	1H NMR(DMSO)7.30(1H，s)，7.60-7.76(2H，m)，7.82- 8.10(7H，m)，8.55(1H，brs)，8.70(1H，s)，12.10(1H，brs).	8.14
237	370.00	(400MHz，MeOH-d4)：4.70-4.85(2H，brs)，6.35-6.45(1H， s)，7.30-7.50(5H，m)，8.05-8.15(1H，d)，8.20-8.25(1H，s)， 8.60-8.70(1H，brs)	4.87	236	320.00		8.14
237	370.00		4.87	238	388.00	1H NMR(DMSO-d6)：3.33(1H，s)，4.75-4.80(2H，m)， 7.35-7.45(4H，m)，8.15(1H，s)，8.20-8.25(2H，m)，8.28- 8.351H，m)，8.50(1H，s)	4.87
239	344.00	1H NMR(DMSO)3.85(3H，s)，6.91-7.00(1H，m)，7.26- 7.49(4H，m)，7.85-8.10(6H，m)，8.50(1H，brs)，8.60(1H， brs)，12.15(1H，brs).	8.38	238	388.00		4.87
239	344.00		8.38	240	308.24	1H NMR(DMSO-d6)：7.22(1H，m)，7.47(2H，m)，7.85 (1H，s)，8.21(1H，s)，8.64(1H，s)，11.19(1H，br s)	4.93
241	299.38	1H NMR(CDCl3)：2.04(4H，s)，3.53(4H，s)，6.22(1H，d)， 6.86(1H，d)，7.44(1H，t)，7.81(1H，s)，8.17(1H，s)，8.87 (1H，s)	5.15	240	308.24		4.93
241	299.38		5.15	242	369.00	1H NMR(DMSO-d6)：4.60-4.70(2H，m)，6.35-6.40(1H， d)，7.05-7.10(1H，d)，7.20-7.25(1H，t)，7.35-7.45(4H，m)， 8.15-8.20(2H，m)，8.55-8.60(1H，s)，12.5(1H，s)	4.99
243	321.00	1H NMR(DMSO-d6)：6.70-6.75(1H，d)，6.90-6.95(1H，t)， 7.30-7.35(3H，qd)，7.50-7.65(3H，m)，8.25-8.30(2H，m)， 8.80(1H，s)，9.05(1H，s)，12.5(1H，s)	4.84	242	369.00		4.99
243	321.00		4.84	244	401.49	1H NMR(DMSO-d6)：4.63(2H，d)，5.20(1H，br s)，6.45 (1H，d)，7.08(1H，d)，7.27(1H，t)，7.37(2H，s)，7.43(1H，t)， 7.64(1H，s)，8.16(2H，d)，8.39(1H，s)，12.48(1H，br s)	5.20
245	513.00	(d6-DMSO，400MHz)3.16(3H，s)，5.30(2H，s)，7.52(1H， d)， 7.60(2H，d)，7.70(1H，d)，7.81(1H，t)，7.91(2H，d)， 8.17(1H，d)，8.28(1H，d)，8.36(1H，s)，12.31(1H，s)	4.89	244	401.49		5.20
245	513.00		4.89	246	245.00	(d6-DMSO，400MHz)5.98(2H，brs)，6.25(1H，d)， 7.01(1H，d)，7.37(1H，t)，8.18(1H，s)，8.24(1H，d)， 8.96(1H，d)，12.12(1H，s)	3.80

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	247	413.00	(d6-DMSO，400MHz)3.15(3H，s)，4.71(2H，s)，6.38(1H， d)， 7.06(1H，d)，7.42(1H，t)，7.65(2H，d)，7.88(2H，d)， 8.18(2H，s)，8.53(1H，s)，12.12(1H，s)	4.00
248	372.00	1H NMR(DMSO-d6)：7.05-7.10(1H，t)，7.35-7.40(1H， m)，7.60-7.65(1H，t)，7.70-7.80(3H，m)，7.82-7.88(1H，d)， 7.95(1H，s)，8.25(1H，s)，8.40(1H，s)，12.5(1H，s)	5.22	247	413.00		4.00
248	372.00		5.22	249	349.00	(d6-DMSO，400MHz)7.56-7.60(2H，m)，7.63(1H，d)， 7.69(1H，d)，7.82(1H，t)，7.97(1H，s)，8.00(2H，d)， 8.27(1H，s)，8.42(1H，s)，9.28(1H，s)，10.81(1H，s)， 12.29(1H，s)	4.59
250	345.00	(d6-DMSO，400MHz)1.53(9H，s)，7.56(2H，dd)， 7.69(1H，t)，8.25(1H，d)，8.36(1H，s)，9.30(1H，s)， 10.06(1H，s)，12.22(1H，s)	4.90	249	349.00		4.59
250	345.00		4.90	251	405.00	NMR(DMSO)4.6(2H，d，CH2)，6.4(H，d，ar)，7.05(H，d， ar)，7.3(H，m，ar)，7.4(H，d，ar)，7.45(H，t，ar)，7.6(H，d， ar)，7.65(H，s，ar)，8.15(2H，s，ar)，8.5(H，s，NH)and 12.15 (H，s，NH).	5.15
252	349.00	1H NMR(DMSO-d6)：1.50-1.55(3H，d)，5.05-5.15(2H， m)，6.30-3.35(1H，d)，6.95-7.05(1H，d)，7.10-7.15(1H，d)， 7.15-7.20(1H，t)，7.25-7.40(3H，m)，7.45-7.50(2H，d)， 8.15(1H，s)，8.20(1H，s)，8.75(1H，s)，12.5(1H，s)	4.93	251	405.00		5.15
252	349.00		4.93	253	315.70	CDCl33.23(6H，m)，6.45(1H，d)，7.03(1H，d)，7.43(1H， m)， 7.5-7.57(3H，m)，7.70-7.73(2H，m)，7.88(1H，s)，8.65(1H， s)， 9.10(1H，s)，9.25(1H，s).	10.37
254	349.00	NMR(DMSO)2.2(3H，s，CH3)，4.5(2H，s，CH2)，6.3(H， s，ar)，6.8-7.4(7H，m，ar)，8.1-8.3(2H，m，ar)and 8.7(H，s， NH).	5.03	253	315.70		10.37
254	349.00		5.03	255	407.00	1H NMR(DMSO)3.01(3H，s)，7.28-7.39(3H，m)，7.70- 8.10(8H，m)，8.45(1H，brs)，8.55(1H，brs)，9.80(1H，brs)， 12.14(1H，brs).
256	407.00	1H NMR(DMSO)2.45(3H，brs)，7.31(1H，brs)，7.51(1H， brs)，7.80-8.15(10H，m)，8.60(1H，brs)，8.67(1H，brs)， 12.21(1H，brs).		255	407.00
256	407.00			257	414.53	1H NMR(DMSO-d6)：1.44(9H，s)，3.41(4H，s)，3.57 (4H，d)，6.69(1H，d)，7.22(1H，d)，7.57(1H，t)，8.27(2H， s)，8.67(1H，s)，12.25(1H，s	2.50
258	365.40	1H NMR(DMSO-d6)：3.70(3H，s)，6.35(1H，d)，6.88(2H， d)，7.03(1H，d)，7.11(1H，t)，7.34(2H，d)，7.37(1H，t)，8.18 (1H，s)，8.21(1H，d)，8.76(1H，s)，12.13(1H，s)	4.78	257	414.53		2.50

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	259	329.70	CDCl31.05(3H，t)，1.7-1.8(2H，m)，3.4-3.5(2H，m)，4.6 (1H，s)， 6.32(1H，d)，7.03(1H，d)，7.45(1H，m)，7.5-7.6(3H，m)， 7.75(2H，d)，7.78(1H，s)，8.65(1H，s)，8.97(1H，s)，9.12 (1H，s)	4.99
260	349.00	(400MHz，MeOH-d4)：1.55-1.60(3H，d)，5.05-5.15(1H， m)，6.30-6.35(1H，d)，6.95-7.05(1H，d)，7.10-7.15(1H，m)， 7.15-7.20(1H，t)，7.25-7.40(3H，m)，7.45-7.50(2H，d)， 7.95(1H，s)8.15(1H，s)，8.75(1H，s)	4.93	259	329.70		4.99
260	349.00		4.93	261	445.00	NMR(DMSO)4.7(2H，d，CH2)，6.35(H，d，ar)，7.15(H，d， ar)，7.2(H，t，ar)，7.3-7.55(7H，m，ar)，7.6(s，H，ar)，8.2(H， s，ar)，8.5(H，s，NH)and 8.9(H，s，NH).	5.30
262	391.00	NMR(DMSO)2.2(3H，s，Me)，4.6(2H，d，CH2)，6.3(H，d， ar)，7.05-7.1(4H，m，ar)，7.25(2H，，d，ar)，7.3-7.45(4H，m， ar)，7.6(2H，d，ar)，8.15(H，s，ar)，8.5(H，s，NH)and 9.05 (H，s，NH).	5.14	261	445.00		5.30
262	391.00		5.14	263	355.00	1H NMR(DMSO-d6)：6.70-6.80(1H，d)，7.10-7.20(1H，t)， 7.30-7.40(2H，m)，7.50-7.60(2H，m)，7.80-7.90(1H，d)， 8.15(1H，s)，8.25(1H，s)，8.50(2H，s)，12.2(1H，s)	4.92
264	349.00	1H NMR(DMSO-d6)：2.95-3.00(2H，t)，3.55-3.60(2H， m)，6.30-6.35(1H，d)，6.65-6.70(1H，t)，7.05-7.10(1H，d)， 7.15-7.20(1H，t)，7.30(4H，m)，7.32-7.40(1H，t)，8.17(1H， s)，8.20(1H，s)，8.85(1H，s)，12.2(1H，s)	4.67	263	355.00		4.92
264	349.00		4.67	265	363.00	NMR(DMSO)6.7(H，d，ar)，6.9(H，t，ar)，7.35-7.4(2H，m， ar)，7.4-7.5(4H，m，ar0，7.5-7.75(5H，m，ar)，8.25(H，s，ar)， 8.6(H，s，ar)，8.9(H，s，ar)，9.3(H，s，NH)and 12.1(1H，s， NH).	4.64
266	397.00	NMR(DMSO)6.8(H，d，ar)，7.0(H，m，ar)，7.2(H，m，ar)， 7.2-7.6(7H，m，ar)，7.65(H，m，ar)，8.0(H，m，ar)，8.2(H，s， ar)，8.4(H，m，NH)，8.5(H，s，ar)，8.7(H，s，ar)and 12.1(H， brs，NH).	5.20	265	363.00		4.64
266	397.00		5.20	267	314.43，314.00	1H NMR(DMSO-d6)：3.11(4H，s)，3.88(4H，d)，6.78 (1H，d)，7.30(1H，d)，7.65(1H，t)，8.30(2H，d)，8.63(1H， s)，8.77(2H，br s)，12.30(1H，s)，DMSO D62.82-2.93(4H， m)，3.48-3.55(4H，m)，6.65(1H，d)，7.15(1H，d)，7.55(1H， t)，8.25-8.30(2H，m)，8.69(1H，s)	3.42，2.7 5
268	287.60	CDCl34.48(2H，s)，6.45(1H，d)，7.12(1H，d)，7.42(1H，t)， 7.5-7.6(3H，m)，7.75(2H，t)，7.88(1H，s)，8.7(1H，s)，8.88 (1H，s)， 9.52(1H，s)	2.79	267	314.43，314.00		3.42，2.7 5

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	269	377.60	CDCl34.7(2H，d)，5.0(1H，s)，6.35(1H，d)，7.08(1H，d)， 7.3-7.4(9H，t)， 7.5-7.6(3H，m)，7.68(2H，d)，7.88(1H，s)，8.65(1H，s)， 8.95(1H，s)， 9.43(1H，s)	5.00
270	289.00	1H NMR(DMSO-d6)：3.45-3.50(2H，m)，3.60-3.65(2H， m)，4.70-4.77(1H，t)，6.25-6.30(1H，d)，6.50-6.55(1H，t)， 7.00-7.05(1H，d)，7.30-7.40(1H，t)，8.20(1H，s)，8.25(1H， s)，8.85(1H，s)，12.2(1H，s)	3.79	269	377.60		5.00
270	289.00		3.79	271	330.00	1H NMR(DMSO-d6)：2.00-2.10(2H，m)，2.80-2.85(6H， s)，3.20-3.30(2H，m)，3.40-3.50(2H，m)，6.25-6.30(1H， m)，6.60-6.80(1H，m)，7.00-7.05(1H，d)，7.30-7.40(1H，t)， 8.20-8.30(2H，m)，8.85(1H，s)，12.2(1H，s)	3.34
272	225.00	(d6-DMSO)2.90(3H，d)，6.24(1H，d)，6.42-6.44(1H，m)， 7.00(1H，d)，7.14(1H，dd)，7.37(1H，t)，8.08(1H，s)， 8.23(1H，d)，8.85(1H，d)，11.87(1H，s)	3.32	271	330.00		3.34
272	225.00		3.32	273	355.00	1H NMR(DMSO-d6)：6.60-6.65(1H，m)，6.70-6.80(1H， d)，7.00-7.10(1H，m)，7.15-7.30(1H，m)，7.20-7.30(1H， m)，7.55-7.65(2H，m)，7.90(1H，s)，8.15(1H，s)，8.30(1H， s)，8.60(1H，s)，8.90-8.95(1H，m)，12.2(1H，s)
274	349.48	1H NMR(DMSO-d6)：3.14(3H，s)，4.92(4H，s)，6.42 (1H，d)，7.09(1H，d)，7.23(1H，t)，7.31(4H，m)，7.48(1H， t)，8.11(1H，s)，8.21(1H，s)，8.55(1H，s)，12.20(1H，br s)	5.25	273	355.00
274	349.48		5.25	275	328.46	1H NMR(DMSO-d6)：2.24(3H，s)，3.31(4H，s)，3.56(4H， s)，6.67(1H，d)，7.19(1H，d)，7.54(1H，t)，8.27(2H，s)，8.69 (1H，s)，12.23(1H，s)	4.37
276	354.64	1H NMR(DMSO-d6)：2.07(3H，s)，3.57(8H，m)，6.70 (1H，d)，7.23(1H，d)，7.58(1H，t)，8.28(2H，s)，8.68(1H， s)，12.25(1H，s)	4.25	275	328.46		4.37
276	354.64		4.25	277	331.70	DMSO 3.55(1H，m)，3.65(1H，m)，4.82(1H，m)，6.35 (1H，d)，6.52(1H，m)， 7.05(1H，d)，7.4(1H，t)，7.55(1H，t)，7.75(1H，d)，8.15 (1H，s)， 8.58(1H，s)，9.08(1H，s)	4.24
278	301.70	DMSO 2.92(3H，s)，6.30(1H，d)，6.51(1H，m)，7.08(1H，d)， 7.35-7.42(2H，m)，7.5-7.6(2H，m)，7.72(2H，d)，8.13(1H，s)， 8.65(1H，s)，9.18(1H，s)	4.62	277	331.70		4.24
278	301.70		4.62	279	315.00	NMR(DMSO)1.1(6H，d，iPr)，2.85(H，m，CH)，3.3(H， brs，NH)，7.55(H，d，ar)，7.65(H，t，ar)，7.85(H，t，ar)，8.2 (H，s，ar)，8.3(H，s，ar)，9.1(H，s，ar)and 10.3(H，s，NH).	4.47
280	363.00	NMR(DMSO)3.85(2H，s，CH2)，7.15(5H，m，ar)，7.6(H， d，ar)，7.7(H，t，ar)，7.9(h，d，ar)，8.3(H，s，ar)，84(H，s，ar)， 9.1(H，s，ar)，10.6(H，s，NH)and 12.3(H，brs，NH).	4.72	279	315.00		4.47

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	281	383.00	(DMSO)7.45-7.7(3H，m，ar)，7.7-7.8(2H，m，ar)，7.8(H，t， ar)，8.0(H，m，ar)，8.25(H，s，ar)，8.4(H，s，ar)，9.2(H，s， ar)，11.1(H，s，NH)，and 12.3(H，s，NH).	4.68
282	383.00	DMSO)6.6(H，m，ar)，7.7(2H，d ar)，7.85(H，t，ar)，8.0(H， m，ar)，8.1(H，s，ar)，8.25(H，s，ar)，8.45(H，s，ar)，9.3(H， s，ar)，10.8(0.5H，s，NH)and 12.3(0.5H，s，NH).	4.95	281	383.00		4.68
282	383.00		4.95	283	287.00	(DMSO)2.2(3H，s，Me)，7.55(H，m，ar)，7.7(H，m，ar)， 7.85(H，m，ar)，8.2(H，m，ar)，8.4(H，m，ar)，10.4(H，s， NH)and 12.3(H，s，NH)	4.05
284	335.00	1H NMR(DMSO-d6)：3.50-3.55(3H，m)，6.40-6.45(1H， m)，7.25-7.30(2H，m)，7.32-7.37(2H，m)，7.45-7.55(3H， m)，8.15(1H，s)，8.30(1H，s)，8.45(1H，s)，12.2(1H，s)	5.27	283	287.00		4.05
284	335.00		5.27	285	386.46	1H NMR(CDCl3)：1.69(3H，d，J＝6.9Hz)，5.29(1H，m)， 5.42(1H，6.8Hz)，7.07(2H，m)，7.44(2H，m)，8.04(1H， m)，8.09(1H，m)，8.27(1H，m)，8.65(1H，m)，8.87(1H，br s)	4.97
286	368.46	1H NMR(CDCl3)：1.69(3H，d，J＝6.8)，5.33(1H，m)，5.45 (1H，m)，7.38(2H，m)，7.47(2H，m)，8.04(1H，d)，8.08(1H， d)，8.27(1H，d)，8.70(2H，m)	4.90	285	386.46		4.97
286	368.46		4.90	287	369.80	DMSO 1.1-1.3(6H，m)，1.6-1.7(2H，m)，2.0-2.08(2H，m)， 4.0(1H，m)， 6.26(1H，d)，6.35(1H，d)，7.0(1H，d)，7.3-7.4(2H，m)，7.52 (2H，t)， 7.7(2H，d)，8.15(1H，s)，8.55(1H，s)，9.1(1H，s)	5.27
288	355.00	(DMSO)1.1-1.5(5H，m，cyhex)，1.6-1.9(5H，m，cyhex)， 2.65(1H，m，cyhex)，7.6(H，d，ar)，7.75(H，t，ar)，7.95(H， d，ar)，8.3(H，s，ar)，8.4(H，s，ar)，9.15(H，s，ar)，10.35(H， s，NH)and 12.2(H，s，NH).	4.95	287	369.80		5.27
288	355.00		4.95	289	313.45	1H NMR(DMSO-d6)：1.55(6H，m)，2.01(2H，s)，4.20 (1H，m)，6.27(1H，d)，6.54(1H，d)，7.01(1H，d)，7.34(1H， t)，8.23(1H，s)，8.30(1H，s)，8.96(1H，s)，12.13(1H，s)	5.09
290	327.45	1H NMR(DMSO-d6)：1.27(3H，m)，1.45(2H，m)，1.69 (1H，d)，1.81(2H，d)，2.09(2H，d)，3.81(1H，m)，6.24(1H， d)，6.39(1H，d)，6.97(1H，d)，7.31(1H，t)，8.20(2H，s)， 8.88(1H，s)，12.20(1H，br s)	5.25	289	313.45		5.09
290	327.45		5.25	291	341.49	1H NMR(DMSO-d6)：1.51(6H，m)，1.67(4H，m)，2.01 (2H，2)，4.02(1H，s)，6.26(1H，d)，6.44(1H，d)，6.98(1H， d)，7.33(1H，t)，8.19(1H，s)，8.24(1H，s)，8.93(1H，s)， 12.13(1H，br s)	5.37
292	273.38	1H NMR(DMSO-d6)：2.94(3H，s)，3.53(3H，s)，6.56(1H， s)，7.05(1H，s)，7.58(1H，s)，8.31(1H，s)，8.36(1H，s)，8.78 (1H，s)	4.59	291	341.49		5.37

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	293	341.55	1H NMR(CDCl3)：2.04(4H，m)，3.61(4H，m)，6.24(1H，d， J＝8.3)，6.98(1H，d，J＝7.4)，7.39(1H，m)，7.48-7.52(3H， m)，7.70(2H，m)，7.88(1H，m)，8.61(1H，s)，9.16(1H，s)， 9.33(1H，br s)	5.32
294	350.00	DMSO)7.7-7.8(2H，m，ar)，7.9(H，t，ar)，8.05(H，d，ar)， 8.15(H，t，ar)，8.25(H，d，ar)，8.3(H，s，ar)，8.45(H，s，ar)， 8.8(H，d，ar)，9.0(H，s，ar)，10.6(H，s，NH)and 12.4(H，s， NH).	4.85	293	341.55		5.32
294	350.00		4.85	295	383.00	(400MHz，MeOH-d4)：7.85-7.95(2H，d)，8.05-8.10(2H， d)，8.25-8.30(2H，s)，8.35-8.37(1H，s)，8.70(1H，s)	3.98
296	350.00	(DMSO)7.6-7.7(H，m，ar)，7.75(H，m，ar)，7.85(H，m，ar)， 8.0(H，m，ar)，8.3(H，m，ar)，8.4(H，m，ar)，8.8(H，s，ar)， 9.15(h，s，ar)，9.3(H，s，ar)，11.0(H，s，ar)and 12.35(H，s， NH)	4.22	295	383.00		3.98
296	350.00		4.22	297	395.55	1H NMR(DMSO-d6)：3.69(6H，d)，4.41(2H，br s)，6.34 (1H，s)，6.88(2H，m)，6.94(2H，s)，7.02(1H，m)，7.36(1H， t)，8.19(2H，m)，8.76(1H，s)，12.13(1H，s)	4.64
298	257.59	1H NMR(DMSO-d6)：2.89(3H，s)，6.26(1H，d)，6.54(1H， d)，7.03(1H，d)，7.38(1H，t)，8.21(1H，s)，8.24(1H，s)，8.94 (1H，s)，12.14(1H，s)	4.40	297	395.55		4.64
298	257.59		4.40	299	354.00	(400MHz，MeOH-d4)：2.35-2.40(3H，s)，7.30-7.45(4H， m)，8.05-8.15(3H，m)，8.20-8.25(1H，s)	4.87
300	368.00	(400MHz，DMSO-d6)：2.20(6H，s)，7.25(3H，m)，7.70- 7.80(1H，s)，8.05(1H，m)，8.15(1H，m)，8.30(1H，m)，9.10 (1H，s)，12.2(1H，s)	4.93	299	354.00		4.87
300	368.00		4.93	301	406.00	(400MHz，DMSO-d6)：7.80-7.85(1H，m)，7.90-7.95(2H， d)，8.05-8.10(2H，d)，8.15-8.35(3H，m)，8.50(1H，s)，8.60 (1H，s)，9.50-9.55(1H，s)，9.85-9.90(1H，s)，12.2(1H，s)	4.53
302		(400MHz，MeOH-d4)：2.10-2.0(1H，m)，2.70-2.80(1H， m)，2.95-3.05(1H，m)，3.10-3.20(1H，m)，5.90-6.00(1H，t)， 7.20-7.40(4H，m)，8.05-8.10(1H，s)，8.15-8.20(2H，d)， 8.85(1H，s)		301	406.00		4.53
302				303	342.60	(DMSO)2.9-3.1(4H，m)，7.0-7.5(6H，m)，7.7-7.8(2H，m)， 7.8-8.2(6H，m)，11.9(0.7H，s)	4.30
304	346.50	(DMSO)7.1-7.2(3H，m)，7.2-7.4(3H，m)，7.8-7.9(2H，m)， 7.9-8.1(3H，m)，8.1-8.2(1H，s)，8.4(1H，s)，8.5(1H，s)，12.3- 12.4(0.7H，s)	4.34	303	342.60		4.30
304	346.50		4.34	305	398.00	(400MHz，CDCl3)：1.65-1.70(3H，d)，5.25-5.30(1H，m)， 5.40-5.45(1H，m)，6.80-6.85(1H，d)，7.0(1H，s)，7.05-7.10 (1H，d)，7.30-7.35(1H，t)，8.05-8.10(2H，m)，8.30(1H，s)， 8.70(1H，s)，9.20-9.50(1H，brs)	4.87
306	384.00	(400MHz，MeOH-d4)：1.65-1.70(3H，d)，5.40-5.50(1H， m)，6.65-6.80(1H，d)，6.95(1H，s)，7.00-7.05(1H，d)，7.15- 7.20(1H，t)，8.00-8.10(2H，m)，8.20(1H，s)，8.70(1H，s)	4.45	305	398.00		4.87

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	307	410.80	CDCl31.7(3H，d)，3.97(3H，s)，5.42(1H，br s)，5.57 (1H，m)， 7.03(2H，t)，7.5-7.6(2H，m)，8.12(1H，s)，8.2(1H，s)，9.1 (1H，s) ，9.52(1H，s)，10.15(1H，br s)	4.64
308	405.00	(d6-DMSO，400MHz)4.73(2H，s)，7.38(2H，d)，7.54(2H， d)，8.30(1H，d)， 8.50(1H，s)，8.62(2H，d)	5.50	307	410.80		4.64
308	405.00		5.50	309	409.80	DMSO 1.62(3H，d)，2.88(3H，m)，5.58(1H，d)，7.1(2H，m)， 7.62(2H，m)，8.1-8.25(3H，m)，8.55(1H，m)，8.72(1H，s)， 9.15(1H，s)，12.3(1H，s)	3.95
310	413.51	1H NMR(DMSO-d6)：1.58(3H，d)，5.50(1H，t)，7.67(2H， d)，7.79(2H，d)，8.16(3H，m)，8.21(2H，d)，8.37(1H，s)	4.82	309	409.80		3.95
310	413.51		4.82	311	402.48	1H NMR(DMSO-d6)：1.71(3H，d)，5.43(1H，m)，7.28 (1H，s)，7.54(2H，d)，7.61(2H，d)，7.66(1H，s)，7.94(1H， s)，8.26(1H，s)，8.47(1H，s)，12.49(1H，s)	4.89
312	388.42	1H NMR(DMSO-d6)：4.74(2H，d)，7.28(1H，t)，7.38(2H， m)，7.48(1H，s)，8.19(1H，s)，8.23(2H，m)，8.33(1H，t)， 8.52(1H，s)，12.33(1H，s)	4.95	311	402.48		4.89
312	388.42		4.95	313	383.50	1H NMR(DMSO-d6)：1.66(3H，d)，5.45(1H，q)，6.85 (2H，d)，7.31(1H，s)，8.20(1H，d)，8.23(1H，s)，8.54(2H， d)	4.64
314	389.00	(d6-DMSO，400MHz)5.69(2H，s)，7.49(2H，d)，7.59(2H， d)， 8.32(1H，s)，8.42(1H，s)，8.65-8.67(2H，m)，12.56(1H，s)	5.32	313	383.50		4.64
314	389.00		5.32	315	306.46	1H NMR(DMSO-d6)：4.48(1H，m)，8.23(1H，s)，8.35 (2H，m)，8.68(1H，s)，12.59(1H，s)	4.80
316	355.46	1H NMR(DMSO-d6)：4.87(2H，d)，7.36(1H，m)，7.51 (1H，d)，7.87(1H，m)，8.12(1H，s)，8.24(1H，s)，8.29(1H， d)，8.43(1H，s)，8.62(2H，d)，12.39(1H，s)	4.10	315	306.46		4.80
316	355.46		4.10	317	355.46	1H NMR(DMSO-d6)：4.86(2H，d)，7.73(1H，m)，8.26 (2H，s)，8.30(1H，d)，8.44(1H，s)，8.54(1H，s)，8.65(1H， d)，8.86(1H，s)12.43(1H，s)	4.10
318	355.46	1H NMR(DMSO-d6)：4.93(2H，d)，7.90(2H，d)，8.16 (1H，s)，8.23(2H，d)，8.31(1H，s)，8.55(1H，s)，8.78(2H， d)，12.37(1H，s)	4.00	317	355.46		4.10
318	355.46		4.00	319	231.38	1H NMR(DMSO-d6)：7.27(1H，t)，8.32(1H，s)，8.41(1H， s)，8.80(3H，m)	4.20
320	455.00	1H NMR(DMSO-d6)：1.55-1.60(3H，d)，2.15-2.20(6H， s)，2.55-2.60(2H，m)，3.95-4.00(2H，m)，5.35-5.40(1H， m)，6.60-6.40(1H，m)，7.00-7.10(2H，m)，7.15-7.20(1H，t)， 8.05-8.10(1H，m)，8.15-8.20(2H，m)，8.25(1H，s)，8.60 (1H，s)，12.2(1H，s)	4.49	319	231.38		4.20

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	321	453.00	1H NMR(DMSO-d6)：1.60-1.70(3H，d)，2.20-2.30(2H， m)，3.4-3.5(4H，m)，5.15-5.20(1H，m)，5.55-5.62(1H，m)， 6.85-6.90(1H，d)，7.05-7.10(1H，s)，7.18-7.23(1H，d)， 7.35-7.40(1H，t)，8.30-8.35(3H，m)，8.50(1H，s)	4.25
322	382.00	NMR(DMSO)1.65(3H，d，CH3)，2.15(3H，s，CH3)，5.55 (H，m，alpha)，7.1(H，d，ar)，7.1-7.2(2H，m，ar)，7.6(2H，m， ar)，8.05(1H，s，ar)，8.2(1H，s，ar)，8.3(1H，s，ar)，8.63(1H， s，ar)and 12.3(1H，s，ar)	4.99	321	453.00		4.25
322	382.00		4.99	323	412.00	NMR(DMSO)1.5(3H，d，CH3)，5.4(H，m alpha)，7.0(H， s，ar)，7.1-7.25(2H，，m，ar)，7.5-7.6(2H，m，ar)，8.3(H，s， ar)，8.4(2H，brs，ar)，8.65(H，s，ar)and 12.4(H，s，ar).	4.10
324	382.00	NMR(DMSO)1.5(3H，s，CH3)，2.25(3H，s，CH3)，5.3(H， m，alpha)，6.2(H，m，ar)，7.3(2H，m，ar)，7.5(2H，m，ar)， 7.75(H，m，ar)，8.2(H，m，ar)，8.3(H，m，ar)，8.65(H，m， ar)and 12.3(H，m，ar)	4.92	323	412.00		4.10
324	382.00		4.92	325	361.44	1H NMR(DMSO-d6)：1.53(3H，m)，1.81(2H，m)，1.98 (1H，m)，2.90(1H，m)，3.31(1H，m)，3.43(1H，m)，3.58 (2H，m)，7.85(1H，s)，8.30(2H，d)，8.36(1H，s)，8.68(1H， d)，8.84(1H，s)，12.52(1H，s)	3.70
326	361.44	1H NMR(DMSO-d6)：1.34(1H，m)，1.60(1H，m)，1.92 (2H，m)，2.20(1H，m)，2.78(2H，m)，3.24(3H，m)，3.54 (1H，m)，7.99(1H，s)，8.23(1H，m)，8.30(2H，d)，8.60(1H， d)，8.70(1H，s)，12.45(1H，s)	3.59	325	361.44		3.70
326	361.44		3.59	327	361.44，361.00	1H NMR(DMSO-d6)：1.41(2H，m)，1.92(2H，m)，2.08 (1H，m)，2.83(2H，m)，3.29(2H，m)，3.44(2H，m)，7.97 (1H，s)，8.20(1H，s)，8.25(1H，s)，8.30(1H，s)，8.48(1H， d)，8.71(1H，s)，12.43(1H，s)，1H NMR(DMSO-d6)：1.41 (2H，m)，1.92(2H，m)，2.08(1H，m)，2.83(2H，m)，3.29 (2H，m)，3.44(2H，m)，8.20(1H，s)，8.25(1H，s)，8.30(1H， s)，8.48(1H，d)，8.71(1H，s)，12.43(1H，s)	3.57， 3.55
328	347.40	1H NMR(DMSO-d6)：1.94(1H，m)，1.96(2H，m)，2.14 (1H，m)，3.20(2H，m)，3.71(2H，m)，3.83(1H，m)，7.89 (1H，s)，8.30(4H，m)，8.69(1H，s)，8.91(1H，s)，12.58(1H， s)	3.67	327	361.44，361.00		3.57， 3.55
328	347.40		3.67	329	347.40	1H NMR(DMSO-d6)：1.77(1H，m)，2.12(1H，m)，2.77 (1H，m)，3.00(1H，m)，3.17(1H，m)，3.34(2H，m)，3.60 (2H，m)，7.98(1H，s)，8.23(1H，d)，8.31(2H，m)，8.71(3H， m)，12.53(1H，s)	3.54
330	394.45	1H NMR(DMSO-d6)：2.04(4H，m)，2.84(2H，m)，3.33 (1H，s)，5.61(1H，m)，7.18(3H，m)，7.27(1H，d)，8.00(1H， d)，8.21(1H，t)，8.23(1H，s)，8.26(1H，s)，8.68(1H，s)， 12.34(1H，s)	5.28	329	347.40		3.54

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	331	483.00	(d6-DMSO，400MHz)1.44(9H，s)，1.54(3H，d)，5.34- 5.37(1H，m)， 7.11(1H，brs)，7.19(2H，d)，7.63(1H，s)，8.10-8.12(2H， m)，8.18(1H，d)， 8.23(1H，d)，8.54(1H，d)，9.27(1H，brs)，12.29(1H，brs)	4.95
332	264.00	NMR(DMSO)7.3(2H，brs，NH2)，8.1(1H，s，ar)，8.2(1H， s，ar)，8.3(1H，s，ar)，8.95(1H，s，ar)and 12.35(1H，s，NH).	3.87	331	483.00		4.95
332	264.00		3.87	333	383.00	(d6-DMSO，400MHz)1.55(3H，d)，5.36-5.40(1H，m)， 6.76(1H，brs)， 6.98(1H，brs)，7.21(2H，brs)，8.16(1H，d)，8.23(1H，d)， 8.26(2H，d)， 8.58(1H，s)，12.36(1H，s)	4.42
334	382.80	DMSO 1.58(3H，d)，4.65(2H，d)，5.28(1H，t)，5.5-5.6 (1H，m)，7.15(2H，m)，7.6(2H，m)，8.05(1H，m)，8.2(1H，s)， 8.26(1H，m)，8.68(1H，s)，11.95(1H，s)	3.90	333	383.00		4.42
334	382.80		3.90	335	456.00	1H NMR(MeOD-d4)：1.60-1.70(3H，d)，3.60(3H，s)，4.65 (2H，s)，5.40-5.45(1H，m)，6.70-6.75(1H，d)，7.03(1H，s)， 7.12-7.18(1H，d)，7.25-7.30(1H，t)，8.00-8.07(2H，m)， 8.15(1H，s)，8.60(1H，s)	4.70
336	442.00	1H NMR(DMSO-d6)：1.35-1.40(3H，d)，4.00-4.05(2H， s)，5.25-5.35(1H，m)，6.50-6.55(1H，d)，6.95-7.00(2H，m)， 7.05-7.15(1H，m)，8.05-8.13(3H，m)，8.18(1H，s)，8.55 (1H，s)，12.5(1H，s)	3.82	335	456.00		4.70
336	442.00		3.82	337	363.00	1H NMR(CD3OD)：1.60-1.70(3H，d)，3.10-3.20(3H，s)， 3.35-3.45(3H，s)，5.30-5.35(1H，m)，8.15-8.20(2H，m)， 8.30-8.35(1H，s)，8.75-8.80(1H，s)	4.07
338	375.00	1H NMR(DMSO-d6)：0.30-0.40(1H，m)，0.42-0.47(1H， m)，1.35-1.40(3H，d)，2.55-2.60(1H，m)，4.40-4.50(1H， m)，7.58-7.63(1H，d)，8.15-8.25(3H，m)，8.28(1H，s)，8.65 (1H，s)，12.0(1H，s)	3.84	337	363.00		4.07
338	375.00		3.84	339	398.47	1H NMR(CDCl3)：1.63(3H，m)，3.44(1H，s)，4.57(2H， m)，5.31(1H，br s)，6.02(1H，br s)，7.06(2H，m)，7.39(2H， m)，8.19(1H，m)，8.30(1H，m)，8.76(1H，br s)，8.93(1H，br s)	4.59
340	349.00，349.00	1H NMR(DMSO-d6)：1.35-1.40(3H，d)，2.55-2.60(3H， m)，4.40-4.50(1H，m)，7.58-7.63(1H，d)，8.00-8.05(1H， m)，8.15-8.25(2H，m)，8.28(1H，s)，8.65(1H，s)，12.0(1H， s)，1H NMR(DMSO-d6)：1.35-1.40(3H，d)，2.55-2.60(3H， m)，4.40-4.50(1H，m)，7.58-7.63(1H，d)，8.00-8.05(1H， m)，8.15-8.25(2H，m)，8.28(1H，s)，8.65(1H，s)，12.0(1H， s)	3.59， 2.84	339	398.47		4.59

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	341	428.00	1H NMR(DMSO-d6)：1.35-1.40(3H，d)，3.6-3.7(2H，m)， 3.95-4.00(2H，m)，4.80-4.90(1H，m)，5.4-5.5(1H.m)，6.7- 6.8(1H，m)，7.00-7.10(2H，m)，7.20-7.25(1H，m)，8.10- 8.25(3H，m)，8.65(1H，s)，12.0(1H，s)	4.47
342		(400MHz，DMSO)1.57(3H，d)，5.50-5.57(1H，m)，7.11- 7.15(2H，m)，7.57-7.60(2H，m)，8.20(1H，d)，8.25(1H，d)， 8.36(1H，s)，9.15(1H，d)，9.45(1H，d)，12.90(1H，brs).		341	428.00		4.47
342				343		(400MHz，DMSO)1.55(3H，d)，4.85(2H，s)，5.45-5.53 (1H，m)，7.09-7.14(2H，m)，7.55-7.58(2H，m)，7.62(1H，s)， 7.72(1H，d)，7.87(1H，s)，7.95(1H，d)，8.10(1H，d)，11.55 (1H，s).
344	333.00	1H NMR(CD3OD)：2.40-2.50(2H，m)，2.6-2.7(2H，m)， 3.50-3.60(3H，m)，3.7-3.8(1H，m)，5.2-5.3(1H，m)，8.40 (1H，s)，8.50(1H，m)，8.55(1H，s)，8.75(1H，s)	3.54	343
344	333.00		3.54	345	347.00，347.40	1H NMR(DMSO-d6)：1.80-1.90(2H，m)，2.1-2.2(2H，m)， 3.05-3.15(2H，m)，3.4-3.5(2H，m)，4.30-4.40(1H，m)， 7.65-7.70(1H，m)，8.30-8.35(2H，m)，8.40-8.50(1H，s)， 8.60-8.70(1H，s)，8.75-8.80(1H，m)，12.0(1H，s)，1H NMR (DMSO-d6)：1.84(2H，m)，2.33(2H，m)，3.14(2H，m)， 3.44(2H，m)，4.36(1H，m)，7.88(1H，s)，8.25(1H，s)，8.30 (2H，d)，8.37(1H，m)，8.60(1H，m)，8.69(1H，s)，12.44 (1H，s)	3.50， 3.50
346	423.56	1.73(3H，d，J 6.8，Me)，3.06(3H，br s，Me)，3.24(3H，br s，Me)，5.53-5.47(1H，m，CH)，5.75(1H，br s，NH)，7.07- 7.03(2H，m，2xArH)，7.46-7.43(2H，m，2x ArH)，8.14(1 H，d，J 3.7，ArH)，8.46(1H，d，J 1.8，ArH)，8.77(2H，s，2x ArH).	4.02	345	347.00，347.40		3.50， 3.50
346	423.56		4.02	347	347.47	1H NMR(DMSO-d6)：1.66(1H，m)，1.85(1H，m)，1.98 (1H，m)，2.11(1H，m)，2.90(2H，m)，3.32(1H，m)，3.47 (1H，m)，4.46(1H，m)，7.57(1H，d)，8.31(3H，m)，8.66(3H， m)，12.47(1H，s)	3.68
348	348.44	1HNMR(DMSO-d6)：1.67(2H，m)，1.96(2H，d)，3.49 (2H，t)，3.96(2H，d)，4.30(1H，m)，7.62(1H，d)，8.18(1H， s)，8.22(1H，s)，8.29(1H，s)，8.72(1H，s)，12.36(1H，s)	4.42	347	347.47		3.68
348	348.44		4.42	349	360.46	1H NMR(DMSO-d6)：1.17(5H，m)，1.70(6H，m)，2.67 (2H，d)，8.27(1H，s)，8.42(2H，s)，8.72(1H，s)，12.57(1H， s)	5.39
350	396.46	(DMSO，D6)；1.55(3H，d，J 6.8，Me)，5.53(1H，t，J 6.8， CH)，7.13-7.09(2H，m，2x ArH)，7.63-7.60(2H，m，2x ArH)，8.15-8.14(1H，m，NH)，8.22-8.19(2H，m，2x ArH)， 8.83(1H，s，ArH)，9.30(1H，s，ArH).	3.27	349	360.46		5.39
350	396.46		3.27	351	392.00	1HNMR(DMSO-d6)：1.35-1.40(9H，s)，1.50-1.55(3H， d)，4.10-4.15(1H，m)4.40-4.50(1H，m)，7.95-8.00(1H，d)， 8.20(1H，s)，8.30(1H，m)，8.35(1H，m)，8.75(1H，s)	4.87

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	352	347.00	(d6-DMSO，400MHz)1.86-1.94(1H，m)，2.28(3H，s)， 2.33(1H，brs)， 2.53-2.57(1H，m)，2.60-2.67(2H，m)，2.84-2.88(1H， m)，4.62(1H，brs)， 7.67(1H，d)，8.17(1H，d)，8.21(1H，s)，8.28(1H，d)，12.35 (1H，s)	4.00
353	255.00	DMSO D67.60(1H，d)，8.32(1H，s)，8.43(1H，s)，8.56 (1H，s)，8.82-8.86(2H，m)12.55(1H，s).	4.52	352	347.00		4.00
353	255.00		4.52	354	382.46	1H NMR(DMSO-d6)：0.95(3H，t)，1.85(1H，m)，1.97 (1H，m)，7.19(1H，t)，7.34(2H，t)，7.53(2H，d)，8.08(1H， d)，8.16(2H，s)，8.26(1H，s)，8.66(1H，s)，12.31(1H，s)	4.92
355	374.50	1H NMR(DMSO-d6)：1.15(8H，m)，1.28(2H，m)，1.72 (2H，m)，1.84(2H，m)，4.23(1H，m)，7.43(1H，d)，8.12(1H， s)，8.18(1H，s)，8.27(1H，s)，8.73(1H，s)，12.32(1H，s)	5.47	354	382.46		4.92
355	374.50		5.47	356	346.43	1H NMR(DMSO-d6)：0.85(1H，m)，1.48(4H，m)，1.68 (1H，d)，1.81(2H，m)，2.04(2H，m)，4.03(1H，m)，7.49(1H， d)，8.13(1H，s)，8.19(1H，s)，8.29(1H，s)，8.73(1H，s)， 12.21(1H，s)	5.25
357	432.70	CDCl30.8(3H，d)，5.45(1H，m)，5.6(1H，br s)，7.1(2H，m)， 7.45(2H，m)，8.15(1H，s)，8.4(1H，s)，8.5-8.6(1H，br s)，8.78 (1H，s)，9.65(1H，br s)	5.00	356	346.43		5.25
357	432.70		5.00	358	439.00	(DMSO)1.27(3H，t，J7.1)，1.56(3H，d，J7.0)，4.17(2H， q，J 7.1)，5.64(1H，t，J 7.0)，7.10(2H，t，J8.9)，7.60-7.56 (2H，m)，8.04-8.00(2H，m)，8.15(1H，d，J3.8)，8.22(1H， d，J2.1)，8.96(1H，br s)，9.65(1H，br s)，11.96(1H，br s).	4.39
359	425.51	1H NMR(DMSO)：1.52(3H，m)，2.85(3H，m)，5.33(1H， m)，7.00(1H，s)，7.15(2H，m)，7.48(2H，m)，8.24(2H，m)， 8.49(1H，s)，8.66(1H，s)，8.87(1H，m)，12.4(1H，br s)	4.82	358	439.00		4.39
359	425.51		4.82	360	336.00	1H NMR(DMSO-d6)：1.45-1.50(3H，d)，4.50-4.60(1H， m)，8.05-8.25(5H，m)，8.60(1H，m)，12.3-12.4(1H，s)， 12.50-1.270(1H，brs)	3.20
361	363.00	1H NMR(CD3OD)：1.10-1.20(3H，t)，1.90-2.20(2H，m)， 2.85(3H，s)，4.65-4.70(1H，m)，8.25-8.35(3H，m)，8.65 (1H，s)	3.92	360	336.00		3.20
361	363.00		3.92	362	377.00	1H NMR(CD3OD)：1.10-1.20(6H，m)，2.3-2.4(1H，m)， 2.80(3H，s)，4.70-4.75(1H，d)，8.25-8.35(3H，m)，8.80 (1H，s)	4.27
363	377.00	1H NMR(CD3OD)：1.05-1.15(6H，m)，1.50-1.60(3H，m)， 3.95-4.05(1H，m)，4.50-4.65(1H，m)，8.10-8.25(3H，m)， 8.80(1H，s)	4.07	362	377.00		4.27
363	377.00		4.07	364	391.00	1H NMR(CD3OD)：0.70-0.80(6H，m)，1.55-1.60(3H，d)， 1.70-1.80(1H，m)，2.85-2.95(1H，m)，3.10-3.15(1H，m)， 4.50-4.65(1H，m)，8.10-8.25(3H，m)，8.80(1H，s)	4.22

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	365	381.00	1H NMR(CD3OD)：1.55-1.60(3H，d)，3.45-3.55(2H，m)， 4.25-4.35(1H，m)，4.40-4.45(1H，m)，4.55-4.65(1H，m)， 8.10-8.25(3H，m)，8.80(1H，s)	3.79
366	362.00	(d6-DMSO，400MHz)1.23-1.33(2H，m)，1.72(2H，d)， 1.99-2.04(1H，m)， 3.27(2H，t)，3.41(2H，t)，3.85-3.89(2H，m)，7.80(1H，t)， 8.14(1H，d)， 8.21(1H，s)，8.28(1H，d)，8.74(1H，d)，12.35(1H，brs)	4.50	365	381.00		3.79
366	362.00		4.50	367	363.00	1H NMR(DMSO-d6)：0.95-1.05(3H，t)，1.35-1.40(3H，d)， 3.00-3.10(2H，m)，4.45-4.55(1H，m)，7.55-7.60(1H，d)， 8.05-8.10(1H，m)，8.18-8.22(2H，m)，8.28(1H，s)，8.70 (1H，s)，	3.92
368	456.00，456.07	1H NMR(DMSO-d6)：1.40-1.50(3H，d)，2.80(3H，s)， 2.85-3.05(2H，m)，3.15-3.25(2H，m)，4.50-4.60(1H，m)， 7.00-7.05(1H，m)，7.60-7.65(1H，d)，8.12-8.17(1H，m)， 8.19(1H，m)，8.22(1H，m)，8.28(1H，s)，8.70(1H，s)，，1H NMR(DMSO)：1.45(3H，d)，2.89(2H，m)，3.15(2H，m)， 3.31(3H，s)，4.55(1H，m)，7.04(1H，s)，7.69(1H，d)，8.19 (2H，m)，8.26(1H，s)，8.67(1H，s)，12.35(1H，s)	3.57， 2.84	367	363.00		3.92
368	456.00，456.07		3.57， 2.84	369	417.00，416.90	1H NMR(CD3OD)：1.55-1.60(3H，d)，3.85-4.00(2H，m)， 4.70-4.80(1H，m)，8.10-8.25(3H，m)，8.80(1H，s)，DMSO d612.4(bs，1H)；8.8(t，1H)；8.7(s，1H)；8.3(s，2H)；8.2(s， 1H)；7.9(bs，1H)；4.7(q，1H)；4.0(m，2H)；1.3(d，3H)	4.09， 2.30
370	412.44	1H NMR(DMSO)：1.60(3H，m)，5.51(1H，br s)，7.08-7.21 (2H，m)，7.49-7.53(2H，m)，8.29(1H，m)，8.39(1H，m)， 8.53(1H，m)，8.79(2H，m)，12.6(1H，s)	4.22	369	417.00，416.90		4.09， 2.30
370	412.44		4.22	371	436.48	1H NMR(CDCl3)：1.64(3H，m)，5.31(1H，m)，5.77(1H， m)，7.05(2H，m)，7.40(2H，m)，7.95(1H，m)，8.32(1H，br s)，8.58(1H，m)，8.94(1H，m)	5.17
372	375.00	(d6-DMSO，400MHz)1.14-1.24(2H，m)，1.75-1.80(5H， m)，2.11(3H，s)， 2.75(2H，d)，3.40(2H，t)，7.80(1H，t)，8.13(1H，d)，8.20 (1H，s)，8.28(1H，d)，8.73(1H，d)，12.35(1H，s)	3.95	371	436.48		5.17
372	375.00		3.95	373	348.00	(d6-DMSO，400MHz)1.66-1.74(1H，m)，1.99-2.08(1H， m)，2.67-2.74(1H，m)，3.49-3.51(2H，m)，3.58-3.67 (2H，m)，3.73(1H，t)，3.79-3.84(1H，m)，7.88(1H，t)，8.16 (1H，d)，8.22(1H，s)，8.29(1H，d)，8.74(1H，d)，12.36(1H， brs)	3.27
374	376.70	CDCl31.75(3H，d)，3.23(1H，s)，5.30-5.35(1H，m)，5.5-5.56 (1H，m)，7.08-7.18(2H，m)，7.5-7.58(2H，m)，8.22(2H，m)， 8.55(1H，br s)，8.9(1H，s)，10.65(1H，br s)	3.54	373	348.00		3.27

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	375		1H NMR(CD3OD)：1.68-1.73(3H，d)，4.50(2H，s)，5.40- 5.50(1H，m)，6.7-6.8(1H，m)，7.05-7.10(1H，m)，7.15-7.20 (1H，d)，7.30-7.40(1H，t)，8.30-8.40(2H，m)，8.45(1H，s)， 8.50(1H，s)	3.25
376	455.00	1H NMR(CD3OD)：1.68-1.73(3H，d)，2.75-2.80(3H，s)， 4.50(2H，s)，5.40-5.50(1H，m)，6.8-6.9(1H，m)，7.05-7.10 (1H，m)，7.15-7.20(1H，d)，7.30-7.40(1H，t)，8.05-8.10 (2H，m)，8.20(1H，s)，8.60(1H，s)	3.38	375			3.25
376	455.00		3.38	377	469.00	1H NMR(CD3OD)：1.68-1.73(3H，d)，2.15-2.20(2H，m)， 2.90-2.95(6H，s)，3.10-3.20(2H，m)，4.05-4.10(2H，m)， 5.50-5.60(1H，m)，6.8-6.9(1H，m)，7.05-7.10(1H，m)， 7.15-7.20(1H，d)，7.30-7.40(1H，t)，8.20-8.24(1H，d)， 8.25-8.30(2H，m)，8.60(1H，s)	3.29
378	406.75	CDCl31.75(3H，d)，3.55(1H，s)，4.65(2H，s)，5.30-5.35 (1H，m)，5.42-5.48(1Hm)，7.1-7.18(2H，m)，7.45-7.52 (2H，m)，8.1-8.18(2H，m)，8.45(1H，br s)，8.78(1H，s)，9.4 (1H，br s)	3.15	377	469.00		3.29
378	406.75		3.15	379	347.47	1H NMR(CDCl3/MeOD)：0.83(2H，m)，1.94(1H，m)， 2.32(1H，m)，3.00(1H，m)，3.30(1H，m)，3.36(2H，m)， 3.46(1H，m)，3.60(1H，m)，3.87(1H，m)，8.15(1H，s)，8.24 (1H，s)，8.29(1H，s)，8.68(1H，s)	3.54
380	333.51	1H NMR(DMSO-d6)：2.15(1H，m)，2.30(2H，m)，3.35 (2H，m)，3.58(1H，m)，4.77(1H，m)，7.87(1H，s)，8.29(3H， m)，8.81(1H，s)，8.94(2H，br s)，12.45(1H，s)	5.00	379	347.47		3.54
380	333.51		5.00	381	333.40	1H NMR(DMSO-d6)：2.17(1H，m)，2.34(1H，m)，3.34 (3H，m)，3.58(1H，m)，4.79(1H，m)，7.87(1H，d)，8.27(3H， m)，8.68(1H，s)，8.81(2H，br s)，12.45(1H，s)	5.00
382	302.37	1H NMR(DMSO-d6)：3.16(1H，s)，4.29(2H，m)，8.29(4H， m)，8.88(1H，s)，12.40(1H，s)	3.22	381	333.40		5.00
382	302.37		3.22	383	403.48	1H NMR(DMSO-d6)：0.82(2H，m)，1.11(1H，m)，1.22 (1H，m)，1.85(2H，t)，1.98(3H，s)，2.07(1H，br s)，3.00 (1H，t)，3.51(1H，s)，3.83(1H，m)，4.40(1H，d)，8.40(1H， s)，8.44(1H，d)，8.65(1H，s)，8.88(1H，s)，9.20(1H，br s)， 12.91(1H，s)	3.18
384	420.80	CDCl31.72(3H，d)，3.55(3H，s)，4.45(2H，s)，5.32-5.36 (1H，m)，5.47-5.53(1H，m)，7.05-7.1(2H，m)，7.45-7.5 (2H，m)，8.15(2H，m)，8.5(1H，br s)，8.85(1H，s)，10.05(1H， br s)	3.59	383	403.48		3.18
384	420.80		3.59	385	391.00	1H NMR(CD3OD)：1.15-1.20(9H，s)，2.80(3H，s)，4.70- 4.75(1H，s)，8.05-8.10(1H，m)，8.12-8.15(2H，m)，8.85 (1H，s)	3.50

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	386	396.53	1H NMR(DMSO)：1.18(3H，t)，1.55(3H，d)，2.56(2H， q)，5.51(1H，m)，7.07-7.15(3H，m)，7.52(2H，m)，7.98 (1H，s)，8.14(1H，s)，8.23(1H，d)，8.60(1H，d)，12.22(1H， s)	3.88
387	365.00	(d6-DMSO，400MHz)2.61(3H，d)，3.82-3.83(2H，m)， 4.60(1H，dd)，5.02(1H，t)，7.32(1H，d)，8.05(1H，d)，8.20 (1H，s)，8.24(1H，d)，8.27(1H，d)，8.66(1H，d)，12.36(1H， brs)	2.55	386	396.53		3.88
387	365.00		2.55	388	379.00	(d6-DMSO，400MHz)2.61(3H，d)，3.30(3H，s)，3.74(2H， brs)，4.82(1H，dd)，7.54(1H，d)，8.13(1H，d)，8.23(2H， brs)，8.27(1H，s)，8.66(1H，s)，12.36(1H，brs)	2.82
389	441.00	1H NMR(CD3OD)：1.68-1.73(3H，d)，2.80-2.85(3H，s)， 3.10-3.25(2H，m)，3.35-3.55(2H，m)，4.55-4.60(1H，m)， 8.10(1H，m)，8.15(1H，s)，8.20(1H，s)，8.75(1H，s)	2.68	388	379.00		2.82
389	441.00		2.68	390	453.00	1H NMR(CD3OD)：1.68-1.73(3H，d)，2.10-2.50(2H，m)， 2.90-3.20(4H，m)，4.50-4.60(2H，m)，8.10-8.15(2H，m)， 8.20(1H，s)，8.80(1H，s)	1.74
391	379.00	1H NMR(CD3OD)：1.68-1.73(3H，d)，3.35-3.40(2H，m)， 3.50-3.60(2H，m)，4.60-4.70(1H，m)，8.10(1H，m)，8.15 (1H，s)，8.20(1H，s)，8.80(1H，s)	2.63	390	453.00		1.74
391	379.00		2.63	392	393.00	1H NMR(CD3OD)：1.68-1.73(3H，d)，3.15-3.20(3H，s)， 3.30-3.60(4H，m)，4.60-4.70(1H，m)，8.10(1H，m)，8.15 (1H，s)，8.20(1H，s)，8.80(1H，s)	2.80
393	391.00	(d6-DMSO，400MHz)0.89(3H，d)，0.94(3H，d)，1.58- 1.81(3H，m)，2.60(3H，d)，4.61-4.67(1H，m)，7.59(1H， d)，8.03(1H，d)，8.21(1H，d)，8.22(1H，s)，8.27(1H，d) 8.68(1H，d)，12.36(1H，s)	3.33	392	393.00		2.80
393	391.00		3.33	394		(400MHz，DMSO)1.56(3H，d)，5.41-5.48(1H，m)，7.15 (2H，t)，7.56(2H，dd)，8.17(1H，d)，8.21(1H，d)，8.28(1H， s)，8.64(1H，d)，8.84(1H，d)，12.75(1H，brs).
395	367.00	(400MHz，DMSO)1.50(3H，d)，5.10-5.14(1H，m)，6.32 (1H，d)，6.99(1H，d)，7.08-7.14(3H，m)，7.34(1H，t)，7.46- 7.49(2H，m)，8.14(1H，s)，8.20(1H，d)，8.64(1H，s)，12.11 (1H，brs).，MeOD-D4：8.35(m，2H)；8.1(s，1H)；7.95(dd， 1H)；7.5(m，2H)；7.2(d，1H)；7.15(m，2H)；6.8(d，1H)；5.0 (m，1H)；1.65(d，3H).	2.50	394
395	367.00		2.50	396		(40OMHz，DMSO)1.60(3H，d)，3.88(3H，s)，7.15(2H，t)， 7.46-7.49(2H，m)，7.98(1H，d)，8.25-8.30(2H，m)，8.34 (1H，d)，8.56(1H，s)，12.65(1H，brs).
397		(40O MHz，DMSO)1.51(3H，s)，5.31-5.36(1H，m)，7.12 (2H，t)，7.41-7.46(3H，m)，7.80-8.08(2H，m)，8.17(1H，d)， 11.98(1H，brs).		396

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	398		(400MHz，DMSO)1.51(3H，d)，5.33-5.38(1H，m)，7.14 (2H，t)，7.42-7.45(2H，m)，7.70-7.76(3H，m)，7.88(1H，d)， 8.21(1H，s)，12.20(1H，brs).
399	339.00	DMSO D62.78-2.92(4H，m)，3.50-3.62(4H，m)，7.05 (1H，s)，7.54(1H，s)，8.27(1H，s)，8.45(1H，s)，8.68(1H，s)	1.24	398
399	339.00		1.24	400	403.00	(d6-DMSO，40OMHz)3.90-3.95(2H，m)，4.12(2H，d)， 7.97(1H，t)，8.15(1H，s)，8.24(1H，d)，8.27(1H，d)，8.63 (1H，d)，8.75(1H，t)，12.34(1H，brs)	2.93
401	350.00	NMR(DMSO)1.3(3H，d，CH3)，2.6-2.8(2H，m，CH2)， 4.65(H，m，alpha)，7.15(H，m，ar)，8.15(H，m，ar)，8.25 (2H，s，ar)，8.7(H，s，NH)，12.1-12.5(2H，NH and COOH， brs x 2)	2.59	400	403.00		2.93
401	350.00		2.59	402	363.00	NMR(DMSO)1.25(3H，d，CH3)，1.75(3H，m，CH3)，3.0 (2H，CH2，m)，4，65(H，m，alpha)，7.5(H，d，ar)，8.0(H，m， NH)，8.1(H，d，ar)，8.15(H，s，ar)，8.25(H，s，ar)，8.7(H，s， NH)and 12.45(H，s，NH).	2.90
403	379.38	1H NMR(DMSO-d6)：1.73(2H，m)，1.99(2H，m)，2.84 (2H，m)，4.55(1H，m)，7.74(2H，br s)，7.95(1H，d)，8.19 (1H，s)，8.28(2H，m)，8.73(1H，s)，12.38(1H，s)，12.99 (1H，br s)	2.21	402	363.00		2.90
403	379.38		2.21	404	418.49	1H NMR(DMSO-d6)：1.74(3H，m)，5.82(1H，m)，7.20 (2H，m)，7.61(2H，m)，7.70(1H，s)，7.84(1H，s)，7.99(1H， s)，8.39(1H，s)，8.54(1H，s)，8.66(1H，s)，8.79(1H，br s)， 9.82(1H，br s)，13.08(1H，br s)	3.85
405	344.00	2.82-2.88(4H，m)，3.47-3.52(4H，m)，4.50(2H，s)，5.31 (1H，br s)，6.61(1H，s)，7.15(1H，s)，8.20(1H，s)，8.25(1H， s)，8.70(1H，s)，12.25(1H，br s)	2.34	404	418.49		3.85
405	344.00		2.34	406	417.00	1H NMR(CD3OD)：1.1-1.4(6H，m)，1.6-2.0(7H，m)，3.0- 3.15(1H，m)，3.65-3.80(1H，m)，5.6-5.7(1H，m)，8.15(1H， m)，8.20-8.25(2H，m)，8.80(1H，s)	3.37
407	429.00	1H NMR(DMSO-d6)：1.45-1.50(3H，d)，3.80-4.00(5H， m)，4.60-4.65(1H，m)，6.80-6.85(1H，m)，7.95(1H，s)，8.10 (1H，s)，8.25(1H，s)，8.70(2H，m)，12.2(1H，s)	3.13	406	417.00		3.37
407	429.00		3.13	408	443.00	1H NMR(DMSO-d6)：1.37-1.47(6H，m)，3.85-4.05(2H， m)，4.10-4.20(2H，qd)，4.60-4.65(1H，m)，6.65-6.70(1H， d)，7.95(1H，s)，8.10(1H，s)，8.25(1H，s)，8.70-8.80(2H， m)，12.2(1H，s)	3.33
409	342.80	DMSO D63.22-3.30(4H，m)，3.86-3.91(4H，m)，7.22 (1H，s)，7.69(1H，s)，8.33(1H，s)，8.46(1H，s)，8.68(1H，s)， 10.07(1H，s)，12.48(1H，s)	2.80	408	443.00		3.33
409	342.80		2.80	410	457.00	1H NMR(DMSO-d6)：1.35-1.40(6H，m)，1.45-1.50(3H， d)，3.80-4.10(2H，m)，4.60-4.65(2H，m)，6.50-6.60(1H， m)，7.95(1H，s)，8.10(1H，s)，8.25(1H，s)，8.70-8.80(2H， m)，12.5(1H，s)	3.46

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	411	423.00	1H NMR(DMSO-d6)：1.45-1.50(3H，d)，3.80-4.00(2H， m)，4.50-4.60(1H，m)，4.75(1H，s)，8.05(1H，m)，8.30-8.40 (2H，m)，8.50-8.60(1H，m)，8.95-9.000(1H，m)，9.20(1H， m)，12.5(1H，s)	3.22
412	338.70	DMSO D62.80-2.90(4H，m)，3.48-3.61(4H，m)，4.43 (1H，s)，6.66(1H，s)，7.25(1H，s)，8.27(1H，s)，8.35(1H，s)， 8.66(1H，s)，12.28(1H，br s).	3.16	411	423.00		3.22
412	338.70		3.16	413	399.00	1H NMR(CD3OD)：1.5-1.6(3H，d)，3.85-4.10(2H，m)， 4.60-4.75(1H，m)，6.40-6.50(1H，s)，8.15(1H，d)，8.20- 8.25(2H，m)，8.90(1H，s)	2.93
414	497.00	1H NMR(CD3OD)：1.5-1.6(3H，d)，3.00-3.10(3H，s)， 3.30-3.60(6H，brm)，3.90-4.05(2H，m)，4.45-4.55(1H，m)， 6.50-6.60(1H，s)，8.20(1H，s)，8.30(1H，s)，8.50(1H，s)， 8.70-8.80(1H，m)	3.08	413	399.00		2.93
414	497.00		3.08	415	583.00	1H NMR(DMSO-d6)：1.30-1.35(3H，d)，1.40(9H，s)， 3.35-3.40(4H，m)，3.65-3.72(4H，m)，3.9-4.0(2H，m)， 4.40-4.50(1H，m)，6.35-6.40(1H，s)，7.10-7.20(1H，m)， 8.15(1H，s)，8.25(1H，s)，8.50(1H，s)，8.60-8.70(1H，m)， 12.5(1H，s)	3.69
416	483.00	1H NMR(CD3OD)：1.50-1.60(3H，d)，3.40-3.45(4H，m)， 3.95-4.05(2H，m)，4.10-4.20(2H，m)，4.6-4.7(1H，m)，6.55 (1H，s)，8.35(1H，s)，8.40(2H，m)，8.90(1H，s)	2.73	415	583.00		3.69
416	483.00		2.73	417	458.00	1H NMR(CD3OD)：1.40-1.50(3H，d)，3.50-3.55(2H，m)， 3.75-3.85(2H，m)，3.95-4.05(2H，m)，4.10-4.20(2H，m)， 4.45-4.55(1H，m)，6.30-6.35(1H，s)，8.00-8.05(1H，s)， 8.25(2H，m)，8.75(1H，s)	2.88
418	467.74	1H NMR(DMSO-d6)：1.43(3H，d)，3.93(2H，m)，4.56 (1H，m)，8.04(1H，s)，8.35(1H，d)，8.39(1H，d)，8.57(1H， m)，8.66(1H，m)，8.99(1H，s)，12.67(1H，s)	3.35	417	458.00		2.88
418	467.74		3.35	419	485.00	1H NMR(CDCl3)：1.50-1.55(3H，d)，2.25-2.30(6H，s)， 2.5-2.7(2H，m)，3.50-3.60(2H，m)，3.80-4.10(2H，m)， 4.50-4.60(1H，m)，5.55-5.60(1H，m)，5.90(1H，s)，7.60- 7.90(2H，m)，8.20(1H，s)，8.45-8.55(1H，brs)，10.5-10.8 (1H，brs)	2.82
420	424.80	1H NMR(DMSO)：1.44(3H，d)，3.91(2H，m)，4.58(1H， m)，8.38(1H，m)，8.66-8.72(3H，m)，9.20(1H，d)	3.12	419	485.00		2.82
420	424.80		3.12	421	453.77	1H NMR(DMSO-d6)：3.92(2H，m)，4.06(2H，s)，8.06(1H， s)，8.33(1H，d)，8.44(1H，s)，8.59(2H，m)，8.95(1H，s)， 12.76(1H，s)	3.22
422	413.02	1H NMR(DMSO)：1.68(3H，d)，5.67(1H，m)，7.19(2H， m)，7.61(2H，m)，8.32(1H，s)，8.47(2H，m)，8.85(1H，m)， 9.18(1H，s)，12.83(1H，br s)	3.90	421	453.77		3.22

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	423	383.76	1H NMR(DMSO)：1.65(2H，m)，5.56(1H，m)，5.75(1H， br s)，7.22(2H，m)，7.50(2H，m)，7.56(1H，s)，8.35(2H，s)， 8.39(1H，m)，12.75(1H，br s)，13.5(1H，s)	3.45
424	481.00	1H NMR(DMSO-d6)：1.45-1.50(3H，d)，3.05-3.20(3H， m)，3.80-4.00(2H，m)，5.30-5.50(1H，m)，8.00-8.10(1H， m)，8.30-8.40(1H，m)，8.50-8.80(2H，m)，12.5(1H，s)	3.67	423	383.76		3.45
424	481.00		3.67	425	439.81	1H NMR(DMSO)：1.52(3H，d)，2.99(6H，m)，5.36(1H， m)，6.43(1H，br s)，7.16(2H，m)，7.49(2H，m)，8.11(1H， m)，8.22(2H，m)，8.51(1H，br s)，12.36(1H，s)	3.56
426	478.00	1H NMR(DMSO-d6)：1.28(9H，s)，1.40-1.50(3H，d)， 2.90-3.15(4H，m)，4.50-4.60(1H，m)，6.70-6.80(1H，m)， 7.60-7.65(1H，d)，8.08-8.13(1H，m)，8.15-8.20(2H，m)， 8.25(1H，m)，8.70(1H，s)，12(1H，s)	3.23	425	439.81		3.56
426	478.00		3.23	427	435.82	1H NMR(DMSO-d6)：3.92(2H，m)，4.24(2H，s)，7.43(1H， m)，7.59(1H，m)，7.77(2H，m)，8.22(2H，s)，8.78(1H，m)， 8.81(1H，m)，8.92(1H，s)，12.35(1H，s)	3.28
428	293.63	1H NMR(DMSO-d6)：1.25(3H，t)，2.93(2H，q)，8.34(1H， s)，8.37(1H，s)，8.57(1H，s)，8.07(1H，s)，12.84(1H，br s)	3.28	427	435.82		3.28
428	293.63		3.28	429	441.00	1H NMR(CD3OD)：1.30-1.50(6H，dd)，1.60-1.70(3H，d)， 3.05-3.15(1H，m)，3.85-4.05(2H，m)，4.80-4.90(1H，m)， 8.10(1H，s)，8.20-8.25(2H，m)，8.80(1H，s)	3.45
430	359.00	1H NMR(CD3OD)：1.30-1.40(6H，d)，2.88(3H，s)，2.95- 3.05(1H，m)，4.20-4.25(2H，m)，8.05(1H，s)，8.20-8.25 (2H，m)，8.80(1H，s)	3.00	429	441.00		3.45
430	359.00		3.00	431	378.73	1H NMR(CD3OD)：1.70-1.75(3H，d)，2.90-3.15(2H，m)， 3.5-3.6(2H，m)；3.80-3.85(1H，m)，8.35-8.45(3H，m)， 8.60-8.70(1H，m)	2.54
432	470.19	1H NMR(CD3OD)：1.30-1.40(6H，d)，1.60(3H，d)，2.95 (3H，s)，3.85-4.20(2H，m)，4.80-4.90(1H，qd)，7.60(1H，s)， 8.05(1H，s)，8.20(1H，s)	3.43	431	378.73		2.54
432	470.19		3.43	433	439.00	1H NMR(CD3OD)：1.45-1.55(3H，d)，1.80-1.90(2H，m)， 2.65-2.80(2H，m)；4.50-4.60(1H，m)，7.00-7.10(5H，m)， 8.10-8.20(3H，m)，8.80(1H，s)	3.33
434	443.00	1H NMR(CD3OD)：1.65-1.75(3H，d)，2.90-2.95(2H，m)， 3.50-3.60(2H，m)；3.70-3.80(3H，m)，4.90-5.00(1H，m)， 7.30(1H，s)，8.40-8.45(2H，m)，8.50(1H，s)，8.60(1H，s)， 8.80(1H，s)	2.77	433	439.00		3.33
434	443.00		2.77	435	448.00	1H NMR(CD3OD)：1.75-1.85(3H，d)，3.05-3.15(2H，m)， 3.25-3.30(2H，m)；3.45-3.55(2H，m)，3.60-3.80(4H，m)， 3.90-4.00(2H，m)，4.95-5.00(1H，m)，8.40-8.45(2H，m)， 8.50(1H，s)，8.60(1H，s)	2.81

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	436	432.00	1H NMR(CD3OD)：1.75-1.85(3H，d)，2.90-2.10(4H，m)， 3.00-3.10(2H，m)；3.20-3.30(2H，m)，3.55-3.75(4H，m)， 4.95-5.00(1H，m)，8.40-8.45(2H，m)，8.50(1H，s)，8.60 (2H，s)	2.64
437	478.19	1H NMR(CD3OD)：1.65-1.70(3H，d)，2.90-3.00(2H，m)， 3.50-3.70(2H，m)，4.80-4.90(1H，m)，6.80-6.90(1H，t)， 6.95-7.05(3H，m)，7.20-7.25(1H，d)，7.35-7.40(1H，d)， 8.35-8.40(3H，m)，8.50(1H，m)	3.18	436	432.00		2.64
437	478.19		3.18	438	440.00	1H NMR(CD3OD)：1.65-1.70(3H，d)，3.70-3.90(4H，m)， 4.80-4.90(1H，m)，7.80-7.85(1H，t)，7.90-7.95(1H，t)， 8.35-8.45(3H，m)，8.50(2H，s)，8.60(1H，m)	2.93
439	446.00	1H NMR(CD3OD)：1.75-1.85(3H，d)，1.90-2.10(6H，m)， 2.80-2.90(2H，m)；3.00-3.10(2H，m)，3.40-3.75(4H，m)， 4.95-5.00(1H，m)，8.40-8.45(2H，m)，8.50(1H，s)，8.60 (2H，s)	2.59	438	440.00		2.93
439	446.00		2.59	440	435.14	1H NMR(CD3OD)：1.00-1.05(6H，d)，1.75-1.85(3H，d)， 3.20-3.40(5H，m)，4.60-4.70(1H，m)，8.10-8.30(3H，m)， 8.80(1H，s)	3.15
441	447.00	1H NMR(CD3OD)：1.75-1.85(3H，d)，3.10-3.80(8H，m)， 4.95-5.00(1H，m)，8.40-8.45(2H，m)，8.50(1H，s)，8.60 (1H，s)	2.66	440	435.14		3.15
441	447.00		2.66	442	443.00	1H NMR(CD3OD)：1.75-1.85(3H，d)，2.05-2.15(2H，m)， 3.55-3.60(1H，m)；3.75-3.80(1H，m)，4.10-4.20(2H，m)， 4.95-5.00(1H，m)，7.50(2H，s)，8.35(1H，s)，8.40-8.60(3H， m)，8.63(1H，s)，8.87(1H，s)	2.75
443	428.00	1H NMR(CD3OD)：1.60-1.70(3H，d)，3.40-3.50(1H，m)， 3.70-3.80(1H，m)；4.00-4.05(2H，m)，4.80-4.90(1H，m)， 5.90(1H，s)，6.60(1H，s)，8.35-8.55(7H，m)，8.6(2H，s)，	3.16	442	443.00		2.75
443	428.00		3.16	444	420.09	1H NMR(DMSO-d6)：1.26(3H，d)，1.68(3H，s)，3.05(4H， m)，4.54(1H，m)，7.78(2H，m)，8.13(1H，s)，8.27(3H，m)， 8.66(1H，s)，12.40(1H，s)	2.68
445	470.12	1H NMR(CDCl3+CD3OD drops)：1.19(5H，m)，1.66 (3H，d)，2.76(2H，m)，3.06(2H，m)，4.69(1H，m)，8.10(1H， s)，8.18(1H，s)，8.30(1H，s)，8.64(1H，s)	2.88	444	420.09		2.68
445	470.12		2.88	446	518.19	1H NMR(CDCl3+CD3OD drops)：2.83(2H，t)，3.33(1H， s)，3.40(1H，m)，3.58(1H，m)，4.05(2H，m)，4.59(1H，m)， 6.94(1H，br s)，7.06(2H，d)，7.56(2H，d)，7.92(1H，s)，8.03 (1H，s)，8.12(1H，s)，8.12(1H，s)，8.71(1H，s)	2.88
447	423.00	1H NMR(CD3OD)：1.05-1.10(3H，t)，1.60-1.70(3H，d)， 2.35-2.40(2H，m)，2.45-2.55(2H，m)；3.40-3.50(2H，m)， 4.55-4.60(1H，m)，8.10(1H，s)，8.15(1H，s)，8.20(1H，s)， 8.80(1H，s)	3.23	446	518.19		2.88

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	448	446.00	1H NMR(CD3OD)：1.60-1.70(4H，m)，1.90-2.05(2H，m)， 2.10-2.20(1H，m)，2.25-2.40(1H，m)；2.70-2.80(3H，m)， 2.90-3.00(1H，m)，3.05-3.10(1H，m)，3.35-3.45(2H，m)， 3.50-3.60(2H，m)，3.65-3.75(2H，m)，4.90-5.00(1H，m)， 8.35-8.40(2H，m)，8.50(1H，s)，8.60-8.65(1H，s)	2.62
449	440.00	1H NMR(CD3OD)：1.65-1.70(3H，d)，3.70-3.90(4H，m)， 4.80-4.90(1H，m)，7.80-7.85(1H，t)，8.35-8.45(3H，m)， 8.45-8.55(2H，s)，8.60(1H，s)，8.75(1H，s)	2.90	448	446.00		2.62
449	440.00		2.90	450	452.0O	(d6-DMSO，400MHz)1.36(3H，d)，2.28(3H，s)，2.78(3H， s)，2.79-2.99(2H，m)，3.15-3.25(2H，m)，4.50(1H，brs)， 6.22(1H，brs)，7.05(1H，brs)，7.38(1H，d)，8.13(1H，brs)， 8.22(1H，s)，8.26(1H，d)，8.77(1H，brs)，12.30(1H，s)	2.76
451	492.00	1HNMR(CD3OD)：1.40-1.45(9H，s)，1.65-1.70(3H，d)， 2.80-2.85(3H，m)，2.95-3.00(1H，m)，3.05-3.10(1H，m)， 3.40-3.50(2H，m)，4.60-4.70(1H，m)，8.15(1H，s)，8.25 (1H，s)，8.30(1H，s)，8.80(1H，s)	3.42	450	452.0O		2.76
451	492.00		3.42	452	392.00	1H NMR(CD3OD)：1.65-1.70(3H，d)，3.20-3.40(2H，m)， 3.70(3H，s)，3.75-3.80(2H，m)，4.50-4.60(1H，m)，6.25- 6.30(1H，d)，6.35-6.40(1H，t)，6.55-6.65(2H，m)，7.90(1H， s)，8.05(1H，s)，8.15(1H，s)，8.55(1H，s)	2.59
453	485.00	1H NMR(CD3OD)：1.65-1.70(3H，d)，3.20-3.40(2H，m)， 3.70(3H，s)，3.75-3.80(2H，m)，4.50-4.60(1H，m)，6.25- 6.30(1H，d)，6.35-6.40(1H，t)，6.55-6.65(2H，m)，7.90(1H， s)，8.05(1H，s)，8.15(1H，s)，8.55(1H，s)	3.13	452	392.00		2.59
453	485.00		3.13	454	484.00	1H NMR(CD3OD)：1.08-1.13(6H，m)，1.55-1.60(3H，d)， 2.85-3.05(2H，m)，3.10-3.25(2H，m)，3.35-3.40(1H，m)， 4.60-4.70(1H，m)，8.10(1H，s)，8.15(1H，s)，8.20(1H，s)， 8.80(1H，s)	2.94
455	468.00	(d6-DMSO，40OMHz)1.39(3H，brs)，2.70-2.96(5H，m)， 3.16-3.26(2H，m)，3.84(3H，s)，4.31-4.36(1H，m)，6.60 (1H，s)，7.03(1.4H，brs)，7.43(0.6H，brs)，8.01(1H，t)，8.26 (1H，s)，8.41(1H，s)，8.70(0.4H，brs)，9.09(0.6H，brs)， 12.39(1H，s)	2.96	454	484.00		2.94
455	468.00		2.96	456	420.00	(d6-DMSO，400MHz)1.81-1.88(1H，m)，1.94-1.98(1H， m)，2.15(6H，s)，2.24-2.28(1H，m)，2.38-2.44(1H，m)， 2.86(3H，s)，3.23(3H，s)，5.38-5.40(1H，m)，7.83(1H，d)， 8.15(1H，s)，8.20(1H，d)，8.28(1H，d)，8.72(1H，d)，12.35 (1H，s)	2.90
457	455.13	1H NMR(DMSO)：1.47(3H，d)，3.36(1H，m)，3.51(1H， m)，3.80(2H，m)，6.64(2H，d)，6.82(1H，t)，7.09(2H，t)， 8.07(1H，br s)，8.28(4H，m)，8.66(1H，s)，12.50(1H，s)	3.29	456	420.00		2.90
457	455.13		3.29	458	512.22	1H NMR(DMSO)：1.45(3H，d)，3.07(4H，m)，4.55(1H， m)，4.93(2H，m)，7.21(1H，m)，7.29(5H，m)，8.01(1H，br s)，8.17(1H，m)，8.28(3H，m)，8.65(1H，s)，12.44(1H，s)	3.34

Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)
Cmpd No.	LC_MASS _PLUS M+1(obs)	NMR_RESULT(1H NMR)	RT (mins)	459	479.16	1H NMR(DMSO+CD3OD drops)：1.41(3H，d)，3.27(2H， m)，3.58(1H，m)，3.60(1H，m)，4.53(1H，m)，7.42(2H，m)， 7.60(2H，m)，8.13(1H，s)，8.24(2H，m)，8.43(1H，s)，8.51 (1H，s)	3.09
460	460.17	1H NMR(DMSO)：1.48(5H，m)，1.75(2H，m)，2.10(2H， t)，2.92(2H，m)，3.05(4H，m)，4.53(1H，m)，7.90(1H，br s)，8.04(1H，m)，8.28(3H，m)，8.66(1H，s)，12.41(1H，s)	2.86	459	479.16		3.09
460	460.17		2.86	461	388.04	1H NMR(DMSO)：1.46(3H，d)，2.59(2H，m)，3.35(1H， m)，4.57(1H，m)，7.95(1H，br s)，8.23(1H，s)，8.28(2H，s)， 8.47(1H，t)，8.65(1H，s)	2.84
462	555.18	1H NMR(DMSO)：1.45(3H，d)，2.60(2H，m)，3.26(2H， m)，3.85(2H，d)，4.56(1H，m)，7.22(1H，t)，7.37(2H，d)， 7.69(1H，d)，8.21(4H，m)，8.66(1H，s)，12.31(1H，s)	3.59	461	388.04		2.84
462	555.18		3.59	463	419.00	1H NMR(CD3OD)：0.70-0.75(3H，t)，1.05-1.15(7H，m)， 1.35-1.45(2H，m)，1.55-1.60(3H，d)，3.90-4.00(1H，m)， 4.60-4.65(1H，m)，8.10(1H，s)，8.15(1H，s)，8.20(1H，s)， 8.80(1H，s)	3.50
464	405.00	1H NMR(CD3OD)：0.70-0.75(6H，t)，1.30-1.40(2H，m)， 1.40-1.50(1H，m)，1.55-1.60(3H，d)，2.90-3.00(1H，m)， 3.15-3.20(1H.m)，4.70-4.75(1H，m)，8.10(1H，s)，8.15 (1H，s)，8.20(1H，s)，8.80(1H，s)	3.40	463	419.00		3.50
464	405.00		3.40	465	391.00	1H NMR(CD3OD)：0.70-0.75(3H，t)，1.05-1.10(3H，d)， 1.35-1.45(2H，m)，1.55-1.60(3H，d)，3.80-3.90(1H，m)， 4.70-4.75(1H，m)，8.10(1H，s)，8.15(1H，s)，8.20(1H，s)， 8.80(1H，s)	3.30
466	407.00	1H NMR(CD3OD)：1.55-1.60(3H，d)，2.40-2.50(2H，m)， 3.35-3.55(2H.m)，4.65-4.70(1H，m)，8.25(1H，s)，8.30- 8.40(2H，m)，8.70(1H，s)	2.50	465	391.00		3.30
466	407.00		2.50	467	420.00	1H NMR(CD3OD)：1.55-1.60(3H，d)，2.30-2.40(2H，m)， 3.35-3.60(5H，m)，4.60-4.70(1H，m)，8.15(1H，s)，8.20 (1H，s)，8.25(1H，s)，8.80(1H，s)	2.80
468	448.00	1H NMR(CD3OD)：1.00-1.10(6H，m)，1.55-1.60(3H，d)， 2.30-2.40(2H，m)，3.35-3.50(3H，m)，3.80-3.90(2H，m)， 4.60-4.70(1H，m)，8.15(1H，s)，8.20(1H，s)，8.25(1H，s)， 8.80(1H，s)	3.00	467	420.00		2.80
468	448.00		3.00	469	484.00	1H NMR(CD3OD)：0.90-1.00(6H，m)，1.55-1.60(3H，d)， 2.95-3.05(1H，m)，3.10-3.25(2H.m).3.50-3.60(1H.m)， 3.70-3.80(1H，m)，4.65-4.70(1H，m)，8.10(1H，s)，8.30- 8.40(2H，m)，8.70(1H，s)	3.00

B) biological data

Embodiment 1:JAK3 suppresses assay method

Use standard radioactivity enzyme assay SCREENED COMPOUND suppresses the ability of JAK3.The DMSO stoste (concentration is 667 μ M-46nM) that will contain the The compounds of this invention of serial dilution is inoculated on the 96 hole polycarbonate flat boards with 1.5 μ L/ holes.Add in flat board with 50 μ L/ holes and to contain 2 μ M poly-(Glu) ₄The kinase buffer liquid of Tyr and 10 μ M ATP (100mM HEPES (pH 7.4), 100mM MgCl ₂, 25mM NaCl, 1mM DTT and 0.01% bovine serum albumin (BSA)).In order to begin reaction, add the 50 μ L kinase buffer liquid that contain 2nM JAK3 enzyme.Whole ATP concentration be 5 μ M[γ- ³³P] ATP (200 μ Ci ³³P ATP/ μ mol ATP (Perkin Elmer, Cambridge, MA)).Room temperature (25 ℃) is after 20 minutes, by add 50 μ L, 20% Tricholroacetic Acids (TCA)/0.4mM ATP and termination reaction in every hole.Using TomTek CellHarvester that whole inclusion in each hole are transferred to 96 hole glass fibre then filters in the flat board.After the washing, add 60 μ L flicker fluid and use Perkin Elmer TopCount detection 33P to mix.After removing the average background value of all data points, thereby use Prism software fitting data to obtain K _i(app).Except eventually poly-(Glu) ₄Tyr concentration is that 15 μ M and whole ATP concentration are outside the 12 μ M, the inhibition of measuring JAK2 as mentioned above.

Embodiment 2:ROCK suppresses assay method

Use standard coupling enzyme system people such as (, (1998) Protein Sci.7,2249) Fox SCREENED COMPOUND suppresses the ability of ROCK I (AA 6-553).Be reflected at and contain 100mM HEPES (pH7.5), 10mM MgCl ₂, 25mM NaCl, 2mM DTT and 1.5%DMSO solution in carry out.In the mensuration final concentration of substrate be 45 μ M ATP (Sigma Chemicals, St Louis, MO) and 200 μ M peptides (American Peptide, Sunnyvale, CA).Be reflected under 30 ℃ and the 45nMROCK I condition and carry out.The final concentration of each component of coupling enzyme system is 2.5mM phosphoenolpyruvic acid, 350 μ M NADH, 30 μ g/ml pyruvate kinases and 10 μ g/ml serum lactic dehydrogenases.

Use standard radioactivity enzyme system SCREENED COMPOUND suppresses the ability of ROCK.Mensuration is to contain 100mM HEPES (pH 7.5), 10mM MgCl ₂, 25mM NaCl, 2mM DTT and 1.5%DMSO solution in carry out.In the mensuration final concentration of substrate be 13 μ M[γ- ³³P] ATP (25mCi ³³P ATP/mmol ATP, Perkin Elmer, Cambridge, MA/Sigma Chemicals, St Louis is MO) with 27 μ M myelin basic protein (MBP).Whole enzyme concn in the mensuration is 5nM ROCK.Room temperature is measured.The DMSO stoste (concentration is 10 μ M-2.6nM) that 1.5 μ L is contained the The compounds of this invention of serial dilution is inoculated on the 96 hole flat boards.In flat board, add 50 μ L solution 1 (100mM HEPES (pH7.5), 10mMMgCl ₂, 26mM[γ- ³³P] ATP).By adding 50 μ L solution 2 (100mM HEPES (pH7.5), 10mM MgCl ₂, 4mM DTT, 54mM MBP and 10nM ROCK) and begin reaction.After 2 hours, (TCA Fisher) finishes reaction with 50 μ L, 30% Tricholroacetic Acid that contains 9mM ATP.The reactant transfer that 140 μ L are finished to glass fibre filter dull and stereotyped (Corning, Cat.No.3511) in, then with 5%TCA washing 3 times.Add 50 μ L Optima Gold scintillating liquids (Perkin Elmer) and last to plate count at Top Count (Perkin Elmer).After removing the average background value of all data points, use Prism software fitting data, thereby obtain K _i(app).

Embodiment 3:Aurora suppresses assay method

Use standard coupling enzyme system (people such as Fox, Protein Sci.7,2249 (1998)) SCREENED COMPOUND suppresses the ability of Aurora-A (AA 1-403).Be reflected at and contain 100mMHEPES (pH 7.5), 10mM MgCl ₂, 25mM NaCl, 300 μ M NADH, 1mM DTT and 3%DMSO solution in carry out.In the mensuration final concentration of substrate be 200 μ M ATP (SigmaChemicals, St Louis, MO) and 800 μ M peptides (LRRASLG, American Peptide, Sunnyvale, CA).Be reflected under 30 ℃ and the 35nM Aurora-A condition and carry out.The final concentration of each component of coupling enzyme system is 2.5mM phosphoenolpyruvic acid, 200 μ M NADH, 60 μ g/ml pyruvate kinases and 20 μ g/ml serum lactic dehydrogenases.

Preparation contains the mensuration stoste buffered soln of top listed all preparations except ATP and target test compound.Under 30 ℃, in 96 hole flat boards, use the target test compound of 2 μ l, 0.002 μ M-30 μ M final concentration to cultivate this mensuration stoste buffered soln (60 μ l) 10 minutes.Usually, the DMSO of the test compound by preparing serial dilution (from 1mM compound stoste) in sub-flat board carries out 12 titration.Begin reaction by adding 5 μ l ATP (final concentration 200 μ M).Under 30 ℃, (Sunnyvale CA) obtained speed of reaction in 10 minutes to use Molecular Devices Spectramax flat bed reader.Use computerized non-linear regression (Prism 3.0, Graphpad software, San Diego, CA), by determining the Ki value as the speed data of inhibitor concentration function.Use Aurora-C albumen, the activity of screening Aurora-C in a similar manner.Use Aurora-B albumen and radioactivity measurement method, described in embodiment 1 and 2, screening Aurora-B activity.

Below table 5 enzyme of describing specific illustrative compound suppress data (K _i).Compound number is corresponding with those compounds of description in the table 1.

Below table 6 enzyme of describing specific illustrative compound suppress data (K _i).Compound number is corresponding with those compounds of description in the table 2.

In table 5 and 6, with regard to specifying enzyme, " A " representative is lower than the K of 0.5 μ M _i, " B " represents the K between the 0.5-5.0 μ M _i, " C " representative is greater than the K of 5.0 μ M _iIf measured a more than K _iValue is then represented average K _iIf the value of providing is not measured K so _iWith regard to ROCK, enzyme-Lian assay method has been used in term " enzyme " expression; Term " ³³P " expression used the radioactivity measurement method.

The enzyme of table 5. table 1 compound suppresses data

The enzyme of table 6 table 2 compound suppresses data

Claims

1. the compound of formula (IB):

Or its pharmacologically acceptable salts, wherein:

R ¹Be hydrogen;

R ²And R ⁴Each is hydrogen naturally;

R ³Be hydrogen or halogen independently;

X is 1,2 or 3;

R ⁵Each appearance independently be halogen, CN, NO ₂, or U-R ', wherein at least one R ⁵Not H;

Each U independently is valence link or the optional C that replaces ₁-C ₆Alkylidene chain, wherein this chain at the most optional the and independent quilt-NR ' of two methylene units-,-S-,-O-,-CS-,-CO ₂-,-OCO-,-CO-,-COCO-,-CONR '-,-NR ' CO-,-NR ' CO ₂-,-SO ₂NR '-,-NR ' SO ₂-,-CONR ' NR '-,-NR ' CONR '-,-OCONR '-,-NR ' NR '-,-NR ' SO ₂NR '-or-the SO-replacement; And

The each appearance of R ' independently is hydrogen or the optional group that replaces, and is selected from: C ₁-C ₆Aliphatic group, the heteroatomic 3-8-unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle to have 0-3, or the heteroatomic 8-12 unit that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated bicyclic system to have 0-5; Or twice appearance of R ' with and their bonded atoms are common forms that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated monocycle or dicyclo;

Wherein the optional substituting group on the unsaturated carbon atom of aryl or heteroaryl be selected from halogen ,-R ^o,-OR ^o,-SR ^o, use R ^oThe optional phenyl (Ph) that replaces, use R ^oOptional replace-O (Ph), use R ^oOptional replacement-(CH ₂) _1-2(Ph), use R ^oOptional replace-CH=CH (Ph), use R ^oOptional 5-6 unit's heteroaryl or the heterocycle that replaces;-NO ₂-CN;-N (R ^o) ₂-NR ^oC (O) R ^o-NR ^oC (S) R ^o-NR ^oC (O) N (R ^o) ₂-NR ^oC (S) N (R ^o) ₂-NR ^oCO ₂R ^o-NR ^oNR ^oC (O) R ^o-NR ^oNR ^oC (O) N (R ^o) ₂-NR ^oNR ^oCO ₂R ^o-C (O) C (O) R ^o-C (O) CH ₂C (O) R ^o-CO ₂R ^o-C (O) R ^o-C (S) R ^o-C (O) N (R ^o) ₂-C (S) N (R ^o) ₂-OC (O) N (R ^o) ₂-OC (O) R ^o-C (O) N (OR ^o) R ^o-C (NOR ^o) R ^o-S (O ₂) R ^o-S (O ₃) R ^o-SO ₂N (R ^o) ₂-S (O) R ^o-NR ^oSO ₂N (R ^o) ₂-NR ^oSO ₂R ^o-N (OR ^o) R ^o-C (=NH)-N (R ^o) ₂Or-(CH ₂) _0-2NHC (O) R ^o, each self-existent R wherein ^oBe selected from hydrogen, the optional C that replaces _1-6Aliphatic group, unsubstituted 5-6 unit's heteroaryl or heterocycle, phenyl ,-(O) Ph or-CH ₂(Ph) or, two self-existent R on same substituting group or the different substituents ^oWith with each R ^oGroup bonded atom is common to form that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated unit or dicyclo; R wherein ^oAliphatic group on optional substituting group be selected from NH ₂, NH (C _1-4Aliphatic group), N (C _1-4Aliphatic group) ₂, halogen, C _1-4Aliphatic group, OH, O (C _1-4Aliphatic group), NO ₂, CN, CO ₂H, CO ₂(C _1-4Aliphatic group), O (halo C _1-4Aliphatic group) or halo C _1-4Aliphatic group, wherein R ^oEach aforesaid C _1-4Aliphatic group all is unsubstituted;

Wherein on aliphatic series or the heterolipid family group or the optional substituting group on the saturated carbon of nonaromatic heterocycles be selected from listed those of the unsaturated carbon of top aryl or heteroaryl, and comprise following in addition :=O ,=S ,=NNHR ^*,=NN (R ^*) ₂,=NNHC (O) R ^*,=NNHCO ₂(alkyl) ,=NNHSO ₂(alkyl) or=NR ^*, each R wherein ^*Independently be selected from hydrogen or C _1-6Aliphatic group;

Wherein the optional substituting group on the nitrogen of nonaromatic heterocycles is selected from-R ⁺,-N (R ⁺) ₂,-C (O) R ⁺,-CO ₂R ⁺,-C (O) C (O) R ⁺,-C (O) CH ₂C (O) R ⁺,-SO ₂R ⁺,-SO ₂N (R ⁺) ₂,-C (=S) N (R ^{+ 1}) ₂,-C (=NH)-N (R ⁺) ₂, or-NR ⁺SO ₂R ⁺R wherein ⁺Be hydrogen, the optional C that replaces _1-6Aliphatic group, the optional phenyl that replaces, optional replace-O (Ph), optional replace-CH ₂(Ph), optional replace-(CH ₂) _1-2(Ph), optional replace-CH=CH (Ph) or have 1-4 first heteroaryl of heteroatomic unsubstituted 5-6 or heterocycle that independently is selected from oxygen, nitrogen or sulphur, or, two self-existent R on same substituting group or the different substituents ⁺With with each R ⁺Group bonded atom is common to form that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated, part is unsaturated or complete undersaturated unit or dicyclo; R wherein ⁺Aliphatic group or the optional substituting group on the phenyl ring be selected from-NH ₂,-NH (C _1-4Aliphatic group) ,-N (C _1-4Aliphatic group) ₂, halogen, C _1-4Aliphatic group ,-OH ,-O (C _1-4Aliphatic group) ,-NO ₂,-CN ,-CO ₂H ,-CO ₂(C _1-4Aliphatic group) ,-O (halogen C _1-4Aliphatic group) or halogen C _1-4Aliphatic group, wherein R ⁺Each aforesaid C _1-4Aliphatic group all is unsubstituted;

Its condition is: if R ³Be H and x is 1, R so ⁵Not-SMe NH ₂Or the optional NH-piperidines that replaces.

2. compound according to claim 1, wherein R ⁵Each appearance independently be R ' ,-CH ₂R ', halogen, CN, NO ₂,-N (R ') ₂,-CH ₂N (R ') ₂,-OR ' ,-CH ₂OR ' ,-SR ' ,-CH ₂SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' ,-NR ' CO (CH ₂) ₂R ' ,-NR ' COOR ' ,-CON (R ') ₂,-SO ₂N (R ') ₂,-CONR ' (CH ₂) ₂N (R ') ₂,-CONR (CH ₂) ₃N (R ') ₂,-CONR ' (CH ₂) ₄N (R ') ₂,-O (CH ₂) ₂OR ', O (CH ₂) ₃OR ', O (CH ₂) ₄OR ' ,-O (CH ₂) ₂N (R ') ₂,-O (CH ₂) ₃N (R ') ₂,-O (CH ₂) ₄N (R ') ₂,-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' (CH ₂) R ' ,-NR ' (CH ₂) ₂R ' ,-NR ' (CH ₂) ₃R ' ,-NR ' (CH ₂) ₄R ' ,-NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-NR ' (CH ₂) ₃N (R ') ₂,-NR ' (CH ₂) ₄N (R ') ₂,-NR ' (CH ₂) OR ' ,-NR ' (CH ₂) ₂OR ' ,-NR ' (CH ₂) ₃OR ' or-NR ' (CH ₂) ₄OR '.

3. following compounds, it is

4. compound according to claim 1, wherein R ³Be selected from H, Cl or F.

5. compound according to claim 1, wherein R ⁵Each appearance independently be selected from R ' ,-CH ₂R ', halogen, CN, NO ₂,-N (R ') ₂,-CH ₂N (R ') ₂,-OR ' ,-CH ₂OR ' ,-SR ' ,-CH ₂SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' COR ⁸R ' ,-NR ' COOR ' ,-CON (R ') ₂,-SO ₂N (R ') ₂,-CONR ' R ⁸N (R ') ₂,-OR ⁸OR ' ,-OR ⁸N (R ') ₂,-NR ' CH (R ⁹) R ' ,-NR ' CH (R ⁹) C (O) OR ' ,-N (R ') R ⁸R ' ,-N (R ') R ⁸R ' ,-N (R ') R ⁸N (R ') ₂,-N (R ') R ⁸OR ' ,-NR ' CH ₂C (O) N (R ') ₂, or-NR ' CH (R ⁹) C (O) N (R ') ₂, R wherein ⁸Be the optional C that replaces ₁-C ₄Alkyl and R ⁹Be the optional C that replaces ₁-C ₆Aliphatic group.

6. compound according to claim 1, wherein x is 2 or 3, and at least two R on the adjacent ring member ⁵Be R ', and wherein said two R ⁵With common form that the 3-12 unit with 0-4 heteroatomic optional replacement that independently is selected from nitrogen, oxygen or sulphur is saturated with their bonded atoms, fractional saturation or complete undersaturated monocycle or dicyclo.

7. compound according to claim 1, wherein x is 1 or 2, and R ⁵Each appearance independently be halogen, R ', CN ,-CH ₂CN ,-(CH ₂) ₂CN, NO ₂,-CH ₂NO ₂,-(CH ₂) ₂NO ₂, CON (R ') ₂,-CH ₂CON (R ') ₂,-(CH ₂) ₂CON (R ') ₂, COOR ' ,-CH ₂COOR ' ,-(CH ₂) ₂COOR ' ,-SO ₂N (R ') ₂,-CH ₂SO ₂N (R ') ₂,-(CH ₂) ₂SO ₂N (R ') ₂,-NR ' SO ₂R ' ,-CH ₂NR ' SO ₂R ' ,-(CH ₂) ₂NR ' SO ₂R ', NR ' CON (R ') ₂,-CH ₂NR ' CON (R ') ₂,-(CH ₂) ₂NR ' CON (R ') ₂,-NR ' SO ₂N (R ') ₂,-CH ₂NR ' SO ₂N (R ') ₂,-(CH ₂) ₂NR ' SO ₂N (R ') ₂,-COCOR ' ,-CH ₂COCOR ' ,-(CH ₂) ₂COCOR ' ,-N (R ') ₂,-CH ₂N (R ') ₂,-(CH ₂) ₂N (R ') ₂,-OR ' ,-CH ₂OR ' ,-(CH ₂) ₂OR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' ,-NR ' CO (CH ₂) ₂R ' ,-CH ₂NR ' COR ' or-(CH ₂) ₂NR ' COR '.

8. compound according to claim 7, wherein R ⁵Each appearance independently be selected from R ' ,-CH ₂R ', halogen ,-CN ,-NO ₂,-N (R ') ₂,-CH ₂N (R ') ₂,-OR ' ,-CH ₂OR ' ,-SR ' ,-CH ₂SR ' ,-COOR ' ,-NR ' COR ' ,-NR ' COCH ₂R ' ,-NR ' CO (CH ₂) ₂R ' ,-NR ' COOR ' ,-CON (R ') ₂,-SO ₂N (R ') ₂,-CONR ' (CH ₂) ₂N (R ') ₂,-CONR (CH ₂) ₃N (R ') ₂,-CONR ' (CH ₂) ₄N (R ') ₂,-O (CH ₂) ₂OR ', O (CH ₂) ₃OR ', O (CH ₂) ₄OR ' ,-O (CH ₂) ₂N (R ') ₂,-O (CH ₂) ₃N (R ') ₂,-O (CH ₂) ₄N (R ') ₂,-NR ' CH (CH ₃) R ', NR ' CH (CF ₃) R ' ,-NR ' CH (CH ₃) C (O) OR ' ,-NR ' CH (CF ₃) C (O) OR ' ,-NR ' (CH ₂) R ' ,-NR ' (CH ₂) ₂R ' ,-NR ' (CH ₂) ₃R ' ,-NR ' (CH ₂) ₄R ' ,-NR ' (CH ₂) N (R ') ₂,-NR ' (CH ₂) ₂N (R ') ₂,-NR ' (CH ₂) ₃N (R ') ₂,-NR ' (CH ₂) ₄N (R ') ₂,-NR ' (CH ₂) OR ' ,-NR ' (CH ₂) ₂OR ' ,-NR ' (CH ₂) ₃OR ' ,-NR ' (CH ₂) ₄OR ' ,-NR ' CH (CH ₂CH ₃) R ' ,-NR ' CH ₂C (O) N (R ') ₂,-NR ' CH (CH ₃) C (O) N (R ') ₂, NR ' CH (CF ₃) C (O) N (R ') ₂,-NR ' CH (CH ₂CH ₃) C (O) N (R ') ₂,-NR ' CH (CH (CH ₃) ₂) C (O) N (R ') ₂,-NR ' CH (C (CH ₃) ₃) C (O) N (R ') ₂,-NR ' CH (CH ₂CH (CH ₃) ₂) C (O) N (R ') ₂, or-NR ' CH (CH ₂CH ₂N (Me) ₂) C (O) N (R ') ₂

9. according to the compound of claim 7, R wherein ⁵at least once occur independently be selected from-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂OMe) R ' ,-NR ' CH (CH ₂OEt) R ' ,-NR ' CH (CH ₂OCF ₃) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OMe) R ' ,-NR ' CH (CH ₂CH ₂OEt) R ' ,-NR ' CH (CH ₂CH ₂OCF ₃) R ' ,-NR ' CH (CH ₃) C (O) OR ' ,-NR ' CH (CF ₃) C (O) OR ' ,-NR ' CH (CH ₃) C (O) N (R ') ₂,-NR ' CH (CF ₃) C (O) N (R ') ₂,-NR ' CH (CH ₂CH ₃) C (O) N (R ') ₂,-NR ' CH (CH ₂OH) C (O) N (R ') ₂,-NR ' CH (CH ₂OMe) C (O) N (R ') ₂,-NR ' CH (CH ₂OEt) C (O) N (R ') ₂Or-NR ' CH (CH ₂OCF ₃) C (O) N (R ') ₂, wherein R ' is the optional C that replaces ₁-C ₄Aliphatic group.

10. compound according to claim 7, wherein said R ⁵NHCH at least once appears being selected from ₂C (O) NHR ' ,-NHCH (CH ₃) C (O) NHR ' ,-NHCH (CH ₂CH ₃) C (O) NHR ' ,-NHCH (CH (CH ₃) ₂) C (O) NHR ' ,-NHCH (C (CH ₃) ₃) C (O) NHR ' ,-NHCH (CH ₂CH (CH ₃) ₂) C (O) NHR ' ,-NHCH (CH ₂OH) C (O) NHR ' ,-NHCH (CH ₂OMe) C (O) NHR ' or-NHCH (CH ₂CH ₂N (Me) ₂) C (O) NHR ', wherein R ' is the optional C that replaces ₁-C ₄Aliphatic group.

11. compound according to claim 7, wherein R ⁵at least once occur independently be selected from-NHR ' ,-NH (CH ₂) R ' ,-NH (CH ₂) ₂R ' ,-NHCH (CH ₃) R ' ,-NHCH ₂C (O) NHR ' ,-NHCH (CH ₃) C (O) NHR ' ,-NHCH (CH ₂CH ₃) C (O) NHR ' ,-NHCH (CH (CH ₃) ₂) C (O) NHR ' ,-NHCH (C (CH ₃) ₃) C (O) NHR ', NHCH (CH ₂CH (CH ₃) ₂) C (O) NHR ' ,-NHCH (CH ₂OH) C (O) NHR ' ,-NHCH (CH ₂OMe) C (O) NHR ' or-NHCH (CH ₂CH ₂N (Me) ₂) C (O) NHR ', wherein R ' is the optional phenyl that replaces.

12. compound according to claim 7, wherein said R ⁵at least once occur be-NHCH (CH ₃) R ', wherein R ' is the optional phenyl that replaces.

13. compound according to claim 7, wherein R ⁵At least once to occur be halogen, CH ₃, CF ₃, COOH, COOMe or OR ', wherein R ' is C ₁-C ₄Aliphatic group.

14. compound according to claim 7, wherein x is 2 or 3 and R ⁵At least once to occur be F.

15. compound according to claim 7, wherein R ⁵Be selected from-NHR ' ,-NH (CH ₂) R ' ,-NH (CH ₂) ₂R ' ,-NHCH (CH ₃) R ' ,-NHCH ₂C (O) NHR ' ,-NHCH (CH ₃) C (O) NHR ' ,-NHCH (CH ₂CH ₃) C (O) NHR ' ,-NHCH (CH (CH ₃) ₂) C (O) NHR ' ,-NHCH (C (CH ₃) ₃) C (O) NHR ' ,-NHCH (CH ₂CH (CH ₃) ₂) C (O) NHR ' ,-NHCH (CH ₂OH) C (O) NHR ' ,-NHCH (CH ₂OMe) C (O) NHR ' or-NHCH (CH ₂CH ₂N (Me) ₂) C (O) NHR ', wherein R ' is the optional phenyl that replaces.

16. compound according to claim 7, wherein R ⁵Be selected from-NR ' CH (CH ₂OH) R ' ,-NR ' CH (CH ₂OMe) R ' ,-NR ' CH (CH ₂OEt) R ' ,-NR ' CH (CH ₂OCF ₃) R ' ,-NR ' CH (CH ₂CH ₂OH) R ' ,-NR ' CH (CH ₂CH ₂OMe) R ' ,-NR ' CH (CH ₂CH ₂OEt) R ' ,-NR ' CH (CH ₂CH ₂OCF ₃) R ' ,-NR ' CH (CH ₃) C (O) OR ' ,-NR ' CH (CF ₃) C (O) OR ' ,-NR ' CH (CH ₃) C (O) N (R ') ₂,-NR ' CH (CF ₃) C (O) N (R ') ₂,-NR ' CH (CH ₂CH ₃) C (O) N (R ') ₂,-NR ' CH (CH ₂OH) C (O) N (R ') ₂,-NR ' CH (CH ₂OMe) C (O) N (R ') ₂,-NR ' CH (CH ₂OEt) C (O) N (R ') ₂Or-NR ' CH (CH ₂OCF ₃) C (O) N (R ') ₂, wherein R ' is the optional C that replaces ₁-C ₄Aliphatic group.

17. be selected from following compound:

18. pharmaceutical composition that comprises any one described compound of claim 1-17 and pharmaceutically acceptable carrier, auxiliary agent or vehicle.

19. any one described compound of claim 1-17 is used for suppressing biological sample or the medicine of patient JAK-3, ROCK or Aurora kinase activity or the purposes in the reagent in preparation.

20. any one described compound of claim 1-17 is used for the treatment of or alleviates purposes in the medicine of following disease or illness in preparation, wherein said disease or illness are selected from: immune response, autoimmune disease, neurodegenerative disorders or entity and hematologic malignancies.

21. according to the purposes of claim 20, wherein said disease or illness are selected from: allergy or type i allergic reaction or asthma, transplant rejection, graft versus host disease, rheumatoid arthritis, amyotrophic lateral sclerosis or multiple sclerosis.

22. purposes according to claim 21, wherein said disease are transplant rejection, graft versus host disease, rheumatoid arthritis, amyotrophic lateral sclerosis or multiple sclerosis.

23. purposes according to claim 19, wherein this disease is hypertension, stenocardia, cerebrovascular atrophy, asthma, peripheral circulation illness, premature labor, cancer, erectile dysfunction, arteriosclerosis, spasm, retinopathy, inflammatory conditions, autoimmune disorder, AIDS, osteoporosis, myocardial hypertrophy, local asphyxia/pour into inductive again to damage or endothelial dysfunction.

24. any one described compound of claim 1-17 is used for preventing or alleviating the purposes of the medicine of following disease or disease serious degree in preparation, wherein said disease or illness are selected from: heart trouble, diabetes, Alzheimer's, the immunodeficiency illness, inflammatory diseases, hypertension, allergic disease, autoimmune disease, destructive osteopathy, osteoporosis, proliferative disorders, catch, immune-mediated disease, virus disease, hyperplasia, perfusion/local asphyxia again in the apoplexy, heart attack, the organ anoxic, the platelet aggregation of thrombin induction, chronic lymphocytic leukemia, acute myelogenous leukemia, acute promyelocytic leukemia, rheumatoid arthritis, asthma, osteoarthritis, local asphyxia, cancer, the liver local asphyxia, myocardial infarction, congestive heart failure, the pathologic immune disorders that relates to the T cell activation, and neurodegenerative disorders.

25. purposes according to claim 24, wherein said cancer are selected from melanoma, lymphoma, neuroblastoma, leukemia or are selected from colon, mammary gland, lung, kidney, ovary, uterine endometrium, pancreas, kidney, central nervous system, uterine cervix, prostatic cancer or cancer of the stomach, chronic lymphocytic leukemia, acute myelogenous leukemia, acute promyelocytic leukemia, acute lymphoblastic leukemia, mastocytosis or gastrointestinal stromal tumors.